{ "title": "Peptide Local Global Compound-by-Country Verification Index", "identifier": "https://peptidelocal.com/data/global-peptide-country-index#dataset", "version": "2026-07-24", "scope": "Compound identity and country-specific official verification routes. Rows are not blanket legal, availability, safety, quality, medical, product-authentication, or seller determinations.", "methodology": "https://peptidelocal.com/methodology", "stats": { "records": 1722, "compounds": 41, "countries": 42, "regions": 5, "languages": 22, "uniqueSourceUrls": 138, "clinicalTrialSourceUrls": 806, "allUniqueSourceUrls": 932, "compoundCountrySourcedRows": 43, "compoundCountryEditorialRows": 0, "identityPlusCountryRouteRows": 1679, "clinicalTrialPrograms": 13, "clinicalTrialTrackedRows": 546, "clinicalTrialMatchedRows": 237, "clinicalTrialRecruitingRows": 150, "clinicalTrialStudyCountryMatches": 1237, "clinicalTrialListedLocations": 15509, "clinicalTrialRecruitingLocations": 4583 }, "clinicalTrialSnapshot": { "source": "ClinicalTrials.gov", "sourceDataset": "https://peptidelocal.com/data/peptide-clinical-trials", "version": "2026-07-24", "boundary": "A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion." }, "dictionary": { "recordId": "Stable Peptide Local identifier for one compound and destination-country verification row.", "compound": "Resolved compound or medicine identity used by the linked Peptide Local evidence record.", "evidenceLane": "Research price board, clinical pipeline profile, or approved medicine record. These lanes are not interchangeable.", "country": "Destination jurisdiction whose official product and seller or supply records are linked.", "region": "One of five geographic discovery groups. The country record remains the verification boundary.", "contentLanguage": "Language used for the localized query and bounded country answer.", "localizedQuery": "Country-language heading for the compound and destination combination.", "localizedAnswer": "Editorial routing answer that preserves the identity lane and states which local claims remain unverified.", "statusSpecificity": "Evidence-depth label distinguishing a sourced compound-country status, a country-specific editorial status without a separate exact source URL, and an identity record joined only to general country verification routes.", "statusEvidenceBasis": "Plain-language boundary explaining what the row's evidence depth can and cannot establish.", "statusEvidenceSourceCount": "Number of compound and destination-specific source URLs attached to the status summary. This excludes the separate identity, product, and seller or supply routes.", "statusEvidencePublishers": "Publishers of the compound and destination-specific status sources, when present.", "statusEvidenceUrls": "Compound and destination-specific source URLs supporting the status summary, when present.", "clinicalTrialScope": "Whether the compound is included in the current thirteen-program ClinicalTrials.gov snapshot. Outside scope is not evidence that no study exists.", "clinicalTrialProgramName": "Canonical program name used by the current intervention-search snapshot, when the row is in scope.", "clinicalTrialRegistryCountry": "ClinicalTrials.gov country label used to match listed study locations to the destination row.", "clinicalTrialSnapshotDate": "ISO date of the ClinicalTrials.gov snapshot used for the country-level counts.", "clinicalTrialRecords": "Number of matched study records that list at least one location in the destination country. Zero is a dated search result, not a permanent conclusion.", "clinicalTrialListedLocations": "Sum of listed facility observations in the destination country across the matched study records.", "clinicalTrialRecruitingLocations": "Sum of destination facilities individually marked Recruiting in the registry snapshot.", "clinicalTrialRecordsWithRecruitingLocations": "Number of matched study records with at least one destination facility individually marked Recruiting.", "clinicalTrialRecordIds": "Exact NCT identifiers for all matched country-level study records in the snapshot.", "clinicalTrialRecordUrls": "Direct ClinicalTrials.gov URLs for all matched country-level study records.", "clinicalTrialFinderUrl": "Peptide Local trial finder filtered to the exact program and registry country.", "clinicalTrialRegistrySearchUrl": "Live ClinicalTrials.gov intervention and country search used to recheck the dated snapshot.", "identitySourceUrl": "Primary compound, medicine, or clinical-program identity source.", "productRecordUrl": "Official national product, medicine, or regulatory record used by the country guide.", "sellerOrSupplyRecordUrl": "Official pharmacy, establishment, professional, seller, or supply record used by the country guide.", "canonicalGuideUrl": "Canonical Peptide Local page for this exact compound and destination-country verification record.", "reviewedDate": "ISO date when the published compound-country record and its source route were reviewed." }, "records": [ { "recordId": "pl-compound-country-kpv-france", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "KPV en France", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=france" }, { "recordId": "pl-compound-country-kpv-united-kingdom", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "KPV in the United Kingdom", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=united-kingdom" }, { "recordId": "pl-compound-country-kpv-germany", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "KPV in Deutschland", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=germany" }, { "recordId": "pl-compound-country-kpv-spain", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "KPV en España", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=spain" }, { "recordId": "pl-compound-country-kpv-italy", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "KPV in Italia", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=italy" }, { "recordId": "pl-compound-country-kpv-netherlands", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "KPV in Nederland", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=netherlands" }, { "recordId": "pl-compound-country-kpv-switzerland", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "KPV in Switzerland", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=switzerland" }, { "recordId": "pl-compound-country-kpv-poland", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "KPV w Polsce", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=poland" }, { "recordId": "pl-compound-country-kpv-ireland", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "KPV in Ireland", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=ireland" }, { "recordId": "pl-compound-country-kpv-portugal", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "KPV em Portugal", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=portugal" }, { "recordId": "pl-compound-country-kpv-sweden", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "KPV i Sverige", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=sweden" }, { "recordId": "pl-compound-country-kpv-turkey", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için KPV", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=turkey" }, { "recordId": "pl-compound-country-kpv-austria", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "KPV in Österreich", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=austria" }, { "recordId": "pl-compound-country-kpv-belgium", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "KPV in België", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=belgium" }, { "recordId": "pl-compound-country-kpv-denmark", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "KPV i Danmark", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=denmark" }, { "recordId": "pl-compound-country-kpv-finland", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "KPV kohteessa Suomi", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=finland" }, { "recordId": "pl-compound-country-kpv-mexico", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "KPV en México", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=mexico" }, { "recordId": "pl-compound-country-kpv-argentina", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "KPV en Argentina", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=argentina" }, { "recordId": "pl-compound-country-kpv-colombia", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "KPV en Colombia", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=colombia" }, { "recordId": "pl-compound-country-kpv-chile", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "KPV en Chile", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=chile" }, { "recordId": "pl-compound-country-kpv-brazil", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "KPV no Brasil", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=brazil" }, { "recordId": "pl-compound-country-kpv-china", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "KPV 在中国的状态与官方记录", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=china" }, { "recordId": "pl-compound-country-kpv-australia", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "KPV in Australia", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=australia" }, { "recordId": "pl-compound-country-kpv-new-zealand", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "KPV in New Zealand", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=new-zealand" }, { "recordId": "pl-compound-country-kpv-india", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "KPV in India", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=india" }, { "recordId": "pl-compound-country-kpv-japan", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のKPV", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=japan" }, { "recordId": "pl-compound-country-kpv-south-korea", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 KPV", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=south-korea" }, { "recordId": "pl-compound-country-kpv-thailand", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "KPV ในประเทศไทย", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=thailand" }, { "recordId": "pl-compound-country-kpv-indonesia", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "KPV di Indonesia", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=indonesia" }, { "recordId": "pl-compound-country-kpv-singapore", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "KPV in Singapore", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=singapore" }, { "recordId": "pl-compound-country-kpv-philippines", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "KPV in the Philippines", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=philippines" }, { "recordId": "pl-compound-country-kpv-malaysia", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "KPV in Malaysia", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=malaysia" }, { "recordId": "pl-compound-country-kpv-taiwan", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "KPV 在台灣的紀錄", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=taiwan" }, { "recordId": "pl-compound-country-kpv-hong-kong", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "KPV 在香港的紀錄", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=hong-kong" }, { "recordId": "pl-compound-country-kpv-vietnam", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "KPV tại Việt Nam", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=vietnam" }, { "recordId": "pl-compound-country-kpv-united-states", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA proposal awaiting advisory-committee discussion and final review", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "KPV in the United States", "localizedAnswer": "FDA staff proposed not adding KPV free base or KPV acetate to the 503A Bulks List, but PCAC recommended inclusion after reported 8-6-1 votes on both reviewed form questions on July 23, 2026. The advice is nonbinding, does not immediately change the list, and is not FDA approval or a final determination. FDA also states that neither form is a component of an FDA-approved drug and that it found no published human administration study.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 2, "statusEvidencePublishers": [ "U.S. Food and Drug Administration" ], "statusEvidenceUrls": [ "https://www.fda.gov/media/193346/download", "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=united-states" }, { "recordId": "pl-compound-country-kpv-canada", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "KPV in Canada", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=canada" }, { "recordId": "pl-compound-country-kpv-united-arab-emirates", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "KPV في الإمارات العربية المتحدة", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=united-arab-emirates" }, { "recordId": "pl-compound-country-kpv-saudi-arabia", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "KPV في المملكة العربية السعودية", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=saudi-arabia" }, { "recordId": "pl-compound-country-kpv-south-africa", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "KPV in South Africa", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=south-africa" }, { "recordId": "pl-compound-country-kpv-nigeria", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "KPV in Nigeria", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=nigeria" }, { "recordId": "pl-compound-country-kpv-kenya", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "KPV in Kenya", "localizedAnswer": "KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/kpv", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/kpv/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kpv&country=kenya" }, { "recordId": "pl-compound-country-bpc-157-france", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "BPC-157 en France", "localizedAnswer": "BPC-157 est suivi comme identité du marché américain de la recherche, et non comme preuve d’autorisation ou d’approvisionnement local en France. Vérifiez la catégorie exacte, l’identité juridique du vendeur et le circuit revendiqué dans les registres officiels de cette page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=france" }, { "recordId": "pl-compound-country-bpc-157-united-kingdom", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "BPC-157 in the United Kingdom", "localizedAnswer": "BPC-157 is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=united-kingdom" }, { "recordId": "pl-compound-country-bpc-157-germany", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "BPC-157 in Deutschland", "localizedAnswer": "BPC-157 wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=germany" }, { "recordId": "pl-compound-country-bpc-157-spain", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "BPC-157 en España", "localizedAnswer": "BPC-157 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=spain" }, { "recordId": "pl-compound-country-bpc-157-italy", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "BPC-157 in Italia", "localizedAnswer": "BPC-157 è seguito come identità del mercato di ricerca statunitense, non come prova di autorizzazione o fornitura locale in Italia. Confronta categoria esatta, identità giuridica del venditore e canale dichiarato con i registri ufficiali di questa pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=italy" }, { "recordId": "pl-compound-country-bpc-157-netherlands", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "BPC-157 in Nederland", "localizedAnswer": "BPC-157 wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=netherlands" }, { "recordId": "pl-compound-country-bpc-157-switzerland", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "BPC-157 in Switzerland", "localizedAnswer": "BPC-157 is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=switzerland" }, { "recordId": "pl-compound-country-bpc-157-poland", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "BPC-157 w Polsce", "localizedAnswer": "BPC-157 jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=poland" }, { "recordId": "pl-compound-country-bpc-157-ireland", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "BPC-157 in Ireland", "localizedAnswer": "BPC-157 is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=ireland" }, { "recordId": "pl-compound-country-bpc-157-portugal", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "BPC-157 em Portugal", "localizedAnswer": "BPC-157 é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=portugal" }, { "recordId": "pl-compound-country-bpc-157-sweden", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "BPC-157 i Sverige", "localizedAnswer": "BPC-157 följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=sweden" }, { "recordId": "pl-compound-country-bpc-157-turkey", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için BPC-157", "localizedAnswer": "BPC-157, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=turkey" }, { "recordId": "pl-compound-country-bpc-157-austria", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "BPC-157 in Österreich", "localizedAnswer": "BPC-157 wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=austria" }, { "recordId": "pl-compound-country-bpc-157-belgium", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "BPC-157 in België", "localizedAnswer": "BPC-157 wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=belgium" }, { "recordId": "pl-compound-country-bpc-157-denmark", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "BPC-157 i Danmark", "localizedAnswer": "BPC-157 følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=denmark" }, { "recordId": "pl-compound-country-bpc-157-finland", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "BPC-157 kohteessa Suomi", "localizedAnswer": "BPC-157 seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=finland" }, { "recordId": "pl-compound-country-bpc-157-mexico", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "BPC-157 en México", "localizedAnswer": "BPC-157 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=mexico" }, { "recordId": "pl-compound-country-bpc-157-argentina", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "BPC-157 en Argentina", "localizedAnswer": "BPC-157 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=argentina" }, { "recordId": "pl-compound-country-bpc-157-colombia", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "BPC-157 en Colombia", "localizedAnswer": "BPC-157 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=colombia" }, { "recordId": "pl-compound-country-bpc-157-chile", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research identity requiring exact Chile product and pharmacy records", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "BPC-157 en Chile", "localizedAnswer": "The attached BPC-157 identity begins with a US FDA compounding safety record, not a Chilean medicine authorization. Chile's ISP pharmaceutical-product register is the route for checking an exact product record, while its pharmacy lists answer a separate seller-authority question. No compound-specific Chile authorization finding is attached here. A same-name listing, local price, vial image, or delivery claim cannot replace those product and seller records.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 2, "statusEvidencePublishers": [ "Instituto de Salud Pública de Chile" ], "statusEvidenceUrls": [ "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=chile" }, { "recordId": "pl-compound-country-bpc-157-brazil", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "BPC-157 no Brasil", "localizedAnswer": "BPC-157 é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=brazil" }, { "recordId": "pl-compound-country-bpc-157-china", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "BPC-157 在中国的状态与官方记录", "localizedAnswer": "BPC-157在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=china" }, { "recordId": "pl-compound-country-bpc-157-australia", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "BPC-157 in Australia", "localizedAnswer": "BPC-157 is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=australia" }, { "recordId": "pl-compound-country-bpc-157-new-zealand", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "BPC-157 in New Zealand", "localizedAnswer": "BPC-157 is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=new-zealand" }, { "recordId": "pl-compound-country-bpc-157-india", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "BPC-157 in India", "localizedAnswer": "BPC-157 is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=india" }, { "recordId": "pl-compound-country-bpc-157-japan", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のBPC-157", "localizedAnswer": "BPC-157は米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=japan" }, { "recordId": "pl-compound-country-bpc-157-south-korea", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 BPC-157", "localizedAnswer": "BPC-157은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=south-korea" }, { "recordId": "pl-compound-country-bpc-157-thailand", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "BPC-157 ในประเทศไทย", "localizedAnswer": "BPC-157 ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=thailand" }, { "recordId": "pl-compound-country-bpc-157-indonesia", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "BPC-157 di Indonesia", "localizedAnswer": "BPC-157 dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=indonesia" }, { "recordId": "pl-compound-country-bpc-157-singapore", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "BPC-157 in Singapore", "localizedAnswer": "BPC-157 is tracked as a US research-market identity, not as an authorization or local supply finding for Singapore. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=singapore" }, { "recordId": "pl-compound-country-bpc-157-philippines", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "BPC-157 in the Philippines", "localizedAnswer": "BPC-157 is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=philippines" }, { "recordId": "pl-compound-country-bpc-157-malaysia", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "BPC-157 in Malaysia", "localizedAnswer": "BPC-157 is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=malaysia" }, { "recordId": "pl-compound-country-bpc-157-taiwan", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "BPC-157 在台灣的紀錄", "localizedAnswer": "BPC-157在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=taiwan" }, { "recordId": "pl-compound-country-bpc-157-hong-kong", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "BPC-157 在香港的紀錄", "localizedAnswer": "BPC-157在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=hong-kong" }, { "recordId": "pl-compound-country-bpc-157-vietnam", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "BPC-157 tại Việt Nam", "localizedAnswer": "BPC-157 được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=vietnam" }, { "recordId": "pl-compound-country-bpc-157-united-states", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "BPC-157 in the United States", "localizedAnswer": "BPC-157 is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=united-states" }, { "recordId": "pl-compound-country-bpc-157-canada", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "BPC-157 in Canada", "localizedAnswer": "BPC-157 is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=canada" }, { "recordId": "pl-compound-country-bpc-157-united-arab-emirates", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "BPC-157 في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع BPC-157 هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=united-arab-emirates" }, { "recordId": "pl-compound-country-bpc-157-saudi-arabia", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "BPC-157 في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع BPC-157 هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=saudi-arabia" }, { "recordId": "pl-compound-country-bpc-157-south-africa", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "BPC-157 in South Africa", "localizedAnswer": "BPC-157 is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=south-africa" }, { "recordId": "pl-compound-country-bpc-157-nigeria", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "BPC-157 in Nigeria", "localizedAnswer": "BPC-157 is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=nigeria" }, { "recordId": "pl-compound-country-bpc-157-kenya", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "BPC-157 in Kenya", "localizedAnswer": "BPC-157 is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/bpc-157", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/bpc-157/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=bpc-157&country=kenya" }, { "recordId": "pl-compound-country-tb-500-france", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "TB-500 en France", "localizedAnswer": "TB-500 est suivi comme identité du marché américain de la recherche, et non comme preuve d’autorisation ou d’approvisionnement local en France. Vérifiez la catégorie exacte, l’identité juridique du vendeur et le circuit revendiqué dans les registres officiels de cette page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=france" }, { "recordId": "pl-compound-country-tb-500-united-kingdom", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "TB-500 in the United Kingdom", "localizedAnswer": "TB-500 is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=united-kingdom" }, { "recordId": "pl-compound-country-tb-500-germany", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "TB-500 in Deutschland", "localizedAnswer": "TB-500 wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=germany" }, { "recordId": "pl-compound-country-tb-500-spain", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "TB-500 en España", "localizedAnswer": "TB-500 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=spain" }, { "recordId": "pl-compound-country-tb-500-italy", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "TB-500 in Italia", "localizedAnswer": "TB-500 è seguito come identità del mercato di ricerca statunitense, non come prova di autorizzazione o fornitura locale in Italia. Confronta categoria esatta, identità giuridica del venditore e canale dichiarato con i registri ufficiali di questa pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=italy" }, { "recordId": "pl-compound-country-tb-500-netherlands", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "TB-500 in Nederland", "localizedAnswer": "TB-500 wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=netherlands" }, { "recordId": "pl-compound-country-tb-500-switzerland", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "TB-500 in Switzerland", "localizedAnswer": "TB-500 is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=switzerland" }, { "recordId": "pl-compound-country-tb-500-poland", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "TB-500 w Polsce", "localizedAnswer": "TB-500 jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=poland" }, { "recordId": "pl-compound-country-tb-500-ireland", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "TB-500 in Ireland", "localizedAnswer": "TB-500 is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=ireland" }, { "recordId": "pl-compound-country-tb-500-portugal", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "TB-500 em Portugal", "localizedAnswer": "TB-500 é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=portugal" }, { "recordId": "pl-compound-country-tb-500-sweden", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "TB-500 i Sverige", "localizedAnswer": "TB-500 följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=sweden" }, { "recordId": "pl-compound-country-tb-500-turkey", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için TB-500", "localizedAnswer": "TB-500, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=turkey" }, { "recordId": "pl-compound-country-tb-500-austria", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "TB-500 in Österreich", "localizedAnswer": "TB-500 wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=austria" }, { "recordId": "pl-compound-country-tb-500-belgium", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "TB-500 in België", "localizedAnswer": "TB-500 wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=belgium" }, { "recordId": "pl-compound-country-tb-500-denmark", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "TB-500 i Danmark", "localizedAnswer": "TB-500 følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=denmark" }, { "recordId": "pl-compound-country-tb-500-finland", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "TB-500 kohteessa Suomi", "localizedAnswer": "TB-500 seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=finland" }, { "recordId": "pl-compound-country-tb-500-mexico", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "TB-500 en México", "localizedAnswer": "TB-500 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=mexico" }, { "recordId": "pl-compound-country-tb-500-argentina", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "TB-500 en Argentina", "localizedAnswer": "TB-500 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=argentina" }, { "recordId": "pl-compound-country-tb-500-colombia", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "TB-500 en Colombia", "localizedAnswer": "TB-500 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=colombia" }, { "recordId": "pl-compound-country-tb-500-chile", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "TB-500 en Chile", "localizedAnswer": "TB-500 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Chile. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=chile" }, { "recordId": "pl-compound-country-tb-500-brazil", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "TB-500 no Brasil", "localizedAnswer": "TB-500 é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=brazil" }, { "recordId": "pl-compound-country-tb-500-china", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "TB-500 在中国的状态与官方记录", "localizedAnswer": "TB-500在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=china" }, { "recordId": "pl-compound-country-tb-500-australia", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "TB-500 in Australia", "localizedAnswer": "TB-500 is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=australia" }, { "recordId": "pl-compound-country-tb-500-new-zealand", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "TB-500 in New Zealand", "localizedAnswer": "TB-500 is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=new-zealand" }, { "recordId": "pl-compound-country-tb-500-india", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "TB-500 in India", "localizedAnswer": "TB-500 is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=india" }, { "recordId": "pl-compound-country-tb-500-japan", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のTB-500", "localizedAnswer": "TB-500は米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=japan" }, { "recordId": "pl-compound-country-tb-500-south-korea", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 TB-500", "localizedAnswer": "TB-500은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=south-korea" }, { "recordId": "pl-compound-country-tb-500-thailand", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "TB-500 ในประเทศไทย", "localizedAnswer": "TB-500 ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=thailand" }, { "recordId": "pl-compound-country-tb-500-indonesia", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "TB-500 di Indonesia", "localizedAnswer": "TB-500 dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=indonesia" }, { "recordId": "pl-compound-country-tb-500-singapore", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "TB-500 in Singapore", "localizedAnswer": "TB-500 is tracked as a US research-market identity, not as an authorization or local supply finding for Singapore. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=singapore" }, { "recordId": "pl-compound-country-tb-500-philippines", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "TB-500 in the Philippines", "localizedAnswer": "TB-500 is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=philippines" }, { "recordId": "pl-compound-country-tb-500-malaysia", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "TB-500 in Malaysia", "localizedAnswer": "TB-500 is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=malaysia" }, { "recordId": "pl-compound-country-tb-500-taiwan", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "TB-500 在台灣的紀錄", "localizedAnswer": "TB-500在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=taiwan" }, { "recordId": "pl-compound-country-tb-500-hong-kong", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "TB-500 在香港的紀錄", "localizedAnswer": "TB-500在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=hong-kong" }, { "recordId": "pl-compound-country-tb-500-vietnam", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "TB-500 tại Việt Nam", "localizedAnswer": "TB-500 được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=vietnam" }, { "recordId": "pl-compound-country-tb-500-united-states", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "TB-500 in the United States", "localizedAnswer": "TB-500 is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=united-states" }, { "recordId": "pl-compound-country-tb-500-canada", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "Named in current Health Canada unauthorized peptide guidance", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "TB-500 in Canada", "localizedAnswer": "Health Canada names TB-500 among injectable peptide drugs often sold illegally and also records seized products labelled as TB-500 or thymosin beta-4. Those records concern unauthorized products and do not authenticate a different listing, seller, presentation, import route, or supply claim.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 2, "statusEvidencePublishers": [ "Health Canada" ], "statusEvidenceUrls": [ "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-bodybuilding-products.html", "https://recalls-rappels.canada.ca/en/alert-recall/unauthorized-injectable-peptide-drugs-seized-optimum-wellness-centre-calgary-alberta" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=canada" }, { "recordId": "pl-compound-country-tb-500-united-arab-emirates", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "TB-500 في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع TB-500 هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=united-arab-emirates" }, { "recordId": "pl-compound-country-tb-500-saudi-arabia", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "TB-500 في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع TB-500 هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=saudi-arabia" }, { "recordId": "pl-compound-country-tb-500-south-africa", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "Named in SAHPRA public guidance on unregistered peptide products", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "TB-500 in South Africa", "localizedAnswer": "SAHPRA names TB-500 among peptide products unlawfully marketed in South Africa and states that products intended to treat, prevent, or alter bodily functions must be registered before sale. That guidance does not authenticate a specific online listing or seller.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "South African Health Products Regulatory Authority" ], "statusEvidenceUrls": [ "https://www.sahpra.org.za/peptide-products-public-information/" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=south-africa" }, { "recordId": "pl-compound-country-tb-500-nigeria", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "TB-500 in Nigeria", "localizedAnswer": "TB-500 is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=nigeria" }, { "recordId": "pl-compound-country-tb-500-kenya", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "TB-500 in Kenya", "localizedAnswer": "TB-500 is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/tb-500", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/tb-500/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tb-500&country=kenya" }, { "recordId": "pl-compound-country-ghk-cu-france", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "GHK-Cu en France", "localizedAnswer": "GHK-Cu est suivi comme identité du marché américain de la recherche, et non comme preuve d’autorisation ou d’approvisionnement local en France. Vérifiez la catégorie exacte, l’identité juridique du vendeur et le circuit revendiqué dans les registres officiels de cette page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=france" }, { "recordId": "pl-compound-country-ghk-cu-united-kingdom", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "GHK-Cu in the United Kingdom", "localizedAnswer": "GHK-Cu is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=united-kingdom" }, { "recordId": "pl-compound-country-ghk-cu-germany", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "GHK-Cu in Deutschland", "localizedAnswer": "GHK-Cu wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=germany" }, { "recordId": "pl-compound-country-ghk-cu-spain", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "GHK-Cu en España", "localizedAnswer": "GHK-Cu se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=spain" }, { "recordId": "pl-compound-country-ghk-cu-italy", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "GHK-Cu in Italia", "localizedAnswer": "GHK-Cu è seguito come identità del mercato di ricerca statunitense, non come prova di autorizzazione o fornitura locale in Italia. Confronta categoria esatta, identità giuridica del venditore e canale dichiarato con i registri ufficiali di questa pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=italy" }, { "recordId": "pl-compound-country-ghk-cu-netherlands", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "GHK-Cu in Nederland", "localizedAnswer": "GHK-Cu wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=netherlands" }, { "recordId": "pl-compound-country-ghk-cu-switzerland", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "GHK-Cu in Switzerland", "localizedAnswer": "GHK-Cu is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=switzerland" }, { "recordId": "pl-compound-country-ghk-cu-poland", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "GHK-Cu w Polsce", "localizedAnswer": "GHK-Cu jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=poland" }, { "recordId": "pl-compound-country-ghk-cu-ireland", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "GHK-Cu in Ireland", "localizedAnswer": "GHK-Cu is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=ireland" }, { "recordId": "pl-compound-country-ghk-cu-portugal", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "GHK-Cu em Portugal", "localizedAnswer": "GHK-Cu é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=portugal" }, { "recordId": "pl-compound-country-ghk-cu-sweden", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "GHK-Cu i Sverige", "localizedAnswer": "GHK-Cu följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=sweden" }, { "recordId": "pl-compound-country-ghk-cu-turkey", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için GHK-Cu", "localizedAnswer": "GHK-Cu, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=turkey" }, { "recordId": "pl-compound-country-ghk-cu-austria", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "GHK-Cu in Österreich", "localizedAnswer": "GHK-Cu wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=austria" }, { "recordId": "pl-compound-country-ghk-cu-belgium", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "GHK-Cu in België", "localizedAnswer": "GHK-Cu wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=belgium" }, { "recordId": "pl-compound-country-ghk-cu-denmark", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "GHK-Cu i Danmark", "localizedAnswer": "GHK-Cu følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=denmark" }, { "recordId": "pl-compound-country-ghk-cu-finland", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "GHK-Cu kohteessa Suomi", "localizedAnswer": "GHK-Cu seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=finland" }, { "recordId": "pl-compound-country-ghk-cu-mexico", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "GHK-Cu en México", "localizedAnswer": "GHK-Cu se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=mexico" }, { "recordId": "pl-compound-country-ghk-cu-argentina", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "GHK-Cu en Argentina", "localizedAnswer": "GHK-Cu se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=argentina" }, { "recordId": "pl-compound-country-ghk-cu-colombia", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "GHK-Cu en Colombia", "localizedAnswer": "GHK-Cu se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=colombia" }, { "recordId": "pl-compound-country-ghk-cu-chile", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "GHK-Cu en Chile", "localizedAnswer": "GHK-Cu se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Chile. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=chile" }, { "recordId": "pl-compound-country-ghk-cu-brazil", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "GHK-Cu no Brasil", "localizedAnswer": "GHK-Cu é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=brazil" }, { "recordId": "pl-compound-country-ghk-cu-china", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "GHK-Cu 在中国的状态与官方记录", "localizedAnswer": "GHK-Cu在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=china" }, { "recordId": "pl-compound-country-ghk-cu-australia", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "GHK-Cu in Australia", "localizedAnswer": "GHK-Cu is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=australia" }, { "recordId": "pl-compound-country-ghk-cu-new-zealand", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "GHK-Cu in New Zealand", "localizedAnswer": "GHK-Cu is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=new-zealand" }, { "recordId": "pl-compound-country-ghk-cu-india", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "GHK-Cu in India", "localizedAnswer": "GHK-Cu is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=india" }, { "recordId": "pl-compound-country-ghk-cu-japan", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のGHK-Cu", "localizedAnswer": "GHK-Cuは米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=japan" }, { "recordId": "pl-compound-country-ghk-cu-south-korea", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 GHK-Cu", "localizedAnswer": "GHK-Cu은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=south-korea" }, { "recordId": "pl-compound-country-ghk-cu-thailand", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "GHK-Cu ในประเทศไทย", "localizedAnswer": "GHK-Cu ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=thailand" }, { "recordId": "pl-compound-country-ghk-cu-indonesia", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "GHK-Cu di Indonesia", "localizedAnswer": "GHK-Cu dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=indonesia" }, { "recordId": "pl-compound-country-ghk-cu-singapore", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "GHK-Cu in Singapore", "localizedAnswer": "GHK-Cu is tracked as a US research-market identity, not as an authorization or local supply finding for Singapore. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=singapore" }, { "recordId": "pl-compound-country-ghk-cu-philippines", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "GHK-Cu in the Philippines", "localizedAnswer": "GHK-Cu is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=philippines" }, { "recordId": "pl-compound-country-ghk-cu-malaysia", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "GHK-Cu in Malaysia", "localizedAnswer": "GHK-Cu is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=malaysia" }, { "recordId": "pl-compound-country-ghk-cu-taiwan", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "GHK-Cu 在台灣的紀錄", "localizedAnswer": "GHK-Cu在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=taiwan" }, { "recordId": "pl-compound-country-ghk-cu-hong-kong", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "GHK-Cu 在香港的紀錄", "localizedAnswer": "GHK-Cu在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=hong-kong" }, { "recordId": "pl-compound-country-ghk-cu-vietnam", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "GHK-Cu tại Việt Nam", "localizedAnswer": "GHK-Cu được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=vietnam" }, { "recordId": "pl-compound-country-ghk-cu-united-states", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "GHK-Cu in the United States", "localizedAnswer": "GHK-Cu is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=united-states" }, { "recordId": "pl-compound-country-ghk-cu-canada", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "Named in current Health Canada unauthorized peptide guidance", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "GHK-Cu in Canada", "localizedAnswer": "Health Canada names GHK-Cu among injectable peptide drugs often sold illegally and records GHK-Cu among unauthorized injectable products seized in Canada. Those records do not authenticate a different listing, seller, presentation, import route, or supply claim.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 2, "statusEvidencePublishers": [ "Health Canada" ], "statusEvidenceUrls": [ "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-bodybuilding-products.html", "https://recalls-rappels.canada.ca/en/alert-recall/unauthorized-injectable-peptide-drugs-seized-optimum-wellness-centre-calgary-alberta" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=canada" }, { "recordId": "pl-compound-country-ghk-cu-united-arab-emirates", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "GHK-Cu في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع GHK-Cu هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=united-arab-emirates" }, { "recordId": "pl-compound-country-ghk-cu-saudi-arabia", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "GHK-Cu في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع GHK-Cu هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=saudi-arabia" }, { "recordId": "pl-compound-country-ghk-cu-south-africa", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "GHK-Cu in South Africa", "localizedAnswer": "GHK-Cu is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=south-africa" }, { "recordId": "pl-compound-country-ghk-cu-nigeria", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "GHK-Cu in Nigeria", "localizedAnswer": "GHK-Cu is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=nigeria" }, { "recordId": "pl-compound-country-ghk-cu-kenya", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "GHK-Cu in Kenya", "localizedAnswer": "GHK-Cu is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/ghk-cu", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/ghk-cu/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ghk-cu&country=kenya" }, { "recordId": "pl-compound-country-semax-france", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Semax en France", "localizedAnswer": "Semax est suivi comme identité du marché américain de la recherche, et non comme preuve d’autorisation ou d’approvisionnement local en France. Vérifiez la catégorie exacte, l’identité juridique du vendeur et le circuit revendiqué dans les registres officiels de cette page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/semax", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=france" }, { "recordId": "pl-compound-country-semax-united-kingdom", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Semax in the United Kingdom", "localizedAnswer": "Semax is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/semax", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=united-kingdom" }, { "recordId": "pl-compound-country-semax-germany", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Semax in Deutschland", "localizedAnswer": "Semax wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/semax", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=germany" }, { "recordId": "pl-compound-country-semax-spain", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Semax en España", "localizedAnswer": "Semax se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/semax", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=spain" }, { "recordId": "pl-compound-country-semax-italy", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Semax in Italia", "localizedAnswer": "Semax è seguito come identità del mercato di ricerca statunitense, non come prova di autorizzazione o fornitura locale in Italia. Confronta categoria esatta, identità giuridica del venditore e canale dichiarato con i registri ufficiali di questa pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/semax", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=italy" }, { "recordId": "pl-compound-country-semax-netherlands", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Semax in Nederland", "localizedAnswer": "Semax wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/semax", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=netherlands" }, { "recordId": "pl-compound-country-semax-switzerland", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Semax in Switzerland", "localizedAnswer": "Semax is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/semax", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=switzerland" }, { "recordId": "pl-compound-country-semax-poland", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Semax w Polsce", "localizedAnswer": "Semax jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/semax", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=poland" }, { "recordId": "pl-compound-country-semax-ireland", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Semax in Ireland", "localizedAnswer": "Semax is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/semax", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=ireland" }, { "recordId": "pl-compound-country-semax-portugal", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Semax em Portugal", "localizedAnswer": "Semax é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/semax", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=portugal" }, { "recordId": "pl-compound-country-semax-sweden", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Semax i Sverige", "localizedAnswer": "Semax följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/semax", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=sweden" }, { "recordId": "pl-compound-country-semax-turkey", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Semax", "localizedAnswer": "Semax, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/semax", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=turkey" }, { "recordId": "pl-compound-country-semax-austria", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Semax in Österreich", "localizedAnswer": "Semax wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/semax", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=austria" }, { "recordId": "pl-compound-country-semax-belgium", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Semax in België", "localizedAnswer": "Semax wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/semax", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=belgium" }, { "recordId": "pl-compound-country-semax-denmark", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Semax i Danmark", "localizedAnswer": "Semax følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/semax", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=denmark" }, { "recordId": "pl-compound-country-semax-finland", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Semax kohteessa Suomi", "localizedAnswer": "Semax seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/semax", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=finland" }, { "recordId": "pl-compound-country-semax-mexico", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Semax en México", "localizedAnswer": "Semax se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/semax", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=mexico" }, { "recordId": "pl-compound-country-semax-argentina", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Semax en Argentina", "localizedAnswer": "Semax se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/semax", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=argentina" }, { "recordId": "pl-compound-country-semax-colombia", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Semax en Colombia", "localizedAnswer": "Semax se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/semax", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=colombia" }, { "recordId": "pl-compound-country-semax-chile", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Semax en Chile", "localizedAnswer": "Semax se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Chile. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/semax", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=chile" }, { "recordId": "pl-compound-country-semax-brazil", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Semax no Brasil", "localizedAnswer": "Semax é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/semax", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=brazil" }, { "recordId": "pl-compound-country-semax-china", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Semax 在中国的状态与官方记录", "localizedAnswer": "Semax在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/semax", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=china" }, { "recordId": "pl-compound-country-semax-australia", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Semax in Australia", "localizedAnswer": "Semax is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/semax", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=australia" }, { "recordId": "pl-compound-country-semax-new-zealand", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Semax in New Zealand", "localizedAnswer": "Semax is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/semax", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=new-zealand" }, { "recordId": "pl-compound-country-semax-india", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Semax in India", "localizedAnswer": "Semax is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/semax", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=india" }, { "recordId": "pl-compound-country-semax-japan", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のSemax / セマックス", "localizedAnswer": "Semax / セマックスは米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/semax", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=japan" }, { "recordId": "pl-compound-country-semax-south-korea", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Semax / 세맥스", "localizedAnswer": "Semax / 세맥스은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/semax", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=south-korea" }, { "recordId": "pl-compound-country-semax-thailand", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Semax ในประเทศไทย", "localizedAnswer": "Semax ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/semax", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=thailand" }, { "recordId": "pl-compound-country-semax-indonesia", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Semax di Indonesia", "localizedAnswer": "Semax dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/semax", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=indonesia" }, { "recordId": "pl-compound-country-semax-singapore", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Semax in Singapore", "localizedAnswer": "Semax is tracked as a US research-market identity, not as an authorization or local supply finding for Singapore. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/semax", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=singapore" }, { "recordId": "pl-compound-country-semax-philippines", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Semax in the Philippines", "localizedAnswer": "Semax is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/semax", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=philippines" }, { "recordId": "pl-compound-country-semax-malaysia", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Semax in Malaysia", "localizedAnswer": "Semax is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/semax", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=malaysia" }, { "recordId": "pl-compound-country-semax-taiwan", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Semax 在台灣的紀錄", "localizedAnswer": "Semax在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/semax", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=taiwan" }, { "recordId": "pl-compound-country-semax-hong-kong", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Semax 在香港的紀錄", "localizedAnswer": "Semax在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/semax", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=hong-kong" }, { "recordId": "pl-compound-country-semax-vietnam", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Semax tại Việt Nam", "localizedAnswer": "Semax được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/semax", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=vietnam" }, { "recordId": "pl-compound-country-semax-united-states", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Semax in the United States", "localizedAnswer": "Semax is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/semax", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=united-states" }, { "recordId": "pl-compound-country-semax-canada", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Semax in Canada", "localizedAnswer": "Semax is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/semax", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=canada" }, { "recordId": "pl-compound-country-semax-united-arab-emirates", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Semax / سيماكس في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع Semax / سيماكس هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/semax", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=united-arab-emirates" }, { "recordId": "pl-compound-country-semax-saudi-arabia", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Semax / سيماكس في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع Semax / سيماكس هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/semax", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=saudi-arabia" }, { "recordId": "pl-compound-country-semax-south-africa", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "Named in SAHPRA public guidance on unregistered peptide products", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Semax in South Africa", "localizedAnswer": "SAHPRA names Semax among peptide products unlawfully marketed in South Africa and states that products intended to treat, prevent, or alter bodily functions must be registered before sale. That guidance does not authenticate a specific online listing or seller.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "South African Health Products Regulatory Authority" ], "statusEvidenceUrls": [ "https://www.sahpra.org.za/peptide-products-public-information/" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/semax", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=south-africa" }, { "recordId": "pl-compound-country-semax-nigeria", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Semax in Nigeria", "localizedAnswer": "Semax is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/semax", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=nigeria" }, { "recordId": "pl-compound-country-semax-kenya", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Semax in Kenya", "localizedAnswer": "Semax is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/semax", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/semax/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semax&country=kenya" }, { "recordId": "pl-compound-country-melanotan-ii-france", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Melanotan II en France", "localizedAnswer": "Melanotan II est suivi comme identité du marché américain de la recherche, et non comme preuve d’autorisation ou d’approvisionnement local en France. Vérifiez la catégorie exacte, l’identité juridique du vendeur et le circuit revendiqué dans les registres officiels de cette page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=france" }, { "recordId": "pl-compound-country-melanotan-ii-united-kingdom", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Melanotan II in the United Kingdom", "localizedAnswer": "Melanotan II is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=united-kingdom" }, { "recordId": "pl-compound-country-melanotan-ii-germany", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Melanotan II in Deutschland", "localizedAnswer": "Melanotan II wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=germany" }, { "recordId": "pl-compound-country-melanotan-ii-spain", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Melanotan II en España", "localizedAnswer": "Melanotan II se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=spain" }, { "recordId": "pl-compound-country-melanotan-ii-italy", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity requiring an exact Italian medicine authorization record", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Melanotan II in Italia", "localizedAnswer": "This page resolves Melanotan II to the US research-market identity tracked by Peptide Local. AIFA states that a medicinal product must have marketing authorization from AIFA or the European Commission before it can be marketed in Italy. The linked search and authorization records are verification routes, not a finding that every same-name offer is lawful or unlawful. No compound-specific Italian authorization record is attached here, so the exact product, presentation, seller, supply route, and intended claim remain unresolved.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 2, "statusEvidencePublishers": [ "Italian Medicines Agency" ], "statusEvidenceUrls": [ "https://medicinali.aifa.gov.it/en/", "https://www.aifa.gov.it/en/web/guest/autorizzazione-dei-farmaci" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=italy" }, { "recordId": "pl-compound-country-melanotan-ii-netherlands", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Melanotan II in Nederland", "localizedAnswer": "Melanotan II wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=netherlands" }, { "recordId": "pl-compound-country-melanotan-ii-switzerland", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Melanotan II in Switzerland", "localizedAnswer": "Melanotan II is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=switzerland" }, { "recordId": "pl-compound-country-melanotan-ii-poland", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Melanotan II w Polsce", "localizedAnswer": "Melanotan II jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=poland" }, { "recordId": "pl-compound-country-melanotan-ii-ireland", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Melanotan II in Ireland", "localizedAnswer": "Melanotan II is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=ireland" }, { "recordId": "pl-compound-country-melanotan-ii-portugal", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Melanotan II em Portugal", "localizedAnswer": "Melanotan II é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=portugal" }, { "recordId": "pl-compound-country-melanotan-ii-sweden", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Melanotan II i Sverige", "localizedAnswer": "Melanotan II följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=sweden" }, { "recordId": "pl-compound-country-melanotan-ii-turkey", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Melanotan II", "localizedAnswer": "Melanotan II, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=turkey" }, { "recordId": "pl-compound-country-melanotan-ii-austria", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Melanotan II in Österreich", "localizedAnswer": "Melanotan II wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=austria" }, { "recordId": "pl-compound-country-melanotan-ii-belgium", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Melanotan II in België", "localizedAnswer": "Melanotan II wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=belgium" }, { "recordId": "pl-compound-country-melanotan-ii-denmark", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Melanotan II i Danmark", "localizedAnswer": "Melanotan II følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=denmark" }, { "recordId": "pl-compound-country-melanotan-ii-finland", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Melanotan II kohteessa Suomi", "localizedAnswer": "Melanotan II seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=finland" }, { "recordId": "pl-compound-country-melanotan-ii-mexico", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Melanotan II en México", "localizedAnswer": "Melanotan II se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=mexico" }, { "recordId": "pl-compound-country-melanotan-ii-argentina", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Melanotan II en Argentina", "localizedAnswer": "Melanotan II se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=argentina" }, { "recordId": "pl-compound-country-melanotan-ii-colombia", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Melanotan II en Colombia", "localizedAnswer": "Melanotan II se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=colombia" }, { "recordId": "pl-compound-country-melanotan-ii-chile", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Melanotan II en Chile", "localizedAnswer": "Melanotan II se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Chile. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=chile" }, { "recordId": "pl-compound-country-melanotan-ii-brazil", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Melanotan II no Brasil", "localizedAnswer": "Melanotan II é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=brazil" }, { "recordId": "pl-compound-country-melanotan-ii-china", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Melanotan II 在中国的状态与官方记录", "localizedAnswer": "Melanotan II在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=china" }, { "recordId": "pl-compound-country-melanotan-ii-australia", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "Prescription-only and not approved for tanning supply in Australia", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Melanotan II in Australia", "localizedAnswer": "The TGA states that Melanotan II is prescription-only in Australia, is not approved for sale or use as a tanning agent, and has no products on the Australian Register of Therapeutic Goods. A same-name listing still requires an exact product, prescription, import, seller, and supply assessment.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "Therapeutic Goods Administration" ], "statusEvidenceUrls": [ "https://www.tga.gov.au/news/media-releases/individual-issued-27-infringement-notices-allegedly-supplying-melanotan-ii" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=australia" }, { "recordId": "pl-compound-country-melanotan-ii-new-zealand", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Melanotan II in New Zealand", "localizedAnswer": "Melanotan II is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=new-zealand" }, { "recordId": "pl-compound-country-melanotan-ii-india", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Melanotan II in India", "localizedAnswer": "Melanotan II is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=india" }, { "recordId": "pl-compound-country-melanotan-ii-japan", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のMelanotan II", "localizedAnswer": "Melanotan IIは米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=japan" }, { "recordId": "pl-compound-country-melanotan-ii-south-korea", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Melanotan II", "localizedAnswer": "Melanotan II은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=south-korea" }, { "recordId": "pl-compound-country-melanotan-ii-thailand", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Melanotan II ในประเทศไทย", "localizedAnswer": "Melanotan II ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=thailand" }, { "recordId": "pl-compound-country-melanotan-ii-indonesia", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Melanotan II di Indonesia", "localizedAnswer": "Melanotan II dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=indonesia" }, { "recordId": "pl-compound-country-melanotan-ii-singapore", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Melanotan II in Singapore", "localizedAnswer": "Melanotan II is tracked as a US research-market identity, not as an authorization or local supply finding for Singapore. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=singapore" }, { "recordId": "pl-compound-country-melanotan-ii-philippines", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Melanotan II in the Philippines", "localizedAnswer": "Melanotan II is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=philippines" }, { "recordId": "pl-compound-country-melanotan-ii-malaysia", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Melanotan II in Malaysia", "localizedAnswer": "Melanotan II is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=malaysia" }, { "recordId": "pl-compound-country-melanotan-ii-taiwan", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Melanotan II 在台灣的紀錄", "localizedAnswer": "Melanotan II在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=taiwan" }, { "recordId": "pl-compound-country-melanotan-ii-hong-kong", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Melanotan II 在香港的紀錄", "localizedAnswer": "Melanotan II在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=hong-kong" }, { "recordId": "pl-compound-country-melanotan-ii-vietnam", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Melanotan II tại Việt Nam", "localizedAnswer": "Melanotan II được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=vietnam" }, { "recordId": "pl-compound-country-melanotan-ii-united-states", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Melanotan II in the United States", "localizedAnswer": "Melanotan II is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=united-states" }, { "recordId": "pl-compound-country-melanotan-ii-canada", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "Named in current Health Canada unauthorized peptide guidance", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Melanotan II in Canada", "localizedAnswer": "Health Canada names melanotan I and II among injectable peptide drugs often sold illegally and records Melanotan-2 among unauthorized products seized in Canada. Those records do not authenticate a different listing, seller, presentation, import route, or supply claim.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 2, "statusEvidencePublishers": [ "Health Canada" ], "statusEvidenceUrls": [ "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-bodybuilding-products.html", "https://recalls-rappels.canada.ca/en/alert-recall/unauthorized-injectable-peptide-drugs-seized-optimum-wellness-centre-calgary-alberta" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=canada" }, { "recordId": "pl-compound-country-melanotan-ii-united-arab-emirates", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Melanotan II / ميلانوتان 2 في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع Melanotan II / ميلانوتان 2 هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=united-arab-emirates" }, { "recordId": "pl-compound-country-melanotan-ii-saudi-arabia", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Melanotan II / ميلانوتان 2 في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع Melanotan II / ميلانوتان 2 هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=saudi-arabia" }, { "recordId": "pl-compound-country-melanotan-ii-south-africa", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "Named in SAHPRA public guidance on unregistered peptide products", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Melanotan II in South Africa", "localizedAnswer": "SAHPRA names Melanotan II among peptide products unlawfully marketed in South Africa and states that products intended to treat, prevent, or alter bodily functions must be registered before sale. That guidance does not authenticate a specific online listing or seller.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "South African Health Products Regulatory Authority" ], "statusEvidenceUrls": [ "https://www.sahpra.org.za/peptide-products-public-information/" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=south-africa" }, { "recordId": "pl-compound-country-melanotan-ii-nigeria", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Melanotan II in Nigeria", "localizedAnswer": "Melanotan II is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=nigeria" }, { "recordId": "pl-compound-country-melanotan-ii-kenya", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Melanotan II in Kenya", "localizedAnswer": "Melanotan II is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/melanotan-ii", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-ii&country=kenya" }, { "recordId": "pl-compound-country-mots-c-france", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "MOTS-c en France", "localizedAnswer": "MOTS-c est suivi comme identité du marché américain de la recherche, et non comme preuve d’autorisation ou d’approvisionnement local en France. Vérifiez la catégorie exacte, l’identité juridique du vendeur et le circuit revendiqué dans les registres officiels de cette page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=france" }, { "recordId": "pl-compound-country-mots-c-united-kingdom", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "MOTS-c in the United Kingdom", "localizedAnswer": "MOTS-c is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=united-kingdom" }, { "recordId": "pl-compound-country-mots-c-germany", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "MOTS-c in Deutschland", "localizedAnswer": "MOTS-c wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=germany" }, { "recordId": "pl-compound-country-mots-c-spain", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "MOTS-c en España", "localizedAnswer": "MOTS-c se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=spain" }, { "recordId": "pl-compound-country-mots-c-italy", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "MOTS-c in Italia", "localizedAnswer": "MOTS-c è seguito come identità del mercato di ricerca statunitense, non come prova di autorizzazione o fornitura locale in Italia. Confronta categoria esatta, identità giuridica del venditore e canale dichiarato con i registri ufficiali di questa pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=italy" }, { "recordId": "pl-compound-country-mots-c-netherlands", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "MOTS-c in Nederland", "localizedAnswer": "MOTS-c wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=netherlands" }, { "recordId": "pl-compound-country-mots-c-switzerland", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "MOTS-c in Switzerland", "localizedAnswer": "MOTS-c is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=switzerland" }, { "recordId": "pl-compound-country-mots-c-poland", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "MOTS-c w Polsce", "localizedAnswer": "MOTS-c jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=poland" }, { "recordId": "pl-compound-country-mots-c-ireland", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "MOTS-c in Ireland", "localizedAnswer": "MOTS-c is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=ireland" }, { "recordId": "pl-compound-country-mots-c-portugal", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "MOTS-c em Portugal", "localizedAnswer": "MOTS-c é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=portugal" }, { "recordId": "pl-compound-country-mots-c-sweden", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "MOTS-c i Sverige", "localizedAnswer": "MOTS-c följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=sweden" }, { "recordId": "pl-compound-country-mots-c-turkey", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için MOTS-c", "localizedAnswer": "MOTS-c, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=turkey" }, { "recordId": "pl-compound-country-mots-c-austria", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "MOTS-c in Österreich", "localizedAnswer": "MOTS-c wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=austria" }, { "recordId": "pl-compound-country-mots-c-belgium", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "MOTS-c in België", "localizedAnswer": "MOTS-c wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=belgium" }, { "recordId": "pl-compound-country-mots-c-denmark", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "MOTS-c i Danmark", "localizedAnswer": "MOTS-c følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=denmark" }, { "recordId": "pl-compound-country-mots-c-finland", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "MOTS-c kohteessa Suomi", "localizedAnswer": "MOTS-c seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=finland" }, { "recordId": "pl-compound-country-mots-c-mexico", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "MOTS-c en México", "localizedAnswer": "MOTS-c se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=mexico" }, { "recordId": "pl-compound-country-mots-c-argentina", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "MOTS-c en Argentina", "localizedAnswer": "MOTS-c se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=argentina" }, { "recordId": "pl-compound-country-mots-c-colombia", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "MOTS-c en Colombia", "localizedAnswer": "MOTS-c se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=colombia" }, { "recordId": "pl-compound-country-mots-c-chile", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "MOTS-c en Chile", "localizedAnswer": "MOTS-c se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Chile. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=chile" }, { "recordId": "pl-compound-country-mots-c-brazil", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "MOTS-c no Brasil", "localizedAnswer": "MOTS-c é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=brazil" }, { "recordId": "pl-compound-country-mots-c-china", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "MOTS-c 在中国的状态与官方记录", "localizedAnswer": "MOTS-c在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=china" }, { "recordId": "pl-compound-country-mots-c-australia", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "MOTS-c in Australia", "localizedAnswer": "MOTS-c is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=australia" }, { "recordId": "pl-compound-country-mots-c-new-zealand", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "MOTS-c in New Zealand", "localizedAnswer": "MOTS-c is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=new-zealand" }, { "recordId": "pl-compound-country-mots-c-india", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "MOTS-c in India", "localizedAnswer": "MOTS-c is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=india" }, { "recordId": "pl-compound-country-mots-c-japan", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のMOTS-c", "localizedAnswer": "MOTS-cは米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=japan" }, { "recordId": "pl-compound-country-mots-c-south-korea", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 MOTS-c", "localizedAnswer": "MOTS-c은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=south-korea" }, { "recordId": "pl-compound-country-mots-c-thailand", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "MOTS-c ในประเทศไทย", "localizedAnswer": "MOTS-c ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=thailand" }, { "recordId": "pl-compound-country-mots-c-indonesia", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "MOTS-c di Indonesia", "localizedAnswer": "MOTS-c dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=indonesia" }, { "recordId": "pl-compound-country-mots-c-singapore", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "MOTS-c in Singapore", "localizedAnswer": "MOTS-c is tracked as a US research-market identity, not as an authorization or local supply finding for Singapore. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=singapore" }, { "recordId": "pl-compound-country-mots-c-philippines", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "MOTS-c in the Philippines", "localizedAnswer": "MOTS-c is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=philippines" }, { "recordId": "pl-compound-country-mots-c-malaysia", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "MOTS-c in Malaysia", "localizedAnswer": "MOTS-c is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=malaysia" }, { "recordId": "pl-compound-country-mots-c-taiwan", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "MOTS-c 在台灣的紀錄", "localizedAnswer": "MOTS-c在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=taiwan" }, { "recordId": "pl-compound-country-mots-c-hong-kong", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "MOTS-c 在香港的紀錄", "localizedAnswer": "MOTS-c在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=hong-kong" }, { "recordId": "pl-compound-country-mots-c-vietnam", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "MOTS-c tại Việt Nam", "localizedAnswer": "MOTS-c được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=vietnam" }, { "recordId": "pl-compound-country-mots-c-united-states", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "MOTS-c in the United States", "localizedAnswer": "MOTS-c is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=united-states" }, { "recordId": "pl-compound-country-mots-c-canada", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "Named in current Health Canada unauthorized peptide guidance", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "MOTS-c in Canada", "localizedAnswer": "Health Canada names MOTS-c among examples of unauthorized injectable peptide drugs identified or seized in Canada. The record does not authenticate a different listing, seller, presentation, import route, or supply claim.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 2, "statusEvidencePublishers": [ "Health Canada" ], "statusEvidenceUrls": [ "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-bodybuilding-products.html", "https://recalls-rappels.canada.ca/en/alert-recall/think-twice-injecting-peptides-bought-online-unauthorized-products-can-seriously-harm" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=canada" }, { "recordId": "pl-compound-country-mots-c-united-arab-emirates", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "MOTS-c في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع MOTS-c هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=united-arab-emirates" }, { "recordId": "pl-compound-country-mots-c-saudi-arabia", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "MOTS-c في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع MOTS-c هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=saudi-arabia" }, { "recordId": "pl-compound-country-mots-c-south-africa", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "MOTS-c in South Africa", "localizedAnswer": "MOTS-c is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=south-africa" }, { "recordId": "pl-compound-country-mots-c-nigeria", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "MOTS-c in Nigeria", "localizedAnswer": "MOTS-c is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=nigeria" }, { "recordId": "pl-compound-country-mots-c-kenya", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "MOTS-c in Kenya", "localizedAnswer": "MOTS-c is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/mots-c", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/mots-c/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mots-c&country=kenya" }, { "recordId": "pl-compound-country-tesamorelin-france", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Tesamorelin en France", "localizedAnswer": "Tesamorelin est suivi comme identité du marché américain de la recherche, et non comme preuve d’autorisation ou d’approvisionnement local en France. Vérifiez la catégorie exacte, l’identité juridique du vendeur et le circuit revendiqué dans les registres officiels de cette page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=france" }, { "recordId": "pl-compound-country-tesamorelin-united-kingdom", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Tesamorelin in the United Kingdom", "localizedAnswer": "Tesamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=united-kingdom" }, { "recordId": "pl-compound-country-tesamorelin-germany", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Tesamorelin in Deutschland", "localizedAnswer": "Tesamorelin wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=germany" }, { "recordId": "pl-compound-country-tesamorelin-spain", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Tesamorelin en España", "localizedAnswer": "Tesamorelin se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=spain" }, { "recordId": "pl-compound-country-tesamorelin-italy", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Tesamorelin in Italia", "localizedAnswer": "Tesamorelin è seguito come identità del mercato di ricerca statunitense, non come prova di autorizzazione o fornitura locale in Italia. Confronta categoria esatta, identità giuridica del venditore e canale dichiarato con i registri ufficiali di questa pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=italy" }, { "recordId": "pl-compound-country-tesamorelin-netherlands", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Tesamorelin in Nederland", "localizedAnswer": "Tesamorelin wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=netherlands" }, { "recordId": "pl-compound-country-tesamorelin-switzerland", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Tesamorelin in Switzerland", "localizedAnswer": "Tesamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=switzerland" }, { "recordId": "pl-compound-country-tesamorelin-poland", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Tesamorelin w Polsce", "localizedAnswer": "Tesamorelin jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=poland" }, { "recordId": "pl-compound-country-tesamorelin-ireland", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Tesamorelin in Ireland", "localizedAnswer": "Tesamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=ireland" }, { "recordId": "pl-compound-country-tesamorelin-portugal", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Tesamorelin em Portugal", "localizedAnswer": "Tesamorelin é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=portugal" }, { "recordId": "pl-compound-country-tesamorelin-sweden", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Tesamorelin i Sverige", "localizedAnswer": "Tesamorelin följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=sweden" }, { "recordId": "pl-compound-country-tesamorelin-turkey", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Tesamorelin", "localizedAnswer": "Tesamorelin, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=turkey" }, { "recordId": "pl-compound-country-tesamorelin-austria", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Tesamorelin in Österreich", "localizedAnswer": "Tesamorelin wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=austria" }, { "recordId": "pl-compound-country-tesamorelin-belgium", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Tesamorelin in België", "localizedAnswer": "Tesamorelin wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=belgium" }, { "recordId": "pl-compound-country-tesamorelin-denmark", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Tesamorelin i Danmark", "localizedAnswer": "Tesamorelin følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=denmark" }, { "recordId": "pl-compound-country-tesamorelin-finland", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Tesamorelin kohteessa Suomi", "localizedAnswer": "Tesamorelin seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=finland" }, { "recordId": "pl-compound-country-tesamorelin-mexico", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Tesamorelin en México", "localizedAnswer": "Tesamorelin se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=mexico" }, { "recordId": "pl-compound-country-tesamorelin-argentina", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Tesamorelin en Argentina", "localizedAnswer": "Tesamorelin se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=argentina" }, { "recordId": "pl-compound-country-tesamorelin-colombia", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Tesamorelin en Colombia", "localizedAnswer": "Tesamorelin se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=colombia" }, { "recordId": "pl-compound-country-tesamorelin-chile", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Tesamorelin en Chile", "localizedAnswer": "Tesamorelin se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Chile. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=chile" }, { "recordId": "pl-compound-country-tesamorelin-brazil", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Tesamorelin no Brasil", "localizedAnswer": "Tesamorelin é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=brazil" }, { "recordId": "pl-compound-country-tesamorelin-china", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Tesamorelin 在中国的状态与官方记录", "localizedAnswer": "Tesamorelin在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=china" }, { "recordId": "pl-compound-country-tesamorelin-australia", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Tesamorelin in Australia", "localizedAnswer": "Tesamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=australia" }, { "recordId": "pl-compound-country-tesamorelin-new-zealand", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Tesamorelin in New Zealand", "localizedAnswer": "Tesamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=new-zealand" }, { "recordId": "pl-compound-country-tesamorelin-india", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Tesamorelin in India", "localizedAnswer": "Tesamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=india" }, { "recordId": "pl-compound-country-tesamorelin-japan", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のTesamorelin / テサモレリン", "localizedAnswer": "Tesamorelin / テサモレリンは米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=japan" }, { "recordId": "pl-compound-country-tesamorelin-south-korea", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Tesamorelin / 테사모렐린", "localizedAnswer": "Tesamorelin / 테사모렐린은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=south-korea" }, { "recordId": "pl-compound-country-tesamorelin-thailand", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Tesamorelin ในประเทศไทย", "localizedAnswer": "Tesamorelin ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=thailand" }, { "recordId": "pl-compound-country-tesamorelin-indonesia", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Tesamorelin di Indonesia", "localizedAnswer": "Tesamorelin dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=indonesia" }, { "recordId": "pl-compound-country-tesamorelin-singapore", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Tesamorelin in Singapore", "localizedAnswer": "Tesamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Singapore. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=singapore" }, { "recordId": "pl-compound-country-tesamorelin-philippines", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Tesamorelin in the Philippines", "localizedAnswer": "Tesamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=philippines" }, { "recordId": "pl-compound-country-tesamorelin-malaysia", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Tesamorelin in Malaysia", "localizedAnswer": "Tesamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=malaysia" }, { "recordId": "pl-compound-country-tesamorelin-taiwan", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Tesamorelin 在台灣的紀錄", "localizedAnswer": "Tesamorelin在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=taiwan" }, { "recordId": "pl-compound-country-tesamorelin-hong-kong", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Tesamorelin 在香港的紀錄", "localizedAnswer": "Tesamorelin在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=hong-kong" }, { "recordId": "pl-compound-country-tesamorelin-vietnam", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Tesamorelin tại Việt Nam", "localizedAnswer": "Tesamorelin được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=vietnam" }, { "recordId": "pl-compound-country-tesamorelin-united-states", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "Research listing separated from FDA-licensed EGRIFTA WR", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Tesamorelin in the United States", "localizedAnswer": "EGRIFTA WR is an FDA-licensed tesamorelin prescription product under BLA 022505, with an 11.6 mg presentation and a defined HIV-lipodystrophy indication. The 10 mg research listings tracked here are not EGRIFTA WR, do not share its label, and do not inherit its approval or supply chain.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "National Library of Medicine, DailyMed" ], "statusEvidenceUrls": [ "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=united-states" }, { "recordId": "pl-compound-country-tesamorelin-canada", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "Named in a Health Canada unauthorized product seizure", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Tesamorelin in Canada", "localizedAnswer": "Health Canada records a seller-labelled 10 mg tesamorelin product among unauthorized health products seized from a Canadian business. That record does not establish the status or identity of every tesamorelin listing, and it does not transfer the US EGRIFTA WR approval to a research vial.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "Health Canada" ], "statusEvidenceUrls": [ "https://recalls-rappels.canada.ca/en/alert-recall/unauthorized-health-products-sold-online-and-seized-rize-fitness-may-pose-serious" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=canada" }, { "recordId": "pl-compound-country-tesamorelin-united-arab-emirates", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Tesamorelin / تيساموريلين في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع Tesamorelin / تيساموريلين هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=united-arab-emirates" }, { "recordId": "pl-compound-country-tesamorelin-saudi-arabia", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Tesamorelin / تيساموريلين في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع Tesamorelin / تيساموريلين هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=saudi-arabia" }, { "recordId": "pl-compound-country-tesamorelin-south-africa", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Tesamorelin in South Africa", "localizedAnswer": "Tesamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=south-africa" }, { "recordId": "pl-compound-country-tesamorelin-nigeria", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Tesamorelin in Nigeria", "localizedAnswer": "Tesamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=nigeria" }, { "recordId": "pl-compound-country-tesamorelin-kenya", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Tesamorelin in Kenya", "localizedAnswer": "Tesamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/tesamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/tesamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tesamorelin&country=kenya" }, { "recordId": "pl-compound-country-aod-9604-france", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "AOD-9604 en France", "localizedAnswer": "AOD-9604 est suivi comme identité du marché américain de la recherche, et non comme preuve d’autorisation ou d’approvisionnement local en France. Vérifiez la catégorie exacte, l’identité juridique du vendeur et le circuit revendiqué dans les registres officiels de cette page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=france" }, { "recordId": "pl-compound-country-aod-9604-united-kingdom", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "AOD-9604 in the United Kingdom", "localizedAnswer": "AOD-9604 is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=united-kingdom" }, { "recordId": "pl-compound-country-aod-9604-germany", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "AOD-9604 in Deutschland", "localizedAnswer": "AOD-9604 wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=germany" }, { "recordId": "pl-compound-country-aod-9604-spain", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "AOD-9604 en España", "localizedAnswer": "AOD-9604 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=spain" }, { "recordId": "pl-compound-country-aod-9604-italy", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "AOD-9604 in Italia", "localizedAnswer": "AOD-9604 è seguito come identità del mercato di ricerca statunitense, non come prova di autorizzazione o fornitura locale in Italia. Confronta categoria esatta, identità giuridica del venditore e canale dichiarato con i registri ufficiali di questa pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=italy" }, { "recordId": "pl-compound-country-aod-9604-netherlands", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "AOD-9604 in Nederland", "localizedAnswer": "AOD-9604 wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=netherlands" }, { "recordId": "pl-compound-country-aod-9604-switzerland", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "AOD-9604 in Switzerland", "localizedAnswer": "AOD-9604 is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=switzerland" }, { "recordId": "pl-compound-country-aod-9604-poland", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "AOD-9604 w Polsce", "localizedAnswer": "AOD-9604 jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=poland" }, { "recordId": "pl-compound-country-aod-9604-ireland", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "AOD-9604 in Ireland", "localizedAnswer": "AOD-9604 is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=ireland" }, { "recordId": "pl-compound-country-aod-9604-portugal", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "AOD-9604 em Portugal", "localizedAnswer": "AOD-9604 é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=portugal" }, { "recordId": "pl-compound-country-aod-9604-sweden", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "AOD-9604 i Sverige", "localizedAnswer": "AOD-9604 följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=sweden" }, { "recordId": "pl-compound-country-aod-9604-turkey", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için AOD-9604", "localizedAnswer": "AOD-9604, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=turkey" }, { "recordId": "pl-compound-country-aod-9604-austria", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "AOD-9604 in Österreich", "localizedAnswer": "AOD-9604 wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=austria" }, { "recordId": "pl-compound-country-aod-9604-belgium", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "AOD-9604 in België", "localizedAnswer": "AOD-9604 wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=belgium" }, { "recordId": "pl-compound-country-aod-9604-denmark", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "AOD-9604 i Danmark", "localizedAnswer": "AOD-9604 følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=denmark" }, { "recordId": "pl-compound-country-aod-9604-finland", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "AOD-9604 kohteessa Suomi", "localizedAnswer": "AOD-9604 seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=finland" }, { "recordId": "pl-compound-country-aod-9604-mexico", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "AOD-9604 en México", "localizedAnswer": "AOD-9604 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=mexico" }, { "recordId": "pl-compound-country-aod-9604-argentina", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "AOD-9604 en Argentina", "localizedAnswer": "AOD-9604 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=argentina" }, { "recordId": "pl-compound-country-aod-9604-colombia", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "AOD-9604 en Colombia", "localizedAnswer": "AOD-9604 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=colombia" }, { "recordId": "pl-compound-country-aod-9604-chile", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "AOD-9604 en Chile", "localizedAnswer": "AOD-9604 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Chile. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=chile" }, { "recordId": "pl-compound-country-aod-9604-brazil", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "AOD-9604 no Brasil", "localizedAnswer": "AOD-9604 é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=brazil" }, { "recordId": "pl-compound-country-aod-9604-china", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "AOD-9604 在中国的状态与官方记录", "localizedAnswer": "AOD-9604在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=china" }, { "recordId": "pl-compound-country-aod-9604-australia", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "AOD-9604 in Australia", "localizedAnswer": "AOD-9604 is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=australia" }, { "recordId": "pl-compound-country-aod-9604-new-zealand", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "AOD-9604 in New Zealand", "localizedAnswer": "AOD-9604 is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=new-zealand" }, { "recordId": "pl-compound-country-aod-9604-india", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "AOD-9604 in India", "localizedAnswer": "AOD-9604 is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=india" }, { "recordId": "pl-compound-country-aod-9604-japan", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のAOD-9604", "localizedAnswer": "AOD-9604は米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=japan" }, { "recordId": "pl-compound-country-aod-9604-south-korea", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 AOD-9604", "localizedAnswer": "AOD-9604은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=south-korea" }, { "recordId": "pl-compound-country-aod-9604-thailand", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "AOD-9604 ในประเทศไทย", "localizedAnswer": "AOD-9604 ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=thailand" }, { "recordId": "pl-compound-country-aod-9604-indonesia", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "AOD-9604 di Indonesia", "localizedAnswer": "AOD-9604 dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=indonesia" }, { "recordId": "pl-compound-country-aod-9604-singapore", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "AOD-9604 in Singapore", "localizedAnswer": "AOD-9604 is tracked as a US research-market identity, not as an authorization or local supply finding for Singapore. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=singapore" }, { "recordId": "pl-compound-country-aod-9604-philippines", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "AOD-9604 in the Philippines", "localizedAnswer": "AOD-9604 is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=philippines" }, { "recordId": "pl-compound-country-aod-9604-malaysia", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "AOD-9604 in Malaysia", "localizedAnswer": "AOD-9604 is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=malaysia" }, { "recordId": "pl-compound-country-aod-9604-taiwan", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "AOD-9604 在台灣的紀錄", "localizedAnswer": "AOD-9604在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=taiwan" }, { "recordId": "pl-compound-country-aod-9604-hong-kong", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "AOD-9604 在香港的紀錄", "localizedAnswer": "AOD-9604在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=hong-kong" }, { "recordId": "pl-compound-country-aod-9604-vietnam", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "AOD-9604 tại Việt Nam", "localizedAnswer": "AOD-9604 được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=vietnam" }, { "recordId": "pl-compound-country-aod-9604-united-states", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "Research listing separated from failed oral trials and the 0 to 12 503A vote", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "AOD-9604 in the United States", "localizedAnswer": "FDA states that AOD-9604 free base and acetate are not components of an approved drug. The largest oral obesity study failed to show a statistically significant weight-loss difference, and the 2024 advisory committee voted 0 to 12 on placing the two forms on the 503A Bulks List. A public 5 mg research vial listing is not an approved product or the historical oral trial formulation.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 2, "statusEvidencePublishers": [ "U.S. Food and Drug Administration" ], "statusEvidenceUrls": [ "https://www.fda.gov/media/183584/download", "https://www.fda.gov/media/185642/download" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=united-states" }, { "recordId": "pl-compound-country-aod-9604-canada", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "Named in a Health Canada unauthorized product seizure", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "AOD-9604 in Canada", "localizedAnswer": "Health Canada records a seller-labelled 5 mg AOD-9604 product among unauthorized injectable peptide products seized from a Canadian business. That finding does not authenticate or determine the status of a different listing, seller, presentation, or supply route.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "Health Canada" ], "statusEvidenceUrls": [ "https://recalls-rappels.canada.ca/en/alert-recall/unauthorized-health-products-sold-online-and-seized-rize-fitness-may-pose-serious" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=canada" }, { "recordId": "pl-compound-country-aod-9604-united-arab-emirates", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "AOD-9604 في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع AOD-9604 هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=united-arab-emirates" }, { "recordId": "pl-compound-country-aod-9604-saudi-arabia", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "AOD-9604 في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع AOD-9604 هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=saudi-arabia" }, { "recordId": "pl-compound-country-aod-9604-south-africa", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "Named in SAHPRA public guidance on unregistered peptide products", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "AOD-9604 in South Africa", "localizedAnswer": "SAHPRA names AOD-9604 among peptide products unlawfully marketed in South Africa and states that products intended to treat, prevent, or alter bodily functions must be registered before sale. That guidance does not authenticate a specific online listing or seller.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "South African Health Products Regulatory Authority" ], "statusEvidenceUrls": [ "https://www.sahpra.org.za/peptide-products-public-information/" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=south-africa" }, { "recordId": "pl-compound-country-aod-9604-nigeria", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "AOD-9604 in Nigeria", "localizedAnswer": "AOD-9604 is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=nigeria" }, { "recordId": "pl-compound-country-aod-9604-kenya", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "AOD-9604 in Kenya", "localizedAnswer": "AOD-9604 is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/aod-9604", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/aod-9604/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=aod-9604&country=kenya" }, { "recordId": "pl-compound-country-ipamorelin-france", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Ipamorelin en France", "localizedAnswer": "Ipamorelin est suivi comme identité du marché américain de la recherche, et non comme preuve d’autorisation ou d’approvisionnement local en France. Vérifiez la catégorie exacte, l’identité juridique du vendeur et le circuit revendiqué dans les registres officiels de cette page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=france" }, { "recordId": "pl-compound-country-ipamorelin-united-kingdom", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Ipamorelin in the United Kingdom", "localizedAnswer": "Ipamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=united-kingdom" }, { "recordId": "pl-compound-country-ipamorelin-germany", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Ipamorelin in Deutschland", "localizedAnswer": "Ipamorelin wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=germany" }, { "recordId": "pl-compound-country-ipamorelin-spain", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Ipamorelin en España", "localizedAnswer": "Ipamorelin se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=spain" }, { "recordId": "pl-compound-country-ipamorelin-italy", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Ipamorelin in Italia", "localizedAnswer": "Ipamorelin è seguito come identità del mercato di ricerca statunitense, non come prova di autorizzazione o fornitura locale in Italia. Confronta categoria esatta, identità giuridica del venditore e canale dichiarato con i registri ufficiali di questa pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=italy" }, { "recordId": "pl-compound-country-ipamorelin-netherlands", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Ipamorelin in Nederland", "localizedAnswer": "Ipamorelin wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=netherlands" }, { "recordId": "pl-compound-country-ipamorelin-switzerland", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Ipamorelin in Switzerland", "localizedAnswer": "Ipamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=switzerland" }, { "recordId": "pl-compound-country-ipamorelin-poland", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Ipamorelin w Polsce", "localizedAnswer": "Ipamorelin jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=poland" }, { "recordId": "pl-compound-country-ipamorelin-ireland", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Ipamorelin in Ireland", "localizedAnswer": "Ipamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=ireland" }, { "recordId": "pl-compound-country-ipamorelin-portugal", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Ipamorelin em Portugal", "localizedAnswer": "Ipamorelin é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=portugal" }, { "recordId": "pl-compound-country-ipamorelin-sweden", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Ipamorelin i Sverige", "localizedAnswer": "Ipamorelin följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=sweden" }, { "recordId": "pl-compound-country-ipamorelin-turkey", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Ipamorelin", "localizedAnswer": "Ipamorelin, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=turkey" }, { "recordId": "pl-compound-country-ipamorelin-austria", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Ipamorelin in Österreich", "localizedAnswer": "Ipamorelin wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=austria" }, { "recordId": "pl-compound-country-ipamorelin-belgium", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Ipamorelin in België", "localizedAnswer": "Ipamorelin wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=belgium" }, { "recordId": "pl-compound-country-ipamorelin-denmark", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Ipamorelin i Danmark", "localizedAnswer": "Ipamorelin følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=denmark" }, { "recordId": "pl-compound-country-ipamorelin-finland", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Ipamorelin kohteessa Suomi", "localizedAnswer": "Ipamorelin seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=finland" }, { "recordId": "pl-compound-country-ipamorelin-mexico", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Ipamorelin en México", "localizedAnswer": "Ipamorelin se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=mexico" }, { "recordId": "pl-compound-country-ipamorelin-argentina", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Ipamorelin en Argentina", "localizedAnswer": "Ipamorelin se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=argentina" }, { "recordId": "pl-compound-country-ipamorelin-colombia", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Ipamorelin en Colombia", "localizedAnswer": "Ipamorelin se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=colombia" }, { "recordId": "pl-compound-country-ipamorelin-chile", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Ipamorelin en Chile", "localizedAnswer": "Ipamorelin se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Chile. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=chile" }, { "recordId": "pl-compound-country-ipamorelin-brazil", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Ipamorelin no Brasil", "localizedAnswer": "Ipamorelin é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=brazil" }, { "recordId": "pl-compound-country-ipamorelin-china", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Ipamorelin 在中国的状态与官方记录", "localizedAnswer": "Ipamorelin在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=china" }, { "recordId": "pl-compound-country-ipamorelin-australia", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Ipamorelin in Australia", "localizedAnswer": "Ipamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=australia" }, { "recordId": "pl-compound-country-ipamorelin-new-zealand", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Ipamorelin in New Zealand", "localizedAnswer": "Ipamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=new-zealand" }, { "recordId": "pl-compound-country-ipamorelin-india", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Ipamorelin in India", "localizedAnswer": "Ipamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=india" }, { "recordId": "pl-compound-country-ipamorelin-japan", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のIpamorelin / イパモレリン", "localizedAnswer": "Ipamorelin / イパモレリンは米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=japan" }, { "recordId": "pl-compound-country-ipamorelin-south-korea", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Ipamorelin / 이파모렐린", "localizedAnswer": "Ipamorelin / 이파모렐린은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=south-korea" }, { "recordId": "pl-compound-country-ipamorelin-thailand", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Ipamorelin ในประเทศไทย", "localizedAnswer": "Ipamorelin ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=thailand" }, { "recordId": "pl-compound-country-ipamorelin-indonesia", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Ipamorelin di Indonesia", "localizedAnswer": "Ipamorelin dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=indonesia" }, { "recordId": "pl-compound-country-ipamorelin-singapore", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Ipamorelin in Singapore", "localizedAnswer": "Ipamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Singapore. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=singapore" }, { "recordId": "pl-compound-country-ipamorelin-philippines", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Ipamorelin in the Philippines", "localizedAnswer": "Ipamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=philippines" }, { "recordId": "pl-compound-country-ipamorelin-malaysia", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Ipamorelin in Malaysia", "localizedAnswer": "Ipamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=malaysia" }, { "recordId": "pl-compound-country-ipamorelin-taiwan", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Ipamorelin 在台灣的紀錄", "localizedAnswer": "Ipamorelin在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=taiwan" }, { "recordId": "pl-compound-country-ipamorelin-hong-kong", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Ipamorelin 在香港的紀錄", "localizedAnswer": "Ipamorelin在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=hong-kong" }, { "recordId": "pl-compound-country-ipamorelin-vietnam", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Ipamorelin tại Việt Nam", "localizedAnswer": "Ipamorelin được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=vietnam" }, { "recordId": "pl-compound-country-ipamorelin-united-states", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Ipamorelin in the United States", "localizedAnswer": "Ipamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=united-states" }, { "recordId": "pl-compound-country-ipamorelin-canada", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "Named in current Health Canada unauthorized peptide guidance", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Ipamorelin in Canada", "localizedAnswer": "Health Canada names ipamorelin among examples of unauthorized injectable peptide drugs identified or seized in Canada. The record does not authenticate a different listing, seller, presentation, import route, or supply claim.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 2, "statusEvidencePublishers": [ "Health Canada" ], "statusEvidenceUrls": [ "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-bodybuilding-products.html", "https://recalls-rappels.canada.ca/en/alert-recall/think-twice-injecting-peptides-bought-online-unauthorized-products-can-seriously-harm" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=canada" }, { "recordId": "pl-compound-country-ipamorelin-united-arab-emirates", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Ipamorelin / إيباموريلين في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع Ipamorelin / إيباموريلين هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=united-arab-emirates" }, { "recordId": "pl-compound-country-ipamorelin-saudi-arabia", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Ipamorelin / إيباموريلين في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع Ipamorelin / إيباموريلين هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=saudi-arabia" }, { "recordId": "pl-compound-country-ipamorelin-south-africa", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "Named in SAHPRA public guidance on unregistered peptide products", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Ipamorelin in South Africa", "localizedAnswer": "SAHPRA names ipamorelin among peptide products unlawfully marketed in South Africa and states that products intended to treat, prevent, or alter bodily functions must be registered before sale. That guidance does not authenticate a specific online listing or seller.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "South African Health Products Regulatory Authority" ], "statusEvidenceUrls": [ "https://www.sahpra.org.za/peptide-products-public-information/" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=south-africa" }, { "recordId": "pl-compound-country-ipamorelin-nigeria", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Ipamorelin in Nigeria", "localizedAnswer": "Ipamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=nigeria" }, { "recordId": "pl-compound-country-ipamorelin-kenya", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Ipamorelin in Kenya", "localizedAnswer": "Ipamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/ipamorelin", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/ipamorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ipamorelin&country=kenya" }, { "recordId": "pl-compound-country-selank-france", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Selank en France", "localizedAnswer": "Selank est suivi comme identité du marché américain de la recherche, et non comme preuve d’autorisation ou d’approvisionnement local en France. Vérifiez la catégorie exacte, l’identité juridique du vendeur et le circuit revendiqué dans les registres officiels de cette page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/selank", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=france" }, { "recordId": "pl-compound-country-selank-united-kingdom", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Selank in the United Kingdom", "localizedAnswer": "Selank is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/selank", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=united-kingdom" }, { "recordId": "pl-compound-country-selank-germany", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Selank in Deutschland", "localizedAnswer": "Selank wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/selank", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=germany" }, { "recordId": "pl-compound-country-selank-spain", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Selank en España", "localizedAnswer": "Selank se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/selank", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=spain" }, { "recordId": "pl-compound-country-selank-italy", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Selank in Italia", "localizedAnswer": "Selank è seguito come identità del mercato di ricerca statunitense, non come prova di autorizzazione o fornitura locale in Italia. Confronta categoria esatta, identità giuridica del venditore e canale dichiarato con i registri ufficiali di questa pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/selank", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=italy" }, { "recordId": "pl-compound-country-selank-netherlands", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Selank in Nederland", "localizedAnswer": "Selank wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/selank", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=netherlands" }, { "recordId": "pl-compound-country-selank-switzerland", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Selank in Switzerland", "localizedAnswer": "Selank is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/selank", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=switzerland" }, { "recordId": "pl-compound-country-selank-poland", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Selank w Polsce", "localizedAnswer": "Selank jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/selank", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=poland" }, { "recordId": "pl-compound-country-selank-ireland", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Selank in Ireland", "localizedAnswer": "Selank is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/selank", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=ireland" }, { "recordId": "pl-compound-country-selank-portugal", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Selank em Portugal", "localizedAnswer": "Selank é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/selank", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=portugal" }, { "recordId": "pl-compound-country-selank-sweden", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Selank i Sverige", "localizedAnswer": "Selank följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/selank", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=sweden" }, { "recordId": "pl-compound-country-selank-turkey", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Selank", "localizedAnswer": "Selank, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/selank", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=turkey" }, { "recordId": "pl-compound-country-selank-austria", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Selank in Österreich", "localizedAnswer": "Selank wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/selank", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=austria" }, { "recordId": "pl-compound-country-selank-belgium", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Selank in België", "localizedAnswer": "Selank wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/selank", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=belgium" }, { "recordId": "pl-compound-country-selank-denmark", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Selank i Danmark", "localizedAnswer": "Selank følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/selank", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=denmark" }, { "recordId": "pl-compound-country-selank-finland", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Selank kohteessa Suomi", "localizedAnswer": "Selank seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/selank", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=finland" }, { "recordId": "pl-compound-country-selank-mexico", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Selank en México", "localizedAnswer": "Selank se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/selank", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=mexico" }, { "recordId": "pl-compound-country-selank-argentina", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Selank en Argentina", "localizedAnswer": "Selank se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/selank", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=argentina" }, { "recordId": "pl-compound-country-selank-colombia", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Selank en Colombia", "localizedAnswer": "Selank se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/selank", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=colombia" }, { "recordId": "pl-compound-country-selank-chile", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Selank en Chile", "localizedAnswer": "Selank se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Chile. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/selank", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=chile" }, { "recordId": "pl-compound-country-selank-brazil", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Selank no Brasil", "localizedAnswer": "Selank é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/selank", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=brazil" }, { "recordId": "pl-compound-country-selank-china", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Selank 在中国的状态与官方记录", "localizedAnswer": "Selank在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/selank", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=china" }, { "recordId": "pl-compound-country-selank-australia", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Selank in Australia", "localizedAnswer": "Selank is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/selank", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=australia" }, { "recordId": "pl-compound-country-selank-new-zealand", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Selank in New Zealand", "localizedAnswer": "Selank is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/selank", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=new-zealand" }, { "recordId": "pl-compound-country-selank-india", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Selank in India", "localizedAnswer": "Selank is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/selank", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=india" }, { "recordId": "pl-compound-country-selank-japan", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のSelank / セランク", "localizedAnswer": "Selank / セランクは米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/selank", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=japan" }, { "recordId": "pl-compound-country-selank-south-korea", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Selank / 셀랑크", "localizedAnswer": "Selank / 셀랑크은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/selank", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=south-korea" }, { "recordId": "pl-compound-country-selank-thailand", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Selank ในประเทศไทย", "localizedAnswer": "Selank ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/selank", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=thailand" }, { "recordId": "pl-compound-country-selank-indonesia", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Selank di Indonesia", "localizedAnswer": "Selank dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/selank", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=indonesia" }, { "recordId": "pl-compound-country-selank-singapore", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Selank in Singapore", "localizedAnswer": "Selank is tracked as a US research-market identity, not as an authorization or local supply finding for Singapore. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/selank", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=singapore" }, { "recordId": "pl-compound-country-selank-philippines", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Selank in the Philippines", "localizedAnswer": "Selank is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/selank", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=philippines" }, { "recordId": "pl-compound-country-selank-malaysia", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Selank in Malaysia", "localizedAnswer": "Selank is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/selank", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=malaysia" }, { "recordId": "pl-compound-country-selank-taiwan", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Selank 在台灣的紀錄", "localizedAnswer": "Selank在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/selank", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=taiwan" }, { "recordId": "pl-compound-country-selank-hong-kong", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Selank 在香港的紀錄", "localizedAnswer": "Selank在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/selank", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=hong-kong" }, { "recordId": "pl-compound-country-selank-vietnam", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Selank tại Việt Nam", "localizedAnswer": "Selank được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/selank", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=vietnam" }, { "recordId": "pl-compound-country-selank-united-states", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Selank in the United States", "localizedAnswer": "Selank is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/selank", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=united-states" }, { "recordId": "pl-compound-country-selank-canada", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Selank in Canada", "localizedAnswer": "Selank is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/selank", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=canada" }, { "recordId": "pl-compound-country-selank-united-arab-emirates", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Selank / سيلانك في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع Selank / سيلانك هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/selank", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=united-arab-emirates" }, { "recordId": "pl-compound-country-selank-saudi-arabia", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Selank / سيلانك في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع Selank / سيلانك هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/selank", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=saudi-arabia" }, { "recordId": "pl-compound-country-selank-south-africa", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "Named in SAHPRA public guidance on unregistered peptide products", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Selank in South Africa", "localizedAnswer": "SAHPRA names Selank among peptide products unlawfully marketed in South Africa and states that products intended to treat, prevent, or alter bodily functions must be registered before sale. That guidance does not authenticate a specific online listing or seller.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "South African Health Products Regulatory Authority" ], "statusEvidenceUrls": [ "https://www.sahpra.org.za/peptide-products-public-information/" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/selank", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=south-africa" }, { "recordId": "pl-compound-country-selank-nigeria", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Selank in Nigeria", "localizedAnswer": "Selank is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/selank", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=nigeria" }, { "recordId": "pl-compound-country-selank-kenya", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Selank in Kenya", "localizedAnswer": "Selank is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/selank", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/selank/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=selank&country=kenya" }, { "recordId": "pl-compound-country-pt-141-france", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "PT-141 / Bremelanotide en France", "localizedAnswer": "PT-141 / Bremelanotide est suivi comme identité du marché américain de la recherche, et non comme preuve d’autorisation ou d’approvisionnement local en France. Vérifiez la catégorie exacte, l’identité juridique du vendeur et le circuit revendiqué dans les registres officiels de cette page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=france" }, { "recordId": "pl-compound-country-pt-141-united-kingdom", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "PT-141 / Bremelanotide in the United Kingdom", "localizedAnswer": "PT-141 / Bremelanotide is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=united-kingdom" }, { "recordId": "pl-compound-country-pt-141-germany", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "PT-141 / Bremelanotide in Deutschland", "localizedAnswer": "PT-141 / Bremelanotide wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=germany" }, { "recordId": "pl-compound-country-pt-141-spain", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "PT-141 / Bremelanotide en España", "localizedAnswer": "PT-141 / Bremelanotide se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=spain" }, { "recordId": "pl-compound-country-pt-141-italy", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "Research listing separated from medicine authorization requirements in Italy", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "PT-141 / Bremelanotide in Italia", "localizedAnswer": "The 10 mg PT-141 research listings tracked here are not the US VYLEESI prescription product and do not inherit its FDA approval. AIFA states that a medicinal product must have marketing authorization from AIFA or the European Commission before it can be marketed in Italy. The linked Italian records must be searched for the exact product and presentation. They do not establish that a same-name online vial is authorized, available, lawful, or equivalent to VYLEESI.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 2, "statusEvidencePublishers": [ "Italian Medicines Agency" ], "statusEvidenceUrls": [ "https://medicinali.aifa.gov.it/en/", "https://www.aifa.gov.it/en/web/guest/autorizzazione-dei-farmaci" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=italy" }, { "recordId": "pl-compound-country-pt-141-netherlands", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "PT-141 / Bremelanotide in Nederland", "localizedAnswer": "PT-141 / Bremelanotide wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=netherlands" }, { "recordId": "pl-compound-country-pt-141-switzerland", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "PT-141 / Bremelanotide in Switzerland", "localizedAnswer": "PT-141 / Bremelanotide is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=switzerland" }, { "recordId": "pl-compound-country-pt-141-poland", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "PT-141 / Bremelanotide w Polsce", "localizedAnswer": "PT-141 / Bremelanotide jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=poland" }, { "recordId": "pl-compound-country-pt-141-ireland", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "PT-141 / Bremelanotide in Ireland", "localizedAnswer": "PT-141 / Bremelanotide is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=ireland" }, { "recordId": "pl-compound-country-pt-141-portugal", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "PT-141 / Bremelanotide em Portugal", "localizedAnswer": "PT-141 / Bremelanotide é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=portugal" }, { "recordId": "pl-compound-country-pt-141-sweden", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "PT-141 / Bremelanotide i Sverige", "localizedAnswer": "PT-141 / Bremelanotide följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=sweden" }, { "recordId": "pl-compound-country-pt-141-turkey", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için PT-141 / Bremelanotide", "localizedAnswer": "PT-141 / Bremelanotide, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=turkey" }, { "recordId": "pl-compound-country-pt-141-austria", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "PT-141 / Bremelanotide in Österreich", "localizedAnswer": "PT-141 / Bremelanotide wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=austria" }, { "recordId": "pl-compound-country-pt-141-belgium", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "PT-141 / Bremelanotide in België", "localizedAnswer": "PT-141 / Bremelanotide wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=belgium" }, { "recordId": "pl-compound-country-pt-141-denmark", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "PT-141 / Bremelanotide i Danmark", "localizedAnswer": "PT-141 / Bremelanotide følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=denmark" }, { "recordId": "pl-compound-country-pt-141-finland", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "PT-141 / Bremelanotide kohteessa Suomi", "localizedAnswer": "PT-141 / Bremelanotide seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=finland" }, { "recordId": "pl-compound-country-pt-141-mexico", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "PT-141 / Bremelanotide en México", "localizedAnswer": "PT-141 / Bremelanotide se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=mexico" }, { "recordId": "pl-compound-country-pt-141-argentina", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "PT-141 / Bremelanotide en Argentina", "localizedAnswer": "PT-141 / Bremelanotide se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=argentina" }, { "recordId": "pl-compound-country-pt-141-colombia", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "PT-141 / Bremelanotide en Colombia", "localizedAnswer": "PT-141 / Bremelanotide se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=colombia" }, { "recordId": "pl-compound-country-pt-141-chile", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "PT-141 / Bremelanotide en Chile", "localizedAnswer": "PT-141 / Bremelanotide se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Chile. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=chile" }, { "recordId": "pl-compound-country-pt-141-brazil", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "PT-141 / Bremelanotide no Brasil", "localizedAnswer": "PT-141 / Bremelanotide é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=brazil" }, { "recordId": "pl-compound-country-pt-141-china", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "PT-141 / Bremelanotide 在中国的状态与官方记录", "localizedAnswer": "PT-141 / Bremelanotide在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=china" }, { "recordId": "pl-compound-country-pt-141-australia", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "PT-141 / Bremelanotide in Australia", "localizedAnswer": "PT-141 / Bremelanotide is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=australia" }, { "recordId": "pl-compound-country-pt-141-new-zealand", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "PT-141 / Bremelanotide in New Zealand", "localizedAnswer": "PT-141 / Bremelanotide is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=new-zealand" }, { "recordId": "pl-compound-country-pt-141-india", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "PT-141 / Bremelanotide in India", "localizedAnswer": "PT-141 / Bremelanotide is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=india" }, { "recordId": "pl-compound-country-pt-141-japan", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のPT-141 / Bremelanotide", "localizedAnswer": "PT-141 / Bremelanotideは米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=japan" }, { "recordId": "pl-compound-country-pt-141-south-korea", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 PT-141 / Bremelanotide", "localizedAnswer": "PT-141 / Bremelanotide은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=south-korea" }, { "recordId": "pl-compound-country-pt-141-thailand", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "PT-141 / Bremelanotide ในประเทศไทย", "localizedAnswer": "PT-141 / Bremelanotide ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=thailand" }, { "recordId": "pl-compound-country-pt-141-indonesia", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "PT-141 / Bremelanotide di Indonesia", "localizedAnswer": "PT-141 / Bremelanotide dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=indonesia" }, { "recordId": "pl-compound-country-pt-141-singapore", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "PT-141 / Bremelanotide in Singapore", "localizedAnswer": "PT-141 / Bremelanotide is tracked as a US research-market identity, not as an authorization or local supply finding for Singapore. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=singapore" }, { "recordId": "pl-compound-country-pt-141-philippines", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "PT-141 / Bremelanotide in the Philippines", "localizedAnswer": "PT-141 / Bremelanotide is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=philippines" }, { "recordId": "pl-compound-country-pt-141-malaysia", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "PT-141 / Bremelanotide in Malaysia", "localizedAnswer": "PT-141 / Bremelanotide is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=malaysia" }, { "recordId": "pl-compound-country-pt-141-taiwan", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "PT-141 / Bremelanotide 在台灣的紀錄", "localizedAnswer": "PT-141 / Bremelanotide在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=taiwan" }, { "recordId": "pl-compound-country-pt-141-hong-kong", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "PT-141 / Bremelanotide 在香港的紀錄", "localizedAnswer": "PT-141 / Bremelanotide在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=hong-kong" }, { "recordId": "pl-compound-country-pt-141-vietnam", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "PT-141 / Bremelanotide tại Việt Nam", "localizedAnswer": "PT-141 / Bremelanotide được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=vietnam" }, { "recordId": "pl-compound-country-pt-141-united-states", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "Research listing separated from FDA-approved VYLEESI", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "PT-141 / Bremelanotide in the United States", "localizedAnswer": "VYLEESI is an FDA-approved bremelanotide prescription product under NDA 210557 with a 1.75 mg autoinjector presentation and product-specific label. The 10 mg PT-141 research listings tracked here are not VYLEESI and do not inherit its approval or regulated supply chain.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "National Library of Medicine, DailyMed" ], "statusEvidenceUrls": [ "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=united-states" }, { "recordId": "pl-compound-country-pt-141-canada", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "Named in a Health Canada unauthorized product seizure", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "PT-141 / Bremelanotide in Canada", "localizedAnswer": "Health Canada records PT-141 among unauthorized injectable peptide products seized in Calgary. That record does not authenticate every same-name listing and does not transfer the identity or approval of the US VYLEESI prescription product to a research vial.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "Health Canada" ], "statusEvidenceUrls": [ "https://recalls-rappels.canada.ca/en/alert-recall/unauthorized-injectable-peptide-drugs-seized-optimum-wellness-centre-calgary-alberta" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=canada" }, { "recordId": "pl-compound-country-pt-141-united-arab-emirates", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "PT-141 / بريميلانوتايد في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع PT-141 / بريميلانوتايد هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=united-arab-emirates" }, { "recordId": "pl-compound-country-pt-141-saudi-arabia", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "PT-141 / بريميلانوتايد في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع PT-141 / بريميلانوتايد هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=saudi-arabia" }, { "recordId": "pl-compound-country-pt-141-south-africa", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "Named in SAHPRA public guidance on unregistered peptide products", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "PT-141 / Bremelanotide in South Africa", "localizedAnswer": "SAHPRA names PT-141 among peptide products unlawfully marketed in South Africa and states that products intended to treat, prevent, or alter bodily functions must be registered before sale. That guidance does not authenticate a specific online listing or seller.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "South African Health Products Regulatory Authority" ], "statusEvidenceUrls": [ "https://www.sahpra.org.za/peptide-products-public-information/" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=south-africa" }, { "recordId": "pl-compound-country-pt-141-nigeria", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "PT-141 / Bremelanotide in Nigeria", "localizedAnswer": "PT-141 / Bremelanotide is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=nigeria" }, { "recordId": "pl-compound-country-pt-141-kenya", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "PT-141 / Bremelanotide in Kenya", "localizedAnswer": "PT-141 / Bremelanotide is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/pt-141", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/pt-141/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pt-141&country=kenya" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-france", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "CJC-1295 no DAC en France", "localizedAnswer": "CJC-1295 no DAC est suivi comme identité du marché américain de la recherche, et non comme preuve d’autorisation ou d’approvisionnement local en France. Vérifiez la catégorie exacte, l’identité juridique du vendeur et le circuit revendiqué dans les registres officiels de cette page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=france" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-united-kingdom", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "CJC-1295 no DAC in the United Kingdom", "localizedAnswer": "CJC-1295 no DAC is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=united-kingdom" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-germany", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "CJC-1295 no DAC in Deutschland", "localizedAnswer": "CJC-1295 no DAC wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=germany" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-spain", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "CJC-1295 no DAC en España", "localizedAnswer": "CJC-1295 no DAC se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=spain" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-italy", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "CJC-1295 no DAC in Italia", "localizedAnswer": "CJC-1295 no DAC è seguito come identità del mercato di ricerca statunitense, non come prova di autorizzazione o fornitura locale in Italia. Confronta categoria esatta, identità giuridica del venditore e canale dichiarato con i registri ufficiali di questa pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=italy" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-netherlands", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "CJC-1295 no DAC in Nederland", "localizedAnswer": "CJC-1295 no DAC wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=netherlands" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-switzerland", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "CJC-1295 no DAC in Switzerland", "localizedAnswer": "CJC-1295 no DAC is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=switzerland" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-poland", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "CJC-1295 no DAC w Polsce", "localizedAnswer": "CJC-1295 no DAC jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=poland" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-ireland", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "CJC-1295 no DAC in Ireland", "localizedAnswer": "CJC-1295 no DAC is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=ireland" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-portugal", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "CJC-1295 no DAC em Portugal", "localizedAnswer": "CJC-1295 no DAC é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=portugal" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-sweden", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "CJC-1295 no DAC i Sverige", "localizedAnswer": "CJC-1295 no DAC följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=sweden" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-turkey", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için CJC-1295 no DAC", "localizedAnswer": "CJC-1295 no DAC, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=turkey" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-austria", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "CJC-1295 no DAC in Österreich", "localizedAnswer": "CJC-1295 no DAC wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=austria" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-belgium", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "CJC-1295 no DAC in België", "localizedAnswer": "CJC-1295 no DAC wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=belgium" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-denmark", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "CJC-1295 no DAC i Danmark", "localizedAnswer": "CJC-1295 no DAC følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=denmark" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-finland", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "CJC-1295 no DAC kohteessa Suomi", "localizedAnswer": "CJC-1295 no DAC seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=finland" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-mexico", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "CJC-1295 no DAC en México", "localizedAnswer": "CJC-1295 no DAC se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=mexico" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-argentina", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "CJC-1295 no DAC en Argentina", "localizedAnswer": "CJC-1295 no DAC se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=argentina" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-colombia", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "CJC-1295 no DAC en Colombia", "localizedAnswer": "CJC-1295 no DAC se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=colombia" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-chile", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "CJC-1295 no DAC en Chile", "localizedAnswer": "CJC-1295 no DAC se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Chile. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=chile" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-brazil", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "CJC-1295 no DAC no Brasil", "localizedAnswer": "CJC-1295 no DAC é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=brazil" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-china", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "CJC-1295 no DAC 在中国的状态与官方记录", "localizedAnswer": "CJC-1295 no DAC在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=china" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-australia", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "CJC-1295 no DAC in Australia", "localizedAnswer": "CJC-1295 no DAC is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=australia" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-new-zealand", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "CJC-1295 no DAC in New Zealand", "localizedAnswer": "CJC-1295 no DAC is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=new-zealand" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-india", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "CJC-1295 no DAC in India", "localizedAnswer": "CJC-1295 no DAC is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=india" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-japan", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のCJC-1295 no DAC", "localizedAnswer": "CJC-1295 no DACは米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=japan" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-south-korea", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 CJC-1295 no DAC", "localizedAnswer": "CJC-1295 no DAC은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=south-korea" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-thailand", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "CJC-1295 no DAC ในประเทศไทย", "localizedAnswer": "CJC-1295 no DAC ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=thailand" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-indonesia", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "CJC-1295 no DAC di Indonesia", "localizedAnswer": "CJC-1295 no DAC dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=indonesia" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-singapore", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "CJC-1295 no DAC in Singapore", "localizedAnswer": "CJC-1295 no DAC is tracked as a US research-market identity, not as an authorization or local supply finding for Singapore. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=singapore" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-philippines", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "CJC-1295 no DAC in the Philippines", "localizedAnswer": "CJC-1295 no DAC is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=philippines" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-malaysia", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "CJC-1295 no DAC in Malaysia", "localizedAnswer": "CJC-1295 no DAC is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=malaysia" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-taiwan", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "CJC-1295 no DAC 在台灣的紀錄", "localizedAnswer": "CJC-1295 no DAC在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=taiwan" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-hong-kong", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "CJC-1295 no DAC 在香港的紀錄", "localizedAnswer": "CJC-1295 no DAC在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=hong-kong" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-vietnam", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "CJC-1295 no DAC tại Việt Nam", "localizedAnswer": "CJC-1295 no DAC được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=vietnam" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-united-states", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "CJC-1295 no DAC in the United States", "localizedAnswer": "CJC-1295 no DAC is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=united-states" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-canada", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "Named in current Health Canada unauthorized peptide guidance", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "CJC-1295 no DAC in Canada", "localizedAnswer": "Health Canada names CJC-1295 among examples of unauthorized injectable peptide drugs identified or seized in Canada. The Canadian records do not resolve a seller's DAC versus no-DAC format. The record does not authenticate a different listing, seller, presentation, import route, or supply claim.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 2, "statusEvidencePublishers": [ "Health Canada" ], "statusEvidenceUrls": [ "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-bodybuilding-products.html", "https://recalls-rappels.canada.ca/en/alert-recall/think-twice-injecting-peptides-bought-online-unauthorized-products-can-seriously-harm" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=canada" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-united-arab-emirates", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "CJC-1295 دون DAC في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع CJC-1295 دون DAC هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=united-arab-emirates" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-saudi-arabia", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "CJC-1295 دون DAC في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع CJC-1295 دون DAC هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=saudi-arabia" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-south-africa", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "Named in SAHPRA public guidance on unregistered peptide products", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "CJC-1295 no DAC in South Africa", "localizedAnswer": "SAHPRA names CJC-1295 among peptide products unlawfully marketed in South Africa and states that products intended to treat, prevent, or alter bodily functions must be registered before sale. That guidance does not authenticate a specific online listing or seller.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "South African Health Products Regulatory Authority" ], "statusEvidenceUrls": [ "https://www.sahpra.org.za/peptide-products-public-information/" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=south-africa" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-nigeria", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "CJC-1295 no DAC in Nigeria", "localizedAnswer": "CJC-1295 no DAC is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=nigeria" }, { "recordId": "pl-compound-country-cjc-1295-no-dac-kenya", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "CJC-1295 no DAC in Kenya", "localizedAnswer": "CJC-1295 no DAC is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/cjc-1295-no-dac", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-no-dac&country=kenya" }, { "recordId": "pl-compound-country-cjc-1295-dac-france", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity requiring exact French product and seller records", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "CJC-1295 DAC en France", "localizedAnswer": "This record resolves seller-labelled CJC-1295 with DAC to a US research-market identity. France's public medicine database and authorized online-pharmacy directory are the relevant verification routes for an exact medicinal product and seller. Those directories do not turn a same-name research vial, local-language listing, or imported product into authorized French supply. No compound-specific French authorization finding is attached here, so product identity, presentation, seller authority, prescription status, and supply remain unresolved.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 2, "statusEvidencePublishers": [ "French Ministry of Health", "French Chamber of Pharmacists" ], "statusEvidenceUrls": [ "https://base-donnees-publique.medicaments.gouv.fr/", "https://www.ordre.pharmacien.fr/je-suis/patient-grand-public/rechercher-un-site-de-vente-en-ligne-habilite-a-vendre-des-medicaments" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=france" }, { "recordId": "pl-compound-country-cjc-1295-dac-united-kingdom", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "CJC-1295 DAC in the United Kingdom", "localizedAnswer": "CJC-1295 DAC is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=united-kingdom" }, { "recordId": "pl-compound-country-cjc-1295-dac-germany", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "CJC-1295 DAC in Deutschland", "localizedAnswer": "CJC-1295 DAC wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=germany" }, { "recordId": "pl-compound-country-cjc-1295-dac-spain", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "CJC-1295 DAC en España", "localizedAnswer": "CJC-1295 DAC se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=spain" }, { "recordId": "pl-compound-country-cjc-1295-dac-italy", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "CJC-1295 DAC in Italia", "localizedAnswer": "CJC-1295 DAC è seguito come identità del mercato di ricerca statunitense, non come prova di autorizzazione o fornitura locale in Italia. Confronta categoria esatta, identità giuridica del venditore e canale dichiarato con i registri ufficiali di questa pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=italy" }, { "recordId": "pl-compound-country-cjc-1295-dac-netherlands", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "CJC-1295 DAC in Nederland", "localizedAnswer": "CJC-1295 DAC wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=netherlands" }, { "recordId": "pl-compound-country-cjc-1295-dac-switzerland", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "CJC-1295 DAC in Switzerland", "localizedAnswer": "CJC-1295 DAC is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=switzerland" }, { "recordId": "pl-compound-country-cjc-1295-dac-poland", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "CJC-1295 DAC w Polsce", "localizedAnswer": "CJC-1295 DAC jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=poland" }, { "recordId": "pl-compound-country-cjc-1295-dac-ireland", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "CJC-1295 DAC in Ireland", "localizedAnswer": "CJC-1295 DAC is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=ireland" }, { "recordId": "pl-compound-country-cjc-1295-dac-portugal", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "CJC-1295 DAC em Portugal", "localizedAnswer": "CJC-1295 DAC é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=portugal" }, { "recordId": "pl-compound-country-cjc-1295-dac-sweden", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "CJC-1295 DAC i Sverige", "localizedAnswer": "CJC-1295 DAC följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=sweden" }, { "recordId": "pl-compound-country-cjc-1295-dac-turkey", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için CJC-1295 DAC", "localizedAnswer": "CJC-1295 DAC, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=turkey" }, { "recordId": "pl-compound-country-cjc-1295-dac-austria", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "CJC-1295 DAC in Österreich", "localizedAnswer": "CJC-1295 DAC wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=austria" }, { "recordId": "pl-compound-country-cjc-1295-dac-belgium", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "CJC-1295 DAC in België", "localizedAnswer": "CJC-1295 DAC wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=belgium" }, { "recordId": "pl-compound-country-cjc-1295-dac-denmark", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "CJC-1295 DAC i Danmark", "localizedAnswer": "CJC-1295 DAC følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=denmark" }, { "recordId": "pl-compound-country-cjc-1295-dac-finland", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "CJC-1295 DAC kohteessa Suomi", "localizedAnswer": "CJC-1295 DAC seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=finland" }, { "recordId": "pl-compound-country-cjc-1295-dac-mexico", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "CJC-1295 DAC en México", "localizedAnswer": "CJC-1295 DAC se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=mexico" }, { "recordId": "pl-compound-country-cjc-1295-dac-argentina", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "CJC-1295 DAC en Argentina", "localizedAnswer": "CJC-1295 DAC se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=argentina" }, { "recordId": "pl-compound-country-cjc-1295-dac-colombia", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "CJC-1295 DAC en Colombia", "localizedAnswer": "CJC-1295 DAC se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=colombia" }, { "recordId": "pl-compound-country-cjc-1295-dac-chile", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "CJC-1295 DAC en Chile", "localizedAnswer": "CJC-1295 DAC se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Chile. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=chile" }, { "recordId": "pl-compound-country-cjc-1295-dac-brazil", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "CJC-1295 DAC no Brasil", "localizedAnswer": "CJC-1295 DAC é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=brazil" }, { "recordId": "pl-compound-country-cjc-1295-dac-china", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "CJC-1295 DAC 在中国的状态与官方记录", "localizedAnswer": "CJC-1295 DAC在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=china" }, { "recordId": "pl-compound-country-cjc-1295-dac-australia", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "CJC-1295 DAC in Australia", "localizedAnswer": "CJC-1295 DAC is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=australia" }, { "recordId": "pl-compound-country-cjc-1295-dac-new-zealand", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "CJC-1295 DAC in New Zealand", "localizedAnswer": "CJC-1295 DAC is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=new-zealand" }, { "recordId": "pl-compound-country-cjc-1295-dac-india", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "CJC-1295 DAC in India", "localizedAnswer": "CJC-1295 DAC is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=india" }, { "recordId": "pl-compound-country-cjc-1295-dac-japan", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のCJC-1295 DAC", "localizedAnswer": "CJC-1295 DACは米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=japan" }, { "recordId": "pl-compound-country-cjc-1295-dac-south-korea", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 CJC-1295 DAC", "localizedAnswer": "CJC-1295 DAC은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=south-korea" }, { "recordId": "pl-compound-country-cjc-1295-dac-thailand", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "CJC-1295 DAC ในประเทศไทย", "localizedAnswer": "CJC-1295 DAC ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=thailand" }, { "recordId": "pl-compound-country-cjc-1295-dac-indonesia", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "CJC-1295 DAC di Indonesia", "localizedAnswer": "CJC-1295 DAC dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=indonesia" }, { "recordId": "pl-compound-country-cjc-1295-dac-singapore", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "CJC-1295 DAC in Singapore", "localizedAnswer": "CJC-1295 DAC is tracked as a US research-market identity, not as an authorization or local supply finding for Singapore. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=singapore" }, { "recordId": "pl-compound-country-cjc-1295-dac-philippines", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "CJC-1295 DAC in the Philippines", "localizedAnswer": "CJC-1295 DAC is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=philippines" }, { "recordId": "pl-compound-country-cjc-1295-dac-malaysia", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "CJC-1295 DAC in Malaysia", "localizedAnswer": "CJC-1295 DAC is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=malaysia" }, { "recordId": "pl-compound-country-cjc-1295-dac-taiwan", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "CJC-1295 DAC 在台灣的紀錄", "localizedAnswer": "CJC-1295 DAC在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=taiwan" }, { "recordId": "pl-compound-country-cjc-1295-dac-hong-kong", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "CJC-1295 DAC 在香港的紀錄", "localizedAnswer": "CJC-1295 DAC在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=hong-kong" }, { "recordId": "pl-compound-country-cjc-1295-dac-vietnam", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "CJC-1295 DAC tại Việt Nam", "localizedAnswer": "CJC-1295 DAC được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=vietnam" }, { "recordId": "pl-compound-country-cjc-1295-dac-united-states", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "CJC-1295 DAC in the United States", "localizedAnswer": "CJC-1295 DAC is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=united-states" }, { "recordId": "pl-compound-country-cjc-1295-dac-canada", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "Named in current Health Canada unauthorized peptide guidance", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "CJC-1295 DAC in Canada", "localizedAnswer": "Health Canada names CJC-1295 among examples of unauthorized injectable peptide drugs identified or seized in Canada. The Canadian records do not resolve a seller's DAC versus no-DAC format. The record does not authenticate a different listing, seller, presentation, import route, or supply claim.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 2, "statusEvidencePublishers": [ "Health Canada" ], "statusEvidenceUrls": [ "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-bodybuilding-products.html", "https://recalls-rappels.canada.ca/en/alert-recall/think-twice-injecting-peptides-bought-online-unauthorized-products-can-seriously-harm" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=canada" }, { "recordId": "pl-compound-country-cjc-1295-dac-united-arab-emirates", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "CJC-1295 مع DAC في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع CJC-1295 مع DAC هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=united-arab-emirates" }, { "recordId": "pl-compound-country-cjc-1295-dac-saudi-arabia", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "CJC-1295 مع DAC في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع CJC-1295 مع DAC هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=saudi-arabia" }, { "recordId": "pl-compound-country-cjc-1295-dac-south-africa", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "Named in SAHPRA public guidance on unregistered peptide products", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "CJC-1295 DAC in South Africa", "localizedAnswer": "SAHPRA names CJC-1295 among peptide products unlawfully marketed in South Africa and states that products intended to treat, prevent, or alter bodily functions must be registered before sale. That guidance does not authenticate a specific online listing or seller.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "South African Health Products Regulatory Authority" ], "statusEvidenceUrls": [ "https://www.sahpra.org.za/peptide-products-public-information/" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=south-africa" }, { "recordId": "pl-compound-country-cjc-1295-dac-nigeria", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "CJC-1295 DAC in Nigeria", "localizedAnswer": "CJC-1295 DAC is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=nigeria" }, { "recordId": "pl-compound-country-cjc-1295-dac-kenya", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "CJC-1295 DAC in Kenya", "localizedAnswer": "CJC-1295 DAC is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/cjc-1295-dac", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cjc-1295-dac&country=kenya" }, { "recordId": "pl-compound-country-retatrutide-france", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Retatrutide en France", "localizedAnswer": "Retatrutide est un programme clinique expérimental. Aucune offre commerciale en France ne peut reprendre automatiquement l’identité clinique, les résultats d’essais ou le statut réglementaire du promoteur. Vérifiez chaque produit et fournisseur dans les registres ci-dessous.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "France", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 33, "clinicalTrialRecruitingLocations": 14, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028", "NCT06383390" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT06383390" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=France#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=France", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=france" }, { "recordId": "pl-compound-country-retatrutide-united-kingdom", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Retatrutide in the United Kingdom", "localizedAnswer": "Retatrutide is an investigational clinical program. No seller listing in the United Kingdom can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "United Kingdom", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 8, "clinicalTrialListedLocations": 87, "clinicalTrialRecruitingLocations": 12, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028", "NCT06297603", "NCT06383390", "NCT05929066", "NCT07232719", "NCT06859268", "NCT05931367", "NCT05936151" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT06297603", "https://clinicaltrials.gov/study/NCT06383390", "https://clinicaltrials.gov/study/NCT05929066", "https://clinicaltrials.gov/study/NCT07232719", "https://clinicaltrials.gov/study/NCT06859268", "https://clinicaltrials.gov/study/NCT05931367", "https://clinicaltrials.gov/study/NCT05936151" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=United%20Kingdom#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=United%20Kingdom", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=united-kingdom" }, { "recordId": "pl-compound-country-retatrutide-germany", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Retatrutide in Deutschland", "localizedAnswer": "Retatrutide ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Deutschland übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Germany", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 4, "clinicalTrialListedLocations": 48, "clinicalTrialRecruitingLocations": 7, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028", "NCT06383390", "NCT06662383", "NCT06982859" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT06383390", "https://clinicaltrials.gov/study/NCT06662383", "https://clinicaltrials.gov/study/NCT06982859" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Germany#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Germany", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=germany" }, { "recordId": "pl-compound-country-retatrutide-spain", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Retatrutide / retatrutida en España", "localizedAnswer": "Retatrutide / retatrutida es un programa clínico en investigación. Ninguna oferta comercial en España puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Spain", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 7, "clinicalTrialListedLocations": 65, "clinicalTrialRecruitingLocations": 12, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028", "NCT06383390", "NCT05929066", "NCT05882045", "NCT05929079", "NCT05931367", "NCT05936151" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT06383390", "https://clinicaltrials.gov/study/NCT05929066", "https://clinicaltrials.gov/study/NCT05882045", "https://clinicaltrials.gov/study/NCT05929079", "https://clinicaltrials.gov/study/NCT05931367", "https://clinicaltrials.gov/study/NCT05936151" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Spain#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Spain", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=spain" }, { "recordId": "pl-compound-country-retatrutide-italy", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Retatrutide in Italia", "localizedAnswer": "Retatrutide è un programma clinico sperimentale. Nessuna offerta commerciale in Italia può ereditare l’identità clinica, i risultati degli studi o lo stato regolatorio dello sponsor. Verifica ogni prodotto e fornitore nei registri riportati sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Italy", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 29, "clinicalTrialRecruitingLocations": 5, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028", "NCT06383390", "NCT05936151" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT06383390", "https://clinicaltrials.gov/study/NCT05936151" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Italy#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Italy", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=italy" }, { "recordId": "pl-compound-country-retatrutide-netherlands", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Retatrutide in Nederland", "localizedAnswer": "Retatrutide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in Nederland neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Netherlands", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 35, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07165028", "NCT06383390" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT06383390" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Netherlands#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Netherlands", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=netherlands" }, { "recordId": "pl-compound-country-retatrutide-switzerland", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Retatrutide in Switzerland", "localizedAnswer": "Retatrutide is an investigational clinical program. No seller listing in Switzerland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Switzerland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 3, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07165028" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Switzerland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Switzerland", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=switzerland" }, { "recordId": "pl-compound-country-retatrutide-poland", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Retatrutide w Polsce", "localizedAnswer": "Retatrutide jest eksperymentalnym programem klinicznym. Żadna oferta handlowa w Polsce nie przejmuje automatycznie tożsamości klinicznej, wyników badań ani statusu regulacyjnego sponsora. Sprawdź każdy produkt i dostawcę w rejestrach poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Poland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 6, "clinicalTrialListedLocations": 67, "clinicalTrialRecruitingLocations": 13, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028", "NCT07035093", "NCT06383390", "NCT06662383", "NCT05929066", "NCT05882045" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT07035093", "https://clinicaltrials.gov/study/NCT06383390", "https://clinicaltrials.gov/study/NCT06662383", "https://clinicaltrials.gov/study/NCT05929066", "https://clinicaltrials.gov/study/NCT05882045" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Poland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Poland", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=poland" }, { "recordId": "pl-compound-country-retatrutide-ireland", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Retatrutide in Ireland", "localizedAnswer": "Retatrutide is an investigational clinical program. No seller listing in Ireland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Ireland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Ireland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Ireland", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=ireland" }, { "recordId": "pl-compound-country-retatrutide-portugal", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Retatrutide / retatrutida em Portugal", "localizedAnswer": "Retatrutide / retatrutida é um programa clínico experimental. Nenhuma oferta comercial em Portugal pode herdar a identidade clínica, os resultados de ensaios ou o estatuto regulamentar do promotor. Verifique cada produto e fornecedor nos registos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Portugal", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 2, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07165028" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Portugal#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Portugal", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=portugal" }, { "recordId": "pl-compound-country-retatrutide-sweden", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Retatrutide i Sverige", "localizedAnswer": "Retatrutide är ett kliniskt prövningsprogram. Inget kommersiellt erbjudande i Sverige kan automatiskt ärva sponsorns kliniska identitet, studieresultat eller regulatoriska status. Kontrollera varje produkt och leverantör i registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Sweden", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 2, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07165028" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Sweden#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Sweden", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=sweden" }, { "recordId": "pl-compound-country-retatrutide-turkey", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Retatrutide / retatrutid", "localizedAnswer": "Retatrutide / retatrutid klinik geliştirme aşamasındaki bir programdır. Türkiye içindeki aynı adlı hiçbir ticari teklif sponsorun klinik kimliğini, çalışma sonuçlarını veya düzenleyici statüsünü otomatik olarak devralamaz. Belirli ürünü, ruhsat sahibini, kuruluşu ve tedarik yolunu aşağıdaki resmi hedef ülke kayıtlarında kontrol edin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Turkey (Türkiye)", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 29, "clinicalTrialRecruitingLocations": 6, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028", "NCT06383390" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT06383390" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Turkey%20(T%C3%BCrkiye)#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Turkey%20(T%C3%BCrkiye)", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=turkey" }, { "recordId": "pl-compound-country-retatrutide-austria", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Retatrutide in Österreich", "localizedAnswer": "Retatrutide ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Österreich übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Austria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 18, "clinicalTrialRecruitingLocations": 4, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028", "NCT06383390", "NCT06982846" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT06383390", "https://clinicaltrials.gov/study/NCT06982846" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Austria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Austria", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=austria" }, { "recordId": "pl-compound-country-retatrutide-belgium", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Retatrutide in België", "localizedAnswer": "Retatrutide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in België neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Belgium", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 32, "clinicalTrialRecruitingLocations": 3, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028", "NCT06383390" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT06383390" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Belgium#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Belgium", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=belgium" }, { "recordId": "pl-compound-country-retatrutide-denmark", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Retatrutide / retatrutid i Danmark", "localizedAnswer": "Retatrutide / retatrutid er et klinisk udviklingsprogram. Et kommercielt tilbud med samme navn i Danmark arver ikke sponsorens kliniske identitet, forsøgsresultater eller regulatoriske status. Kontrollér det konkrete produkt, tilladelsesindehaveren, virksomheden og forsyningsvejen i de officielle registre for destinationen nedenfor.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Denmark", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 6, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT06383390" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06383390" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Denmark#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Denmark", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=denmark" }, { "recordId": "pl-compound-country-retatrutide-finland", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Retatrutide / retatrutidi kohteessa Suomi", "localizedAnswer": "Retatrutide / retatrutidi on kliininen kehitysohjelma. Samanniminen kaupallinen tarjous kohteessa Suomi ei peri sponsorin kliinistä identiteettiä, tutkimustuloksia tai sääntelyasemaa. Tarkista täsmällinen tuote, luvanhaltija, toimija ja toimitusreitti alla olevista kohdemaan virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Finland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Finland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Finland", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=finland" }, { "recordId": "pl-compound-country-retatrutide-mexico", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Retatrutide / retatrutida en México", "localizedAnswer": "Retatrutide / retatrutida es un programa clínico en investigación. Ninguna oferta comercial en México puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Mexico", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 9, "clinicalTrialListedLocations": 131, "clinicalTrialRecruitingLocations": 6, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028", "NCT06297603", "NCT06383390", "NCT05929066", "NCT05882045", "NCT05929079", "NCT06260722", "NCT06354660", "NCT05931367" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT06297603", "https://clinicaltrials.gov/study/NCT06383390", "https://clinicaltrials.gov/study/NCT05929066", "https://clinicaltrials.gov/study/NCT05882045", "https://clinicaltrials.gov/study/NCT05929079", "https://clinicaltrials.gov/study/NCT06260722", "https://clinicaltrials.gov/study/NCT06354660", "https://clinicaltrials.gov/study/NCT05931367" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Mexico#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Mexico", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=mexico" }, { "recordId": "pl-compound-country-retatrutide-argentina", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program requiring an exact ANMAT medicine record", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Retatrutide / retatrutida en Argentina", "localizedAnswer": "Retatrutide remains an investigational Lilly clinical program and is not a commercial product merely because a seller uses the name. ANMAT's medicine services are the official route for checking an exact medicine, authorization holder, presentation, market status, and related safety records in Argentina. This page does not treat the absence of an attached compound-specific result as proof of a blanket legal status. Any offer still requires an exact ANMAT product record and a verified seller and supply path.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "Argentina National Administration of Drugs, Foods and Medical Devices" ], "statusEvidenceUrls": [ "https://www.argentina.gob.ar/anmat/regulados/medicamentos" ], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Argentina", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 9, "clinicalTrialListedLocations": 156, "clinicalTrialRecruitingLocations": 17, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028", "NCT07035093", "NCT06297603", "NCT06383390", "NCT06662383", "NCT07357415", "NCT05882045", "NCT05929079", "NCT06260722" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT07035093", "https://clinicaltrials.gov/study/NCT06297603", "https://clinicaltrials.gov/study/NCT06383390", "https://clinicaltrials.gov/study/NCT06662383", "https://clinicaltrials.gov/study/NCT07357415", "https://clinicaltrials.gov/study/NCT05882045", "https://clinicaltrials.gov/study/NCT05929079", "https://clinicaltrials.gov/study/NCT06260722" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Argentina#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Argentina", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=argentina" }, { "recordId": "pl-compound-country-retatrutide-colombia", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Retatrutide / retatrutida en Colombia", "localizedAnswer": "Retatrutide / retatrutida es un programa clínico en investigación. Ninguna oferta comercial en Colombia puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Colombia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Colombia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Colombia", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=colombia" }, { "recordId": "pl-compound-country-retatrutide-chile", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Retatrutide / retatrutida en Chile", "localizedAnswer": "Retatrutide / retatrutida es un programa clínico en investigación. Ninguna oferta comercial en Chile puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Chile", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Chile#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Chile", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=chile" }, { "recordId": "pl-compound-country-retatrutide-brazil", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Retatrutide / retatrutida no Brasil", "localizedAnswer": "Retatrutide / retatrutida é um programa clínico experimental. Nenhuma oferta comercial no Brasil pode herdar a identidade clínica, os resultados de ensaios ou o status regulatório do patrocinador. Verifique cada produto e fornecedor nos registros abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Brazil", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 87, "clinicalTrialRecruitingLocations": 23, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028", "NCT06297603", "NCT06383390", "NCT05929066", "NCT05929079" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT06297603", "https://clinicaltrials.gov/study/NCT06383390", "https://clinicaltrials.gov/study/NCT05929066", "https://clinicaltrials.gov/study/NCT05929079" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Brazil#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Brazil", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=brazil" }, { "recordId": "pl-compound-country-retatrutide-china", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Retatrutide / 瑞他鲁肽 在中国的状态与官方记录", "localizedAnswer": "Retatrutide / 瑞他鲁肽在此对应一个临床与监管项目。项目在某一国家的试验、批准或公司公告，不能自动证明同名商品在中国获批、可得或由有资质的卖方提供。请分别核对目的地的具体药品记录、批准持有人、剂型规格、经营主体和供应路径，并保持临床证据与在线商品身份相互独立。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "China", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 43, "clinicalTrialRecruitingLocations": 40, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07165028", "NCT07467447", "NCT05548231" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT07467447", "https://clinicaltrials.gov/study/NCT05548231" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=China#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=China", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=china" }, { "recordId": "pl-compound-country-retatrutide-australia", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Retatrutide in Australia", "localizedAnswer": "Retatrutide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Australia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 6, "clinicalTrialListedLocations": 78, "clinicalTrialRecruitingLocations": 15, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028", "NCT06383390", "NCT05929066", "NCT05882045", "NCT05929079", "NCT05931367" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT06383390", "https://clinicaltrials.gov/study/NCT05929066", "https://clinicaltrials.gov/study/NCT05882045", "https://clinicaltrials.gov/study/NCT05929079", "https://clinicaltrials.gov/study/NCT05931367" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Australia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Australia", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=australia" }, { "recordId": "pl-compound-country-retatrutide-new-zealand", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Retatrutide in New Zealand", "localizedAnswer": "Retatrutide is an investigational clinical program. No seller listing in New Zealand can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "New Zealand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 12, "clinicalTrialRecruitingLocations": 1, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028", "NCT06383390" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT06383390" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=New%20Zealand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=New%20Zealand", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=new-zealand" }, { "recordId": "pl-compound-country-retatrutide-india", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Retatrutide in India", "localizedAnswer": "Retatrutide is an investigational clinical program. No seller listing in India can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "India", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 75, "clinicalTrialRecruitingLocations": 10, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028", "NCT06383390", "NCT05929066", "NCT05929079", "NCT06354660" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT06383390", "https://clinicaltrials.gov/study/NCT05929066", "https://clinicaltrials.gov/study/NCT05929079", "https://clinicaltrials.gov/study/NCT06354660" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=India#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=India", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=india" }, { "recordId": "pl-compound-country-retatrutide-japan", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のRetatrutide / レタトルチド", "localizedAnswer": "Retatrutide / レタトルチドは臨床開発中のプログラムです。スポンサーの臨床上の同一性、試験結果、規制上の位置付けを、日本の同名オンライン商品や販売者が自動的に引き継ぐことはありません。目的地の製品、承認保持者、施設、供給経路を下記の公的記録で確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Japan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 69, "clinicalTrialRecruitingLocations": 65, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028", "NCT04823208" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT04823208" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Japan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Japan", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=japan" }, { "recordId": "pl-compound-country-retatrutide-south-korea", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Not approved or available for public use; verify Korea product and provider records", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Retatrutide / 레타트루타이드", "localizedAnswer": "Lilly states that retatrutide has not been approved by any regulatory agency, is not available for public use, and is legally available only through Lilly-sponsored clinical trials. A South Korean listing cannot inherit that clinical identity. Check the exact pharmaceutical-product authorization in the MFDS public dataset and verify the provider or pharmacy separately through the HIRA service before interpreting any local offer.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 3, "statusEvidencePublishers": [ "Eli Lilly and Company", "Ministry of Food and Drug Safety via Public Data Portal", "Health Insurance Review and Assessment Service" ], "statusEvidenceUrls": [ "https://www.lilly.com/news/stories/what-to-know-about-retatrutide", "https://www.data.go.kr/en/data/15095677/openapi.do", "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000" ], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "South Korea", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 20, "clinicalTrialRecruitingLocations": 17, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=South%20Korea#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=South%20Korea", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=south-korea" }, { "recordId": "pl-compound-country-retatrutide-thailand", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Retatrutide / เรตาทรูไทด์ ในประเทศไทย", "localizedAnswer": "Retatrutide / เรตาทรูไทด์ เป็นโครงการที่อยู่ระหว่างการพัฒนาทางคลินิก สินค้าหรือผู้ขายชื่อเดียวกันในประเทศไทยไม่สามารถรับช่วงตัวตนทางคลินิก ผลการทดลอง หรือสถานะด้านกฎระเบียบของผู้สนับสนุนโดยอัตโนมัติ ให้ตรวจผลิตภัณฑ์ ผู้ถือทะเบียน สถานประกอบการ และเส้นทางการจัดหาที่แน่นอนในบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Thailand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Thailand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Thailand", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=thailand" }, { "recordId": "pl-compound-country-retatrutide-indonesia", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Retatrutide di Indonesia", "localizedAnswer": "Retatrutide adalah program yang sedang dikembangkan secara klinis. Produk atau penjual dengan nama sama di Indonesia tidak otomatis mewarisi identitas klinis sponsor, hasil uji, atau status regulasinya. Periksa produk, pemegang izin, fasilitas, dan jalur pasok yang tepat dalam catatan resmi tujuan di bawah.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Indonesia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Indonesia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Indonesia", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=indonesia" }, { "recordId": "pl-compound-country-retatrutide-singapore", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Retatrutide in Singapore", "localizedAnswer": "Retatrutide is an investigational clinical program. No seller listing in Singapore can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Singapore", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 2, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT06808802", "NCT03841630" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06808802", "https://clinicaltrials.gov/study/NCT03841630" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Singapore#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Singapore", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=singapore" }, { "recordId": "pl-compound-country-retatrutide-philippines", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Retatrutide in the Philippines", "localizedAnswer": "Retatrutide is an investigational clinical program. No seller listing in the Philippines can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Philippines", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Philippines#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Philippines", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=philippines" }, { "recordId": "pl-compound-country-retatrutide-malaysia", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Retatrutide in Malaysia", "localizedAnswer": "Retatrutide is an investigational clinical program. No seller listing in Malaysia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Malaysia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Malaysia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Malaysia", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=malaysia" }, { "recordId": "pl-compound-country-retatrutide-taiwan", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Retatrutide / 瑞他魯肽 在台灣的紀錄", "localizedAnswer": "Retatrutide / 瑞他魯肽是臨床開發中的計畫。贊助者的臨床身分、試驗結果或法規狀態，不會自動移轉給台灣的同名網路商品或提供者。必須利用下方紀錄核對目的地的具體產品、許可證持有者、機構與供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Taiwan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 15, "clinicalTrialRecruitingLocations": 12, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Taiwan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Taiwan", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=taiwan" }, { "recordId": "pl-compound-country-retatrutide-hong-kong", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Not approved or available for public use; Hong Kong registration still requires an exact record", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Retatrutide / 瑞他魯肽 在香港的紀錄", "localizedAnswer": "Lilly states that retatrutide has not been approved by any regulatory agency, is not available for public use, and is legally available only through Lilly-sponsored clinical trials. Hong Kong's Drug Office states that pharmaceutical products must be registered before they can be sold or offered for sale. The product database and licensed-dealer register answer separate questions, so a same-name listing or delivery claim cannot establish registered supply.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 3, "statusEvidencePublishers": [ "Eli Lilly and Company", "Hong Kong Department of Health Drug Office" ], "statusEvidenceUrls": [ "https://www.lilly.com/news/stories/what-to-know-about-retatrutide", "https://www.drugoffice.gov.hk/eps/do/en/consumer/search_drug_database.html", "https://www.drugoffice.gov.hk/eps/do/en/pharmaceutical_trade/search_drug_dealers.html" ], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Hong Kong", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 3, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07165028" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Hong%20Kong#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Hong%20Kong", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=hong-kong" }, { "recordId": "pl-compound-country-retatrutide-vietnam", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Retatrutide tại Việt Nam", "localizedAnswer": "Retatrutide là một chương trình đang phát triển lâm sàng. Không đề nghị thương mại nào tại Việt Nam tự động kế thừa danh tính lâm sàng, kết quả thử nghiệm hoặc tình trạng quản lý của nhà tài trợ. Cần kiểm tra sản phẩm, chủ sở hữu giấy phép, cơ sở và đường cung ứng cụ thể trong các hồ sơ chính thức của điểm đến ở dưới.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Vietnam", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Vietnam#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Vietnam", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=vietnam" }, { "recordId": "pl-compound-country-retatrutide-united-states", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Retatrutide in the United States", "localizedAnswer": "Retatrutide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "United States", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 26, "clinicalTrialListedLocations": 825, "clinicalTrialRecruitingLocations": 134, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028", "NCT07035093", "NCT06297603", "NCT06383390", "NCT06662383", "NCT07357415", "NCT05929066", "NCT05882045", "NCT07232719", "NCT05929079", "NCT06260722", "NCT06354660", "NCT06859268", "NCT05931367", "NCT05936151", "NCT06313528", "NCT05916560", "NCT05959096", "NCT06039826", "NCT06003465", "NCT05611957", "NCT04881760", "NCT05757531", "NCT04867785", "NCT05445232", "NCT04143802" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT07035093", "https://clinicaltrials.gov/study/NCT06297603", "https://clinicaltrials.gov/study/NCT06383390", "https://clinicaltrials.gov/study/NCT06662383", "https://clinicaltrials.gov/study/NCT07357415", "https://clinicaltrials.gov/study/NCT05929066", "https://clinicaltrials.gov/study/NCT05882045", "https://clinicaltrials.gov/study/NCT07232719", "https://clinicaltrials.gov/study/NCT05929079", "https://clinicaltrials.gov/study/NCT06260722", "https://clinicaltrials.gov/study/NCT06354660", "https://clinicaltrials.gov/study/NCT06859268", "https://clinicaltrials.gov/study/NCT05931367", "https://clinicaltrials.gov/study/NCT05936151", "https://clinicaltrials.gov/study/NCT06313528", "https://clinicaltrials.gov/study/NCT05916560", "https://clinicaltrials.gov/study/NCT05959096", "https://clinicaltrials.gov/study/NCT06039826", "https://clinicaltrials.gov/study/NCT06003465", "https://clinicaltrials.gov/study/NCT05611957", "https://clinicaltrials.gov/study/NCT04881760", "https://clinicaltrials.gov/study/NCT05757531", "https://clinicaltrials.gov/study/NCT04867785", "https://clinicaltrials.gov/study/NCT05445232", "https://clinicaltrials.gov/study/NCT04143802" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=United%20States#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=United%20States", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=united-states" }, { "recordId": "pl-compound-country-retatrutide-canada", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Retatrutide in Canada", "localizedAnswer": "Retatrutide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Canada", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 10, "clinicalTrialListedLocations": 117, "clinicalTrialRecruitingLocations": 5, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07165028", "NCT07035093", "NCT06383390", "NCT07357415", "NCT05929066", "NCT05882045", "NCT06260722", "NCT06859268", "NCT05931367", "NCT05936151" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07165028", "https://clinicaltrials.gov/study/NCT07035093", "https://clinicaltrials.gov/study/NCT06383390", "https://clinicaltrials.gov/study/NCT07357415", "https://clinicaltrials.gov/study/NCT05929066", "https://clinicaltrials.gov/study/NCT05882045", "https://clinicaltrials.gov/study/NCT06260722", "https://clinicaltrials.gov/study/NCT06859268", "https://clinicaltrials.gov/study/NCT05931367", "https://clinicaltrials.gov/study/NCT05936151" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Canada#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Canada", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=canada" }, { "recordId": "pl-compound-country-retatrutide-united-arab-emirates", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Retatrutide / ريتاتروتايد في الإمارات العربية المتحدة", "localizedAnswer": "Retatrutide / ريتاتروتايد برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في الإمارات العربية المتحدة أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "United Arab Emirates", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=United%20Arab%20Emirates#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=United%20Arab%20Emirates", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=united-arab-emirates" }, { "recordId": "pl-compound-country-retatrutide-saudi-arabia", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Retatrutide / ريتاتروتايد في المملكة العربية السعودية", "localizedAnswer": "Retatrutide / ريتاتروتايد برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في المملكة العربية السعودية أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Saudi Arabia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Saudi%20Arabia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Saudi%20Arabia", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=saudi-arabia" }, { "recordId": "pl-compound-country-retatrutide-south-africa", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational program named in a SAHPRA unauthorized product warning", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Retatrutide in South Africa", "localizedAnswer": "Lilly states that retatrutide is investigational, is not available for public use, and is legally available only through Lilly clinical trials. SAHPRA's public warning identifies products sold under the retatrutide name among falsified or unauthorized GLP-1 agonist products found in the South African market. Neither a seller listing nor a familiar name establishes an authorized product. The exact product record, seller identity, and supply route must be checked through current SAHPRA sources.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 3, "statusEvidencePublishers": [ "Eli Lilly and Company", "South African Health Products Regulatory Authority" ], "statusEvidenceUrls": [ "https://www.lilly.com/news/stories/what-to-know-about-retatrutide", "https://www.sahpra.org.za/wp-content/uploads/2024/11/Media-Statement-SAHPRA-position-falsified-GPL-1-agonist-products.pdf", "https://medsinfo.sahpra.org.za/" ], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "South Africa", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=South%20Africa#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=South%20Africa", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=south-africa" }, { "recordId": "pl-compound-country-retatrutide-nigeria", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Retatrutide in Nigeria", "localizedAnswer": "Retatrutide is an investigational clinical program. No seller listing in Nigeria can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Nigeria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Nigeria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Nigeria", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=nigeria" }, { "recordId": "pl-compound-country-retatrutide-kenya", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Not approved or available for public use; verify Kenya product and facility claims", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Retatrutide in Kenya", "localizedAnswer": "Lilly states that retatrutide has not been approved by any regulatory agency, is not available for public use, and is legally available only through Lilly-sponsored clinical trials. A Kenya listing cannot inherit that clinical identity. The Pharmacy and Poisons Board product register and facilities licence register answer separate questions about an exact product and the entity offering it. Both records must match before interpreting a local offer.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 3, "statusEvidencePublishers": [ "Eli Lilly and Company", "Kenya Pharmacy and Poisons Board" ], "statusEvidenceUrls": [ "https://www.lilly.com/news/stories/what-to-know-about-retatrutide", "https://prims.pharmacyboardkenya.org/pharma_register_public/", "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities" ], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Retatrutide", "clinicalTrialRegistryCountry": "Kenya", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=retatrutide&country=Kenya#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Retatrutide&locStr=Kenya", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/retatrutide", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/retatrutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=retatrutide&country=kenya" }, { "recordId": "pl-compound-country-mazdutide-france", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Mazdutide en France", "localizedAnswer": "Mazdutide est un programme clinique expérimental. Aucune offre commerciale en France ne peut reprendre automatiquement l’identité clinique, les résultats d’essais ou le statut réglementaire du promoteur. Vérifiez chaque produit et fournisseur dans les registres ci-dessous.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "France", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=France#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=France", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=france" }, { "recordId": "pl-compound-country-mazdutide-united-kingdom", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Mazdutide in the United Kingdom", "localizedAnswer": "Mazdutide is an investigational clinical program. No seller listing in the United Kingdom can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "United Kingdom", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 2, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT03325387", "NCT02972645" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT03325387", "https://clinicaltrials.gov/study/NCT02972645" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=United%20Kingdom#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=United%20Kingdom", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=united-kingdom" }, { "recordId": "pl-compound-country-mazdutide-germany", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Mazdutide in Deutschland", "localizedAnswer": "Mazdutide ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Deutschland übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Germany", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 1, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT03928379" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT03928379" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Germany#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Germany", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=germany" }, { "recordId": "pl-compound-country-mazdutide-spain", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Mazdutide en España", "localizedAnswer": "Mazdutide es un programa clínico en investigación. Ninguna oferta comercial en España puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Spain", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Spain#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Spain", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=spain" }, { "recordId": "pl-compound-country-mazdutide-italy", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Mazdutide in Italia", "localizedAnswer": "Mazdutide è un programma clinico sperimentale. Nessuna offerta commerciale in Italia può ereditare l’identità clinica, i risultati degli studi o lo stato regolatorio dello sponsor. Verifica ogni prodotto e fornitore nei registri riportati sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Italy", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Italy#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Italy", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=italy" }, { "recordId": "pl-compound-country-mazdutide-netherlands", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Mazdutide in Nederland", "localizedAnswer": "Mazdutide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in Nederland neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Netherlands", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Netherlands#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Netherlands", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=netherlands" }, { "recordId": "pl-compound-country-mazdutide-switzerland", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Mazdutide in Switzerland", "localizedAnswer": "Mazdutide is an investigational clinical program. No seller listing in Switzerland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Switzerland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Switzerland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Switzerland", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=switzerland" }, { "recordId": "pl-compound-country-mazdutide-poland", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Mazdutide w Polsce", "localizedAnswer": "Mazdutide jest eksperymentalnym programem klinicznym. Żadna oferta handlowa w Polsce nie przejmuje automatycznie tożsamości klinicznej, wyników badań ani statusu regulacyjnego sponsora. Sprawdź każdy produkt i dostawcę w rejestrach poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Poland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Poland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Poland", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=poland" }, { "recordId": "pl-compound-country-mazdutide-ireland", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Mazdutide in Ireland", "localizedAnswer": "Mazdutide is an investigational clinical program. No seller listing in Ireland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Ireland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Ireland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Ireland", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=ireland" }, { "recordId": "pl-compound-country-mazdutide-portugal", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Mazdutide em Portugal", "localizedAnswer": "Mazdutide é um programa clínico experimental. Nenhuma oferta comercial em Portugal pode herdar a identidade clínica, os resultados de ensaios ou o estatuto regulamentar do promotor. Verifique cada produto e fornecedor nos registos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Portugal", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Portugal#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Portugal", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=portugal" }, { "recordId": "pl-compound-country-mazdutide-sweden", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Mazdutide i Sverige", "localizedAnswer": "Mazdutide är ett kliniskt prövningsprogram. Inget kommersiellt erbjudande i Sverige kan automatiskt ärva sponsorns kliniska identitet, studieresultat eller regulatoriska status. Kontrollera varje produkt och leverantör i registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Sweden", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Sweden#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Sweden", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=sweden" }, { "recordId": "pl-compound-country-mazdutide-turkey", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Mazdutide", "localizedAnswer": "Mazdutide klinik geliştirme aşamasındaki bir programdır. Türkiye içindeki aynı adlı hiçbir ticari teklif sponsorun klinik kimliğini, çalışma sonuçlarını veya düzenleyici statüsünü otomatik olarak devralamaz. Belirli ürünü, ruhsat sahibini, kuruluşu ve tedarik yolunu aşağıdaki resmi hedef ülke kayıtlarında kontrol edin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Turkey (Türkiye)", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Turkey%20(T%C3%BCrkiye)#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Turkey%20(T%C3%BCrkiye)", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=turkey" }, { "recordId": "pl-compound-country-mazdutide-austria", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Mazdutide in Österreich", "localizedAnswer": "Mazdutide ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Österreich übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Austria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Austria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Austria", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=austria" }, { "recordId": "pl-compound-country-mazdutide-belgium", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Mazdutide in België", "localizedAnswer": "Mazdutide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in België neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Belgium", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Belgium#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Belgium", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=belgium" }, { "recordId": "pl-compound-country-mazdutide-denmark", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Mazdutide i Danmark", "localizedAnswer": "Mazdutide er et klinisk udviklingsprogram. Et kommercielt tilbud med samme navn i Danmark arver ikke sponsorens kliniske identitet, forsøgsresultater eller regulatoriske status. Kontrollér det konkrete produkt, tilladelsesindehaveren, virksomheden og forsyningsvejen i de officielle registre for destinationen nedenfor.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Denmark", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Denmark#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Denmark", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=denmark" }, { "recordId": "pl-compound-country-mazdutide-finland", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Mazdutide kohteessa Suomi", "localizedAnswer": "Mazdutide on kliininen kehitysohjelma. Samanniminen kaupallinen tarjous kohteessa Suomi ei peri sponsorin kliinistä identiteettiä, tutkimustuloksia tai sääntelyasemaa. Tarkista täsmällinen tuote, luvanhaltija, toimija ja toimitusreitti alla olevista kohdemaan virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Finland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Finland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Finland", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=finland" }, { "recordId": "pl-compound-country-mazdutide-mexico", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Mazdutide en México", "localizedAnswer": "Mazdutide es un programa clínico en investigación. Ninguna oferta comercial en México puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Mexico", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Mexico#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Mexico", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=mexico" }, { "recordId": "pl-compound-country-mazdutide-argentina", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Mazdutide en Argentina", "localizedAnswer": "Mazdutide es un programa clínico en investigación. Ninguna oferta comercial en Argentina puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Argentina", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 4, "clinicalTrialRecruitingLocations": 4, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT06143956" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06143956" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Argentina#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Argentina", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=argentina" }, { "recordId": "pl-compound-country-mazdutide-colombia", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Mazdutide en Colombia", "localizedAnswer": "Mazdutide es un programa clínico en investigación. Ninguna oferta comercial en Colombia puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Colombia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Colombia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Colombia", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=colombia" }, { "recordId": "pl-compound-country-mazdutide-chile", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Mazdutide en Chile", "localizedAnswer": "Mazdutide es un programa clínico en investigación. Ninguna oferta comercial en Chile puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Chile", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Chile#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Chile", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=chile" }, { "recordId": "pl-compound-country-mazdutide-brazil", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Mazdutide no Brasil", "localizedAnswer": "Mazdutide é um programa clínico experimental. Nenhuma oferta comercial no Brasil pode herdar a identidade clínica, os resultados de ensaios ou o status regulatório do patrocinador. Verifique cada produto e fornecedor nos registros abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Brazil", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Brazil#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Brazil", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=brazil" }, { "recordId": "pl-compound-country-mazdutide-china", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "NMPA-approved medicine in China", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Mazdutide / 玛仕度肽 在中国的状态与官方记录", "localizedAnswer": "Mazdutide / 玛仕度肽已获得中国国家药监局用于成人超重或肥胖慢性体重管理以及成人2型糖尿病血糖控制的批准。该批准只说明特定中国药品与适应症的监管状态，不能自动验证同名网络商品、研究材料、复配产品、诊所服务或卖方。仍需在国家药监局和企业信用公示系统中核对具体批准、持有人、剂型规格、经营主体与供应路径。", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 2, "statusEvidencePublishers": [ "Innovent Biologics" ], "statusEvidenceUrls": [ "https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=546", "https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=556" ], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "China", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 29, "clinicalTrialListedLocations": 85, "clinicalTrialRecruitingLocations": 26, "clinicalTrialRecordsWithRecruitingLocations": 9, "clinicalTrialRecordIds": [ "NCT07633639", "NCT07469800", "NCT07517042", "NCT07083154", "NCT07255209", "NCT06937749", "NCT06862908", "NCT06931028", "NCT06519656", "NCT07718126", "NCT07657676", "NCT07654062", "NCT06184568", "NCT06884293", "NCT07417306", "NCT07000955", "NCT04904913", "NCT06536023", "NCT07135141", "NCT05607680", "NCT06164873", "NCT05606913", "NCT05628311", "NCT05793450", "NCT04965506", "NCT04440345", "NCT05815680", "NCT04466904", "NCT04773977" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07633639", "https://clinicaltrials.gov/study/NCT07469800", "https://clinicaltrials.gov/study/NCT07517042", "https://clinicaltrials.gov/study/NCT07083154", "https://clinicaltrials.gov/study/NCT07255209", "https://clinicaltrials.gov/study/NCT06937749", "https://clinicaltrials.gov/study/NCT06862908", "https://clinicaltrials.gov/study/NCT06931028", "https://clinicaltrials.gov/study/NCT06519656", "https://clinicaltrials.gov/study/NCT07718126", "https://clinicaltrials.gov/study/NCT07657676", "https://clinicaltrials.gov/study/NCT07654062", "https://clinicaltrials.gov/study/NCT06184568", "https://clinicaltrials.gov/study/NCT06884293", "https://clinicaltrials.gov/study/NCT07417306", "https://clinicaltrials.gov/study/NCT07000955", "https://clinicaltrials.gov/study/NCT04904913", "https://clinicaltrials.gov/study/NCT06536023", "https://clinicaltrials.gov/study/NCT07135141", "https://clinicaltrials.gov/study/NCT05607680", "https://clinicaltrials.gov/study/NCT06164873", "https://clinicaltrials.gov/study/NCT05606913", "https://clinicaltrials.gov/study/NCT05628311", "https://clinicaltrials.gov/study/NCT05793450", "https://clinicaltrials.gov/study/NCT04965506", "https://clinicaltrials.gov/study/NCT04440345", "https://clinicaltrials.gov/study/NCT05815680", "https://clinicaltrials.gov/study/NCT04466904", "https://clinicaltrials.gov/study/NCT04773977" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=China#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=China", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=china" }, { "recordId": "pl-compound-country-mazdutide-australia", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Mazdutide in Australia", "localizedAnswer": "Mazdutide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Australia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Australia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Australia", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=australia" }, { "recordId": "pl-compound-country-mazdutide-new-zealand", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Mazdutide in New Zealand", "localizedAnswer": "Mazdutide is an investigational clinical program. No seller listing in New Zealand can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "New Zealand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=New%20Zealand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=New%20Zealand", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=new-zealand" }, { "recordId": "pl-compound-country-mazdutide-india", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Mazdutide in India", "localizedAnswer": "Mazdutide is an investigational clinical program. No seller listing in India can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "India", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=India#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=India", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=india" }, { "recordId": "pl-compound-country-mazdutide-japan", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のMazdutide / マズデュチド", "localizedAnswer": "Mazdutide / マズデュチドは臨床開発中のプログラムです。スポンサーの臨床上の同一性、試験結果、規制上の位置付けを、日本の同名オンライン商品や販売者が自動的に引き継ぐことはありません。目的地の製品、承認保持者、施設、供給経路を下記の公的記録で確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Japan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Japan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Japan", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=japan" }, { "recordId": "pl-compound-country-mazdutide-south-korea", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Mazdutide / 마즈두타이드", "localizedAnswer": "Mazdutide / 마즈두타이드은 임상 개발 중인 프로그램입니다. 후원사의 임상 신원, 시험 결과 또는 규제 상태를 대한민국의 동명 온라인 상품이나 판매자가 자동으로 이어받을 수 없습니다. 목적지의 정확한 제품, 허가권자, 기관과 공급 경로를 아래 공식 기록에서 확인해야 합니다.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "South Korea", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=South%20Korea#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=South%20Korea", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=south-korea" }, { "recordId": "pl-compound-country-mazdutide-thailand", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Mazdutide ในประเทศไทย", "localizedAnswer": "Mazdutide เป็นโครงการที่อยู่ระหว่างการพัฒนาทางคลินิก สินค้าหรือผู้ขายชื่อเดียวกันในประเทศไทยไม่สามารถรับช่วงตัวตนทางคลินิก ผลการทดลอง หรือสถานะด้านกฎระเบียบของผู้สนับสนุนโดยอัตโนมัติ ให้ตรวจผลิตภัณฑ์ ผู้ถือทะเบียน สถานประกอบการ และเส้นทางการจัดหาที่แน่นอนในบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Thailand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Thailand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Thailand", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=thailand" }, { "recordId": "pl-compound-country-mazdutide-indonesia", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Mazdutide di Indonesia", "localizedAnswer": "Mazdutide adalah program yang sedang dikembangkan secara klinis. Produk atau penjual dengan nama sama di Indonesia tidak otomatis mewarisi identitas klinis sponsor, hasil uji, atau status regulasinya. Periksa produk, pemegang izin, fasilitas, dan jalur pasok yang tepat dalam catatan resmi tujuan di bawah.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Indonesia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Indonesia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Indonesia", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=indonesia" }, { "recordId": "pl-compound-country-mazdutide-singapore", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Mazdutide in Singapore", "localizedAnswer": "Mazdutide is an investigational clinical program. No seller listing in Singapore can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Singapore", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Singapore#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Singapore", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=singapore" }, { "recordId": "pl-compound-country-mazdutide-philippines", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Mazdutide in the Philippines", "localizedAnswer": "Mazdutide is an investigational clinical program. No seller listing in the Philippines can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Philippines", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Philippines#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Philippines", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=philippines" }, { "recordId": "pl-compound-country-mazdutide-malaysia", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Mazdutide in Malaysia", "localizedAnswer": "Mazdutide is an investigational clinical program. No seller listing in Malaysia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Malaysia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Malaysia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Malaysia", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=malaysia" }, { "recordId": "pl-compound-country-mazdutide-taiwan", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Mazdutide 在台灣的紀錄", "localizedAnswer": "Mazdutide是臨床開發中的計畫。贊助者的臨床身分、試驗結果或法規狀態，不會自動移轉給台灣的同名網路商品或提供者。必須利用下方紀錄核對目的地的具體產品、許可證持有者、機構與供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Taiwan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Taiwan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Taiwan", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=taiwan" }, { "recordId": "pl-compound-country-mazdutide-hong-kong", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Mazdutide 在香港的紀錄", "localizedAnswer": "Mazdutide是臨床開發中的計劃。贊助者的臨床身分、試驗結果或監管狀態，不會自動轉移給香港的同名網上商品或銷售商。必須透過下方紀錄核對目的地的指定產品、註冊持有人、持牌實體和供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Hong Kong", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Hong%20Kong#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Hong%20Kong", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=hong-kong" }, { "recordId": "pl-compound-country-mazdutide-vietnam", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Mazdutide tại Việt Nam", "localizedAnswer": "Mazdutide là một chương trình đang phát triển lâm sàng. Không đề nghị thương mại nào tại Việt Nam tự động kế thừa danh tính lâm sàng, kết quả thử nghiệm hoặc tình trạng quản lý của nhà tài trợ. Cần kiểm tra sản phẩm, chủ sở hữu giấy phép, cơ sở và đường cung ứng cụ thể trong các hồ sơ chính thức của điểm đến ở dưới.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Vietnam", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Vietnam#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Vietnam", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=vietnam" }, { "recordId": "pl-compound-country-mazdutide-united-states", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Mazdutide in the United States", "localizedAnswer": "Mazdutide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "United States", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 4, "clinicalTrialListedLocations": 107, "clinicalTrialRecruitingLocations": 43, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT06143956", "NCT06817356", "NCT06124807", "NCT05623839" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06143956", "https://clinicaltrials.gov/study/NCT06817356", "https://clinicaltrials.gov/study/NCT06124807", "https://clinicaltrials.gov/study/NCT05623839" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=United%20States#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=United%20States", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=united-states" }, { "recordId": "pl-compound-country-mazdutide-canada", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Mazdutide in Canada", "localizedAnswer": "Mazdutide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Canada", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Canada#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Canada", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=canada" }, { "recordId": "pl-compound-country-mazdutide-united-arab-emirates", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Mazdutide / مازدوتايد في الإمارات العربية المتحدة", "localizedAnswer": "Mazdutide / مازدوتايد برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في الإمارات العربية المتحدة أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "United Arab Emirates", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=United%20Arab%20Emirates#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=United%20Arab%20Emirates", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=united-arab-emirates" }, { "recordId": "pl-compound-country-mazdutide-saudi-arabia", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Mazdutide / مازدوتايد في المملكة العربية السعودية", "localizedAnswer": "Mazdutide / مازدوتايد برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في المملكة العربية السعودية أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Saudi Arabia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Saudi%20Arabia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Saudi%20Arabia", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=saudi-arabia" }, { "recordId": "pl-compound-country-mazdutide-south-africa", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Mazdutide in South Africa", "localizedAnswer": "Mazdutide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "South Africa", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=South%20Africa#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=South%20Africa", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=south-africa" }, { "recordId": "pl-compound-country-mazdutide-nigeria", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Mazdutide in Nigeria", "localizedAnswer": "Mazdutide is an investigational clinical program. No seller listing in Nigeria can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Nigeria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Nigeria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Nigeria", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=nigeria" }, { "recordId": "pl-compound-country-mazdutide-kenya", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Mazdutide in Kenya", "localizedAnswer": "Mazdutide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Mazdutide", "clinicalTrialRegistryCountry": "Kenya", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=mazdutide&country=Kenya#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Mazdutide&locStr=Kenya", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/mazdutide", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/mazdutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=mazdutide&country=kenya" }, { "recordId": "pl-compound-country-ecnoglutide-france", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Ecnoglutide en France", "localizedAnswer": "Ecnoglutide est un programme clinique expérimental. Aucune offre commerciale en France ne peut reprendre automatiquement l’identité clinique, les résultats d’essais ou le statut réglementaire du promoteur. Vérifiez chaque produit et fournisseur dans les registres ci-dessous.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "France", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=France#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=France", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=france" }, { "recordId": "pl-compound-country-ecnoglutide-united-kingdom", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Ecnoglutide in the United Kingdom", "localizedAnswer": "Ecnoglutide is an investigational clinical program. No seller listing in the United Kingdom can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "United Kingdom", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=United%20Kingdom#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=United%20Kingdom", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=united-kingdom" }, { "recordId": "pl-compound-country-ecnoglutide-germany", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Ecnoglutide in Deutschland", "localizedAnswer": "Ecnoglutide ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Deutschland übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Germany", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Germany#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Germany", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=germany" }, { "recordId": "pl-compound-country-ecnoglutide-spain", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Ecnoglutide en España", "localizedAnswer": "Ecnoglutide es un programa clínico en investigación. Ninguna oferta comercial en España puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Spain", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Spain#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Spain", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=spain" }, { "recordId": "pl-compound-country-ecnoglutide-italy", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Ecnoglutide in Italia", "localizedAnswer": "Ecnoglutide è un programma clinico sperimentale. Nessuna offerta commerciale in Italia può ereditare l’identità clinica, i risultati degli studi o lo stato regolatorio dello sponsor. Verifica ogni prodotto e fornitore nei registri riportati sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Italy", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Italy#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Italy", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=italy" }, { "recordId": "pl-compound-country-ecnoglutide-netherlands", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Ecnoglutide in Nederland", "localizedAnswer": "Ecnoglutide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in Nederland neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Netherlands", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Netherlands#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Netherlands", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=netherlands" }, { "recordId": "pl-compound-country-ecnoglutide-switzerland", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Ecnoglutide in Switzerland", "localizedAnswer": "Ecnoglutide is an investigational clinical program. No seller listing in Switzerland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Switzerland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Switzerland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Switzerland", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=switzerland" }, { "recordId": "pl-compound-country-ecnoglutide-poland", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Ecnoglutide w Polsce", "localizedAnswer": "Ecnoglutide jest eksperymentalnym programem klinicznym. Żadna oferta handlowa w Polsce nie przejmuje automatycznie tożsamości klinicznej, wyników badań ani statusu regulacyjnego sponsora. Sprawdź każdy produkt i dostawcę w rejestrach poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Poland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Poland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Poland", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=poland" }, { "recordId": "pl-compound-country-ecnoglutide-ireland", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Ecnoglutide in Ireland", "localizedAnswer": "Ecnoglutide is an investigational clinical program. No seller listing in Ireland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Ireland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Ireland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Ireland", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=ireland" }, { "recordId": "pl-compound-country-ecnoglutide-portugal", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Ecnoglutide em Portugal", "localizedAnswer": "Ecnoglutide é um programa clínico experimental. Nenhuma oferta comercial em Portugal pode herdar a identidade clínica, os resultados de ensaios ou o estatuto regulamentar do promotor. Verifique cada produto e fornecedor nos registos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Portugal", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Portugal#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Portugal", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=portugal" }, { "recordId": "pl-compound-country-ecnoglutide-sweden", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Ecnoglutide i Sverige", "localizedAnswer": "Ecnoglutide är ett kliniskt prövningsprogram. Inget kommersiellt erbjudande i Sverige kan automatiskt ärva sponsorns kliniska identitet, studieresultat eller regulatoriska status. Kontrollera varje produkt och leverantör i registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Sweden", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Sweden#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Sweden", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=sweden" }, { "recordId": "pl-compound-country-ecnoglutide-turkey", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Ecnoglutide", "localizedAnswer": "Ecnoglutide klinik geliştirme aşamasındaki bir programdır. Türkiye içindeki aynı adlı hiçbir ticari teklif sponsorun klinik kimliğini, çalışma sonuçlarını veya düzenleyici statüsünü otomatik olarak devralamaz. Belirli ürünü, ruhsat sahibini, kuruluşu ve tedarik yolunu aşağıdaki resmi hedef ülke kayıtlarında kontrol edin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Turkey (Türkiye)", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Turkey%20(T%C3%BCrkiye)#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Turkey%20(T%C3%BCrkiye)", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=turkey" }, { "recordId": "pl-compound-country-ecnoglutide-austria", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Ecnoglutide in Österreich", "localizedAnswer": "Ecnoglutide ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Österreich übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Austria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Austria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Austria", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=austria" }, { "recordId": "pl-compound-country-ecnoglutide-belgium", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Ecnoglutide in België", "localizedAnswer": "Ecnoglutide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in België neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Belgium", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Belgium#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Belgium", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=belgium" }, { "recordId": "pl-compound-country-ecnoglutide-denmark", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Ecnoglutide i Danmark", "localizedAnswer": "Ecnoglutide er et klinisk udviklingsprogram. Et kommercielt tilbud med samme navn i Danmark arver ikke sponsorens kliniske identitet, forsøgsresultater eller regulatoriske status. Kontrollér det konkrete produkt, tilladelsesindehaveren, virksomheden og forsyningsvejen i de officielle registre for destinationen nedenfor.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Denmark", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Denmark#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Denmark", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=denmark" }, { "recordId": "pl-compound-country-ecnoglutide-finland", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Ecnoglutide kohteessa Suomi", "localizedAnswer": "Ecnoglutide on kliininen kehitysohjelma. Samanniminen kaupallinen tarjous kohteessa Suomi ei peri sponsorin kliinistä identiteettiä, tutkimustuloksia tai sääntelyasemaa. Tarkista täsmällinen tuote, luvanhaltija, toimija ja toimitusreitti alla olevista kohdemaan virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Finland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Finland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Finland", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=finland" }, { "recordId": "pl-compound-country-ecnoglutide-mexico", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Ecnoglutide en México", "localizedAnswer": "Ecnoglutide es un programa clínico en investigación. Ninguna oferta comercial en México puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Mexico", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Mexico#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Mexico", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=mexico" }, { "recordId": "pl-compound-country-ecnoglutide-argentina", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Ecnoglutide en Argentina", "localizedAnswer": "Ecnoglutide es un programa clínico en investigación. Ninguna oferta comercial en Argentina puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Argentina", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Argentina#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Argentina", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=argentina" }, { "recordId": "pl-compound-country-ecnoglutide-colombia", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Ecnoglutide en Colombia", "localizedAnswer": "Ecnoglutide es un programa clínico en investigación. Ninguna oferta comercial en Colombia puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Colombia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Colombia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Colombia", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=colombia" }, { "recordId": "pl-compound-country-ecnoglutide-chile", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Ecnoglutide en Chile", "localizedAnswer": "Ecnoglutide es un programa clínico en investigación. Ninguna oferta comercial en Chile puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Chile", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Chile#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Chile", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=chile" }, { "recordId": "pl-compound-country-ecnoglutide-brazil", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Ecnoglutide no Brasil", "localizedAnswer": "Ecnoglutide é um programa clínico experimental. Nenhuma oferta comercial no Brasil pode herdar a identidade clínica, os resultados de ensaios ou o status regulatório do patrocinador. Verifique cada produto e fornecedor nos registros abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Brazil", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Brazil#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Brazil", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=brazil" }, { "recordId": "pl-compound-country-ecnoglutide-china", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "NMPA-approved medicine in China", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Ecnoglutide / 埃诺格鲁肽 在中国的状态与官方记录", "localizedAnswer": "Ecnoglutide / 埃诺格鲁肽注射液已获得中国国家药监局用于成人2型糖尿病血糖控制以及中国成人超重或肥胖慢性体重管理的批准。该中国批准不能自动验证同名网络商品、科研材料、进口产品、诊所服务或卖方，也不代表其他国家已经批准。仍需在国家药监局和企业信用公示系统中核对具体批准、持有人、剂型规格、经营主体与供应路径。", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 2, "statusEvidencePublishers": [ "Sciwind Biosciences" ], "statusEvidenceUrls": [ "https://www.sciwindbio.com/portal/index/newsdetail/id/125/category_id/5.html", "https://www.sciwindbio.com/portal/index/newsdetail/id/122/category_id/5.html" ], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "China", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 9, "clinicalTrialListedLocations": 9, "clinicalTrialRecruitingLocations": 3, "clinicalTrialRecordsWithRecruitingLocations": 3, "clinicalTrialRecordIds": [ "NCT07387094", "NCT07434050", "NCT07243171", "NCT07143227", "NCT07073417", "NCT05680155", "NCT05680129", "NCT06335134", "NCT05813795" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07387094", "https://clinicaltrials.gov/study/NCT07434050", "https://clinicaltrials.gov/study/NCT07243171", "https://clinicaltrials.gov/study/NCT07143227", "https://clinicaltrials.gov/study/NCT07073417", "https://clinicaltrials.gov/study/NCT05680155", "https://clinicaltrials.gov/study/NCT05680129", "https://clinicaltrials.gov/study/NCT06335134", "https://clinicaltrials.gov/study/NCT05813795" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=China#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=China", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=china" }, { "recordId": "pl-compound-country-ecnoglutide-australia", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Ecnoglutide in Australia", "localizedAnswer": "Ecnoglutide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Australia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 3, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT05184322", "NCT05111912", "NCT04389775" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT05184322", "https://clinicaltrials.gov/study/NCT05111912", "https://clinicaltrials.gov/study/NCT04389775" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Australia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Australia", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=australia" }, { "recordId": "pl-compound-country-ecnoglutide-new-zealand", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Ecnoglutide in New Zealand", "localizedAnswer": "Ecnoglutide is an investigational clinical program. No seller listing in New Zealand can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "New Zealand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=New%20Zealand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=New%20Zealand", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=new-zealand" }, { "recordId": "pl-compound-country-ecnoglutide-india", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Ecnoglutide in India", "localizedAnswer": "Ecnoglutide is an investigational clinical program. No seller listing in India can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "India", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=India#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=India", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=india" }, { "recordId": "pl-compound-country-ecnoglutide-japan", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のEcnoglutide / エクノグルチド", "localizedAnswer": "Ecnoglutide / エクノグルチドは臨床開発中のプログラムです。スポンサーの臨床上の同一性、試験結果、規制上の位置付けを、日本の同名オンライン商品や販売者が自動的に引き継ぐことはありません。目的地の製品、承認保持者、施設、供給経路を下記の公的記録で確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Japan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Japan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Japan", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=japan" }, { "recordId": "pl-compound-country-ecnoglutide-south-korea", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Ecnoglutide / 에크노글루타이드", "localizedAnswer": "Ecnoglutide / 에크노글루타이드은 임상 개발 중인 프로그램입니다. 후원사의 임상 신원, 시험 결과 또는 규제 상태를 대한민국의 동명 온라인 상품이나 판매자가 자동으로 이어받을 수 없습니다. 목적지의 정확한 제품, 허가권자, 기관과 공급 경로를 아래 공식 기록에서 확인해야 합니다.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "South Korea", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=South%20Korea#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=South%20Korea", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=south-korea" }, { "recordId": "pl-compound-country-ecnoglutide-thailand", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Ecnoglutide ในประเทศไทย", "localizedAnswer": "Ecnoglutide เป็นโครงการที่อยู่ระหว่างการพัฒนาทางคลินิก สินค้าหรือผู้ขายชื่อเดียวกันในประเทศไทยไม่สามารถรับช่วงตัวตนทางคลินิก ผลการทดลอง หรือสถานะด้านกฎระเบียบของผู้สนับสนุนโดยอัตโนมัติ ให้ตรวจผลิตภัณฑ์ ผู้ถือทะเบียน สถานประกอบการ และเส้นทางการจัดหาที่แน่นอนในบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Thailand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Thailand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Thailand", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=thailand" }, { "recordId": "pl-compound-country-ecnoglutide-indonesia", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Ecnoglutide di Indonesia", "localizedAnswer": "Ecnoglutide adalah program yang sedang dikembangkan secara klinis. Produk atau penjual dengan nama sama di Indonesia tidak otomatis mewarisi identitas klinis sponsor, hasil uji, atau status regulasinya. Periksa produk, pemegang izin, fasilitas, dan jalur pasok yang tepat dalam catatan resmi tujuan di bawah.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Indonesia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Indonesia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Indonesia", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=indonesia" }, { "recordId": "pl-compound-country-ecnoglutide-singapore", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Ecnoglutide in Singapore", "localizedAnswer": "Ecnoglutide is an investigational clinical program. No seller listing in Singapore can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Singapore", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Singapore#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Singapore", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=singapore" }, { "recordId": "pl-compound-country-ecnoglutide-philippines", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Ecnoglutide in the Philippines", "localizedAnswer": "Ecnoglutide is an investigational clinical program. No seller listing in the Philippines can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Philippines", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Philippines#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Philippines", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=philippines" }, { "recordId": "pl-compound-country-ecnoglutide-malaysia", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Ecnoglutide in Malaysia", "localizedAnswer": "Ecnoglutide is an investigational clinical program. No seller listing in Malaysia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Malaysia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Malaysia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Malaysia", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=malaysia" }, { "recordId": "pl-compound-country-ecnoglutide-taiwan", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Ecnoglutide 在台灣的紀錄", "localizedAnswer": "Ecnoglutide是臨床開發中的計畫。贊助者的臨床身分、試驗結果或法規狀態，不會自動移轉給台灣的同名網路商品或提供者。必須利用下方紀錄核對目的地的具體產品、許可證持有者、機構與供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Taiwan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Taiwan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Taiwan", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=taiwan" }, { "recordId": "pl-compound-country-ecnoglutide-hong-kong", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Ecnoglutide 在香港的紀錄", "localizedAnswer": "Ecnoglutide是臨床開發中的計劃。贊助者的臨床身分、試驗結果或監管狀態，不會自動轉移給香港的同名網上商品或銷售商。必須透過下方紀錄核對目的地的指定產品、註冊持有人、持牌實體和供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Hong Kong", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Hong%20Kong#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Hong%20Kong", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=hong-kong" }, { "recordId": "pl-compound-country-ecnoglutide-vietnam", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Ecnoglutide tại Việt Nam", "localizedAnswer": "Ecnoglutide là một chương trình đang phát triển lâm sàng. Không đề nghị thương mại nào tại Việt Nam tự động kế thừa danh tính lâm sàng, kết quả thử nghiệm hoặc tình trạng quản lý của nhà tài trợ. Cần kiểm tra sản phẩm, chủ sở hữu giấy phép, cơ sở và đường cung ứng cụ thể trong các hồ sơ chính thức của điểm đến ở dưới.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Vietnam", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Vietnam#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Vietnam", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=vietnam" }, { "recordId": "pl-compound-country-ecnoglutide-united-states", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Ecnoglutide in the United States", "localizedAnswer": "Ecnoglutide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "United States", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 39, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07281937", "NCT07553299" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07281937", "https://clinicaltrials.gov/study/NCT07553299" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=United%20States#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=United%20States", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=united-states" }, { "recordId": "pl-compound-country-ecnoglutide-canada", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Ecnoglutide in Canada", "localizedAnswer": "Ecnoglutide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Canada", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Canada#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Canada", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=canada" }, { "recordId": "pl-compound-country-ecnoglutide-united-arab-emirates", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Ecnoglutide / إكنوغلوتايد في الإمارات العربية المتحدة", "localizedAnswer": "Ecnoglutide / إكنوغلوتايد برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في الإمارات العربية المتحدة أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "United Arab Emirates", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=United%20Arab%20Emirates#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=United%20Arab%20Emirates", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=united-arab-emirates" }, { "recordId": "pl-compound-country-ecnoglutide-saudi-arabia", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Ecnoglutide / إكنوغلوتايد في المملكة العربية السعودية", "localizedAnswer": "Ecnoglutide / إكنوغلوتايد برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في المملكة العربية السعودية أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Saudi Arabia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Saudi%20Arabia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Saudi%20Arabia", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=saudi-arabia" }, { "recordId": "pl-compound-country-ecnoglutide-south-africa", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Ecnoglutide in South Africa", "localizedAnswer": "Ecnoglutide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "South Africa", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=South%20Africa#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=South%20Africa", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=south-africa" }, { "recordId": "pl-compound-country-ecnoglutide-nigeria", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Ecnoglutide in Nigeria", "localizedAnswer": "Ecnoglutide is an investigational clinical program. No seller listing in Nigeria can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Nigeria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Nigeria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Nigeria", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=nigeria" }, { "recordId": "pl-compound-country-ecnoglutide-kenya", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Ecnoglutide in Kenya", "localizedAnswer": "Ecnoglutide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Ecnoglutide", "clinicalTrialRegistryCountry": "Kenya", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=ecnoglutide&country=Kenya#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Ecnoglutide&locStr=Kenya", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/ecnoglutide", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=ecnoglutide&country=kenya" }, { "recordId": "pl-compound-country-enicepatide-france", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Enicepatide en France", "localizedAnswer": "Enicepatide est un programme clinique expérimental. Aucune offre commerciale en France ne peut reprendre automatiquement l’identité clinique, les résultats d’essais ou le statut réglementaire du promoteur. Vérifiez chaque produit et fournisseur dans les registres ci-dessous.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "France", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 14, "clinicalTrialRecruitingLocations": 14, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07351045", "NCT07351058" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351045", "https://clinicaltrials.gov/study/NCT07351058" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=France#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=France", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=france" }, { "recordId": "pl-compound-country-enicepatide-united-kingdom", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Enicepatide in the United Kingdom", "localizedAnswer": "Enicepatide is an investigational clinical program. No seller listing in the United Kingdom can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "United Kingdom", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 18, "clinicalTrialRecruitingLocations": 18, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07351045", "NCT07351058" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351045", "https://clinicaltrials.gov/study/NCT07351058" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=United%20Kingdom#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=United%20Kingdom", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=united-kingdom" }, { "recordId": "pl-compound-country-enicepatide-germany", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Enicepatide in Deutschland", "localizedAnswer": "Enicepatide ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Deutschland übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Germany", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 19, "clinicalTrialRecruitingLocations": 18, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07351045", "NCT07351058" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351045", "https://clinicaltrials.gov/study/NCT07351058" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Germany#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Germany", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=germany" }, { "recordId": "pl-compound-country-enicepatide-spain", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Enicepatide en España", "localizedAnswer": "Enicepatide es un programa clínico en investigación. Ninguna oferta comercial en España puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Spain", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 18, "clinicalTrialRecruitingLocations": 18, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07351045", "NCT07351058" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351045", "https://clinicaltrials.gov/study/NCT07351058" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Spain#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Spain", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=spain" }, { "recordId": "pl-compound-country-enicepatide-italy", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Enicepatide in Italia", "localizedAnswer": "Enicepatide è un programma clinico sperimentale. Nessuna offerta commerciale in Italia può ereditare l’identità clinica, i risultati degli studi o lo stato regolatorio dello sponsor. Verifica ogni prodotto e fornitore nei registri riportati sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Italy", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 15, "clinicalTrialRecruitingLocations": 15, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07351045", "NCT07351058" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351045", "https://clinicaltrials.gov/study/NCT07351058" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Italy#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Italy", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=italy" }, { "recordId": "pl-compound-country-enicepatide-netherlands", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Enicepatide in Nederland", "localizedAnswer": "Enicepatide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in Nederland neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Netherlands", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 2, "clinicalTrialRecruitingLocations": 2, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07351045" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351045" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Netherlands#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Netherlands", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=netherlands" }, { "recordId": "pl-compound-country-enicepatide-switzerland", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Enicepatide in Switzerland", "localizedAnswer": "Enicepatide is an investigational clinical program. No seller listing in Switzerland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Switzerland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Switzerland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Switzerland", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=switzerland" }, { "recordId": "pl-compound-country-enicepatide-poland", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Enicepatide w Polsce", "localizedAnswer": "Enicepatide jest eksperymentalnym programem klinicznym. Żadna oferta handlowa w Polsce nie przejmuje automatycznie tożsamości klinicznej, wyników badań ani statusu regulacyjnego sponsora. Sprawdź każdy produkt i dostawcę w rejestrach poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Poland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 20, "clinicalTrialRecruitingLocations": 20, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07351045", "NCT07351058" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351045", "https://clinicaltrials.gov/study/NCT07351058" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Poland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Poland", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=poland" }, { "recordId": "pl-compound-country-enicepatide-ireland", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Enicepatide in Ireland", "localizedAnswer": "Enicepatide is an investigational clinical program. No seller listing in Ireland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Ireland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Ireland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Ireland", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=ireland" }, { "recordId": "pl-compound-country-enicepatide-portugal", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Enicepatide em Portugal", "localizedAnswer": "Enicepatide é um programa clínico experimental. Nenhuma oferta comercial em Portugal pode herdar a identidade clínica, os resultados de ensaios ou o estatuto regulamentar do promotor. Verifique cada produto e fornecedor nos registos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Portugal", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Portugal#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Portugal", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=portugal" }, { "recordId": "pl-compound-country-enicepatide-sweden", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Enicepatide i Sverige", "localizedAnswer": "Enicepatide är ett kliniskt prövningsprogram. Inget kommersiellt erbjudande i Sverige kan automatiskt ärva sponsorns kliniska identitet, studieresultat eller regulatoriska status. Kontrollera varje produkt och leverantör i registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Sweden", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Sweden#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Sweden", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=sweden" }, { "recordId": "pl-compound-country-enicepatide-turkey", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Enicepatide", "localizedAnswer": "Enicepatide klinik geliştirme aşamasındaki bir programdır. Türkiye içindeki aynı adlı hiçbir ticari teklif sponsorun klinik kimliğini, çalışma sonuçlarını veya düzenleyici statüsünü otomatik olarak devralamaz. Belirli ürünü, ruhsat sahibini, kuruluşu ve tedarik yolunu aşağıdaki resmi hedef ülke kayıtlarında kontrol edin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Turkey (Türkiye)", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 4, "clinicalTrialRecruitingLocations": 4, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07351058" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351058" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Turkey%20(T%C3%BCrkiye)#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Turkey%20(T%C3%BCrkiye)", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=turkey" }, { "recordId": "pl-compound-country-enicepatide-austria", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Enicepatide in Österreich", "localizedAnswer": "Enicepatide ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Österreich übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Austria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Austria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Austria", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=austria" }, { "recordId": "pl-compound-country-enicepatide-belgium", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Enicepatide in België", "localizedAnswer": "Enicepatide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in België neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Belgium", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 5, "clinicalTrialRecruitingLocations": 5, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07351045" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351045" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Belgium#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Belgium", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=belgium" }, { "recordId": "pl-compound-country-enicepatide-denmark", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Enicepatide i Danmark", "localizedAnswer": "Enicepatide er et klinisk udviklingsprogram. Et kommercielt tilbud med samme navn i Danmark arver ikke sponsorens kliniske identitet, forsøgsresultater eller regulatoriske status. Kontrollér det konkrete produkt, tilladelsesindehaveren, virksomheden og forsyningsvejen i de officielle registre for destinationen nedenfor.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Denmark", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Denmark#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Denmark", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=denmark" }, { "recordId": "pl-compound-country-enicepatide-finland", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Enicepatide kohteessa Suomi", "localizedAnswer": "Enicepatide on kliininen kehitysohjelma. Samanniminen kaupallinen tarjous kohteessa Suomi ei peri sponsorin kliinistä identiteettiä, tutkimustuloksia tai sääntelyasemaa. Tarkista täsmällinen tuote, luvanhaltija, toimija ja toimitusreitti alla olevista kohdemaan virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Finland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Finland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Finland", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=finland" }, { "recordId": "pl-compound-country-enicepatide-mexico", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Enicepatide en México", "localizedAnswer": "Enicepatide es un programa clínico en investigación. Ninguna oferta comercial en México puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Mexico", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 13, "clinicalTrialRecruitingLocations": 3, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07351058", "NCT06628362", "NCT04838405" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351058", "https://clinicaltrials.gov/study/NCT06628362", "https://clinicaltrials.gov/study/NCT04838405" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Mexico#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Mexico", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=mexico" }, { "recordId": "pl-compound-country-enicepatide-argentina", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Enicepatide en Argentina", "localizedAnswer": "Enicepatide es un programa clínico en investigación. Ninguna oferta comercial en Argentina puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Argentina", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 15, "clinicalTrialRecruitingLocations": 14, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07351045", "NCT07351058", "NCT06628362" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351045", "https://clinicaltrials.gov/study/NCT07351058", "https://clinicaltrials.gov/study/NCT06628362" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Argentina#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Argentina", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=argentina" }, { "recordId": "pl-compound-country-enicepatide-colombia", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Enicepatide en Colombia", "localizedAnswer": "Enicepatide es un programa clínico en investigación. Ninguna oferta comercial en Colombia puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Colombia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Colombia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Colombia", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=colombia" }, { "recordId": "pl-compound-country-enicepatide-chile", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Enicepatide en Chile", "localizedAnswer": "Enicepatide es un programa clínico en investigación. Ninguna oferta comercial en Chile puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Chile", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Chile#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Chile", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=chile" }, { "recordId": "pl-compound-country-enicepatide-brazil", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Enicepatide no Brasil", "localizedAnswer": "Enicepatide é um programa clínico experimental. Nenhuma oferta comercial no Brasil pode herdar a identidade clínica, os resultados de ensaios ou o status regulatório do patrocinador. Verifique cada produto e fornecedor nos registros abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Brazil", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 2, "clinicalTrialRecruitingLocations": 2, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07351045" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351045" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Brazil#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Brazil", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=brazil" }, { "recordId": "pl-compound-country-enicepatide-china", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Enicepatide 在中国的状态与官方记录", "localizedAnswer": "Enicepatide在此对应一个临床与监管项目。项目在某一国家的试验、批准或公司公告，不能自动证明同名商品在中国获批、可得或由有资质的卖方提供。请分别核对目的地的具体药品记录、批准持有人、剂型规格、经营主体和供应路径，并保持临床证据与在线商品身份相互独立。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "China", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 4, "clinicalTrialListedLocations": 47, "clinicalTrialRecruitingLocations": 47, "clinicalTrialRecordsWithRecruitingLocations": 4, "clinicalTrialRecordIds": [ "NCT07351045", "NCT07351058", "NCT07670416", "NCT07626515" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351045", "https://clinicaltrials.gov/study/NCT07351058", "https://clinicaltrials.gov/study/NCT07670416", "https://clinicaltrials.gov/study/NCT07626515" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=China#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=China", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=china" }, { "recordId": "pl-compound-country-enicepatide-australia", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Enicepatide in Australia", "localizedAnswer": "Enicepatide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Australia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 9, "clinicalTrialRecruitingLocations": 8, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07351045", "NCT07351058", "NCT04838405" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351045", "https://clinicaltrials.gov/study/NCT07351058", "https://clinicaltrials.gov/study/NCT04838405" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Australia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Australia", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=australia" }, { "recordId": "pl-compound-country-enicepatide-new-zealand", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Enicepatide in New Zealand", "localizedAnswer": "Enicepatide is an investigational clinical program. No seller listing in New Zealand can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "New Zealand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 5, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT06628362" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06628362" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=New%20Zealand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=New%20Zealand", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=new-zealand" }, { "recordId": "pl-compound-country-enicepatide-india", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Enicepatide in India", "localizedAnswer": "Enicepatide is an investigational clinical program. No seller listing in India can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "India", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=India#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=India", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=india" }, { "recordId": "pl-compound-country-enicepatide-japan", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のEnicepatide / エニセパチド", "localizedAnswer": "Enicepatide / エニセパチドは臨床開発中のプログラムです。スポンサーの臨床上の同一性、試験結果、規制上の位置付けを、日本の同名オンライン商品や販売者が自動的に引き継ぐことはありません。目的地の製品、承認保持者、施設、供給経路を下記の公的記録で確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Japan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 12, "clinicalTrialRecruitingLocations": 12, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07351045", "NCT07351058" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351045", "https://clinicaltrials.gov/study/NCT07351058" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Japan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Japan", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=japan" }, { "recordId": "pl-compound-country-enicepatide-south-korea", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Enicepatide / 에니세파타이드", "localizedAnswer": "Enicepatide / 에니세파타이드은 임상 개발 중인 프로그램입니다. 후원사의 임상 신원, 시험 결과 또는 규제 상태를 대한민국의 동명 온라인 상품이나 판매자가 자동으로 이어받을 수 없습니다. 목적지의 정확한 제품, 허가권자, 기관과 공급 경로를 아래 공식 기록에서 확인해야 합니다.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "South Korea", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 13, "clinicalTrialRecruitingLocations": 13, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07351045", "NCT07351058" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351045", "https://clinicaltrials.gov/study/NCT07351058" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=South%20Korea#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=South%20Korea", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=south-korea" }, { "recordId": "pl-compound-country-enicepatide-thailand", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Enicepatide ในประเทศไทย", "localizedAnswer": "Enicepatide เป็นโครงการที่อยู่ระหว่างการพัฒนาทางคลินิก สินค้าหรือผู้ขายชื่อเดียวกันในประเทศไทยไม่สามารถรับช่วงตัวตนทางคลินิก ผลการทดลอง หรือสถานะด้านกฎระเบียบของผู้สนับสนุนโดยอัตโนมัติ ให้ตรวจผลิตภัณฑ์ ผู้ถือทะเบียน สถานประกอบการ และเส้นทางการจัดหาที่แน่นอนในบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Thailand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 6, "clinicalTrialRecruitingLocations": 6, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07351058" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351058" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Thailand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Thailand", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=thailand" }, { "recordId": "pl-compound-country-enicepatide-indonesia", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Enicepatide di Indonesia", "localizedAnswer": "Enicepatide adalah program yang sedang dikembangkan secara klinis. Produk atau penjual dengan nama sama di Indonesia tidak otomatis mewarisi identitas klinis sponsor, hasil uji, atau status regulasinya. Periksa produk, pemegang izin, fasilitas, dan jalur pasok yang tepat dalam catatan resmi tujuan di bawah.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Indonesia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Indonesia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Indonesia", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=indonesia" }, { "recordId": "pl-compound-country-enicepatide-singapore", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Enicepatide in Singapore", "localizedAnswer": "Enicepatide is an investigational clinical program. No seller listing in Singapore can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Singapore", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Singapore#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Singapore", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=singapore" }, { "recordId": "pl-compound-country-enicepatide-philippines", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Enicepatide in the Philippines", "localizedAnswer": "Enicepatide is an investigational clinical program. No seller listing in the Philippines can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Philippines", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Philippines#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Philippines", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=philippines" }, { "recordId": "pl-compound-country-enicepatide-malaysia", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Enicepatide in Malaysia", "localizedAnswer": "Enicepatide is an investigational clinical program. No seller listing in Malaysia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Malaysia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Malaysia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Malaysia", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=malaysia" }, { "recordId": "pl-compound-country-enicepatide-taiwan", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Enicepatide 在台灣的紀錄", "localizedAnswer": "Enicepatide是臨床開發中的計畫。贊助者的臨床身分、試驗結果或法規狀態，不會自動移轉給台灣的同名網路商品或提供者。必須利用下方紀錄核對目的地的具體產品、許可證持有者、機構與供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Taiwan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 16, "clinicalTrialRecruitingLocations": 16, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07351045", "NCT07351058" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351045", "https://clinicaltrials.gov/study/NCT07351058" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Taiwan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Taiwan", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=taiwan" }, { "recordId": "pl-compound-country-enicepatide-hong-kong", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Enicepatide 在香港的紀錄", "localizedAnswer": "Enicepatide是臨床開發中的計劃。贊助者的臨床身分、試驗結果或監管狀態，不會自動轉移給香港的同名網上商品或銷售商。必須透過下方紀錄核對目的地的指定產品、註冊持有人、持牌實體和供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Hong Kong", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Hong%20Kong#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Hong%20Kong", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=hong-kong" }, { "recordId": "pl-compound-country-enicepatide-vietnam", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Enicepatide tại Việt Nam", "localizedAnswer": "Enicepatide là một chương trình đang phát triển lâm sàng. Không đề nghị thương mại nào tại Việt Nam tự động kế thừa danh tính lâm sàng, kết quả thử nghiệm hoặc tình trạng quản lý của nhà tài trợ. Cần kiểm tra sản phẩm, chủ sở hữu giấy phép, cơ sở và đường cung ứng cụ thể trong các hồ sơ chính thức của điểm đến ở dưới.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Vietnam", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Vietnam#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Vietnam", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=vietnam" }, { "recordId": "pl-compound-country-enicepatide-united-states", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Enicepatide in the United States", "localizedAnswer": "Enicepatide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "United States", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 4, "clinicalTrialListedLocations": 157, "clinicalTrialRecruitingLocations": 71, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07351045", "NCT07351058", "NCT06628362", "NCT06525935" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351045", "https://clinicaltrials.gov/study/NCT07351058", "https://clinicaltrials.gov/study/NCT06628362", "https://clinicaltrials.gov/study/NCT06525935" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=United%20States#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=United%20States", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=united-states" }, { "recordId": "pl-compound-country-enicepatide-canada", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Enicepatide in Canada", "localizedAnswer": "Enicepatide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Canada", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 17, "clinicalTrialRecruitingLocations": 15, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07351045", "NCT07351058", "NCT06628362" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07351045", "https://clinicaltrials.gov/study/NCT07351058", "https://clinicaltrials.gov/study/NCT06628362" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Canada#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Canada", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=canada" }, { "recordId": "pl-compound-country-enicepatide-united-arab-emirates", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Enicepatide / إينيسباتايد في الإمارات العربية المتحدة", "localizedAnswer": "Enicepatide / إينيسباتايد برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في الإمارات العربية المتحدة أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "United Arab Emirates", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=United%20Arab%20Emirates#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=United%20Arab%20Emirates", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=united-arab-emirates" }, { "recordId": "pl-compound-country-enicepatide-saudi-arabia", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Enicepatide / إينيسباتايد في المملكة العربية السعودية", "localizedAnswer": "Enicepatide / إينيسباتايد برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في المملكة العربية السعودية أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Saudi Arabia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Saudi%20Arabia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Saudi%20Arabia", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=saudi-arabia" }, { "recordId": "pl-compound-country-enicepatide-south-africa", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Enicepatide in South Africa", "localizedAnswer": "Enicepatide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "South Africa", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=South%20Africa#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=South%20Africa", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=south-africa" }, { "recordId": "pl-compound-country-enicepatide-nigeria", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Enicepatide in Nigeria", "localizedAnswer": "Enicepatide is an investigational clinical program. No seller listing in Nigeria can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Nigeria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Nigeria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Nigeria", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=nigeria" }, { "recordId": "pl-compound-country-enicepatide-kenya", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Enicepatide in Kenya", "localizedAnswer": "Enicepatide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Enicepatide", "clinicalTrialRegistryCountry": "Kenya", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=enicepatide&country=Kenya#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Enicepatide&locStr=Kenya", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/enicepatide", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/enicepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=enicepatide&country=kenya" }, { "recordId": "pl-compound-country-eloralintide-france", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Eloralintide en France", "localizedAnswer": "Eloralintide est un programme clinique expérimental. Aucune offre commerciale en France ne peut reprendre automatiquement l’identité clinique, les résultats d’essais ou le statut réglementaire du promoteur. Vérifiez chaque produit et fournisseur dans les registres ci-dessous.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "France", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=France#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=France", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=france" }, { "recordId": "pl-compound-country-eloralintide-united-kingdom", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Eloralintide in the United Kingdom", "localizedAnswer": "Eloralintide is an investigational clinical program. No seller listing in the United Kingdom can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "United Kingdom", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 17, "clinicalTrialRecruitingLocations": 17, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07321886", "NCT07353931" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07321886", "https://clinicaltrials.gov/study/NCT07353931" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=United%20Kingdom#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=United%20Kingdom", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=united-kingdom" }, { "recordId": "pl-compound-country-eloralintide-germany", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Eloralintide in Deutschland", "localizedAnswer": "Eloralintide ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Deutschland übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Germany", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 37, "clinicalTrialRecruitingLocations": 20, "clinicalTrialRecordsWithRecruitingLocations": 4, "clinicalTrialRecordIds": [ "NCT07321886", "NCT07353931", "NCT07369011", "NCT07665879", "NCT07282600" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07321886", "https://clinicaltrials.gov/study/NCT07353931", "https://clinicaltrials.gov/study/NCT07369011", "https://clinicaltrials.gov/study/NCT07665879", "https://clinicaltrials.gov/study/NCT07282600" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Germany#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Germany", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=germany" }, { "recordId": "pl-compound-country-eloralintide-spain", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Eloralintide en España", "localizedAnswer": "Eloralintide es un programa clínico en investigación. Ninguna oferta comercial en España puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Spain", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 28, "clinicalTrialRecruitingLocations": 16, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07369011", "NCT07392190", "NCT07282600" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07369011", "https://clinicaltrials.gov/study/NCT07392190", "https://clinicaltrials.gov/study/NCT07282600" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Spain#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Spain", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=spain" }, { "recordId": "pl-compound-country-eloralintide-italy", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Eloralintide in Italia", "localizedAnswer": "Eloralintide è un programma clinico sperimentale. Nessuna offerta commerciale in Italia può ereditare l’identità clinica, i risultati degli studi o lo stato regolatorio dello sponsor. Verifica ogni prodotto e fornitore nei registri riportati sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Italy", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Italy#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Italy", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=italy" }, { "recordId": "pl-compound-country-eloralintide-netherlands", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Eloralintide in Nederland", "localizedAnswer": "Eloralintide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in Nederland neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Netherlands", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Netherlands#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Netherlands", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=netherlands" }, { "recordId": "pl-compound-country-eloralintide-switzerland", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Eloralintide in Switzerland", "localizedAnswer": "Eloralintide is an investigational clinical program. No seller listing in Switzerland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Switzerland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Switzerland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Switzerland", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=switzerland" }, { "recordId": "pl-compound-country-eloralintide-poland", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Eloralintide w Polsce", "localizedAnswer": "Eloralintide jest eksperymentalnym programem klinicznym. Żadna oferta handlowa w Polsce nie przejmuje automatycznie tożsamości klinicznej, wyników badań ani statusu regulacyjnego sponsora. Sprawdź każdy produkt i dostawcę w rejestrach poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Poland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 17, "clinicalTrialRecruitingLocations": 17, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07282600", "NCT07321886" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07282600", "https://clinicaltrials.gov/study/NCT07321886" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Poland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Poland", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=poland" }, { "recordId": "pl-compound-country-eloralintide-ireland", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Eloralintide in Ireland", "localizedAnswer": "Eloralintide is an investigational clinical program. No seller listing in Ireland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Ireland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Ireland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Ireland", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=ireland" }, { "recordId": "pl-compound-country-eloralintide-portugal", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Eloralintide em Portugal", "localizedAnswer": "Eloralintide é um programa clínico experimental. Nenhuma oferta comercial em Portugal pode herdar a identidade clínica, os resultados de ensaios ou o estatuto regulamentar do promotor. Verifique cada produto e fornecedor nos registos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Portugal", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Portugal#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Portugal", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=portugal" }, { "recordId": "pl-compound-country-eloralintide-sweden", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Eloralintide i Sverige", "localizedAnswer": "Eloralintide är ett kliniskt prövningsprogram. Inget kommersiellt erbjudande i Sverige kan automatiskt ärva sponsorns kliniska identitet, studieresultat eller regulatoriska status. Kontrollera varje produkt och leverantör i registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Sweden", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 1, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07665879" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07665879" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Sweden#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Sweden", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=sweden" }, { "recordId": "pl-compound-country-eloralintide-turkey", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Eloralintide", "localizedAnswer": "Eloralintide klinik geliştirme aşamasındaki bir programdır. Türkiye içindeki aynı adlı hiçbir ticari teklif sponsorun klinik kimliğini, çalışma sonuçlarını veya düzenleyici statüsünü otomatik olarak devralamaz. Belirli ürünü, ruhsat sahibini, kuruluşu ve tedarik yolunu aşağıdaki resmi hedef ülke kayıtlarında kontrol edin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Turkey (Türkiye)", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Turkey%20(T%C3%BCrkiye)#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Turkey%20(T%C3%BCrkiye)", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=turkey" }, { "recordId": "pl-compound-country-eloralintide-austria", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Eloralintide in Österreich", "localizedAnswer": "Eloralintide ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Österreich übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Austria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Austria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Austria", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=austria" }, { "recordId": "pl-compound-country-eloralintide-belgium", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Eloralintide in België", "localizedAnswer": "Eloralintide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in België neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Belgium", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 21, "clinicalTrialRecruitingLocations": 16, "clinicalTrialRecordsWithRecruitingLocations": 3, "clinicalTrialRecordIds": [ "NCT07321886", "NCT07353931", "NCT07392190" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07321886", "https://clinicaltrials.gov/study/NCT07353931", "https://clinicaltrials.gov/study/NCT07392190" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Belgium#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Belgium", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=belgium" }, { "recordId": "pl-compound-country-eloralintide-denmark", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Eloralintide i Danmark", "localizedAnswer": "Eloralintide er et klinisk udviklingsprogram. Et kommercielt tilbud med samme navn i Danmark arver ikke sponsorens kliniske identitet, forsøgsresultater eller regulatoriske status. Kontrollér det konkrete produkt, tilladelsesindehaveren, virksomheden og forsyningsvejen i de officielle registre for destinationen nedenfor.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Denmark", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 3, "clinicalTrialRecruitingLocations": 3, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07353931" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07353931" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Denmark#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Denmark", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=denmark" }, { "recordId": "pl-compound-country-eloralintide-finland", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Eloralintide kohteessa Suomi", "localizedAnswer": "Eloralintide on kliininen kehitysohjelma. Samanniminen kaupallinen tarjous kohteessa Suomi ei peri sponsorin kliinistä identiteettiä, tutkimustuloksia tai sääntelyasemaa. Tarkista täsmällinen tuote, luvanhaltija, toimija ja toimitusreitti alla olevista kohdemaan virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Finland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Finland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Finland", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=finland" }, { "recordId": "pl-compound-country-eloralintide-mexico", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Eloralintide en México", "localizedAnswer": "Eloralintide es un programa clínico en investigación. Ninguna oferta comercial en México puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Mexico", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 20, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07282600", "NCT07353931", "NCT07392190" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07282600", "https://clinicaltrials.gov/study/NCT07353931", "https://clinicaltrials.gov/study/NCT07392190" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Mexico#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Mexico", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=mexico" }, { "recordId": "pl-compound-country-eloralintide-argentina", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Eloralintide en Argentina", "localizedAnswer": "Eloralintide es un programa clínico en investigación. Ninguna oferta comercial en Argentina puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Argentina", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 7, "clinicalTrialListedLocations": 61, "clinicalTrialRecruitingLocations": 10, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06143956", "NCT07215559", "NCT07282600", "NCT07321886", "NCT07353931", "NCT07369011", "NCT06603571" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06143956", "https://clinicaltrials.gov/study/NCT07215559", "https://clinicaltrials.gov/study/NCT07282600", "https://clinicaltrials.gov/study/NCT07321886", "https://clinicaltrials.gov/study/NCT07353931", "https://clinicaltrials.gov/study/NCT07369011", "https://clinicaltrials.gov/study/NCT06603571" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Argentina#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Argentina", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=argentina" }, { "recordId": "pl-compound-country-eloralintide-colombia", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Eloralintide en Colombia", "localizedAnswer": "Eloralintide es un programa clínico en investigación. Ninguna oferta comercial en Colombia puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Colombia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Colombia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Colombia", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=colombia" }, { "recordId": "pl-compound-country-eloralintide-chile", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Eloralintide en Chile", "localizedAnswer": "Eloralintide es un programa clínico en investigación. Ninguna oferta comercial en Chile puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Chile", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Chile#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Chile", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=chile" }, { "recordId": "pl-compound-country-eloralintide-brazil", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Eloralintide no Brasil", "localizedAnswer": "Eloralintide é um programa clínico experimental. Nenhuma oferta comercial no Brasil pode herdar a identidade clínica, os resultados de ensaios ou o status regulatório do patrocinador. Verifique cada produto e fornecedor nos registros abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Brazil", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 4, "clinicalTrialListedLocations": 34, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07321886", "NCT07353931", "NCT07369011", "NCT07392190" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07321886", "https://clinicaltrials.gov/study/NCT07353931", "https://clinicaltrials.gov/study/NCT07369011", "https://clinicaltrials.gov/study/NCT07392190" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Brazil#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Brazil", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=brazil" }, { "recordId": "pl-compound-country-eloralintide-china", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Eloralintide 在中国的状态与官方记录", "localizedAnswer": "Eloralintide在此对应一个临床与监管项目。项目在某一国家的试验、批准或公司公告，不能自动证明同名商品在中国获批、可得或由有资质的卖方提供。请分别核对目的地的具体药品记录、批准持有人、剂型规格、经营主体和供应路径，并保持临床证据与在线商品身份相互独立。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "China", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 96, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07282600", "NCT07321886", "NCT07353931", "NCT07369011", "NCT07392190" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07282600", "https://clinicaltrials.gov/study/NCT07321886", "https://clinicaltrials.gov/study/NCT07353931", "https://clinicaltrials.gov/study/NCT07369011", "https://clinicaltrials.gov/study/NCT07392190" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=China#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=China", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=china" }, { "recordId": "pl-compound-country-eloralintide-australia", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Eloralintide in Australia", "localizedAnswer": "Eloralintide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Australia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 4, "clinicalTrialListedLocations": 37, "clinicalTrialRecruitingLocations": 34, "clinicalTrialRecordsWithRecruitingLocations": 4, "clinicalTrialRecordIds": [ "NCT07215559", "NCT07321886", "NCT07369011", "NCT07392190" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07215559", "https://clinicaltrials.gov/study/NCT07321886", "https://clinicaltrials.gov/study/NCT07369011", "https://clinicaltrials.gov/study/NCT07392190" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Australia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Australia", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=australia" }, { "recordId": "pl-compound-country-eloralintide-new-zealand", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Eloralintide in New Zealand", "localizedAnswer": "Eloralintide is an investigational clinical program. No seller listing in New Zealand can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "New Zealand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=New%20Zealand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=New%20Zealand", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=new-zealand" }, { "recordId": "pl-compound-country-eloralintide-india", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Eloralintide in India", "localizedAnswer": "Eloralintide is an investigational clinical program. No seller listing in India can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "India", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 28, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07282600", "NCT07321886", "NCT07369011" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07282600", "https://clinicaltrials.gov/study/NCT07321886", "https://clinicaltrials.gov/study/NCT07369011" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=India#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=India", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=india" }, { "recordId": "pl-compound-country-eloralintide-japan", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のEloralintide / エロラリンチド", "localizedAnswer": "Eloralintide / エロラリンチドは臨床開発中のプログラムです。スポンサーの臨床上の同一性、試験結果、規制上の位置付けを、日本の同名オンライン商品や販売者が自動的に引き継ぐことはありません。目的地の製品、承認保持者、施設、供給経路を下記の公的記録で確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Japan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 6, "clinicalTrialListedLocations": 63, "clinicalTrialRecruitingLocations": 60, "clinicalTrialRecordsWithRecruitingLocations": 5, "clinicalTrialRecordIds": [ "NCT07282600", "NCT07321886", "NCT07353931", "NCT07369011", "NCT07392190", "NCT06297616" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07282600", "https://clinicaltrials.gov/study/NCT07321886", "https://clinicaltrials.gov/study/NCT07353931", "https://clinicaltrials.gov/study/NCT07369011", "https://clinicaltrials.gov/study/NCT07392190", "https://clinicaltrials.gov/study/NCT06297616" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Japan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Japan", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=japan" }, { "recordId": "pl-compound-country-eloralintide-south-korea", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Eloralintide / 엘로랄린타이드", "localizedAnswer": "Eloralintide / 엘로랄린타이드은 임상 개발 중인 프로그램입니다. 후원사의 임상 신원, 시험 결과 또는 규제 상태를 대한민국의 동명 온라인 상품이나 판매자가 자동으로 이어받을 수 없습니다. 목적지의 정확한 제품, 허가권자, 기관과 공급 경로를 아래 공식 기록에서 확인해야 합니다.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "South Korea", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 4, "clinicalTrialListedLocations": 22, "clinicalTrialRecruitingLocations": 20, "clinicalTrialRecordsWithRecruitingLocations": 4, "clinicalTrialRecordIds": [ "NCT07282600", "NCT07321886", "NCT07353931", "NCT07369011" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07282600", "https://clinicaltrials.gov/study/NCT07321886", "https://clinicaltrials.gov/study/NCT07353931", "https://clinicaltrials.gov/study/NCT07369011" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=South%20Korea#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=South%20Korea", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=south-korea" }, { "recordId": "pl-compound-country-eloralintide-thailand", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Eloralintide ในประเทศไทย", "localizedAnswer": "Eloralintide เป็นโครงการที่อยู่ระหว่างการพัฒนาทางคลินิก สินค้าหรือผู้ขายชื่อเดียวกันในประเทศไทยไม่สามารถรับช่วงตัวตนทางคลินิก ผลการทดลอง หรือสถานะด้านกฎระเบียบของผู้สนับสนุนโดยอัตโนมัติ ให้ตรวจผลิตภัณฑ์ ผู้ถือทะเบียน สถานประกอบการ และเส้นทางการจัดหาที่แน่นอนในบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Thailand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Thailand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Thailand", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=thailand" }, { "recordId": "pl-compound-country-eloralintide-indonesia", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Eloralintide di Indonesia", "localizedAnswer": "Eloralintide adalah program yang sedang dikembangkan secara klinis. Produk atau penjual dengan nama sama di Indonesia tidak otomatis mewarisi identitas klinis sponsor, hasil uji, atau status regulasinya. Periksa produk, pemegang izin, fasilitas, dan jalur pasok yang tepat dalam catatan resmi tujuan di bawah.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Indonesia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Indonesia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Indonesia", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=indonesia" }, { "recordId": "pl-compound-country-eloralintide-singapore", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Eloralintide in Singapore", "localizedAnswer": "Eloralintide is an investigational clinical program. No seller listing in Singapore can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Singapore", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 1, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT06916091" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06916091" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Singapore#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Singapore", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=singapore" }, { "recordId": "pl-compound-country-eloralintide-philippines", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Eloralintide in the Philippines", "localizedAnswer": "Eloralintide is an investigational clinical program. No seller listing in the Philippines can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Philippines", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Philippines#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Philippines", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=philippines" }, { "recordId": "pl-compound-country-eloralintide-malaysia", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Eloralintide in Malaysia", "localizedAnswer": "Eloralintide is an investigational clinical program. No seller listing in Malaysia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Malaysia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Malaysia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Malaysia", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=malaysia" }, { "recordId": "pl-compound-country-eloralintide-taiwan", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Eloralintide 在台灣的紀錄", "localizedAnswer": "Eloralintide是臨床開發中的計畫。贊助者的臨床身分、試驗結果或法規狀態，不會自動移轉給台灣的同名網路商品或提供者。必須利用下方紀錄核對目的地的具體產品、許可證持有者、機構與供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Taiwan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 29, "clinicalTrialRecruitingLocations": 22, "clinicalTrialRecordsWithRecruitingLocations": 5, "clinicalTrialRecordIds": [ "NCT07282600", "NCT07321886", "NCT07353931", "NCT07369011", "NCT07392190" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07282600", "https://clinicaltrials.gov/study/NCT07321886", "https://clinicaltrials.gov/study/NCT07353931", "https://clinicaltrials.gov/study/NCT07369011", "https://clinicaltrials.gov/study/NCT07392190" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Taiwan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Taiwan", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=taiwan" }, { "recordId": "pl-compound-country-eloralintide-hong-kong", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Eloralintide 在香港的紀錄", "localizedAnswer": "Eloralintide是臨床開發中的計劃。贊助者的臨床身分、試驗結果或監管狀態，不會自動轉移給香港的同名網上商品或銷售商。必須透過下方紀錄核對目的地的指定產品、註冊持有人、持牌實體和供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Hong Kong", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Hong%20Kong#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Hong%20Kong", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=hong-kong" }, { "recordId": "pl-compound-country-eloralintide-vietnam", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Eloralintide tại Việt Nam", "localizedAnswer": "Eloralintide là một chương trình đang phát triển lâm sàng. Không đề nghị thương mại nào tại Việt Nam tự động kế thừa danh tính lâm sàng, kết quả thử nghiệm hoặc tình trạng quản lý của nhà tài trợ. Cần kiểm tra sản phẩm, chủ sở hữu giấy phép, cơ sở và đường cung ứng cụ thể trong các hồ sơ chính thức của điểm đến ở dưới.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Vietnam", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Vietnam#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Vietnam", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=vietnam" }, { "recordId": "pl-compound-country-eloralintide-united-states", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Eloralintide in the United States", "localizedAnswer": "Eloralintide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "United States", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 16, "clinicalTrialListedLocations": 443, "clinicalTrialRecruitingLocations": 322, "clinicalTrialRecordsWithRecruitingLocations": 10, "clinicalTrialRecordIds": [ "NCT06143956", "NCT07215559", "NCT07282600", "NCT07321886", "NCT07353931", "NCT07369011", "NCT07392190", "NCT07589608", "NCT07401862", "NCT07426380", "NCT06603571", "NCT07701083", "NCT06230523", "NCT06916065", "NCT06345066", "NCT05295940" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06143956", "https://clinicaltrials.gov/study/NCT07215559", "https://clinicaltrials.gov/study/NCT07282600", "https://clinicaltrials.gov/study/NCT07321886", "https://clinicaltrials.gov/study/NCT07353931", "https://clinicaltrials.gov/study/NCT07369011", "https://clinicaltrials.gov/study/NCT07392190", "https://clinicaltrials.gov/study/NCT07589608", "https://clinicaltrials.gov/study/NCT07401862", "https://clinicaltrials.gov/study/NCT07426380", "https://clinicaltrials.gov/study/NCT06603571", "https://clinicaltrials.gov/study/NCT07701083", "https://clinicaltrials.gov/study/NCT06230523", "https://clinicaltrials.gov/study/NCT06916065", "https://clinicaltrials.gov/study/NCT06345066", "https://clinicaltrials.gov/study/NCT05295940" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=United%20States#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=United%20States", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=united-states" }, { "recordId": "pl-compound-country-eloralintide-canada", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Eloralintide in Canada", "localizedAnswer": "Eloralintide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Canada", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 23, "clinicalTrialRecruitingLocations": 21, "clinicalTrialRecordsWithRecruitingLocations": 3, "clinicalTrialRecordIds": [ "NCT07321886", "NCT07353931", "NCT07369011" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07321886", "https://clinicaltrials.gov/study/NCT07353931", "https://clinicaltrials.gov/study/NCT07369011" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Canada#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Canada", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=canada" }, { "recordId": "pl-compound-country-eloralintide-united-arab-emirates", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Eloralintide / إلورالينتايد في الإمارات العربية المتحدة", "localizedAnswer": "Eloralintide / إلورالينتايد برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في الإمارات العربية المتحدة أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "United Arab Emirates", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=United%20Arab%20Emirates#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=United%20Arab%20Emirates", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=united-arab-emirates" }, { "recordId": "pl-compound-country-eloralintide-saudi-arabia", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Eloralintide / إلورالينتايد في المملكة العربية السعودية", "localizedAnswer": "Eloralintide / إلورالينتايد برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في المملكة العربية السعودية أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Saudi Arabia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Saudi%20Arabia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Saudi%20Arabia", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=saudi-arabia" }, { "recordId": "pl-compound-country-eloralintide-south-africa", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Eloralintide in South Africa", "localizedAnswer": "Eloralintide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "South Africa", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=South%20Africa#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=South%20Africa", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=south-africa" }, { "recordId": "pl-compound-country-eloralintide-nigeria", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Eloralintide in Nigeria", "localizedAnswer": "Eloralintide is an investigational clinical program. No seller listing in Nigeria can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Nigeria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Nigeria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Nigeria", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=nigeria" }, { "recordId": "pl-compound-country-eloralintide-kenya", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Eloralintide in Kenya", "localizedAnswer": "Eloralintide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Eloralintide", "clinicalTrialRegistryCountry": "Kenya", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=eloralintide&country=Kenya#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Eloralintide&locStr=Kenya", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/eloralintide", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/eloralintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=eloralintide&country=kenya" }, { "recordId": "pl-compound-country-cagrilintide-france", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Cagrilintide en France", "localizedAnswer": "Cagrilintide est un programme clinique expérimental. Aucune offre commerciale en France ne peut reprendre automatiquement l’identité clinique, les résultats d’essais ou le statut réglementaire du promoteur. Vérifiez chaque produit et fournisseur dans les registres ci-dessous.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "France", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 9, "clinicalTrialListedLocations": 57, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07564414", "NCT05567796", "NCT05669755", "NCT07220642", "NCT06388187", "NCT06131372", "NCT06409130", "NCT06797869", "NCT05016882" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT07220642", "https://clinicaltrials.gov/study/NCT06388187", "https://clinicaltrials.gov/study/NCT06131372", "https://clinicaltrials.gov/study/NCT06409130", "https://clinicaltrials.gov/study/NCT06797869", "https://clinicaltrials.gov/study/NCT05016882" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=France#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=France", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=france" }, { "recordId": "pl-compound-country-cagrilintide-united-kingdom", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Cagrilintide in the United Kingdom", "localizedAnswer": "Cagrilintide is an investigational clinical program. No seller listing in the United Kingdom can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "United Kingdom", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 13, "clinicalTrialListedLocations": 108, "clinicalTrialRecruitingLocations": 4, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07253285", "NCT07411560", "NCT05567796", "NCT05669755", "NCT06065540", "NCT07220642", "NCT06388187", "NCT07220759", "NCT05394519", "NCT06780449", "NCT06797869", "NCT05016882", "NCT03856047" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT07411560", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07220642", "https://clinicaltrials.gov/study/NCT06388187", "https://clinicaltrials.gov/study/NCT07220759", "https://clinicaltrials.gov/study/NCT05394519", "https://clinicaltrials.gov/study/NCT06780449", "https://clinicaltrials.gov/study/NCT06797869", "https://clinicaltrials.gov/study/NCT05016882", "https://clinicaltrials.gov/study/NCT03856047" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=United%20Kingdom#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=United%20Kingdom", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=united-kingdom" }, { "recordId": "pl-compound-country-cagrilintide-germany", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Cagrilintide / Cagrilintid in Deutschland", "localizedAnswer": "Cagrilintide / Cagrilintid ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Deutschland übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Germany", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 16, "clinicalTrialListedLocations": 90, "clinicalTrialRecruitingLocations": 2, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07597018", "NCT07557953", "NCT05567796", "NCT05669755", "NCT06534411", "NCT06065540", "NCT07220642", "NCT06388187", "NCT06409130", "NCT06403761", "NCT05394519", "NCT06207877", "NCT06267092", "NCT05564104", "NCT05016882", "NCT05804162" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07597018", "https://clinicaltrials.gov/study/NCT07557953", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07220642", "https://clinicaltrials.gov/study/NCT06388187", "https://clinicaltrials.gov/study/NCT06409130", "https://clinicaltrials.gov/study/NCT06403761", "https://clinicaltrials.gov/study/NCT05394519", "https://clinicaltrials.gov/study/NCT06207877", "https://clinicaltrials.gov/study/NCT06267092", "https://clinicaltrials.gov/study/NCT05564104", "https://clinicaltrials.gov/study/NCT05016882", "https://clinicaltrials.gov/study/NCT05804162" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Germany#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Germany", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=germany" }, { "recordId": "pl-compound-country-cagrilintide-spain", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Cagrilintide / cagrilintida en España", "localizedAnswer": "Cagrilintide / cagrilintida es un programa clínico en investigación. Ninguna oferta comercial en España puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Spain", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 11, "clinicalTrialListedLocations": 92, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT07564414", "NCT05567796", "NCT05669755", "NCT06534411", "NCT07357740", "NCT06065540", "NCT06131372", "NCT06409130", "NCT06797869", "NCT05016882" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT07357740", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT06131372", "https://clinicaltrials.gov/study/NCT06409130", "https://clinicaltrials.gov/study/NCT06797869", "https://clinicaltrials.gov/study/NCT05016882" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Spain#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Spain", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=spain" }, { "recordId": "pl-compound-country-cagrilintide-italy", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Cagrilintide in Italia", "localizedAnswer": "Cagrilintide è un programma clinico sperimentale. Nessuna offerta commerciale in Italia può ereditare l’identità clinica, i risultati degli studi o lo stato regolatorio dello sponsor. Verifica ogni prodotto e fornitore nei registri riportati sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Italy", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 9, "clinicalTrialListedLocations": 85, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT07564414", "NCT05567796", "NCT05669755", "NCT06065540", "NCT07220642", "NCT06323174", "NCT06409130", "NCT05016882" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07220642", "https://clinicaltrials.gov/study/NCT06323174", "https://clinicaltrials.gov/study/NCT06409130", "https://clinicaltrials.gov/study/NCT05016882" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Italy#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Italy", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=italy" }, { "recordId": "pl-compound-country-cagrilintide-netherlands", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Cagrilintide in Nederland", "localizedAnswer": "Cagrilintide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in Nederland neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Netherlands", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 28, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT07564414", "NCT05567796", "NCT05669755", "NCT06409130" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06409130" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Netherlands#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Netherlands", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=netherlands" }, { "recordId": "pl-compound-country-cagrilintide-switzerland", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Cagrilintide in Switzerland", "localizedAnswer": "Cagrilintide is an investigational clinical program. No seller listing in Switzerland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Switzerland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 8, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07357766", "NCT07220759" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07357766", "https://clinicaltrials.gov/study/NCT07220759" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Switzerland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Switzerland", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=switzerland" }, { "recordId": "pl-compound-country-cagrilintide-poland", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Cagrilintide w Polsce", "localizedAnswer": "Cagrilintide jest eksperymentalnym programem klinicznym. Żadna oferta handlowa w Polsce nie przejmuje automatycznie tożsamości klinicznej, wyników badań ani statusu regulacyjnego sponsora. Sprawdź każdy produkt i dostawcę w rejestrach poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Poland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 14, "clinicalTrialListedLocations": 203, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT07564414", "NCT05567796", "NCT05669755", "NCT06534411", "NCT07357766", "NCT06065540", "NCT07220642", "NCT06323174", "NCT06131372", "NCT06409130", "NCT05394519", "NCT05016882", "NCT03856047" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT07357766", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07220642", "https://clinicaltrials.gov/study/NCT06323174", "https://clinicaltrials.gov/study/NCT06131372", "https://clinicaltrials.gov/study/NCT06409130", "https://clinicaltrials.gov/study/NCT05394519", "https://clinicaltrials.gov/study/NCT05016882", "https://clinicaltrials.gov/study/NCT03856047" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Poland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Poland", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=poland" }, { "recordId": "pl-compound-country-cagrilintide-ireland", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Cagrilintide in Ireland", "localizedAnswer": "Cagrilintide is an investigational clinical program. No seller listing in Ireland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Ireland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 16, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT05669755", "NCT05394519", "NCT03856047" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT05394519", "https://clinicaltrials.gov/study/NCT03856047" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Ireland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Ireland", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=ireland" }, { "recordId": "pl-compound-country-cagrilintide-portugal", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Cagrilintide / cagrilintida em Portugal", "localizedAnswer": "Cagrilintide / cagrilintida é um programa clínico experimental. Nenhuma oferta comercial em Portugal pode herdar a identidade clínica, os resultados de ensaios ou o estatuto regulamentar do promotor. Verifique cada produto e fornecedor nos registos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Portugal", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 26, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT07564414", "NCT07357766", "NCT06780449", "NCT05016882" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT07357766", "https://clinicaltrials.gov/study/NCT06780449", "https://clinicaltrials.gov/study/NCT05016882" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Portugal#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Portugal", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=portugal" }, { "recordId": "pl-compound-country-cagrilintide-sweden", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Cagrilintide i Sverige", "localizedAnswer": "Cagrilintide är ett kliniskt prövningsprogram. Inget kommersiellt erbjudande i Sverige kan automatiskt ärva sponsorns kliniska identitet, studieresultat eller regulatoriska status. Kontrollera varje produkt och leverantör i registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Sweden", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 9, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT06065540" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT06065540" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Sweden#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Sweden", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=sweden" }, { "recordId": "pl-compound-country-cagrilintide-turkey", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Cagrilintide / kagrilintid", "localizedAnswer": "Cagrilintide / kagrilintid klinik geliştirme aşamasındaki bir programdır. Türkiye içindeki aynı adlı hiçbir ticari teklif sponsorun klinik kimliğini, çalışma sonuçlarını veya düzenleyici statüsünü otomatik olarak devralamaz. Belirli ürünü, ruhsat sahibini, kuruluşu ve tedarik yolunu aşağıdaki resmi hedef ülke kayıtlarında kontrol edin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Turkey (Türkiye)", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 4, "clinicalTrialListedLocations": 81, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT05567796", "NCT05669755", "NCT06065540", "NCT05016882" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT05016882" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Turkey%20(T%C3%BCrkiye)#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Turkey%20(T%C3%BCrkiye)", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=turkey" }, { "recordId": "pl-compound-country-cagrilintide-austria", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Cagrilintide / Cagrilintid in Österreich", "localizedAnswer": "Cagrilintide / Cagrilintid ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Österreich übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Austria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 16, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT07564414", "NCT05394519" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05394519" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Austria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Austria", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=austria" }, { "recordId": "pl-compound-country-cagrilintide-belgium", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Cagrilintide in België", "localizedAnswer": "Cagrilintide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in België neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Belgium", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 26, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT07564414", "NCT05567796", "NCT06780449", "NCT05016882" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT06780449", "https://clinicaltrials.gov/study/NCT05016882" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Belgium#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Belgium", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=belgium" }, { "recordId": "pl-compound-country-cagrilintide-denmark", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Cagrilintide i Danmark", "localizedAnswer": "Cagrilintide er et klinisk udviklingsprogram. Et kommercielt tilbud med samme navn i Danmark arver ikke sponsorens kliniske identitet, forsøgsresultater eller regulatoriske status. Kontrollér det konkrete produkt, tilladelsesindehaveren, virksomheden og forsyningsvejen i de officielle registre for destinationen nedenfor.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Denmark", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 14, "clinicalTrialListedLocations": 54, "clinicalTrialRecruitingLocations": 2, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07527195", "NCT07010432", "NCT07253285", "NCT05567796", "NCT05669755", "NCT07357740", "NCT07357766", "NCT06065540", "NCT06409130", "NCT06780449", "NCT04940078", "NCT06797869", "NCT05016882", "NCT03856047" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07527195", "https://clinicaltrials.gov/study/NCT07010432", "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT07357740", "https://clinicaltrials.gov/study/NCT07357766", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT06409130", "https://clinicaltrials.gov/study/NCT06780449", "https://clinicaltrials.gov/study/NCT04940078", "https://clinicaltrials.gov/study/NCT06797869", "https://clinicaltrials.gov/study/NCT05016882", "https://clinicaltrials.gov/study/NCT03856047" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Denmark#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Denmark", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=denmark" }, { "recordId": "pl-compound-country-cagrilintide-finland", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Cagrilintide kohteessa Suomi", "localizedAnswer": "Cagrilintide on kliininen kehitysohjelma. Samanniminen kaupallinen tarjous kohteessa Suomi ei peri sponsorin kliinistä identiteettiä, tutkimustuloksia tai sääntelyasemaa. Tarkista täsmällinen tuote, luvanhaltija, toimija ja toimitusreitti alla olevista kohdemaan virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Finland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 13, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT05567796", "NCT06065540", "NCT03856047" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT03856047" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Finland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Finland", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=finland" }, { "recordId": "pl-compound-country-cagrilintide-mexico", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Cagrilintide / cagrilintida en México", "localizedAnswer": "Cagrilintide / cagrilintida es un programa clínico en investigación. Ninguna oferta comercial en México puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Mexico", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 29, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT05567796", "NCT05669755", "NCT06065540", "NCT07282613" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07282613" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Mexico#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Mexico", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=mexico" }, { "recordId": "pl-compound-country-cagrilintide-argentina", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Cagrilintide / cagrilintida en Argentina", "localizedAnswer": "Cagrilintide / cagrilintida es un programa clínico en investigación. Ninguna oferta comercial en Argentina puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Argentina", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 10, "clinicalTrialListedLocations": 75, "clinicalTrialRecruitingLocations": 14, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07564414", "NCT05567796", "NCT05669755", "NCT06534411", "NCT06065540", "NCT07220642", "NCT07282613", "NCT06221969", "NCT07220759", "NCT06131372" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07220642", "https://clinicaltrials.gov/study/NCT07282613", "https://clinicaltrials.gov/study/NCT06221969", "https://clinicaltrials.gov/study/NCT07220759", "https://clinicaltrials.gov/study/NCT06131372" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Argentina#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Argentina", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=argentina" }, { "recordId": "pl-compound-country-cagrilintide-colombia", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Cagrilintide / cagrilintida en Colombia", "localizedAnswer": "Cagrilintide / cagrilintida es un programa clínico en investigación. Ninguna oferta comercial en Colombia puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Colombia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 21, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT05669755", "NCT06065540", "NCT07282613", "NCT06221969" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07282613", "https://clinicaltrials.gov/study/NCT06221969" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Colombia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Colombia", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=colombia" }, { "recordId": "pl-compound-country-cagrilintide-chile", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Cagrilintide / cagrilintida en Chile", "localizedAnswer": "Cagrilintide / cagrilintida es un programa clínico en investigación. Ninguna oferta comercial en Chile puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Chile", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Chile#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Chile", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=chile" }, { "recordId": "pl-compound-country-cagrilintide-brazil", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Cagrilintide / cagrilintida no Brasil", "localizedAnswer": "Cagrilintide / cagrilintida é um programa clínico experimental. Nenhuma oferta comercial no Brasil pode herdar a identidade clínica, os resultados de ensaios ou o status regulatório do patrocinador. Verifique cada produto e fornecedor nos registros abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Brazil", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 31, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT05669755", "NCT06534411", "NCT06065540", "NCT07282613", "NCT06131372" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07282613", "https://clinicaltrials.gov/study/NCT06131372" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Brazil#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Brazil", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=brazil" }, { "recordId": "pl-compound-country-cagrilintide-china", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Cagrilintide 在中国的状态与官方记录", "localizedAnswer": "Cagrilintide在此对应一个临床与监管项目。项目在某一国家的试验、批准或公司公告，不能自动证明同名商品在中国获批、可得或由有资质的卖方提供。请分别核对目的地的具体药品记录、批准持有人、剂型规格、经营主体和供应路径，并保持临床证据与在线商品身份相互独立。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "China", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 6, "clinicalTrialListedLocations": 70, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT06065540", "NCT06323174", "NCT05996848", "NCT06323161", "NCT05254158" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT06323174", "https://clinicaltrials.gov/study/NCT05996848", "https://clinicaltrials.gov/study/NCT06323161", "https://clinicaltrials.gov/study/NCT05254158" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=China#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=China", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=china" }, { "recordId": "pl-compound-country-cagrilintide-australia", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Cagrilintide in Australia", "localizedAnswer": "Cagrilintide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Australia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 10, "clinicalTrialListedLocations": 77, "clinicalTrialRecruitingLocations": 10, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07253285", "NCT07564414", "NCT05567796", "NCT05669755", "NCT06534411", "NCT06065540", "NCT07220642", "NCT06221969", "NCT06409130", "NCT05016882" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07220642", "https://clinicaltrials.gov/study/NCT06221969", "https://clinicaltrials.gov/study/NCT06409130", "https://clinicaltrials.gov/study/NCT05016882" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Australia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Australia", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=australia" }, { "recordId": "pl-compound-country-cagrilintide-new-zealand", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Cagrilintide in New Zealand", "localizedAnswer": "Cagrilintide is an investigational clinical program. No seller listing in New Zealand can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "New Zealand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=New%20Zealand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=New%20Zealand", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=new-zealand" }, { "recordId": "pl-compound-country-cagrilintide-india", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Cagrilintide in India", "localizedAnswer": "Cagrilintide is an investigational clinical program. No seller listing in India can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "India", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 10, "clinicalTrialListedLocations": 210, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT05567796", "NCT05669755", "NCT06534411", "NCT06065540", "NCT07282613", "NCT06221969", "NCT06131372", "NCT05394519", "NCT05016882" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07282613", "https://clinicaltrials.gov/study/NCT06221969", "https://clinicaltrials.gov/study/NCT06131372", "https://clinicaltrials.gov/study/NCT05394519", "https://clinicaltrials.gov/study/NCT05016882" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=India#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=India", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=india" }, { "recordId": "pl-compound-country-cagrilintide-japan", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のCagrilintide / カグリリンチド", "localizedAnswer": "Cagrilintide / カグリリンチドは臨床開発中のプログラムです。スポンサーの臨床上の同一性、試験結果、規制上の位置付けを、日本の同名オンライン商品や販売者が自動的に引き継ぐことはありません。目的地の製品、承認保持者、施設、供給経路を下記の公的記録で確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Japan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 10, "clinicalTrialListedLocations": 138, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT05567796", "NCT05669755", "NCT06065540", "NCT06131372", "NCT06409130", "NCT05394519", "NCT05813925", "NCT06323161", "NCT05016882", "NCT03856047" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT06131372", "https://clinicaltrials.gov/study/NCT06409130", "https://clinicaltrials.gov/study/NCT05394519", "https://clinicaltrials.gov/study/NCT05813925", "https://clinicaltrials.gov/study/NCT06323161", "https://clinicaltrials.gov/study/NCT05016882", "https://clinicaltrials.gov/study/NCT03856047" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Japan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Japan", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=japan" }, { "recordId": "pl-compound-country-cagrilintide-south-korea", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Cagrilintide / 카그릴린타이드", "localizedAnswer": "Cagrilintide / 카그릴린타이드은 임상 개발 중인 프로그램입니다. 후원사의 임상 신원, 시험 결과 또는 규제 상태를 대한민국의 동명 온라인 상품이나 판매자가 자동으로 이어받을 수 없습니다. 목적지의 정확한 제품, 허가권자, 기관과 공급 경로를 아래 공식 기록에서 확인해야 합니다.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "South Korea", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 4, "clinicalTrialListedLocations": 36, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT05567796", "NCT06065540", "NCT07220759", "NCT05016882" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07220759", "https://clinicaltrials.gov/study/NCT05016882" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=South%20Korea#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=South%20Korea", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=south-korea" }, { "recordId": "pl-compound-country-cagrilintide-thailand", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Cagrilintide / คาไกรลินไทด์ ในประเทศไทย", "localizedAnswer": "Cagrilintide / คาไกรลินไทด์ เป็นโครงการที่อยู่ระหว่างการพัฒนาทางคลินิก สินค้าหรือผู้ขายชื่อเดียวกันในประเทศไทยไม่สามารถรับช่วงตัวตนทางคลินิก ผลการทดลอง หรือสถานะด้านกฎระเบียบของผู้สนับสนุนโดยอัตโนมัติ ให้ตรวจผลิตภัณฑ์ ผู้ถือทะเบียน สถานประกอบการ และเส้นทางการจัดหาที่แน่นอนในบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Thailand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 7, "clinicalTrialListedLocations": 47, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT05669755", "NCT07357740", "NCT07357766", "NCT07282613", "NCT06131372", "NCT05394519" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT07357740", "https://clinicaltrials.gov/study/NCT07357766", "https://clinicaltrials.gov/study/NCT07282613", "https://clinicaltrials.gov/study/NCT06131372", "https://clinicaltrials.gov/study/NCT05394519" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Thailand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Thailand", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=thailand" }, { "recordId": "pl-compound-country-cagrilintide-indonesia", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Cagrilintide di Indonesia", "localizedAnswer": "Cagrilintide adalah program yang sedang dikembangkan secara klinis. Produk atau penjual dengan nama sama di Indonesia tidak otomatis mewarisi identitas klinis sponsor, hasil uji, atau status regulasinya. Periksa produk, pemegang izin, fasilitas, dan jalur pasok yang tepat dalam catatan resmi tujuan di bawah.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Indonesia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Indonesia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Indonesia", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=indonesia" }, { "recordId": "pl-compound-country-cagrilintide-singapore", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Cagrilintide in Singapore", "localizedAnswer": "Cagrilintide is an investigational clinical program. No seller listing in Singapore can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Singapore", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 4, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT05016882" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT05016882" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Singapore#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Singapore", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=singapore" }, { "recordId": "pl-compound-country-cagrilintide-philippines", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Cagrilintide in the Philippines", "localizedAnswer": "Cagrilintide is an investigational clinical program. No seller listing in the Philippines can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Philippines", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Philippines#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Philippines", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=philippines" }, { "recordId": "pl-compound-country-cagrilintide-malaysia", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Cagrilintide in Malaysia", "localizedAnswer": "Cagrilintide is an investigational clinical program. No seller listing in Malaysia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Malaysia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 7, "clinicalTrialListedLocations": 50, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT05669755", "NCT07357740", "NCT07357766", "NCT07282613", "NCT05394519", "NCT05016882" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT07357740", "https://clinicaltrials.gov/study/NCT07357766", "https://clinicaltrials.gov/study/NCT07282613", "https://clinicaltrials.gov/study/NCT05394519", "https://clinicaltrials.gov/study/NCT05016882" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Malaysia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Malaysia", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=malaysia" }, { "recordId": "pl-compound-country-cagrilintide-taiwan", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Cagrilintide / 卡格列林肽 在台灣的紀錄", "localizedAnswer": "Cagrilintide / 卡格列林肽是臨床開發中的計畫。贊助者的臨床身分、試驗結果或法規狀態，不會自動移轉給台灣的同名網路商品或提供者。必須利用下方紀錄核對目的地的具體產品、許可證持有者、機構與供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Taiwan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 9, "clinicalTrialListedLocations": 35, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT05567796", "NCT06534411", "NCT07357766", "NCT06065540", "NCT07282613", "NCT06221969", "NCT05813925", "NCT05016882" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT07357766", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07282613", "https://clinicaltrials.gov/study/NCT06221969", "https://clinicaltrials.gov/study/NCT05813925", "https://clinicaltrials.gov/study/NCT05016882" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Taiwan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Taiwan", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=taiwan" }, { "recordId": "pl-compound-country-cagrilintide-hong-kong", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Cagrilintide / 卡格列林肽 在香港的紀錄", "localizedAnswer": "Cagrilintide / 卡格列林肽是臨床開發中的計劃。贊助者的臨床身分、試驗結果或監管狀態，不會自動轉移給香港的同名網上商品或銷售商。必須透過下方紀錄核對目的地的指定產品、註冊持有人、持牌實體和供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Hong Kong", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Hong%20Kong#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Hong%20Kong", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=hong-kong" }, { "recordId": "pl-compound-country-cagrilintide-vietnam", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Cagrilintide tại Việt Nam", "localizedAnswer": "Cagrilintide là một chương trình đang phát triển lâm sàng. Không đề nghị thương mại nào tại Việt Nam tự động kế thừa danh tính lâm sàng, kết quả thử nghiệm hoặc tình trạng quản lý của nhà tài trợ. Cần kiểm tra sản phẩm, chủ sở hữu giấy phép, cơ sở và đường cung ứng cụ thể trong các hồ sơ chính thức của điểm đến ở dưới.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Vietnam", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Vietnam#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Vietnam", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=vietnam" }, { "recordId": "pl-compound-country-cagrilintide-united-states", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Cagrilintide in the United States", "localizedAnswer": "Cagrilintide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "United States", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 36, "clinicalTrialListedLocations": 1072, "clinicalTrialRecruitingLocations": 118, "clinicalTrialRecordsWithRecruitingLocations": 5, "clinicalTrialRecordIds": [ "NCT07253285", "NCT07564414", "NCT07607587", "NCT07184086", "NCT06719011", "NCT07011667", "NCT05567796", "NCT05669755", "NCT06534411", "NCT07357740", "NCT07357766", "NCT07605052", "NCT06065540", "NCT07220642", "NCT07282613", "NCT06388187", "NCT06221969", "NCT07220759", "NCT06323174", "NCT06131372", "NCT06409130", "NCT06131437", "NCT05394519", "NCT06780449", "NCT04982575", "NCT06797869", "NCT06323161", "NCT05016882", "NCT06716307", "NCT03856047", "NCT03600480", "NCT04209049", "NCT03617081", "NCT03787225", "NCT02958085", "NCT02300844" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT07607587", "https://clinicaltrials.gov/study/NCT07184086", "https://clinicaltrials.gov/study/NCT06719011", "https://clinicaltrials.gov/study/NCT07011667", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT07357740", "https://clinicaltrials.gov/study/NCT07357766", "https://clinicaltrials.gov/study/NCT07605052", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07220642", "https://clinicaltrials.gov/study/NCT07282613", "https://clinicaltrials.gov/study/NCT06388187", "https://clinicaltrials.gov/study/NCT06221969", "https://clinicaltrials.gov/study/NCT07220759", "https://clinicaltrials.gov/study/NCT06323174", "https://clinicaltrials.gov/study/NCT06131372", "https://clinicaltrials.gov/study/NCT06409130", "https://clinicaltrials.gov/study/NCT06131437", "https://clinicaltrials.gov/study/NCT05394519", "https://clinicaltrials.gov/study/NCT06780449", "https://clinicaltrials.gov/study/NCT04982575", "https://clinicaltrials.gov/study/NCT06797869", "https://clinicaltrials.gov/study/NCT06323161", "https://clinicaltrials.gov/study/NCT05016882", "https://clinicaltrials.gov/study/NCT06716307", "https://clinicaltrials.gov/study/NCT03856047", "https://clinicaltrials.gov/study/NCT03600480", "https://clinicaltrials.gov/study/NCT04209049", "https://clinicaltrials.gov/study/NCT03617081", "https://clinicaltrials.gov/study/NCT03787225", "https://clinicaltrials.gov/study/NCT02958085", "https://clinicaltrials.gov/study/NCT02300844" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=United%20States#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=United%20States", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=united-states" }, { "recordId": "pl-compound-country-cagrilintide-canada", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Cagrilintide in Canada", "localizedAnswer": "Cagrilintide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Canada", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 19, "clinicalTrialListedLocations": 187, "clinicalTrialRecruitingLocations": 20, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07564414", "NCT05567796", "NCT05669755", "NCT06534411", "NCT06065540", "NCT07220642", "NCT06289504", "NCT06388187", "NCT06221969", "NCT07220759", "NCT06131372", "NCT06409130", "NCT05394519", "NCT06780449", "NCT04940078", "NCT06797869", "NCT05016882", "NCT03856047", "NCT04074174" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07220642", "https://clinicaltrials.gov/study/NCT06289504", "https://clinicaltrials.gov/study/NCT06388187", "https://clinicaltrials.gov/study/NCT06221969", "https://clinicaltrials.gov/study/NCT07220759", "https://clinicaltrials.gov/study/NCT06131372", "https://clinicaltrials.gov/study/NCT06409130", "https://clinicaltrials.gov/study/NCT05394519", "https://clinicaltrials.gov/study/NCT06780449", "https://clinicaltrials.gov/study/NCT04940078", "https://clinicaltrials.gov/study/NCT06797869", "https://clinicaltrials.gov/study/NCT05016882", "https://clinicaltrials.gov/study/NCT03856047", "https://clinicaltrials.gov/study/NCT04074174" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Canada#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Canada", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=canada" }, { "recordId": "pl-compound-country-cagrilintide-united-arab-emirates", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Cagrilintide / كاغريلينتايد في الإمارات العربية المتحدة", "localizedAnswer": "Cagrilintide / كاغريلينتايد برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في الإمارات العربية المتحدة أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "United Arab Emirates", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=United%20Arab%20Emirates#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=United%20Arab%20Emirates", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=united-arab-emirates" }, { "recordId": "pl-compound-country-cagrilintide-saudi-arabia", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Cagrilintide / كاغريلينتايد في المملكة العربية السعودية", "localizedAnswer": "Cagrilintide / كاغريلينتايد برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في المملكة العربية السعودية أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Saudi Arabia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 5, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT06323174" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06323174" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Saudi%20Arabia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Saudi%20Arabia", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=saudi-arabia" }, { "recordId": "pl-compound-country-cagrilintide-south-africa", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Cagrilintide in South Africa", "localizedAnswer": "Cagrilintide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "South Africa", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 8, "clinicalTrialListedLocations": 73, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07564414", "NCT05567796", "NCT05669755", "NCT07357766", "NCT06065540", "NCT06221969", "NCT06323161", "NCT03856047" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT07357766", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT06221969", "https://clinicaltrials.gov/study/NCT06323161", "https://clinicaltrials.gov/study/NCT03856047" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=South%20Africa#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=South%20Africa", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=south-africa" }, { "recordId": "pl-compound-country-cagrilintide-nigeria", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Cagrilintide in Nigeria", "localizedAnswer": "Cagrilintide is an investigational clinical program. No seller listing in Nigeria can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Nigeria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Nigeria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Nigeria", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=nigeria" }, { "recordId": "pl-compound-country-cagrilintide-kenya", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Cagrilintide in Kenya", "localizedAnswer": "Cagrilintide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Cagrilintide", "clinicalTrialRegistryCountry": "Kenya", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrilintide&country=Kenya#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Cagrilintide&locStr=Kenya", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/cagrilintide", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrilintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrilintide&country=kenya" }, { "recordId": "pl-compound-country-petrelintide-france", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Petrelintide en France", "localizedAnswer": "Petrelintide est un programme clinique expérimental. Aucune offre commerciale en France ne peut reprendre automatiquement l’identité clinique, les résultats d’essais ou le statut réglementaire du promoteur. Vérifiez chaque produit et fournisseur dans les registres ci-dessous.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "France", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=France#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=France", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=france" }, { "recordId": "pl-compound-country-petrelintide-united-kingdom", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Petrelintide in the United Kingdom", "localizedAnswer": "Petrelintide is an investigational clinical program. No seller listing in the United Kingdom can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "United Kingdom", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=United%20Kingdom#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=United%20Kingdom", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=united-kingdom" }, { "recordId": "pl-compound-country-petrelintide-germany", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Petrelintide / Petrelintid in Deutschland", "localizedAnswer": "Petrelintide / Petrelintid ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Deutschland übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Germany", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 4, "clinicalTrialListedLocations": 4, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07338214", "NCT07076030", "NCT05613387", "NCT05096598" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07338214", "https://clinicaltrials.gov/study/NCT07076030", "https://clinicaltrials.gov/study/NCT05613387", "https://clinicaltrials.gov/study/NCT05096598" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Germany#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Germany", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=germany" }, { "recordId": "pl-compound-country-petrelintide-spain", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Petrelintide en España", "localizedAnswer": "Petrelintide es un programa clínico en investigación. Ninguna oferta comercial en España puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Spain", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Spain#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Spain", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=spain" }, { "recordId": "pl-compound-country-petrelintide-italy", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Petrelintide in Italia", "localizedAnswer": "Petrelintide è un programma clinico sperimentale. Nessuna offerta commerciale in Italia può ereditare l’identità clinica, i risultati degli studi o lo stato regolatorio dello sponsor. Verifica ogni prodotto e fornitore nei registri riportati sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Italy", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Italy#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Italy", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=italy" }, { "recordId": "pl-compound-country-petrelintide-netherlands", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Petrelintide in Nederland", "localizedAnswer": "Petrelintide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in Nederland neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Netherlands", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Netherlands#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Netherlands", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=netherlands" }, { "recordId": "pl-compound-country-petrelintide-switzerland", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Petrelintide in Switzerland", "localizedAnswer": "Petrelintide is an investigational clinical program. No seller listing in Switzerland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Switzerland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Switzerland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Switzerland", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=switzerland" }, { "recordId": "pl-compound-country-petrelintide-poland", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Petrelintide w Polsce", "localizedAnswer": "Petrelintide jest eksperymentalnym programem klinicznym. Żadna oferta handlowa w Polsce nie przejmuje automatycznie tożsamości klinicznej, wyników badań ani statusu regulacyjnego sponsora. Sprawdź każdy produkt i dostawcę w rejestrach poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Poland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 8, "clinicalTrialRecruitingLocations": 1, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07682818", "NCT06662539" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07682818", "https://clinicaltrials.gov/study/NCT06662539" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Poland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Poland", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=poland" }, { "recordId": "pl-compound-country-petrelintide-ireland", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Petrelintide in Ireland", "localizedAnswer": "Petrelintide is an investigational clinical program. No seller listing in Ireland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Ireland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Ireland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Ireland", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=ireland" }, { "recordId": "pl-compound-country-petrelintide-portugal", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Petrelintide em Portugal", "localizedAnswer": "Petrelintide é um programa clínico experimental. Nenhuma oferta comercial em Portugal pode herdar a identidade clínica, os resultados de ensaios ou o estatuto regulamentar do promotor. Verifique cada produto e fornecedor nos registos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Portugal", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Portugal#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Portugal", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=portugal" }, { "recordId": "pl-compound-country-petrelintide-sweden", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Petrelintide i Sverige", "localizedAnswer": "Petrelintide är ett kliniskt prövningsprogram. Inget kommersiellt erbjudande i Sverige kan automatiskt ärva sponsorns kliniska identitet, studieresultat eller regulatoriska status. Kontrollera varje produkt och leverantör i registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Sweden", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Sweden#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Sweden", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=sweden" }, { "recordId": "pl-compound-country-petrelintide-turkey", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Petrelintide", "localizedAnswer": "Petrelintide klinik geliştirme aşamasındaki bir programdır. Türkiye içindeki aynı adlı hiçbir ticari teklif sponsorun klinik kimliğini, çalışma sonuçlarını veya düzenleyici statüsünü otomatik olarak devralamaz. Belirli ürünü, ruhsat sahibini, kuruluşu ve tedarik yolunu aşağıdaki resmi hedef ülke kayıtlarında kontrol edin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Turkey (Türkiye)", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Turkey%20(T%C3%BCrkiye)#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Turkey%20(T%C3%BCrkiye)", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=turkey" }, { "recordId": "pl-compound-country-petrelintide-austria", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Petrelintide / Petrelintid in Österreich", "localizedAnswer": "Petrelintide / Petrelintid ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Österreich übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Austria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Austria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Austria", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=austria" }, { "recordId": "pl-compound-country-petrelintide-belgium", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Petrelintide in België", "localizedAnswer": "Petrelintide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in België neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Belgium", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Belgium#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Belgium", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=belgium" }, { "recordId": "pl-compound-country-petrelintide-denmark", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Petrelintide i Danmark", "localizedAnswer": "Petrelintide er et klinisk udviklingsprogram. Et kommercielt tilbud med samme navn i Danmark arver ikke sponsorens kliniske identitet, forsøgsresultater eller regulatoriske status. Kontrollér det konkrete produkt, tilladelsesindehaveren, virksomheden og forsyningsvejen i de officielle registre for destinationen nedenfor.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Denmark", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Denmark#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Denmark", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=denmark" }, { "recordId": "pl-compound-country-petrelintide-finland", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Petrelintide kohteessa Suomi", "localizedAnswer": "Petrelintide on kliininen kehitysohjelma. Samanniminen kaupallinen tarjous kohteessa Suomi ei peri sponsorin kliinistä identiteettiä, tutkimustuloksia tai sääntelyasemaa. Tarkista täsmällinen tuote, luvanhaltija, toimija ja toimitusreitti alla olevista kohdemaan virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Finland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Finland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Finland", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=finland" }, { "recordId": "pl-compound-country-petrelintide-mexico", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Petrelintide en México", "localizedAnswer": "Petrelintide es un programa clínico en investigación. Ninguna oferta comercial en México puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Mexico", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Mexico#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Mexico", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=mexico" }, { "recordId": "pl-compound-country-petrelintide-argentina", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Petrelintide en Argentina", "localizedAnswer": "Petrelintide es un programa clínico en investigación. Ninguna oferta comercial en Argentina puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Argentina", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Argentina#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Argentina", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=argentina" }, { "recordId": "pl-compound-country-petrelintide-colombia", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Petrelintide en Colombia", "localizedAnswer": "Petrelintide es un programa clínico en investigación. Ninguna oferta comercial en Colombia puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Colombia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Colombia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Colombia", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=colombia" }, { "recordId": "pl-compound-country-petrelintide-chile", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Petrelintide en Chile", "localizedAnswer": "Petrelintide es un programa clínico en investigación. Ninguna oferta comercial en Chile puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Chile", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Chile#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Chile", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=chile" }, { "recordId": "pl-compound-country-petrelintide-brazil", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Petrelintide no Brasil", "localizedAnswer": "Petrelintide é um programa clínico experimental. Nenhuma oferta comercial no Brasil pode herdar a identidade clínica, os resultados de ensaios ou o status regulatório do patrocinador. Verifique cada produto e fornecedor nos registros abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Brazil", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Brazil#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Brazil", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=brazil" }, { "recordId": "pl-compound-country-petrelintide-china", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Petrelintide 在中国的状态与官方记录", "localizedAnswer": "Petrelintide在此对应一个临床与监管项目。项目在某一国家的试验、批准或公司公告，不能自动证明同名商品在中国获批、可得或由有资质的卖方提供。请分别核对目的地的具体药品记录、批准持有人、剂型规格、经营主体和供应路径，并保持临床证据与在线商品身份相互独立。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "China", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=China#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=China", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=china" }, { "recordId": "pl-compound-country-petrelintide-australia", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Petrelintide in Australia", "localizedAnswer": "Petrelintide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Australia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Australia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Australia", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=australia" }, { "recordId": "pl-compound-country-petrelintide-new-zealand", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Petrelintide in New Zealand", "localizedAnswer": "Petrelintide is an investigational clinical program. No seller listing in New Zealand can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "New Zealand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=New%20Zealand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=New%20Zealand", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=new-zealand" }, { "recordId": "pl-compound-country-petrelintide-india", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Petrelintide in India", "localizedAnswer": "Petrelintide is an investigational clinical program. No seller listing in India can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "India", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=India#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=India", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=india" }, { "recordId": "pl-compound-country-petrelintide-japan", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のPetrelintide / ペトレリンチド", "localizedAnswer": "Petrelintide / ペトレリンチドは臨床開発中のプログラムです。スポンサーの臨床上の同一性、試験結果、規制上の位置付けを、日本の同名オンライン商品や販売者が自動的に引き継ぐことはありません。目的地の製品、承認保持者、施設、供給経路を下記の公的記録で確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Japan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Japan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Japan", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=japan" }, { "recordId": "pl-compound-country-petrelintide-south-korea", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Petrelintide / 페트렐린타이드", "localizedAnswer": "Petrelintide / 페트렐린타이드은 임상 개발 중인 프로그램입니다. 후원사의 임상 신원, 시험 결과 또는 규제 상태를 대한민국의 동명 온라인 상품이나 판매자가 자동으로 이어받을 수 없습니다. 목적지의 정확한 제품, 허가권자, 기관과 공급 경로를 아래 공식 기록에서 확인해야 합니다.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "South Korea", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 1, "clinicalTrialRecruitingLocations": 1, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT06951854" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06951854" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=South%20Korea#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=South%20Korea", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=south-korea" }, { "recordId": "pl-compound-country-petrelintide-thailand", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Petrelintide ในประเทศไทย", "localizedAnswer": "Petrelintide เป็นโครงการที่อยู่ระหว่างการพัฒนาทางคลินิก สินค้าหรือผู้ขายชื่อเดียวกันในประเทศไทยไม่สามารถรับช่วงตัวตนทางคลินิก ผลการทดลอง หรือสถานะด้านกฎระเบียบของผู้สนับสนุนโดยอัตโนมัติ ให้ตรวจผลิตภัณฑ์ ผู้ถือทะเบียน สถานประกอบการ และเส้นทางการจัดหาที่แน่นอนในบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Thailand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Thailand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Thailand", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=thailand" }, { "recordId": "pl-compound-country-petrelintide-indonesia", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Petrelintide di Indonesia", "localizedAnswer": "Petrelintide adalah program yang sedang dikembangkan secara klinis. Produk atau penjual dengan nama sama di Indonesia tidak otomatis mewarisi identitas klinis sponsor, hasil uji, atau status regulasinya. Periksa produk, pemegang izin, fasilitas, dan jalur pasok yang tepat dalam catatan resmi tujuan di bawah.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Indonesia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Indonesia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Indonesia", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=indonesia" }, { "recordId": "pl-compound-country-petrelintide-singapore", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Petrelintide in Singapore", "localizedAnswer": "Petrelintide is an investigational clinical program. No seller listing in Singapore can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Singapore", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Singapore#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Singapore", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=singapore" }, { "recordId": "pl-compound-country-petrelintide-philippines", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Petrelintide in the Philippines", "localizedAnswer": "Petrelintide is an investigational clinical program. No seller listing in the Philippines can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Philippines", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Philippines#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Philippines", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=philippines" }, { "recordId": "pl-compound-country-petrelintide-malaysia", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Petrelintide in Malaysia", "localizedAnswer": "Petrelintide is an investigational clinical program. No seller listing in Malaysia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Malaysia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Malaysia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Malaysia", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=malaysia" }, { "recordId": "pl-compound-country-petrelintide-taiwan", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Petrelintide 在台灣的紀錄", "localizedAnswer": "Petrelintide是臨床開發中的計畫。贊助者的臨床身分、試驗結果或法規狀態，不會自動移轉給台灣的同名網路商品或提供者。必須利用下方紀錄核對目的地的具體產品、許可證持有者、機構與供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Taiwan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Taiwan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Taiwan", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=taiwan" }, { "recordId": "pl-compound-country-petrelintide-hong-kong", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Petrelintide 在香港的紀錄", "localizedAnswer": "Petrelintide是臨床開發中的計劃。贊助者的臨床身分、試驗結果或監管狀態，不會自動轉移給香港的同名網上商品或銷售商。必須透過下方紀錄核對目的地的指定產品、註冊持有人、持牌實體和供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Hong Kong", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Hong%20Kong#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Hong%20Kong", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=hong-kong" }, { "recordId": "pl-compound-country-petrelintide-vietnam", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Petrelintide tại Việt Nam", "localizedAnswer": "Petrelintide là một chương trình đang phát triển lâm sàng. Không đề nghị thương mại nào tại Việt Nam tự động kế thừa danh tính lâm sàng, kết quả thử nghiệm hoặc tình trạng quản lý của nhà tài trợ. Cần kiểm tra sản phẩm, chủ sở hữu giấy phép, cơ sở và đường cung ứng cụ thể trong các hồ sơ chính thức của điểm đến ở dưới.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Vietnam", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Vietnam#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Vietnam", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=vietnam" }, { "recordId": "pl-compound-country-petrelintide-united-states", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Petrelintide in the United States", "localizedAnswer": "Petrelintide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "United States", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 67, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT06662539", "NCT06926842" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06662539", "https://clinicaltrials.gov/study/NCT06926842" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=United%20States#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=United%20States", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=united-states" }, { "recordId": "pl-compound-country-petrelintide-canada", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Petrelintide in Canada", "localizedAnswer": "Petrelintide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Canada", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Canada#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Canada", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=canada" }, { "recordId": "pl-compound-country-petrelintide-united-arab-emirates", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Petrelintide / بيتريلينتايد في الإمارات العربية المتحدة", "localizedAnswer": "Petrelintide / بيتريلينتايد برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في الإمارات العربية المتحدة أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "United Arab Emirates", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=United%20Arab%20Emirates#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=United%20Arab%20Emirates", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=united-arab-emirates" }, { "recordId": "pl-compound-country-petrelintide-saudi-arabia", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Petrelintide / بيتريلينتايد في المملكة العربية السعودية", "localizedAnswer": "Petrelintide / بيتريلينتايد برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في المملكة العربية السعودية أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Saudi Arabia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Saudi%20Arabia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Saudi%20Arabia", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=saudi-arabia" }, { "recordId": "pl-compound-country-petrelintide-south-africa", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Petrelintide in South Africa", "localizedAnswer": "Petrelintide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "South Africa", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=South%20Africa#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=South%20Africa", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=south-africa" }, { "recordId": "pl-compound-country-petrelintide-nigeria", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Petrelintide in Nigeria", "localizedAnswer": "Petrelintide is an investigational clinical program. No seller listing in Nigeria can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Nigeria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Nigeria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Nigeria", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=nigeria" }, { "recordId": "pl-compound-country-petrelintide-kenya", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Petrelintide in Kenya", "localizedAnswer": "Petrelintide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Petrelintide", "clinicalTrialRegistryCountry": "Kenya", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=petrelintide&country=Kenya#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Petrelintide&locStr=Kenya", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/petrelintide", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/petrelintide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=petrelintide&country=kenya" }, { "recordId": "pl-compound-country-cagrisema-france", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "CagriSema en France", "localizedAnswer": "CagriSema est un programme clinique expérimental. Aucune offre commerciale en France ne peut reprendre automatiquement l’identité clinique, les résultats d’essais ou le statut réglementaire du promoteur. Vérifiez chaque produit et fournisseur dans les registres ci-dessous.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "France", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 7, "clinicalTrialListedLocations": 47, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07564414", "NCT05567796", "NCT05669755", "NCT06388187", "NCT06131372", "NCT06409130", "NCT06797869" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06388187", "https://clinicaltrials.gov/study/NCT06131372", "https://clinicaltrials.gov/study/NCT06409130", "https://clinicaltrials.gov/study/NCT06797869" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=France#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=France", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=france" }, { "recordId": "pl-compound-country-cagrisema-united-kingdom", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "CagriSema in the United Kingdom", "localizedAnswer": "CagriSema is an investigational clinical program. No seller listing in the United Kingdom can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "United Kingdom", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 8, "clinicalTrialListedLocations": 89, "clinicalTrialRecruitingLocations": 3, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07253285", "NCT05567796", "NCT05669755", "NCT06065540", "NCT06388187", "NCT05394519", "NCT06780449", "NCT06797869" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT06388187", "https://clinicaltrials.gov/study/NCT05394519", "https://clinicaltrials.gov/study/NCT06780449", "https://clinicaltrials.gov/study/NCT06797869" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=United%20Kingdom#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=United%20Kingdom", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=united-kingdom" }, { "recordId": "pl-compound-country-cagrisema-germany", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "CagriSema in Deutschland", "localizedAnswer": "CagriSema ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Deutschland übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Germany", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 10, "clinicalTrialListedLocations": 76, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT05567796", "NCT05669755", "NCT06534411", "NCT06065540", "NCT06388187", "NCT06409130", "NCT06403761", "NCT05394519", "NCT06207877", "NCT06267092" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT06388187", "https://clinicaltrials.gov/study/NCT06409130", "https://clinicaltrials.gov/study/NCT06403761", "https://clinicaltrials.gov/study/NCT05394519", "https://clinicaltrials.gov/study/NCT06207877", "https://clinicaltrials.gov/study/NCT06267092" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Germany#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Germany", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=germany" }, { "recordId": "pl-compound-country-cagrisema-spain", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "CagriSema en España", "localizedAnswer": "CagriSema es un programa clínico en investigación. Ninguna oferta comercial en España puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Spain", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 10, "clinicalTrialListedLocations": 86, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT07564414", "NCT05567796", "NCT05669755", "NCT06534411", "NCT07357740", "NCT06065540", "NCT06131372", "NCT06409130", "NCT06797869" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT07357740", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT06131372", "https://clinicaltrials.gov/study/NCT06409130", "https://clinicaltrials.gov/study/NCT06797869" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Spain#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Spain", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=spain" }, { "recordId": "pl-compound-country-cagrisema-italy", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "CagriSema in Italia", "localizedAnswer": "CagriSema è un programma clinico sperimentale. Nessuna offerta commerciale in Italia può ereditare l’identità clinica, i risultati degli studi o lo stato regolatorio dello sponsor. Verifica ogni prodotto e fornitore nei registri riportati sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Italy", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 7, "clinicalTrialListedLocations": 73, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT07564414", "NCT05567796", "NCT05669755", "NCT06065540", "NCT06323174", "NCT06409130" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT06323174", "https://clinicaltrials.gov/study/NCT06409130" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Italy#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Italy", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=italy" }, { "recordId": "pl-compound-country-cagrisema-netherlands", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "CagriSema in Nederland", "localizedAnswer": "CagriSema is een klinisch onderzoeksprogramma. Geen commercieel aanbod in Nederland neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Netherlands", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 28, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT07564414", "NCT05567796", "NCT05669755", "NCT06409130" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06409130" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Netherlands#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Netherlands", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=netherlands" }, { "recordId": "pl-compound-country-cagrisema-switzerland", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "CagriSema in Switzerland", "localizedAnswer": "CagriSema is an investigational clinical program. No seller listing in Switzerland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Switzerland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 4, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07357766" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07357766" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Switzerland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Switzerland", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=switzerland" }, { "recordId": "pl-compound-country-cagrisema-poland", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "CagriSema w Polsce", "localizedAnswer": "CagriSema jest eksperymentalnym programem klinicznym. Żadna oferta handlowa w Polsce nie przejmuje automatycznie tożsamości klinicznej, wyników badań ani statusu regulacyjnego sponsora. Sprawdź każdy produkt i dostawcę w rejestrach poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Poland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 11, "clinicalTrialListedLocations": 185, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT07564414", "NCT05567796", "NCT05669755", "NCT06534411", "NCT07357766", "NCT06065540", "NCT06323174", "NCT06131372", "NCT06409130", "NCT05394519" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT07357766", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT06323174", "https://clinicaltrials.gov/study/NCT06131372", "https://clinicaltrials.gov/study/NCT06409130", "https://clinicaltrials.gov/study/NCT05394519" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Poland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Poland", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=poland" }, { "recordId": "pl-compound-country-cagrisema-ireland", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "CagriSema in Ireland", "localizedAnswer": "CagriSema is an investigational clinical program. No seller listing in Ireland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Ireland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 15, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT05669755", "NCT05394519" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT05394519" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Ireland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Ireland", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=ireland" }, { "recordId": "pl-compound-country-cagrisema-portugal", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational program requiring exact EU and Portuguese medicine records", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "CagriSema em Portugal", "localizedAnswer": "CagriSema remains investigational while its US FDA application is under review. The linked EMA record is a paediatric investigation plan waiver for cagrilintide and semaglutide, not a marketing authorization. INFARMED's medicine and pharmacy services are the Portuguese verification routes for an exact product, market status, and seller. No compound-specific Portuguese marketing authorization finding is attached here, so a local-language listing or imported vial cannot inherit the clinical program's identity or status.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 3, "statusEvidencePublishers": [ "Novo Nordisk", "European Medicines Agency", "INFARMED" ], "statusEvidenceUrls": [ "https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916501", "https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003059-pip02-23", "https://www.infarmed.pt/web/infarmed/servicos-on-line" ], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Portugal", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 4, "clinicalTrialListedLocations": 23, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT07564414", "NCT07357766", "NCT06780449" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT07357766", "https://clinicaltrials.gov/study/NCT06780449" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Portugal#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Portugal", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=portugal" }, { "recordId": "pl-compound-country-cagrisema-sweden", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "CagriSema i Sverige", "localizedAnswer": "CagriSema är ett kliniskt prövningsprogram. Inget kommersiellt erbjudande i Sverige kan automatiskt ärva sponsorns kliniska identitet, studieresultat eller regulatoriska status. Kontrollera varje produkt och leverantör i registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Sweden", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 9, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT06065540" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT06065540" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Sweden#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Sweden", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=sweden" }, { "recordId": "pl-compound-country-cagrisema-turkey", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için CagriSema", "localizedAnswer": "CagriSema klinik geliştirme aşamasındaki bir programdır. Türkiye içindeki aynı adlı hiçbir ticari teklif sponsorun klinik kimliğini, çalışma sonuçlarını veya düzenleyici statüsünü otomatik olarak devralamaz. Belirli ürünü, ruhsat sahibini, kuruluşu ve tedarik yolunu aşağıdaki resmi hedef ülke kayıtlarında kontrol edin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Turkey (Türkiye)", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 72, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT05567796", "NCT05669755", "NCT06065540" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06065540" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Turkey%20(T%C3%BCrkiye)#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Turkey%20(T%C3%BCrkiye)", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=turkey" }, { "recordId": "pl-compound-country-cagrisema-austria", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "CagriSema in Österreich", "localizedAnswer": "CagriSema ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Österreich übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Austria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 16, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT07564414", "NCT05394519" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05394519" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Austria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Austria", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=austria" }, { "recordId": "pl-compound-country-cagrisema-belgium", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "CagriSema in België", "localizedAnswer": "CagriSema is een klinisch onderzoeksprogramma. Geen commercieel aanbod in België neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Belgium", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 4, "clinicalTrialListedLocations": 22, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT07564414", "NCT05567796", "NCT06780449" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT06780449" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Belgium#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Belgium", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=belgium" }, { "recordId": "pl-compound-country-cagrisema-denmark", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "CagriSema i Danmark", "localizedAnswer": "CagriSema er et klinisk udviklingsprogram. Et kommercielt tilbud med samme navn i Danmark arver ikke sponsorens kliniske identitet, forsøgsresultater eller regulatoriske status. Kontrollér det konkrete produkt, tilladelsesindehaveren, virksomheden og forsyningsvejen i de officielle registre for destinationen nedenfor.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Denmark", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 11, "clinicalTrialListedLocations": 48, "clinicalTrialRecruitingLocations": 2, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07527195", "NCT07010432", "NCT07253285", "NCT05567796", "NCT05669755", "NCT07357740", "NCT07357766", "NCT06065540", "NCT06409130", "NCT06780449", "NCT06797869" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07527195", "https://clinicaltrials.gov/study/NCT07010432", "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT07357740", "https://clinicaltrials.gov/study/NCT07357766", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT06409130", "https://clinicaltrials.gov/study/NCT06780449", "https://clinicaltrials.gov/study/NCT06797869" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Denmark#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Denmark", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=denmark" }, { "recordId": "pl-compound-country-cagrisema-finland", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "CagriSema kohteessa Suomi", "localizedAnswer": "CagriSema on kliininen kehitysohjelma. Samanniminen kaupallinen tarjous kohteessa Suomi ei peri sponsorin kliinistä identiteettiä, tutkimustuloksia tai sääntelyasemaa. Tarkista täsmällinen tuote, luvanhaltija, toimija ja toimitusreitti alla olevista kohdemaan virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Finland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 9, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT05567796", "NCT06065540" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT06065540" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Finland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Finland", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=finland" }, { "recordId": "pl-compound-country-cagrisema-mexico", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "CagriSema en México", "localizedAnswer": "CagriSema es un programa clínico en investigación. Ninguna oferta comercial en México puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Mexico", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 29, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT05567796", "NCT05669755", "NCT06065540", "NCT07282613" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07282613" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Mexico#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Mexico", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=mexico" }, { "recordId": "pl-compound-country-cagrisema-argentina", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "CagriSema en Argentina", "localizedAnswer": "CagriSema es un programa clínico en investigación. Ninguna oferta comercial en Argentina puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Argentina", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 8, "clinicalTrialListedLocations": 70, "clinicalTrialRecruitingLocations": 14, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07564414", "NCT05567796", "NCT05669755", "NCT06534411", "NCT06065540", "NCT07282613", "NCT06221969", "NCT06131372" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07282613", "https://clinicaltrials.gov/study/NCT06221969", "https://clinicaltrials.gov/study/NCT06131372" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Argentina#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Argentina", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=argentina" }, { "recordId": "pl-compound-country-cagrisema-colombia", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "CagriSema en Colombia", "localizedAnswer": "CagriSema es un programa clínico en investigación. Ninguna oferta comercial en Colombia puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Colombia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 21, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT05669755", "NCT06065540", "NCT07282613", "NCT06221969" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07282613", "https://clinicaltrials.gov/study/NCT06221969" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Colombia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Colombia", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=colombia" }, { "recordId": "pl-compound-country-cagrisema-chile", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "CagriSema en Chile", "localizedAnswer": "CagriSema es un programa clínico en investigación. Ninguna oferta comercial en Chile puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Chile", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Chile#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Chile", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=chile" }, { "recordId": "pl-compound-country-cagrisema-brazil", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "CagriSema no Brasil", "localizedAnswer": "CagriSema é um programa clínico experimental. Nenhuma oferta comercial no Brasil pode herdar a identidade clínica, os resultados de ensaios ou o status regulatório do patrocinador. Verifique cada produto e fornecedor nos registros abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Brazil", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 31, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT05669755", "NCT06534411", "NCT06065540", "NCT07282613", "NCT06131372" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07282613", "https://clinicaltrials.gov/study/NCT06131372" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Brazil#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Brazil", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=brazil" }, { "recordId": "pl-compound-country-cagrisema-china", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "CagriSema 在中国的状态与官方记录", "localizedAnswer": "CagriSema在此对应一个临床与监管项目。项目在某一国家的试验、批准或公司公告，不能自动证明同名商品在中国获批、可得或由有资质的卖方提供。请分别核对目的地的具体药品记录、批准持有人、剂型规格、经营主体和供应路径，并保持临床证据与在线商品身份相互独立。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "China", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 69, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT06065540", "NCT06323174", "NCT05996848", "NCT06323161" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT06323174", "https://clinicaltrials.gov/study/NCT05996848", "https://clinicaltrials.gov/study/NCT06323161" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=China#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=China", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=china" }, { "recordId": "pl-compound-country-cagrisema-australia", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "CagriSema in Australia", "localizedAnswer": "CagriSema is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Australia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 8, "clinicalTrialListedLocations": 65, "clinicalTrialRecruitingLocations": 10, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07253285", "NCT07564414", "NCT05567796", "NCT05669755", "NCT06534411", "NCT06065540", "NCT06221969", "NCT06409130" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT06221969", "https://clinicaltrials.gov/study/NCT06409130" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Australia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Australia", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=australia" }, { "recordId": "pl-compound-country-cagrisema-new-zealand", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "CagriSema in New Zealand", "localizedAnswer": "CagriSema is an investigational clinical program. No seller listing in New Zealand can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "New Zealand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=New%20Zealand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=New%20Zealand", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=new-zealand" }, { "recordId": "pl-compound-country-cagrisema-india", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "CagriSema in India", "localizedAnswer": "CagriSema is an investigational clinical program. No seller listing in India can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "India", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 9, "clinicalTrialListedLocations": 192, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT05567796", "NCT05669755", "NCT06534411", "NCT06065540", "NCT07282613", "NCT06221969", "NCT06131372", "NCT05394519" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07282613", "https://clinicaltrials.gov/study/NCT06221969", "https://clinicaltrials.gov/study/NCT06131372", "https://clinicaltrials.gov/study/NCT05394519" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=India#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=India", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=india" }, { "recordId": "pl-compound-country-cagrisema-japan", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のCagriSema", "localizedAnswer": "CagriSemaは臨床開発中のプログラムです。スポンサーの臨床上の同一性、試験結果、規制上の位置付けを、日本の同名オンライン商品や販売者が自動的に引き継ぐことはありません。目的地の製品、承認保持者、施設、供給経路を下記の公的記録で確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Japan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 8, "clinicalTrialListedLocations": 118, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT05567796", "NCT05669755", "NCT06065540", "NCT06131372", "NCT06409130", "NCT05394519", "NCT05813925", "NCT06323161" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT06131372", "https://clinicaltrials.gov/study/NCT06409130", "https://clinicaltrials.gov/study/NCT05394519", "https://clinicaltrials.gov/study/NCT05813925", "https://clinicaltrials.gov/study/NCT06323161" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Japan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Japan", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=japan" }, { "recordId": "pl-compound-country-cagrisema-south-korea", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 CagriSema", "localizedAnswer": "CagriSema은 임상 개발 중인 프로그램입니다. 후원사의 임상 신원, 시험 결과 또는 규제 상태를 대한민국의 동명 온라인 상품이나 판매자가 자동으로 이어받을 수 없습니다. 목적지의 정확한 제품, 허가권자, 기관과 공급 경로를 아래 공식 기록에서 확인해야 합니다.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "South Korea", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 20, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT05567796", "NCT06065540" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT06065540" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=South%20Korea#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=South%20Korea", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=south-korea" }, { "recordId": "pl-compound-country-cagrisema-thailand", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "CagriSema ในประเทศไทย", "localizedAnswer": "CagriSema เป็นโครงการที่อยู่ระหว่างการพัฒนาทางคลินิก สินค้าหรือผู้ขายชื่อเดียวกันในประเทศไทยไม่สามารถรับช่วงตัวตนทางคลินิก ผลการทดลอง หรือสถานะด้านกฎระเบียบของผู้สนับสนุนโดยอัตโนมัติ ให้ตรวจผลิตภัณฑ์ ผู้ถือทะเบียน สถานประกอบการ และเส้นทางการจัดหาที่แน่นอนในบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Thailand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 7, "clinicalTrialListedLocations": 47, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT05669755", "NCT07357740", "NCT07357766", "NCT07282613", "NCT06131372", "NCT05394519" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT07357740", "https://clinicaltrials.gov/study/NCT07357766", "https://clinicaltrials.gov/study/NCT07282613", "https://clinicaltrials.gov/study/NCT06131372", "https://clinicaltrials.gov/study/NCT05394519" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Thailand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Thailand", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=thailand" }, { "recordId": "pl-compound-country-cagrisema-indonesia", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "CagriSema di Indonesia", "localizedAnswer": "CagriSema adalah program yang sedang dikembangkan secara klinis. Produk atau penjual dengan nama sama di Indonesia tidak otomatis mewarisi identitas klinis sponsor, hasil uji, atau status regulasinya. Periksa produk, pemegang izin, fasilitas, dan jalur pasok yang tepat dalam catatan resmi tujuan di bawah.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Indonesia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Indonesia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Indonesia", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=indonesia" }, { "recordId": "pl-compound-country-cagrisema-singapore", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "CagriSema in Singapore", "localizedAnswer": "CagriSema is an investigational clinical program. No seller listing in Singapore can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Singapore", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Singapore#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Singapore", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=singapore" }, { "recordId": "pl-compound-country-cagrisema-philippines", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "CagriSema in the Philippines", "localizedAnswer": "CagriSema is an investigational clinical program. No seller listing in the Philippines can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Philippines", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Philippines#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Philippines", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=philippines" }, { "recordId": "pl-compound-country-cagrisema-malaysia", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "CagriSema in Malaysia", "localizedAnswer": "CagriSema is an investigational clinical program. No seller listing in Malaysia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Malaysia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 6, "clinicalTrialListedLocations": 47, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT05669755", "NCT07357740", "NCT07357766", "NCT07282613", "NCT05394519" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT07357740", "https://clinicaltrials.gov/study/NCT07357766", "https://clinicaltrials.gov/study/NCT07282613", "https://clinicaltrials.gov/study/NCT05394519" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Malaysia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Malaysia", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=malaysia" }, { "recordId": "pl-compound-country-cagrisema-taiwan", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "CagriSema 在台灣的紀錄", "localizedAnswer": "CagriSema是臨床開發中的計畫。贊助者的臨床身分、試驗結果或法規狀態，不會自動移轉給台灣的同名網路商品或提供者。必須利用下方紀錄核對目的地的具體產品、許可證持有者、機構與供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Taiwan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 8, "clinicalTrialListedLocations": 31, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07253285", "NCT05567796", "NCT06534411", "NCT07357766", "NCT06065540", "NCT07282613", "NCT06221969", "NCT05813925" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT07357766", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07282613", "https://clinicaltrials.gov/study/NCT06221969", "https://clinicaltrials.gov/study/NCT05813925" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Taiwan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Taiwan", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=taiwan" }, { "recordId": "pl-compound-country-cagrisema-hong-kong", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "CagriSema 在香港的紀錄", "localizedAnswer": "CagriSema是臨床開發中的計劃。贊助者的臨床身分、試驗結果或監管狀態，不會自動轉移給香港的同名網上商品或銷售商。必須透過下方紀錄核對目的地的指定產品、註冊持有人、持牌實體和供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Hong Kong", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Hong%20Kong#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Hong%20Kong", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=hong-kong" }, { "recordId": "pl-compound-country-cagrisema-vietnam", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "CagriSema tại Việt Nam", "localizedAnswer": "CagriSema là một chương trình đang phát triển lâm sàng. Không đề nghị thương mại nào tại Việt Nam tự động kế thừa danh tính lâm sàng, kết quả thử nghiệm hoặc tình trạng quản lý của nhà tài trợ. Cần kiểm tra sản phẩm, chủ sở hữu giấy phép, cơ sở và đường cung ứng cụ thể trong các hồ sơ chính thức của điểm đến ở dưới.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Vietnam", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Vietnam#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Vietnam", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=vietnam" }, { "recordId": "pl-compound-country-cagrisema-united-states", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "CagriSema in the United States", "localizedAnswer": "CagriSema is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "United States", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 22, "clinicalTrialListedLocations": 906, "clinicalTrialRecruitingLocations": 106, "clinicalTrialRecordsWithRecruitingLocations": 3, "clinicalTrialRecordIds": [ "NCT07253285", "NCT07564414", "NCT07184086", "NCT07011667", "NCT05567796", "NCT05669755", "NCT06534411", "NCT07357740", "NCT07357766", "NCT06065540", "NCT07282613", "NCT06388187", "NCT06221969", "NCT06323174", "NCT06131372", "NCT06409130", "NCT06131437", "NCT05394519", "NCT06780449", "NCT06797869", "NCT06323161", "NCT06716307" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07253285", "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT07184086", "https://clinicaltrials.gov/study/NCT07011667", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT07357740", "https://clinicaltrials.gov/study/NCT07357766", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT07282613", "https://clinicaltrials.gov/study/NCT06388187", "https://clinicaltrials.gov/study/NCT06221969", "https://clinicaltrials.gov/study/NCT06323174", "https://clinicaltrials.gov/study/NCT06131372", "https://clinicaltrials.gov/study/NCT06409130", "https://clinicaltrials.gov/study/NCT06131437", "https://clinicaltrials.gov/study/NCT05394519", "https://clinicaltrials.gov/study/NCT06780449", "https://clinicaltrials.gov/study/NCT06797869", "https://clinicaltrials.gov/study/NCT06323161", "https://clinicaltrials.gov/study/NCT06716307" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=United%20States#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=United%20States", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=united-states" }, { "recordId": "pl-compound-country-cagrisema-canada", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "CagriSema in Canada", "localizedAnswer": "CagriSema is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Canada", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 13, "clinicalTrialListedLocations": 156, "clinicalTrialRecruitingLocations": 20, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07564414", "NCT05567796", "NCT05669755", "NCT06534411", "NCT06065540", "NCT06289504", "NCT06388187", "NCT06221969", "NCT06131372", "NCT06409130", "NCT05394519", "NCT06780449", "NCT06797869" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT06534411", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT06289504", "https://clinicaltrials.gov/study/NCT06388187", "https://clinicaltrials.gov/study/NCT06221969", "https://clinicaltrials.gov/study/NCT06131372", "https://clinicaltrials.gov/study/NCT06409130", "https://clinicaltrials.gov/study/NCT05394519", "https://clinicaltrials.gov/study/NCT06780449", "https://clinicaltrials.gov/study/NCT06797869" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Canada#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Canada", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=canada" }, { "recordId": "pl-compound-country-cagrisema-united-arab-emirates", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "CagriSema في الإمارات العربية المتحدة", "localizedAnswer": "CagriSema برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في الإمارات العربية المتحدة أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "United Arab Emirates", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=United%20Arab%20Emirates#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=United%20Arab%20Emirates", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=united-arab-emirates" }, { "recordId": "pl-compound-country-cagrisema-saudi-arabia", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "CagriSema في المملكة العربية السعودية", "localizedAnswer": "CagriSema برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في المملكة العربية السعودية أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Saudi Arabia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 5, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT06323174" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06323174" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Saudi%20Arabia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Saudi%20Arabia", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=saudi-arabia" }, { "recordId": "pl-compound-country-cagrisema-south-africa", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational program requiring an exact SAHPRA product record", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "CagriSema in South Africa", "localizedAnswer": "Novo Nordisk states that CagriSema was submitted to the US FDA in December 2025 and that an FDA decision is anticipated by late 2026. That US review does not establish South African authorization or supply. SAHPRA's registered-product service is the official route for checking an exact South African product record. No compound-specific South African authorization finding is attached here, so an online offer cannot inherit the sponsor program's identity, evidence, or regulatory status.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 2, "statusEvidencePublishers": [ "Novo Nordisk", "South African Health Products Regulatory Authority" ], "statusEvidenceUrls": [ "https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916501", "https://medsinfo.sahpra.org.za/" ], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "South Africa", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 7, "clinicalTrialListedLocations": 68, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07564414", "NCT05567796", "NCT05669755", "NCT07357766", "NCT06065540", "NCT06221969", "NCT06323161" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07564414", "https://clinicaltrials.gov/study/NCT05567796", "https://clinicaltrials.gov/study/NCT05669755", "https://clinicaltrials.gov/study/NCT07357766", "https://clinicaltrials.gov/study/NCT06065540", "https://clinicaltrials.gov/study/NCT06221969", "https://clinicaltrials.gov/study/NCT06323161" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=South%20Africa#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=South%20Africa", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=south-africa" }, { "recordId": "pl-compound-country-cagrisema-nigeria", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "CagriSema in Nigeria", "localizedAnswer": "CagriSema is an investigational clinical program. No seller listing in Nigeria can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Nigeria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Nigeria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Nigeria", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=nigeria" }, { "recordId": "pl-compound-country-cagrisema-kenya", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "CagriSema in Kenya", "localizedAnswer": "CagriSema is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "CagriSema", "clinicalTrialRegistryCountry": "Kenya", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=cagrisema&country=Kenya#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=CagriSema&locStr=Kenya", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/cagrisema", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/cagrisema/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=cagrisema&country=kenya" }, { "recordId": "pl-compound-country-maritide-france", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "MariTide en France", "localizedAnswer": "MariTide est un programme clinique expérimental. Aucune offre commerciale en France ne peut reprendre automatiquement l’identité clinique, les résultats d’essais ou le statut réglementaire du promoteur. Vérifiez chaque produit et fournisseur dans les registres ci-dessous.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "France", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 4, "clinicalTrialListedLocations": 40, "clinicalTrialRecruitingLocations": 40, "clinicalTrialRecordsWithRecruitingLocations": 4, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT07225686", "NCT07226765" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT07225686", "https://clinicaltrials.gov/study/NCT07226765" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=France#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=France", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=france" }, { "recordId": "pl-compound-country-maritide-united-kingdom", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "MariTide in the United Kingdom", "localizedAnswer": "MariTide is an investigational clinical program. No seller listing in the United Kingdom can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "United Kingdom", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 4, "clinicalTrialListedLocations": 73, "clinicalTrialRecruitingLocations": 47, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT06858878", "NCT06858839" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT06858878", "https://clinicaltrials.gov/study/NCT06858839" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=United%20Kingdom#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=United%20Kingdom", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=united-kingdom" }, { "recordId": "pl-compound-country-maritide-germany", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "MariTide in Deutschland", "localizedAnswer": "MariTide ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Deutschland übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Germany", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 7, "clinicalTrialListedLocations": 135, "clinicalTrialRecruitingLocations": 82, "clinicalTrialRecordsWithRecruitingLocations": 4, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT07225686", "NCT07226765", "NCT05669599", "NCT06858878", "NCT06858839" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT07225686", "https://clinicaltrials.gov/study/NCT07226765", "https://clinicaltrials.gov/study/NCT05669599", "https://clinicaltrials.gov/study/NCT06858878", "https://clinicaltrials.gov/study/NCT06858839" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Germany#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Germany", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=germany" }, { "recordId": "pl-compound-country-maritide-spain", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "MariTide en España", "localizedAnswer": "MariTide es un programa clínico en investigación. Ninguna oferta comercial en España puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Spain", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 7, "clinicalTrialListedLocations": 82, "clinicalTrialRecruitingLocations": 62, "clinicalTrialRecordsWithRecruitingLocations": 4, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT07225686", "NCT07226765", "NCT05669599", "NCT06660173", "NCT06858839" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT07225686", "https://clinicaltrials.gov/study/NCT07226765", "https://clinicaltrials.gov/study/NCT05669599", "https://clinicaltrials.gov/study/NCT06660173", "https://clinicaltrials.gov/study/NCT06858839" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Spain#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Spain", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=spain" }, { "recordId": "pl-compound-country-maritide-italy", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "MariTide in Italia", "localizedAnswer": "MariTide è un programma clinico sperimentale. Nessuna offerta commerciale in Italia può ereditare l’identità clinica, i risultati degli studi o lo stato regolatorio dello sponsor. Verifica ogni prodotto e fornitore nei registri riportati sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Italy", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 50, "clinicalTrialRecruitingLocations": 29, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT06858878", "NCT06660173", "NCT06858839" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT06858878", "https://clinicaltrials.gov/study/NCT06660173", "https://clinicaltrials.gov/study/NCT06858839" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Italy#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Italy", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=italy" }, { "recordId": "pl-compound-country-maritide-netherlands", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "MariTide in Nederland", "localizedAnswer": "MariTide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in Nederland neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Netherlands", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 47, "clinicalTrialRecruitingLocations": 46, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Netherlands#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Netherlands", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=netherlands" }, { "recordId": "pl-compound-country-maritide-switzerland", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "MariTide in Switzerland", "localizedAnswer": "MariTide is an investigational clinical program. No seller listing in Switzerland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Switzerland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 17, "clinicalTrialRecruitingLocations": 12, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT06858839" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT06858839" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Switzerland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Switzerland", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=switzerland" }, { "recordId": "pl-compound-country-maritide-poland", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "MariTide w Polsce", "localizedAnswer": "MariTide jest eksperymentalnym programem klinicznym. Żadna oferta handlowa w Polsce nie przejmuje automatycznie tożsamości klinicznej, wyników badań ani statusu regulacyjnego sponsora. Sprawdź każdy produkt i dostawcę w rejestrach poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Poland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 8, "clinicalTrialListedLocations": 104, "clinicalTrialRecruitingLocations": 67, "clinicalTrialRecordsWithRecruitingLocations": 4, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT07225686", "NCT07226765", "NCT05669599", "NCT06858878", "NCT06660173", "NCT06858839" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT07225686", "https://clinicaltrials.gov/study/NCT07226765", "https://clinicaltrials.gov/study/NCT05669599", "https://clinicaltrials.gov/study/NCT06858878", "https://clinicaltrials.gov/study/NCT06660173", "https://clinicaltrials.gov/study/NCT06858839" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Poland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Poland", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=poland" }, { "recordId": "pl-compound-country-maritide-ireland", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "MariTide in Ireland", "localizedAnswer": "MariTide is an investigational clinical program. No seller listing in Ireland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Ireland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Ireland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Ireland", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=ireland" }, { "recordId": "pl-compound-country-maritide-portugal", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "MariTide em Portugal", "localizedAnswer": "MariTide é um programa clínico experimental. Nenhuma oferta comercial em Portugal pode herdar a identidade clínica, os resultados de ensaios ou o estatuto regulamentar do promotor. Verifique cada produto e fornecedor nos registos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Portugal", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 18, "clinicalTrialRecruitingLocations": 18, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Portugal#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Portugal", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=portugal" }, { "recordId": "pl-compound-country-maritide-sweden", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "MariTide i Sverige", "localizedAnswer": "MariTide är ett kliniskt prövningsprogram. Inget kommersiellt erbjudande i Sverige kan automatiskt ärva sponsorns kliniska identitet, studieresultat eller regulatoriska status. Kontrollera varje produkt och leverantör i registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Sweden", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 20, "clinicalTrialRecruitingLocations": 15, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT06660173" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT06660173" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Sweden#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Sweden", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=sweden" }, { "recordId": "pl-compound-country-maritide-turkey", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için MariTide", "localizedAnswer": "MariTide klinik geliştirme aşamasındaki bir programdır. Türkiye içindeki aynı adlı hiçbir ticari teklif sponsorun klinik kimliğini, çalışma sonuçlarını veya düzenleyici statüsünü otomatik olarak devralamaz. Belirli ürünü, ruhsat sahibini, kuruluşu ve tedarik yolunu aşağıdaki resmi hedef ülke kayıtlarında kontrol edin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Turkey (Türkiye)", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 32, "clinicalTrialRecruitingLocations": 32, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Turkey%20(T%C3%BCrkiye)#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Turkey%20(T%C3%BCrkiye)", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=turkey" }, { "recordId": "pl-compound-country-maritide-austria", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "MariTide in Österreich", "localizedAnswer": "MariTide ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Österreich übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Austria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 25, "clinicalTrialRecruitingLocations": 21, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT06660173" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT06660173" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Austria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Austria", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=austria" }, { "recordId": "pl-compound-country-maritide-belgium", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "MariTide in België", "localizedAnswer": "MariTide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in België neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Belgium", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 34, "clinicalTrialRecruitingLocations": 26, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT06858839" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT06858839" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Belgium#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Belgium", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=belgium" }, { "recordId": "pl-compound-country-maritide-denmark", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "MariTide i Danmark", "localizedAnswer": "MariTide er et klinisk udviklingsprogram. Et kommercielt tilbud med samme navn i Danmark arver ikke sponsorens kliniske identitet, forsøgsresultater eller regulatoriske status. Kontrollér det konkrete produkt, tilladelsesindehaveren, virksomheden og forsyningsvejen i de officielle registre for destinationen nedenfor.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Denmark", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 26, "clinicalTrialRecruitingLocations": 19, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT06858839" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT06858839" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Denmark#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Denmark", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=denmark" }, { "recordId": "pl-compound-country-maritide-finland", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "MariTide kohteessa Suomi", "localizedAnswer": "MariTide on kliininen kehitysohjelma. Samanniminen kaupallinen tarjous kohteessa Suomi ei peri sponsorin kliinistä identiteettiä, tutkimustuloksia tai sääntelyasemaa. Tarkista täsmällinen tuote, luvanhaltija, toimija ja toimitusreitti alla olevista kohdemaan virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Finland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 13, "clinicalTrialRecruitingLocations": 10, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT06858839" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT06858839" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Finland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Finland", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=finland" }, { "recordId": "pl-compound-country-maritide-mexico", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "MariTide en México", "localizedAnswer": "MariTide es un programa clínico en investigación. Ninguna oferta comercial en México puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Mexico", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 17, "clinicalTrialRecruitingLocations": 17, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Mexico#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Mexico", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=mexico" }, { "recordId": "pl-compound-country-maritide-argentina", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "MariTide en Argentina", "localizedAnswer": "MariTide es un programa clínico en investigación. Ninguna oferta comercial en Argentina puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Argentina", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 4, "clinicalTrialListedLocations": 68, "clinicalTrialRecruitingLocations": 53, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT06858878", "NCT06858839" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT06858878", "https://clinicaltrials.gov/study/NCT06858839" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Argentina#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Argentina", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=argentina" }, { "recordId": "pl-compound-country-maritide-colombia", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "MariTide en Colombia", "localizedAnswer": "MariTide es un programa clínico en investigación. Ninguna oferta comercial en Colombia puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Colombia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 15, "clinicalTrialRecruitingLocations": 15, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Colombia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Colombia", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=colombia" }, { "recordId": "pl-compound-country-maritide-chile", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "MariTide en Chile", "localizedAnswer": "MariTide es un programa clínico en investigación. Ninguna oferta comercial en Chile puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Chile", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 17, "clinicalTrialRecruitingLocations": 17, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Chile#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Chile", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=chile" }, { "recordId": "pl-compound-country-maritide-brazil", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "MariTide no Brasil", "localizedAnswer": "MariTide é um programa clínico experimental. Nenhuma oferta comercial no Brasil pode herdar a identidade clínica, os resultados de ensaios ou o status regulatório do patrocinador. Verifique cada produto e fornecedor nos registros abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Brazil", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 4, "clinicalTrialListedLocations": 64, "clinicalTrialRecruitingLocations": 64, "clinicalTrialRecordsWithRecruitingLocations": 4, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT07225686", "NCT07226765" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT07225686", "https://clinicaltrials.gov/study/NCT07226765" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Brazil#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Brazil", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=brazil" }, { "recordId": "pl-compound-country-maritide-china", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "MariTide 在中国的状态与官方记录", "localizedAnswer": "MariTide在此对应一个临床与监管项目。项目在某一国家的试验、批准或公司公告，不能自动证明同名商品在中国获批、可得或由有资质的卖方提供。请分别核对目的地的具体药品记录、批准持有人、剂型规格、经营主体和供应路径，并保持临床证据与在线商品身份相互独立。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "China", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 90, "clinicalTrialRecruitingLocations": 90, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=China#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=China", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=china" }, { "recordId": "pl-compound-country-maritide-australia", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "MariTide in Australia", "localizedAnswer": "MariTide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Australia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 6, "clinicalTrialListedLocations": 57, "clinicalTrialRecruitingLocations": 39, "clinicalTrialRecordsWithRecruitingLocations": 4, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT07225686", "NCT07226765", "NCT05669599", "NCT06858839" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT07225686", "https://clinicaltrials.gov/study/NCT07226765", "https://clinicaltrials.gov/study/NCT05669599", "https://clinicaltrials.gov/study/NCT06858839" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Australia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Australia", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=australia" }, { "recordId": "pl-compound-country-maritide-new-zealand", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "MariTide in New Zealand", "localizedAnswer": "MariTide is an investigational clinical program. No seller listing in New Zealand can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "New Zealand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=New%20Zealand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=New%20Zealand", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=new-zealand" }, { "recordId": "pl-compound-country-maritide-india", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "MariTide in India", "localizedAnswer": "MariTide is an investigational clinical program. No seller listing in India can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "India", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=India#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=India", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=india" }, { "recordId": "pl-compound-country-maritide-japan", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のMariTide", "localizedAnswer": "MariTideは臨床開発中のプログラムです。スポンサーの臨床上の同一性、試験結果、規制上の位置付けを、日本の同名オンライン商品や販売者が自動的に引き継ぐことはありません。目的地の製品、承認保持者、施設、供給経路を下記の公的記録で確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Japan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 9, "clinicalTrialListedLocations": 135, "clinicalTrialRecruitingLocations": 70, "clinicalTrialRecordsWithRecruitingLocations": 4, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT07225686", "NCT07226765", "NCT05669599", "NCT06858878", "NCT06987695", "NCT06660173", "NCT06858839" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT07225686", "https://clinicaltrials.gov/study/NCT07226765", "https://clinicaltrials.gov/study/NCT05669599", "https://clinicaltrials.gov/study/NCT06858878", "https://clinicaltrials.gov/study/NCT06987695", "https://clinicaltrials.gov/study/NCT06660173", "https://clinicaltrials.gov/study/NCT06858839" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Japan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Japan", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=japan" }, { "recordId": "pl-compound-country-maritide-south-korea", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 MariTide", "localizedAnswer": "MariTide은 임상 개발 중인 프로그램입니다. 후원사의 임상 신원, 시험 결과 또는 규제 상태를 대한민국의 동명 온라인 상품이나 판매자가 자동으로 이어받을 수 없습니다. 목적지의 정확한 제품, 허가권자, 기관과 공급 경로를 아래 공식 기록에서 확인해야 합니다.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "South Korea", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 6, "clinicalTrialListedLocations": 59, "clinicalTrialRecruitingLocations": 18, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT05669599", "NCT06858878", "NCT06660173", "NCT06858839" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT05669599", "https://clinicaltrials.gov/study/NCT06858878", "https://clinicaltrials.gov/study/NCT06660173", "https://clinicaltrials.gov/study/NCT06858839" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=South%20Korea#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=South%20Korea", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=south-korea" }, { "recordId": "pl-compound-country-maritide-thailand", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "MariTide ในประเทศไทย", "localizedAnswer": "MariTide เป็นโครงการที่อยู่ระหว่างการพัฒนาทางคลินิก สินค้าหรือผู้ขายชื่อเดียวกันในประเทศไทยไม่สามารถรับช่วงตัวตนทางคลินิก ผลการทดลอง หรือสถานะด้านกฎระเบียบของผู้สนับสนุนโดยอัตโนมัติ ให้ตรวจผลิตภัณฑ์ ผู้ถือทะเบียน สถานประกอบการ และเส้นทางการจัดหาที่แน่นอนในบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Thailand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Thailand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Thailand", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=thailand" }, { "recordId": "pl-compound-country-maritide-indonesia", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "MariTide di Indonesia", "localizedAnswer": "MariTide adalah program yang sedang dikembangkan secara klinis. Produk atau penjual dengan nama sama di Indonesia tidak otomatis mewarisi identitas klinis sponsor, hasil uji, atau status regulasinya. Periksa produk, pemegang izin, fasilitas, dan jalur pasok yang tepat dalam catatan resmi tujuan di bawah.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Indonesia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Indonesia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Indonesia", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=indonesia" }, { "recordId": "pl-compound-country-maritide-singapore", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "MariTide in Singapore", "localizedAnswer": "MariTide is an investigational clinical program. No seller listing in Singapore can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Singapore", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 6, "clinicalTrialRecruitingLocations": 6, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07037433" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Singapore#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Singapore", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=singapore" }, { "recordId": "pl-compound-country-maritide-philippines", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "MariTide in the Philippines", "localizedAnswer": "MariTide is an investigational clinical program. No seller listing in the Philippines can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Philippines", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Philippines#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Philippines", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=philippines" }, { "recordId": "pl-compound-country-maritide-malaysia", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "MariTide in Malaysia", "localizedAnswer": "MariTide is an investigational clinical program. No seller listing in Malaysia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Malaysia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Malaysia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Malaysia", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=malaysia" }, { "recordId": "pl-compound-country-maritide-taiwan", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "MariTide 在台灣的紀錄", "localizedAnswer": "MariTide是臨床開發中的計畫。贊助者的臨床身分、試驗結果或法規狀態，不會自動移轉給台灣的同名網路商品或提供者。必須利用下方紀錄核對目的地的具體產品、許可證持有者、機構與供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Taiwan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 4, "clinicalTrialListedLocations": 22, "clinicalTrialRecruitingLocations": 14, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT05669599", "NCT06660173" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT05669599", "https://clinicaltrials.gov/study/NCT06660173" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Taiwan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Taiwan", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=taiwan" }, { "recordId": "pl-compound-country-maritide-hong-kong", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "MariTide 在香港的紀錄", "localizedAnswer": "MariTide是臨床開發中的計劃。贊助者的臨床身分、試驗結果或監管狀態，不會自動轉移給香港的同名網上商品或銷售商。必須透過下方紀錄核對目的地的指定產品、註冊持有人、持牌實體和供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Hong Kong", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 7, "clinicalTrialRecruitingLocations": 4, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT05669599", "NCT06352892", "NCT06660173" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT05669599", "https://clinicaltrials.gov/study/NCT06352892", "https://clinicaltrials.gov/study/NCT06660173" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Hong%20Kong#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Hong%20Kong", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=hong-kong" }, { "recordId": "pl-compound-country-maritide-vietnam", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "MariTide tại Việt Nam", "localizedAnswer": "MariTide là một chương trình đang phát triển lâm sàng. Không đề nghị thương mại nào tại Việt Nam tự động kế thừa danh tính lâm sàng, kết quả thử nghiệm hoặc tình trạng quản lý của nhà tài trợ. Cần kiểm tra sản phẩm, chủ sở hữu giấy phép, cơ sở và đường cung ứng cụ thể trong các hồ sơ chính thức của điểm đến ở dưới.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Vietnam", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Vietnam#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Vietnam", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=vietnam" }, { "recordId": "pl-compound-country-maritide-united-states", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "MariTide in the United States", "localizedAnswer": "MariTide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "United States", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 23, "clinicalTrialListedLocations": 568, "clinicalTrialRecruitingLocations": 340, "clinicalTrialRecordsWithRecruitingLocations": 6, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07575399", "NCT07037459", "NCT07441252", "NCT07225686", "NCT07226765", "NCT07717814", "NCT07523711", "NCT07313761", "NCT07226778", "NCT07160257", "NCT07428525", "NCT07429032", "NCT07429045", "NCT07229157", "NCT05669599", "NCT06858878", "NCT07310563", "NCT04478708", "NCT06660173", "NCT06858839", "NCT06976372", "NCT05056246" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07575399", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT07441252", "https://clinicaltrials.gov/study/NCT07225686", "https://clinicaltrials.gov/study/NCT07226765", "https://clinicaltrials.gov/study/NCT07717814", "https://clinicaltrials.gov/study/NCT07523711", "https://clinicaltrials.gov/study/NCT07313761", "https://clinicaltrials.gov/study/NCT07226778", "https://clinicaltrials.gov/study/NCT07160257", "https://clinicaltrials.gov/study/NCT07428525", "https://clinicaltrials.gov/study/NCT07429032", "https://clinicaltrials.gov/study/NCT07429045", "https://clinicaltrials.gov/study/NCT07229157", "https://clinicaltrials.gov/study/NCT05669599", "https://clinicaltrials.gov/study/NCT06858878", "https://clinicaltrials.gov/study/NCT07310563", "https://clinicaltrials.gov/study/NCT04478708", "https://clinicaltrials.gov/study/NCT06660173", "https://clinicaltrials.gov/study/NCT06858839", "https://clinicaltrials.gov/study/NCT06976372", "https://clinicaltrials.gov/study/NCT05056246" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=United%20States#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=United%20States", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=united-states" }, { "recordId": "pl-compound-country-maritide-canada", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "MariTide in Canada", "localizedAnswer": "MariTide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Canada", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 7, "clinicalTrialListedLocations": 82, "clinicalTrialRecruitingLocations": 45, "clinicalTrialRecordsWithRecruitingLocations": 4, "clinicalTrialRecordIds": [ "NCT07037433", "NCT07037459", "NCT07225686", "NCT07226765", "NCT05669599", "NCT06858878", "NCT06858839" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07037433", "https://clinicaltrials.gov/study/NCT07037459", "https://clinicaltrials.gov/study/NCT07225686", "https://clinicaltrials.gov/study/NCT07226765", "https://clinicaltrials.gov/study/NCT05669599", "https://clinicaltrials.gov/study/NCT06858878", "https://clinicaltrials.gov/study/NCT06858839" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Canada#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Canada", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=canada" }, { "recordId": "pl-compound-country-maritide-united-arab-emirates", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "MariTide في الإمارات العربية المتحدة", "localizedAnswer": "MariTide برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في الإمارات العربية المتحدة أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "United Arab Emirates", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=United%20Arab%20Emirates#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=United%20Arab%20Emirates", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=united-arab-emirates" }, { "recordId": "pl-compound-country-maritide-saudi-arabia", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "MariTide في المملكة العربية السعودية", "localizedAnswer": "MariTide برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في المملكة العربية السعودية أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Saudi Arabia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Saudi%20Arabia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Saudi%20Arabia", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=saudi-arabia" }, { "recordId": "pl-compound-country-maritide-south-africa", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "MariTide in South Africa", "localizedAnswer": "MariTide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "South Africa", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=South%20Africa#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=South%20Africa", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=south-africa" }, { "recordId": "pl-compound-country-maritide-nigeria", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "MariTide in Nigeria", "localizedAnswer": "MariTide is an investigational clinical program. No seller listing in Nigeria can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Nigeria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Nigeria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Nigeria", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=nigeria" }, { "recordId": "pl-compound-country-maritide-kenya", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "MariTide in Kenya", "localizedAnswer": "MariTide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "MariTide", "clinicalTrialRegistryCountry": "Kenya", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=maritide&country=Kenya#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=MariTide&locStr=Kenya", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/maritide", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/maritide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=maritide&country=kenya" }, { "recordId": "pl-compound-country-survodutide-france", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Survodutide en France", "localizedAnswer": "Survodutide est un programme clinique expérimental. Aucune offre commerciale en France ne peut reprendre automatiquement l’identité clinique, les résultats d’essais ou le statut réglementaire du promoteur. Vérifiez chaque produit et fournisseur dans les registres ci-dessous.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "France", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 32, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT04771273" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT04771273" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=France#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=France", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=france" }, { "recordId": "pl-compound-country-survodutide-united-kingdom", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Survodutide in the United Kingdom", "localizedAnswer": "Survodutide is an investigational clinical program. No seller listing in the United Kingdom can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "United Kingdom", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 9, "clinicalTrialListedLocations": 91, "clinicalTrialRecruitingLocations": 36, "clinicalTrialRecordsWithRecruitingLocations": 3, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT07407348", "NCT06077864", "NCT06066528", "NCT06066515", "NCT04771273", "NCT04667377", "NCT04153929" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT07407348", "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT06066528", "https://clinicaltrials.gov/study/NCT06066515", "https://clinicaltrials.gov/study/NCT04771273", "https://clinicaltrials.gov/study/NCT04667377", "https://clinicaltrials.gov/study/NCT04153929" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=United%20Kingdom#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=United%20Kingdom", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=united-kingdom" }, { "recordId": "pl-compound-country-survodutide-germany", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Survodutide in Deutschland", "localizedAnswer": "Survodutide ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Deutschland übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Germany", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 20, "clinicalTrialListedLocations": 92, "clinicalTrialRecruitingLocations": 23, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864", "NCT06066528", "NCT07413913", "NCT06200467", "NCT06352411", "NCT06772532", "NCT07071974", "NCT07221591", "NCT06066515", "NCT05896384", "NCT06352424", "NCT05751226", "NCT04771273", "NCT05296733", "NCT04667377", "NCT04153929", "NCT03591718", "NCT03175211" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT06066528", "https://clinicaltrials.gov/study/NCT07413913", "https://clinicaltrials.gov/study/NCT06200467", "https://clinicaltrials.gov/study/NCT06352411", "https://clinicaltrials.gov/study/NCT06772532", "https://clinicaltrials.gov/study/NCT07071974", "https://clinicaltrials.gov/study/NCT07221591", "https://clinicaltrials.gov/study/NCT06066515", "https://clinicaltrials.gov/study/NCT05896384", "https://clinicaltrials.gov/study/NCT06352424", "https://clinicaltrials.gov/study/NCT05751226", "https://clinicaltrials.gov/study/NCT04771273", "https://clinicaltrials.gov/study/NCT05296733", "https://clinicaltrials.gov/study/NCT04667377", "https://clinicaltrials.gov/study/NCT04153929", "https://clinicaltrials.gov/study/NCT03591718", "https://clinicaltrials.gov/study/NCT03175211" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Germany#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Germany", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=germany" }, { "recordId": "pl-compound-country-survodutide-spain", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Survodutide / survodutida en España", "localizedAnswer": "Survodutide / survodutida es un programa clínico en investigación. Ninguna oferta comercial en España puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Spain", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 7, "clinicalTrialListedLocations": 53, "clinicalTrialRecruitingLocations": 16, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864", "NCT06066528", "NCT06309992", "NCT04771273", "NCT04153929" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT06066528", "https://clinicaltrials.gov/study/NCT06309992", "https://clinicaltrials.gov/study/NCT04771273", "https://clinicaltrials.gov/study/NCT04153929" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Spain#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Spain", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=spain" }, { "recordId": "pl-compound-country-survodutide-italy", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Survodutide in Italia", "localizedAnswer": "Survodutide è un programma clinico sperimentale. Nessuna offerta commerciale in Italia può ereditare l’identità clinica, i risultati degli studi o lo stato regolatorio dello sponsor. Verifica ogni prodotto e fornitore nei registri riportati sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Italy", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 4, "clinicalTrialListedLocations": 37, "clinicalTrialRecruitingLocations": 16, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864", "NCT04771273" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT04771273" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Italy#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Italy", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=italy" }, { "recordId": "pl-compound-country-survodutide-netherlands", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Survodutide in Nederland", "localizedAnswer": "Survodutide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in Nederland neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Netherlands", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 9, "clinicalTrialListedLocations": 27, "clinicalTrialRecruitingLocations": 8, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864", "NCT05202353", "NCT06066528", "NCT06066515", "NCT04771273", "NCT04667377", "NCT05421338" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT05202353", "https://clinicaltrials.gov/study/NCT06066528", "https://clinicaltrials.gov/study/NCT06066515", "https://clinicaltrials.gov/study/NCT04771273", "https://clinicaltrials.gov/study/NCT04667377", "https://clinicaltrials.gov/study/NCT05421338" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Netherlands#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Netherlands", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=netherlands" }, { "recordId": "pl-compound-country-survodutide-switzerland", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Survodutide in Switzerland", "localizedAnswer": "Survodutide is an investigational clinical program. No seller listing in Switzerland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Switzerland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 7, "clinicalTrialRecruitingLocations": 6, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Switzerland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Switzerland", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=switzerland" }, { "recordId": "pl-compound-country-survodutide-poland", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Survodutide w Polsce", "localizedAnswer": "Survodutide jest eksperymentalnym programem klinicznym. Żadna oferta handlowa w Polsce nie przejmuje automatycznie tożsamości klinicznej, wyników badań ani statusu regulacyjnego sponsora. Sprawdź każdy produkt i dostawcę w rejestrach poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Poland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 9, "clinicalTrialListedLocations": 81, "clinicalTrialRecruitingLocations": 18, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864", "NCT06066528", "NCT06066515", "NCT04771273", "NCT05296733", "NCT04667377", "NCT04153929" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT06066528", "https://clinicaltrials.gov/study/NCT06066515", "https://clinicaltrials.gov/study/NCT04771273", "https://clinicaltrials.gov/study/NCT05296733", "https://clinicaltrials.gov/study/NCT04667377", "https://clinicaltrials.gov/study/NCT04153929" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Poland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Poland", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=poland" }, { "recordId": "pl-compound-country-survodutide-ireland", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Survodutide in Ireland", "localizedAnswer": "Survodutide is an investigational clinical program. No seller listing in Ireland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Ireland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 2, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT06077864" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06077864" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Ireland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Ireland", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=ireland" }, { "recordId": "pl-compound-country-survodutide-portugal", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Survodutide / survodutida em Portugal", "localizedAnswer": "Survodutide / survodutida é um programa clínico experimental. Nenhuma oferta comercial em Portugal pode herdar a identidade clínica, os resultados de ensaios ou o estatuto regulamentar do promotor. Verifique cada produto e fornecedor nos registos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Portugal", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 14, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT06077864", "NCT04771273" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT04771273" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Portugal#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Portugal", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=portugal" }, { "recordId": "pl-compound-country-survodutide-sweden", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Survodutide i Sverige", "localizedAnswer": "Survodutide är ett kliniskt prövningsprogram. Inget kommersiellt erbjudande i Sverige kan automatiskt ärva sponsorns kliniska identitet, studieresultat eller regulatoriska status. Kontrollera varje produkt och leverantör i registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Sweden", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 12, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT06066528", "NCT06066515", "NCT04667377" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06066528", "https://clinicaltrials.gov/study/NCT06066515", "https://clinicaltrials.gov/study/NCT04667377" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Sweden#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Sweden", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=sweden" }, { "recordId": "pl-compound-country-survodutide-turkey", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Survodutide / survodutid", "localizedAnswer": "Survodutide / survodutid klinik geliştirme aşamasındaki bir programdır. Türkiye içindeki aynı adlı hiçbir ticari teklif sponsorun klinik kimliğini, çalışma sonuçlarını veya düzenleyici statüsünü otomatik olarak devralamaz. Belirli ürünü, ruhsat sahibini, kuruluşu ve tedarik yolunu aşağıdaki resmi hedef ülke kayıtlarında kontrol edin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Turkey (Türkiye)", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 29, "clinicalTrialRecruitingLocations": 14, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Turkey%20(T%C3%BCrkiye)#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Turkey%20(T%C3%BCrkiye)", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=turkey" }, { "recordId": "pl-compound-country-survodutide-austria", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Survodutide in Österreich", "localizedAnswer": "Survodutide ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Österreich übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Austria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 24, "clinicalTrialRecruitingLocations": 11, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864", "NCT04771273", "NCT04153929" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT04771273", "https://clinicaltrials.gov/study/NCT04153929" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Austria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Austria", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=austria" }, { "recordId": "pl-compound-country-survodutide-belgium", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Survodutide in België", "localizedAnswer": "Survodutide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in België neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Belgium", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 8, "clinicalTrialListedLocations": 26, "clinicalTrialRecruitingLocations": 9, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864", "NCT06066528", "NCT06564441", "NCT06066515", "NCT04771273", "NCT04667377" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT06066528", "https://clinicaltrials.gov/study/NCT06564441", "https://clinicaltrials.gov/study/NCT06066515", "https://clinicaltrials.gov/study/NCT04771273", "https://clinicaltrials.gov/study/NCT04667377" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Belgium#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Belgium", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=belgium" }, { "recordId": "pl-compound-country-survodutide-denmark", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Survodutide i Danmark", "localizedAnswer": "Survodutide er et klinisk udviklingsprogram. Et kommercielt tilbud med samme navn i Danmark arver ikke sponsorens kliniske identitet, forsøgsresultater eller regulatoriske status. Kontrollér det konkrete produkt, tilladelsesindehaveren, virksomheden og forsyningsvejen i de officielle registre for destinationen nedenfor.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Denmark", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 6, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT06077864", "NCT06066528" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT06066528" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Denmark#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Denmark", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=denmark" }, { "recordId": "pl-compound-country-survodutide-finland", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Survodutide kohteessa Suomi", "localizedAnswer": "Survodutide on kliininen kehitysohjelma. Samanniminen kaupallinen tarjous kohteessa Suomi ei peri sponsorin kliinistä identiteettiä, tutkimustuloksia tai sääntelyasemaa. Tarkista täsmällinen tuote, luvanhaltija, toimija ja toimitusreitti alla olevista kohdemaan virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Finland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 12, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT06077864", "NCT06066528", "NCT06066515" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT06066528", "https://clinicaltrials.gov/study/NCT06066515" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Finland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Finland", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=finland" }, { "recordId": "pl-compound-country-survodutide-mexico", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Survodutide / survodutida en México", "localizedAnswer": "Survodutide / survodutida es un programa clínico en investigación. Ninguna oferta comercial en México puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Mexico", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 22, "clinicalTrialRecruitingLocations": 3, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Mexico#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Mexico", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=mexico" }, { "recordId": "pl-compound-country-survodutide-argentina", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Survodutide / survodutida en Argentina", "localizedAnswer": "Survodutide / survodutida es un programa clínico en investigación. Ninguna oferta comercial en Argentina puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Argentina", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 35, "clinicalTrialRecruitingLocations": 15, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Argentina#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Argentina", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=argentina" }, { "recordId": "pl-compound-country-survodutide-colombia", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Survodutide / survodutida en Colombia", "localizedAnswer": "Survodutide / survodutida es un programa clínico en investigación. Ninguna oferta comercial en Colombia puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Colombia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Colombia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Colombia", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=colombia" }, { "recordId": "pl-compound-country-survodutide-chile", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Survodutide / survodutida en Chile", "localizedAnswer": "Survodutide / survodutida es un programa clínico en investigación. Ninguna oferta comercial en Chile puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Chile", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 6, "clinicalTrialRecruitingLocations": 6, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Chile#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Chile", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=chile" }, { "recordId": "pl-compound-country-survodutide-brazil", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Survodutide / survodutida no Brasil", "localizedAnswer": "Survodutide / survodutida é um programa clínico experimental. Nenhuma oferta comercial no Brasil pode herdar a identidade clínica, os resultados de ensaios ou o status regulatório do patrocinador. Verifique cada produto e fornecedor nos registros abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Brazil", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 31, "clinicalTrialRecruitingLocations": 12, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Brazil#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Brazil", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=brazil" }, { "recordId": "pl-compound-country-survodutide-china", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Survodutide 在中国的状态与官方记录", "localizedAnswer": "Survodutide在此对应一个临床与监管项目。项目在某一国家的试验、批准或公司公告，不能自动证明同名商品在中国获批、可得或由有资质的卖方提供。请分别核对目的地的具体药品记录、批准持有人、剂型规格、经营主体和供应路径，并保持临床证据与在线商品身份相互独立。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "China", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 9, "clinicalTrialListedLocations": 223, "clinicalTrialRecruitingLocations": 83, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864", "NCT06066528", "NCT06214741", "NCT06066515", "NCT06492135", "NCT04771273", "NCT04667377" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT06066528", "https://clinicaltrials.gov/study/NCT06214741", "https://clinicaltrials.gov/study/NCT06066515", "https://clinicaltrials.gov/study/NCT06492135", "https://clinicaltrials.gov/study/NCT04771273", "https://clinicaltrials.gov/study/NCT04667377" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=China#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=China", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=china" }, { "recordId": "pl-compound-country-survodutide-australia", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Survodutide in Australia", "localizedAnswer": "Survodutide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Australia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 8, "clinicalTrialListedLocations": 57, "clinicalTrialRecruitingLocations": 13, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864", "NCT06066528", "NCT06066515", "NCT04771273", "NCT04667377", "NCT04153929" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT06066528", "https://clinicaltrials.gov/study/NCT06066515", "https://clinicaltrials.gov/study/NCT04771273", "https://clinicaltrials.gov/study/NCT04667377", "https://clinicaltrials.gov/study/NCT04153929" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Australia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Australia", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=australia" }, { "recordId": "pl-compound-country-survodutide-new-zealand", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Survodutide in New Zealand", "localizedAnswer": "Survodutide is an investigational clinical program. No seller listing in New Zealand can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "New Zealand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 9, "clinicalTrialListedLocations": 34, "clinicalTrialRecruitingLocations": 8, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864", "NCT06066528", "NCT06066515", "NCT04771273", "NCT05296733", "NCT04667377", "NCT04153929" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT06066528", "https://clinicaltrials.gov/study/NCT06066515", "https://clinicaltrials.gov/study/NCT04771273", "https://clinicaltrials.gov/study/NCT05296733", "https://clinicaltrials.gov/study/NCT04667377", "https://clinicaltrials.gov/study/NCT04153929" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=New%20Zealand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=New%20Zealand", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=new-zealand" }, { "recordId": "pl-compound-country-survodutide-india", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Survodutide in India", "localizedAnswer": "Survodutide is an investigational clinical program. No seller listing in India can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "India", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 35, "clinicalTrialRecruitingLocations": 24, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=India#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=India", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=india" }, { "recordId": "pl-compound-country-survodutide-japan", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のSurvodutide / スルボデュチド", "localizedAnswer": "Survodutide / スルボデュチドは臨床開発中のプログラムです。スポンサーの臨床上の同一性、試験結果、規制上の位置付けを、日本の同名オンライン商品や販売者が自動的に引き継ぐことはありません。目的地の製品、承認保持者、施設、供給経路を下記の公的記録で確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Japan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 8, "clinicalTrialListedLocations": 196, "clinicalTrialRecruitingLocations": 92, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864", "NCT06066528", "NCT06176365", "NCT06066515", "NCT04771273", "NCT04384081" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT06066528", "https://clinicaltrials.gov/study/NCT06176365", "https://clinicaltrials.gov/study/NCT06066515", "https://clinicaltrials.gov/study/NCT04771273", "https://clinicaltrials.gov/study/NCT04384081" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Japan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Japan", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=japan" }, { "recordId": "pl-compound-country-survodutide-south-korea", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Survodutide / 서보두타이드", "localizedAnswer": "Survodutide / 서보두타이드은 임상 개발 중인 프로그램입니다. 후원사의 임상 신원, 시험 결과 또는 규제 상태를 대한민국의 동명 온라인 상품이나 판매자가 자동으로 이어받을 수 없습니다. 목적지의 정확한 제품, 허가권자, 기관과 공급 경로를 아래 공식 기록에서 확인해야 합니다.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "South Korea", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 8, "clinicalTrialListedLocations": 63, "clinicalTrialRecruitingLocations": 20, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864", "NCT06066528", "NCT06066515", "NCT04771273", "NCT04667377", "NCT04153929" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT06066528", "https://clinicaltrials.gov/study/NCT06066515", "https://clinicaltrials.gov/study/NCT04771273", "https://clinicaltrials.gov/study/NCT04667377", "https://clinicaltrials.gov/study/NCT04153929" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=South%20Korea#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=South%20Korea", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=south-korea" }, { "recordId": "pl-compound-country-survodutide-thailand", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Survodutide / เซอร์โวดูไทด์ ในประเทศไทย", "localizedAnswer": "Survodutide / เซอร์โวดูไทด์ เป็นโครงการที่อยู่ระหว่างการพัฒนาทางคลินิก สินค้าหรือผู้ขายชื่อเดียวกันในประเทศไทยไม่สามารถรับช่วงตัวตนทางคลินิก ผลการทดลอง หรือสถานะด้านกฎระเบียบของผู้สนับสนุนโดยอัตโนมัติ ให้ตรวจผลิตภัณฑ์ ผู้ถือทะเบียน สถานประกอบการ และเส้นทางการจัดหาที่แน่นอนในบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Thailand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Thailand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Thailand", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=thailand" }, { "recordId": "pl-compound-country-survodutide-indonesia", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Survodutide di Indonesia", "localizedAnswer": "Survodutide adalah program yang sedang dikembangkan secara klinis. Produk atau penjual dengan nama sama di Indonesia tidak otomatis mewarisi identitas klinis sponsor, hasil uji, atau status regulasinya. Periksa produk, pemegang izin, fasilitas, dan jalur pasok yang tepat dalam catatan resmi tujuan di bawah.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Indonesia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Indonesia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Indonesia", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=indonesia" }, { "recordId": "pl-compound-country-survodutide-singapore", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Survodutide in Singapore", "localizedAnswer": "Survodutide is an investigational clinical program. No seller listing in Singapore can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Singapore", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 8, "clinicalTrialRecruitingLocations": 6, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT04771273" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT04771273" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Singapore#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Singapore", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=singapore" }, { "recordId": "pl-compound-country-survodutide-philippines", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Survodutide in the Philippines", "localizedAnswer": "Survodutide is an investigational clinical program. No seller listing in the Philippines can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Philippines", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Philippines#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Philippines", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=philippines" }, { "recordId": "pl-compound-country-survodutide-malaysia", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Survodutide in Malaysia", "localizedAnswer": "Survodutide is an investigational clinical program. No seller listing in Malaysia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Malaysia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 11, "clinicalTrialRecruitingLocations": 8, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT04771273" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT04771273" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Malaysia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Malaysia", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=malaysia" }, { "recordId": "pl-compound-country-survodutide-taiwan", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Survodutide 在台灣的紀錄", "localizedAnswer": "Survodutide是臨床開發中的計畫。贊助者的臨床身分、試驗結果或法規狀態，不會自動移轉給台灣的同名網路商品或提供者。必須利用下方紀錄核對目的地的具體產品、許可證持有者、機構與供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Taiwan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 33, "clinicalTrialRecruitingLocations": 18, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864", "NCT04771273", "NCT04153929" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT04771273", "https://clinicaltrials.gov/study/NCT04153929" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Taiwan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Taiwan", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=taiwan" }, { "recordId": "pl-compound-country-survodutide-hong-kong", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Survodutide 在香港的紀錄", "localizedAnswer": "Survodutide是臨床開發中的計劃。贊助者的臨床身分、試驗結果或監管狀態，不會自動轉移給香港的同名網上商品或銷售商。必須透過下方紀錄核對目的地的指定產品、註冊持有人、持牌實體和供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Hong Kong", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 5, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT06077864", "NCT04771273" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT04771273" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Hong%20Kong#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Hong%20Kong", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=hong-kong" }, { "recordId": "pl-compound-country-survodutide-vietnam", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Survodutide tại Việt Nam", "localizedAnswer": "Survodutide là một chương trình đang phát triển lâm sàng. Không đề nghị thương mại nào tại Việt Nam tự động kế thừa danh tính lâm sàng, kết quả thử nghiệm hoặc tình trạng quản lý của nhà tài trợ. Cần kiểm tra sản phẩm, chủ sở hữu giấy phép, cơ sở và đường cung ứng cụ thể trong các hồ sơ chính thức của điểm đến ở dưới.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Vietnam", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Vietnam#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Vietnam", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=vietnam" }, { "recordId": "pl-compound-country-survodutide-united-states", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Survodutide in the United States", "localizedAnswer": "Survodutide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "United States", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 11, "clinicalTrialListedLocations": 626, "clinicalTrialRecruitingLocations": 251, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864", "NCT06066528", "NCT06745284", "NCT06309992", "NCT06066515", "NCT04771273", "NCT05296733", "NCT04667377", "NCT04153929" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT06066528", "https://clinicaltrials.gov/study/NCT06745284", "https://clinicaltrials.gov/study/NCT06309992", "https://clinicaltrials.gov/study/NCT06066515", "https://clinicaltrials.gov/study/NCT04771273", "https://clinicaltrials.gov/study/NCT05296733", "https://clinicaltrials.gov/study/NCT04667377", "https://clinicaltrials.gov/study/NCT04153929" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=United%20States#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=United%20States", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=united-states" }, { "recordId": "pl-compound-country-survodutide-canada", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Survodutide in Canada", "localizedAnswer": "Survodutide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Canada", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 8, "clinicalTrialListedLocations": 77, "clinicalTrialRecruitingLocations": 11, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864", "NCT06066528", "NCT06066515", "NCT04771273", "NCT04667377", "NCT04153929" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864", "https://clinicaltrials.gov/study/NCT06066528", "https://clinicaltrials.gov/study/NCT06066515", "https://clinicaltrials.gov/study/NCT04771273", "https://clinicaltrials.gov/study/NCT04667377", "https://clinicaltrials.gov/study/NCT04153929" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Canada#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Canada", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=canada" }, { "recordId": "pl-compound-country-survodutide-united-arab-emirates", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Survodutide / سورفودوتايد في الإمارات العربية المتحدة", "localizedAnswer": "Survodutide / سورفودوتايد برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في الإمارات العربية المتحدة أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "United Arab Emirates", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=United%20Arab%20Emirates#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=United%20Arab%20Emirates", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=united-arab-emirates" }, { "recordId": "pl-compound-country-survodutide-saudi-arabia", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Survodutide / سورفودوتايد في المملكة العربية السعودية", "localizedAnswer": "Survodutide / سورفودوتايد برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في المملكة العربية السعودية أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Saudi Arabia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 8, "clinicalTrialRecruitingLocations": 1, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457", "NCT06077864" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457", "https://clinicaltrials.gov/study/NCT06077864" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Saudi%20Arabia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Saudi%20Arabia", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=saudi-arabia" }, { "recordId": "pl-compound-country-survodutide-south-africa", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Survodutide in South Africa", "localizedAnswer": "Survodutide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "South Africa", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 5, "clinicalTrialRecruitingLocations": 3, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT06632444", "NCT06632457" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT06632444", "https://clinicaltrials.gov/study/NCT06632457" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=South%20Africa#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=South%20Africa", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=south-africa" }, { "recordId": "pl-compound-country-survodutide-nigeria", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Survodutide in Nigeria", "localizedAnswer": "Survodutide is an investigational clinical program. No seller listing in Nigeria can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Nigeria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Nigeria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Nigeria", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=nigeria" }, { "recordId": "pl-compound-country-survodutide-kenya", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Survodutide in Kenya", "localizedAnswer": "Survodutide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Survodutide", "clinicalTrialRegistryCountry": "Kenya", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=survodutide&country=Kenya#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Survodutide&locStr=Kenya", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/survodutide", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/survodutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=survodutide&country=kenya" }, { "recordId": "pl-compound-country-vk2735-france", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "VK2735 en France", "localizedAnswer": "VK2735 est un programme clinique expérimental. Aucune offre commerciale en France ne peut reprendre automatiquement l’identité clinique, les résultats d’essais ou le statut réglementaire du promoteur. Vérifiez chaque produit et fournisseur dans les registres ci-dessous.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "France", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=France#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=France", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=france" }, { "recordId": "pl-compound-country-vk2735-united-kingdom", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "VK2735 in the United Kingdom", "localizedAnswer": "VK2735 is an investigational clinical program. No seller listing in the United Kingdom can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "United Kingdom", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=United%20Kingdom#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=United%20Kingdom", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=united-kingdom" }, { "recordId": "pl-compound-country-vk2735-germany", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "VK2735 in Deutschland", "localizedAnswer": "VK2735 ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Deutschland übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Germany", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Germany#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Germany", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=germany" }, { "recordId": "pl-compound-country-vk2735-spain", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "VK2735 en España", "localizedAnswer": "VK2735 es un programa clínico en investigación. Ninguna oferta comercial en España puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Spain", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Spain#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Spain", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=spain" }, { "recordId": "pl-compound-country-vk2735-italy", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "VK2735 in Italia", "localizedAnswer": "VK2735 è un programma clinico sperimentale. Nessuna offerta commerciale in Italia può ereditare l’identità clinica, i risultati degli studi o lo stato regolatorio dello sponsor. Verifica ogni prodotto e fornitore nei registri riportati sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Italy", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Italy#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Italy", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=italy" }, { "recordId": "pl-compound-country-vk2735-netherlands", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "VK2735 in Nederland", "localizedAnswer": "VK2735 is een klinisch onderzoeksprogramma. Geen commercieel aanbod in Nederland neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Netherlands", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Netherlands#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Netherlands", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=netherlands" }, { "recordId": "pl-compound-country-vk2735-switzerland", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "VK2735 in Switzerland", "localizedAnswer": "VK2735 is an investigational clinical program. No seller listing in Switzerland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Switzerland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Switzerland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Switzerland", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=switzerland" }, { "recordId": "pl-compound-country-vk2735-poland", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "VK2735 w Polsce", "localizedAnswer": "VK2735 jest eksperymentalnym programem klinicznym. Żadna oferta handlowa w Polsce nie przejmuje automatycznie tożsamości klinicznej, wyników badań ani statusu regulacyjnego sponsora. Sprawdź każdy produkt i dostawcę w rejestrach poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Poland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Poland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Poland", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=poland" }, { "recordId": "pl-compound-country-vk2735-ireland", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "VK2735 in Ireland", "localizedAnswer": "VK2735 is an investigational clinical program. No seller listing in Ireland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Ireland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Ireland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Ireland", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=ireland" }, { "recordId": "pl-compound-country-vk2735-portugal", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "VK2735 em Portugal", "localizedAnswer": "VK2735 é um programa clínico experimental. Nenhuma oferta comercial em Portugal pode herdar a identidade clínica, os resultados de ensaios ou o estatuto regulamentar do promotor. Verifique cada produto e fornecedor nos registos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Portugal", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Portugal#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Portugal", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=portugal" }, { "recordId": "pl-compound-country-vk2735-sweden", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "VK2735 i Sverige", "localizedAnswer": "VK2735 är ett kliniskt prövningsprogram. Inget kommersiellt erbjudande i Sverige kan automatiskt ärva sponsorns kliniska identitet, studieresultat eller regulatoriska status. Kontrollera varje produkt och leverantör i registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Sweden", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Sweden#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Sweden", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=sweden" }, { "recordId": "pl-compound-country-vk2735-turkey", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için VK2735", "localizedAnswer": "VK2735 klinik geliştirme aşamasındaki bir programdır. Türkiye içindeki aynı adlı hiçbir ticari teklif sponsorun klinik kimliğini, çalışma sonuçlarını veya düzenleyici statüsünü otomatik olarak devralamaz. Belirli ürünü, ruhsat sahibini, kuruluşu ve tedarik yolunu aşağıdaki resmi hedef ülke kayıtlarında kontrol edin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Turkey (Türkiye)", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Turkey%20(T%C3%BCrkiye)#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Turkey%20(T%C3%BCrkiye)", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=turkey" }, { "recordId": "pl-compound-country-vk2735-austria", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "VK2735 in Österreich", "localizedAnswer": "VK2735 ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Österreich übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Austria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Austria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Austria", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=austria" }, { "recordId": "pl-compound-country-vk2735-belgium", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "VK2735 in België", "localizedAnswer": "VK2735 is een klinisch onderzoeksprogramma. Geen commercieel aanbod in België neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Belgium", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Belgium#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Belgium", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=belgium" }, { "recordId": "pl-compound-country-vk2735-denmark", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "VK2735 i Danmark", "localizedAnswer": "VK2735 er et klinisk udviklingsprogram. Et kommercielt tilbud med samme navn i Danmark arver ikke sponsorens kliniske identitet, forsøgsresultater eller regulatoriske status. Kontrollér det konkrete produkt, tilladelsesindehaveren, virksomheden og forsyningsvejen i de officielle registre for destinationen nedenfor.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Denmark", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Denmark#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Denmark", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=denmark" }, { "recordId": "pl-compound-country-vk2735-finland", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "VK2735 kohteessa Suomi", "localizedAnswer": "VK2735 on kliininen kehitysohjelma. Samanniminen kaupallinen tarjous kohteessa Suomi ei peri sponsorin kliinistä identiteettiä, tutkimustuloksia tai sääntelyasemaa. Tarkista täsmällinen tuote, luvanhaltija, toimija ja toimitusreitti alla olevista kohdemaan virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Finland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Finland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Finland", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=finland" }, { "recordId": "pl-compound-country-vk2735-mexico", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "VK2735 en México", "localizedAnswer": "VK2735 es un programa clínico en investigación. Ninguna oferta comercial en México puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Mexico", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Mexico#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Mexico", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=mexico" }, { "recordId": "pl-compound-country-vk2735-argentina", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "VK2735 en Argentina", "localizedAnswer": "VK2735 es un programa clínico en investigación. Ninguna oferta comercial en Argentina puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Argentina", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Argentina#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Argentina", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=argentina" }, { "recordId": "pl-compound-country-vk2735-colombia", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "VK2735 en Colombia", "localizedAnswer": "VK2735 es un programa clínico en investigación. Ninguna oferta comercial en Colombia puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Colombia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Colombia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Colombia", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=colombia" }, { "recordId": "pl-compound-country-vk2735-chile", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "VK2735 en Chile", "localizedAnswer": "VK2735 es un programa clínico en investigación. Ninguna oferta comercial en Chile puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Chile", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Chile#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Chile", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=chile" }, { "recordId": "pl-compound-country-vk2735-brazil", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "VK2735 no Brasil", "localizedAnswer": "VK2735 é um programa clínico experimental. Nenhuma oferta comercial no Brasil pode herdar a identidade clínica, os resultados de ensaios ou o status regulatório do patrocinador. Verifique cada produto e fornecedor nos registros abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Brazil", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Brazil#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Brazil", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=brazil" }, { "recordId": "pl-compound-country-vk2735-china", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "VK2735 在中国的状态与官方记录", "localizedAnswer": "VK2735在此对应一个临床与监管项目。项目在某一国家的试验、批准或公司公告，不能自动证明同名商品在中国获批、可得或由有资质的卖方提供。请分别核对目的地的具体药品记录、批准持有人、剂型规格、经营主体和供应路径，并保持临床证据与在线商品身份相互独立。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "China", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=China#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=China", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=china" }, { "recordId": "pl-compound-country-vk2735-australia", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "VK2735 in Australia", "localizedAnswer": "VK2735 is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Australia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 1, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT05203237" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT05203237" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Australia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Australia", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=australia" }, { "recordId": "pl-compound-country-vk2735-new-zealand", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "VK2735 in New Zealand", "localizedAnswer": "VK2735 is an investigational clinical program. No seller listing in New Zealand can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "New Zealand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=New%20Zealand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=New%20Zealand", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=new-zealand" }, { "recordId": "pl-compound-country-vk2735-india", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "VK2735 in India", "localizedAnswer": "VK2735 is an investigational clinical program. No seller listing in India can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "India", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=India#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=India", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=india" }, { "recordId": "pl-compound-country-vk2735-japan", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のVK2735", "localizedAnswer": "VK2735は臨床開発中のプログラムです。スポンサーの臨床上の同一性、試験結果、規制上の位置付けを、日本の同名オンライン商品や販売者が自動的に引き継ぐことはありません。目的地の製品、承認保持者、施設、供給経路を下記の公的記録で確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Japan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Japan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Japan", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=japan" }, { "recordId": "pl-compound-country-vk2735-south-korea", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 VK2735", "localizedAnswer": "VK2735은 임상 개발 중인 프로그램입니다. 후원사의 임상 신원, 시험 결과 또는 규제 상태를 대한민국의 동명 온라인 상품이나 판매자가 자동으로 이어받을 수 없습니다. 목적지의 정확한 제품, 허가권자, 기관과 공급 경로를 아래 공식 기록에서 확인해야 합니다.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "South Korea", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=South%20Korea#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=South%20Korea", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=south-korea" }, { "recordId": "pl-compound-country-vk2735-thailand", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "VK2735 ในประเทศไทย", "localizedAnswer": "VK2735 เป็นโครงการที่อยู่ระหว่างการพัฒนาทางคลินิก สินค้าหรือผู้ขายชื่อเดียวกันในประเทศไทยไม่สามารถรับช่วงตัวตนทางคลินิก ผลการทดลอง หรือสถานะด้านกฎระเบียบของผู้สนับสนุนโดยอัตโนมัติ ให้ตรวจผลิตภัณฑ์ ผู้ถือทะเบียน สถานประกอบการ และเส้นทางการจัดหาที่แน่นอนในบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Thailand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Thailand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Thailand", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=thailand" }, { "recordId": "pl-compound-country-vk2735-indonesia", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "VK2735 di Indonesia", "localizedAnswer": "VK2735 adalah program yang sedang dikembangkan secara klinis. Produk atau penjual dengan nama sama di Indonesia tidak otomatis mewarisi identitas klinis sponsor, hasil uji, atau status regulasinya. Periksa produk, pemegang izin, fasilitas, dan jalur pasok yang tepat dalam catatan resmi tujuan di bawah.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Indonesia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Indonesia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Indonesia", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=indonesia" }, { "recordId": "pl-compound-country-vk2735-singapore", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "VK2735 in Singapore", "localizedAnswer": "VK2735 is an investigational clinical program. No seller listing in Singapore can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Singapore", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Singapore#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Singapore", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=singapore" }, { "recordId": "pl-compound-country-vk2735-philippines", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "VK2735 in the Philippines", "localizedAnswer": "VK2735 is an investigational clinical program. No seller listing in the Philippines can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Philippines", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Philippines#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Philippines", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=philippines" }, { "recordId": "pl-compound-country-vk2735-malaysia", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "VK2735 in Malaysia", "localizedAnswer": "VK2735 is an investigational clinical program. No seller listing in Malaysia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Malaysia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Malaysia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Malaysia", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=malaysia" }, { "recordId": "pl-compound-country-vk2735-taiwan", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "VK2735 在台灣的紀錄", "localizedAnswer": "VK2735是臨床開發中的計畫。贊助者的臨床身分、試驗結果或法規狀態，不會自動移轉給台灣的同名網路商品或提供者。必須利用下方紀錄核對目的地的具體產品、許可證持有者、機構與供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Taiwan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Taiwan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Taiwan", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=taiwan" }, { "recordId": "pl-compound-country-vk2735-hong-kong", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "VK2735 在香港的紀錄", "localizedAnswer": "VK2735是臨床開發中的計劃。贊助者的臨床身分、試驗結果或監管狀態，不會自動轉移給香港的同名網上商品或銷售商。必須透過下方紀錄核對目的地的指定產品、註冊持有人、持牌實體和供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Hong Kong", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Hong%20Kong#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Hong%20Kong", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=hong-kong" }, { "recordId": "pl-compound-country-vk2735-vietnam", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "VK2735 tại Việt Nam", "localizedAnswer": "VK2735 là một chương trình đang phát triển lâm sàng. Không đề nghị thương mại nào tại Việt Nam tự động kế thừa danh tính lâm sàng, kết quả thử nghiệm hoặc tình trạng quản lý của nhà tài trợ. Cần kiểm tra sản phẩm, chủ sở hữu giấy phép, cơ sở và đường cung ứng cụ thể trong các hồ sơ chính thức của điểm đến ở dưới.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Vietnam", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Vietnam#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Vietnam", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=vietnam" }, { "recordId": "pl-compound-country-vk2735-united-states", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "VK2735 in the United States", "localizedAnswer": "VK2735 is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "United States", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 4, "clinicalTrialListedLocations": 295, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07104383", "NCT07104500", "NCT06828055", "NCT06068946" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07104383", "https://clinicaltrials.gov/study/NCT07104500", "https://clinicaltrials.gov/study/NCT06828055", "https://clinicaltrials.gov/study/NCT06068946" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=United%20States#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=United%20States", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=united-states" }, { "recordId": "pl-compound-country-vk2735-canada", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "VK2735 in Canada", "localizedAnswer": "VK2735 is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Canada", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Canada#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Canada", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=canada" }, { "recordId": "pl-compound-country-vk2735-united-arab-emirates", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "VK2735 في الإمارات العربية المتحدة", "localizedAnswer": "VK2735 برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في الإمارات العربية المتحدة أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "United Arab Emirates", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=United%20Arab%20Emirates#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=United%20Arab%20Emirates", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=united-arab-emirates" }, { "recordId": "pl-compound-country-vk2735-saudi-arabia", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "VK2735 في المملكة العربية السعودية", "localizedAnswer": "VK2735 برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في المملكة العربية السعودية أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Saudi Arabia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Saudi%20Arabia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Saudi%20Arabia", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=saudi-arabia" }, { "recordId": "pl-compound-country-vk2735-south-africa", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "VK2735 in South Africa", "localizedAnswer": "VK2735 is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "South Africa", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=South%20Africa#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=South%20Africa", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=south-africa" }, { "recordId": "pl-compound-country-vk2735-nigeria", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "VK2735 in Nigeria", "localizedAnswer": "VK2735 is an investigational clinical program. No seller listing in Nigeria can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Nigeria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Nigeria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Nigeria", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=nigeria" }, { "recordId": "pl-compound-country-vk2735-kenya", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "VK2735 in Kenya", "localizedAnswer": "VK2735 is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "VK2735", "clinicalTrialRegistryCountry": "Kenya", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=vk2735&country=Kenya#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=VK2735&locStr=Kenya", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/vk2735", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/vk2735/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vk2735&country=kenya" }, { "recordId": "pl-compound-country-pemvidutide-france", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Pemvidutide en France", "localizedAnswer": "Pemvidutide est un programme clinique expérimental. Aucune offre commerciale en France ne peut reprendre automatiquement l’identité clinique, les résultats d’essais ou le statut réglementaire du promoteur. Vérifiez chaque produit et fournisseur dans les registres ci-dessous.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "France", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=France#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=France", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=france" }, { "recordId": "pl-compound-country-pemvidutide-united-kingdom", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Pemvidutide in the United Kingdom", "localizedAnswer": "Pemvidutide is an investigational clinical program. No seller listing in the United Kingdom can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "United Kingdom", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=United%20Kingdom#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=United%20Kingdom", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=united-kingdom" }, { "recordId": "pl-compound-country-pemvidutide-germany", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Pemvidutide in Deutschland", "localizedAnswer": "Pemvidutide ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Deutschland übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Germany", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Germany#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Germany", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=germany" }, { "recordId": "pl-compound-country-pemvidutide-spain", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Pemvidutide en España", "localizedAnswer": "Pemvidutide es un programa clínico en investigación. Ninguna oferta comercial en España puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Spain", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Spain#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Spain", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=spain" }, { "recordId": "pl-compound-country-pemvidutide-italy", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Pemvidutide in Italia", "localizedAnswer": "Pemvidutide è un programma clinico sperimentale. Nessuna offerta commerciale in Italia può ereditare l’identità clinica, i risultati degli studi o lo stato regolatorio dello sponsor. Verifica ogni prodotto e fornitore nei registri riportati sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Italy", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Italy#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Italy", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=italy" }, { "recordId": "pl-compound-country-pemvidutide-netherlands", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Pemvidutide in Nederland", "localizedAnswer": "Pemvidutide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in Nederland neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Netherlands", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Netherlands#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Netherlands", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=netherlands" }, { "recordId": "pl-compound-country-pemvidutide-switzerland", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Pemvidutide in Switzerland", "localizedAnswer": "Pemvidutide is an investigational clinical program. No seller listing in Switzerland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Switzerland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Switzerland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Switzerland", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=switzerland" }, { "recordId": "pl-compound-country-pemvidutide-poland", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Pemvidutide w Polsce", "localizedAnswer": "Pemvidutide jest eksperymentalnym programem klinicznym. Żadna oferta handlowa w Polsce nie przejmuje automatycznie tożsamości klinicznej, wyników badań ani statusu regulacyjnego sponsora. Sprawdź każdy produkt i dostawcę w rejestrach poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Poland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Poland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Poland", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=poland" }, { "recordId": "pl-compound-country-pemvidutide-ireland", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Pemvidutide in Ireland", "localizedAnswer": "Pemvidutide is an investigational clinical program. No seller listing in Ireland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Ireland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Ireland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Ireland", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=ireland" }, { "recordId": "pl-compound-country-pemvidutide-portugal", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Pemvidutide em Portugal", "localizedAnswer": "Pemvidutide é um programa clínico experimental. Nenhuma oferta comercial em Portugal pode herdar a identidade clínica, os resultados de ensaios ou o estatuto regulamentar do promotor. Verifique cada produto e fornecedor nos registos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Portugal", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Portugal#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Portugal", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=portugal" }, { "recordId": "pl-compound-country-pemvidutide-sweden", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Pemvidutide i Sverige", "localizedAnswer": "Pemvidutide är ett kliniskt prövningsprogram. Inget kommersiellt erbjudande i Sverige kan automatiskt ärva sponsorns kliniska identitet, studieresultat eller regulatoriska status. Kontrollera varje produkt och leverantör i registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Sweden", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Sweden#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Sweden", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=sweden" }, { "recordId": "pl-compound-country-pemvidutide-turkey", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Pemvidutide", "localizedAnswer": "Pemvidutide klinik geliştirme aşamasındaki bir programdır. Türkiye içindeki aynı adlı hiçbir ticari teklif sponsorun klinik kimliğini, çalışma sonuçlarını veya düzenleyici statüsünü otomatik olarak devralamaz. Belirli ürünü, ruhsat sahibini, kuruluşu ve tedarik yolunu aşağıdaki resmi hedef ülke kayıtlarında kontrol edin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Turkey (Türkiye)", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Turkey%20(T%C3%BCrkiye)#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Turkey%20(T%C3%BCrkiye)", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=turkey" }, { "recordId": "pl-compound-country-pemvidutide-austria", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Pemvidutide in Österreich", "localizedAnswer": "Pemvidutide ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Österreich übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Austria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Austria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Austria", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=austria" }, { "recordId": "pl-compound-country-pemvidutide-belgium", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Pemvidutide in België", "localizedAnswer": "Pemvidutide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in België neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Belgium", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Belgium#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Belgium", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=belgium" }, { "recordId": "pl-compound-country-pemvidutide-denmark", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Pemvidutide i Danmark", "localizedAnswer": "Pemvidutide er et klinisk udviklingsprogram. Et kommercielt tilbud med samme navn i Danmark arver ikke sponsorens kliniske identitet, forsøgsresultater eller regulatoriske status. Kontrollér det konkrete produkt, tilladelsesindehaveren, virksomheden og forsyningsvejen i de officielle registre for destinationen nedenfor.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Denmark", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Denmark#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Denmark", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=denmark" }, { "recordId": "pl-compound-country-pemvidutide-finland", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Pemvidutide kohteessa Suomi", "localizedAnswer": "Pemvidutide on kliininen kehitysohjelma. Samanniminen kaupallinen tarjous kohteessa Suomi ei peri sponsorin kliinistä identiteettiä, tutkimustuloksia tai sääntelyasemaa. Tarkista täsmällinen tuote, luvanhaltija, toimija ja toimitusreitti alla olevista kohdemaan virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Finland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Finland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Finland", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=finland" }, { "recordId": "pl-compound-country-pemvidutide-mexico", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Pemvidutide en México", "localizedAnswer": "Pemvidutide es un programa clínico en investigación. Ninguna oferta comercial en México puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Mexico", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Mexico#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Mexico", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=mexico" }, { "recordId": "pl-compound-country-pemvidutide-argentina", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Pemvidutide en Argentina", "localizedAnswer": "Pemvidutide es un programa clínico en investigación. Ninguna oferta comercial en Argentina puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Argentina", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Argentina#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Argentina", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=argentina" }, { "recordId": "pl-compound-country-pemvidutide-colombia", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Pemvidutide en Colombia", "localizedAnswer": "Pemvidutide es un programa clínico en investigación. Ninguna oferta comercial en Colombia puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Colombia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Colombia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Colombia", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=colombia" }, { "recordId": "pl-compound-country-pemvidutide-chile", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Pemvidutide en Chile", "localizedAnswer": "Pemvidutide es un programa clínico en investigación. Ninguna oferta comercial en Chile puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Chile", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Chile#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Chile", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=chile" }, { "recordId": "pl-compound-country-pemvidutide-brazil", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Pemvidutide no Brasil", "localizedAnswer": "Pemvidutide é um programa clínico experimental. Nenhuma oferta comercial no Brasil pode herdar a identidade clínica, os resultados de ensaios ou o status regulatório do patrocinador. Verifique cada produto e fornecedor nos registros abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Brazil", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Brazil#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Brazil", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=brazil" }, { "recordId": "pl-compound-country-pemvidutide-china", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Pemvidutide 在中国的状态与官方记录", "localizedAnswer": "Pemvidutide在此对应一个临床与监管项目。项目在某一国家的试验、批准或公司公告，不能自动证明同名商品在中国获批、可得或由有资质的卖方提供。请分别核对目的地的具体药品记录、批准持有人、剂型规格、经营主体和供应路径，并保持临床证据与在线商品身份相互独立。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "China", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=China#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=China", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=china" }, { "recordId": "pl-compound-country-pemvidutide-australia", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Pemvidutide in Australia", "localizedAnswer": "Pemvidutide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Australia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 13, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT05989711", "NCT04561245", "NCT04972396" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT05989711", "https://clinicaltrials.gov/study/NCT04561245", "https://clinicaltrials.gov/study/NCT04972396" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Australia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Australia", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=australia" }, { "recordId": "pl-compound-country-pemvidutide-new-zealand", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Pemvidutide in New Zealand", "localizedAnswer": "Pemvidutide is an investigational clinical program. No seller listing in New Zealand can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "New Zealand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=New%20Zealand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=New%20Zealand", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=new-zealand" }, { "recordId": "pl-compound-country-pemvidutide-india", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Pemvidutide in India", "localizedAnswer": "Pemvidutide is an investigational clinical program. No seller listing in India can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "India", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=India#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=India", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=india" }, { "recordId": "pl-compound-country-pemvidutide-japan", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のPemvidutide / ペムビデュチド", "localizedAnswer": "Pemvidutide / ペムビデュチドは臨床開発中のプログラムです。スポンサーの臨床上の同一性、試験結果、規制上の位置付けを、日本の同名オンライン商品や販売者が自動的に引き継ぐことはありません。目的地の製品、承認保持者、施設、供給経路を下記の公的記録で確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Japan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Japan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Japan", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=japan" }, { "recordId": "pl-compound-country-pemvidutide-south-korea", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Pemvidutide / 펨비두타이드", "localizedAnswer": "Pemvidutide / 펨비두타이드은 임상 개발 중인 프로그램입니다. 후원사의 임상 신원, 시험 결과 또는 규제 상태를 대한민국의 동명 온라인 상품이나 판매자가 자동으로 이어받을 수 없습니다. 목적지의 정확한 제품, 허가권자, 기관과 공급 경로를 아래 공식 기록에서 확인해야 합니다.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "South Korea", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=South%20Korea#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=South%20Korea", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=south-korea" }, { "recordId": "pl-compound-country-pemvidutide-thailand", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Pemvidutide ในประเทศไทย", "localizedAnswer": "Pemvidutide เป็นโครงการที่อยู่ระหว่างการพัฒนาทางคลินิก สินค้าหรือผู้ขายชื่อเดียวกันในประเทศไทยไม่สามารถรับช่วงตัวตนทางคลินิก ผลการทดลอง หรือสถานะด้านกฎระเบียบของผู้สนับสนุนโดยอัตโนมัติ ให้ตรวจผลิตภัณฑ์ ผู้ถือทะเบียน สถานประกอบการ และเส้นทางการจัดหาที่แน่นอนในบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Thailand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Thailand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Thailand", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=thailand" }, { "recordId": "pl-compound-country-pemvidutide-indonesia", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Pemvidutide di Indonesia", "localizedAnswer": "Pemvidutide adalah program yang sedang dikembangkan secara klinis. Produk atau penjual dengan nama sama di Indonesia tidak otomatis mewarisi identitas klinis sponsor, hasil uji, atau status regulasinya. Periksa produk, pemegang izin, fasilitas, dan jalur pasok yang tepat dalam catatan resmi tujuan di bawah.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Indonesia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Indonesia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Indonesia", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=indonesia" }, { "recordId": "pl-compound-country-pemvidutide-singapore", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Pemvidutide in Singapore", "localizedAnswer": "Pemvidutide is an investigational clinical program. No seller listing in Singapore can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Singapore", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Singapore#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Singapore", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=singapore" }, { "recordId": "pl-compound-country-pemvidutide-philippines", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Pemvidutide in the Philippines", "localizedAnswer": "Pemvidutide is an investigational clinical program. No seller listing in the Philippines can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Philippines", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Philippines#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Philippines", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=philippines" }, { "recordId": "pl-compound-country-pemvidutide-malaysia", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Pemvidutide in Malaysia", "localizedAnswer": "Pemvidutide is an investigational clinical program. No seller listing in Malaysia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Malaysia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Malaysia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Malaysia", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=malaysia" }, { "recordId": "pl-compound-country-pemvidutide-taiwan", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Pemvidutide 在台灣的紀錄", "localizedAnswer": "Pemvidutide是臨床開發中的計畫。贊助者的臨床身分、試驗結果或法規狀態，不會自動移轉給台灣的同名網路商品或提供者。必須利用下方紀錄核對目的地的具體產品、許可證持有者、機構與供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Taiwan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Taiwan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Taiwan", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=taiwan" }, { "recordId": "pl-compound-country-pemvidutide-hong-kong", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Pemvidutide 在香港的紀錄", "localizedAnswer": "Pemvidutide是臨床開發中的計劃。贊助者的臨床身分、試驗結果或監管狀態，不會自動轉移給香港的同名網上商品或銷售商。必須透過下方紀錄核對目的地的指定產品、註冊持有人、持牌實體和供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Hong Kong", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Hong%20Kong#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Hong%20Kong", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=hong-kong" }, { "recordId": "pl-compound-country-pemvidutide-vietnam", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Pemvidutide tại Việt Nam", "localizedAnswer": "Pemvidutide là một chương trình đang phát triển lâm sàng. Không đề nghị thương mại nào tại Việt Nam tự động kế thừa danh tính lâm sàng, kết quả thử nghiệm hoặc tình trạng quản lý của nhà tài trợ. Cần kiểm tra sản phẩm, chủ sở hữu giấy phép, cơ sở và đường cung ứng cụ thể trong các hồ sơ chính thức của điểm đến ở dưới.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Vietnam", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Vietnam#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Vietnam", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=vietnam" }, { "recordId": "pl-compound-country-pemvidutide-united-states", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Pemvidutide in the United States", "localizedAnswer": "Pemvidutide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "United States", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 7, "clinicalTrialListedLocations": 149, "clinicalTrialRecruitingLocations": 8, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07009860", "NCT05989711", "NCT06987513", "NCT05134662", "NCT05295875", "NCT05006885", "NCT05292911" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07009860", "https://clinicaltrials.gov/study/NCT05989711", "https://clinicaltrials.gov/study/NCT06987513", "https://clinicaltrials.gov/study/NCT05134662", "https://clinicaltrials.gov/study/NCT05295875", "https://clinicaltrials.gov/study/NCT05006885", "https://clinicaltrials.gov/study/NCT05292911" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=United%20States#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=United%20States", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=united-states" }, { "recordId": "pl-compound-country-pemvidutide-canada", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Pemvidutide in Canada", "localizedAnswer": "Pemvidutide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Canada", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Canada#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Canada", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=canada" }, { "recordId": "pl-compound-country-pemvidutide-united-arab-emirates", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Pemvidutide / بيمفيدوتايد في الإمارات العربية المتحدة", "localizedAnswer": "Pemvidutide / بيمفيدوتايد برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في الإمارات العربية المتحدة أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "United Arab Emirates", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=United%20Arab%20Emirates#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=United%20Arab%20Emirates", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=united-arab-emirates" }, { "recordId": "pl-compound-country-pemvidutide-saudi-arabia", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Pemvidutide / بيمفيدوتايد في المملكة العربية السعودية", "localizedAnswer": "Pemvidutide / بيمفيدوتايد برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في المملكة العربية السعودية أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Saudi Arabia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Saudi%20Arabia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Saudi%20Arabia", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=saudi-arabia" }, { "recordId": "pl-compound-country-pemvidutide-south-africa", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Pemvidutide in South Africa", "localizedAnswer": "Pemvidutide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "South Africa", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=South%20Africa#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=South%20Africa", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=south-africa" }, { "recordId": "pl-compound-country-pemvidutide-nigeria", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Pemvidutide in Nigeria", "localizedAnswer": "Pemvidutide is an investigational clinical program. No seller listing in Nigeria can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Nigeria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Nigeria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Nigeria", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=nigeria" }, { "recordId": "pl-compound-country-pemvidutide-kenya", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Pemvidutide in Kenya", "localizedAnswer": "Pemvidutide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Pemvidutide", "clinicalTrialRegistryCountry": "Kenya", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=pemvidutide&country=Kenya#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Pemvidutide&locStr=Kenya", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/pemvidutide", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/pemvidutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=pemvidutide&country=kenya" }, { "recordId": "pl-compound-country-amycretin-france", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Amycretin / Zenagamtide en France", "localizedAnswer": "Amycretin / Zenagamtide est un programme clinique expérimental. Aucune offre commerciale en France ne peut reprendre automatiquement l’identité clinique, les résultats d’essais ou le statut réglementaire du promoteur. Vérifiez chaque produit et fournisseur dans les registres ci-dessous.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "France", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 25, "clinicalTrialRecruitingLocations": 18, "clinicalTrialRecordsWithRecruitingLocations": 3, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07339423", "NCT07503210" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07339423", "https://clinicaltrials.gov/study/NCT07503210" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=France#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=France", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=france" }, { "recordId": "pl-compound-country-amycretin-united-kingdom", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Amycretin / Zenagamtide in the United Kingdom", "localizedAnswer": "Amycretin / Zenagamtide is an investigational clinical program. No seller listing in the United Kingdom can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "United Kingdom", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 53, "clinicalTrialRecruitingLocations": 37, "clinicalTrialRecordsWithRecruitingLocations": 3, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07339423", "NCT07503210" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07339423", "https://clinicaltrials.gov/study/NCT07503210" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=United%20Kingdom#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=United%20Kingdom", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=united-kingdom" }, { "recordId": "pl-compound-country-amycretin-germany", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Amycretin / Zenagamtide in Deutschland", "localizedAnswer": "Amycretin / Zenagamtide ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Deutschland übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Germany", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 10, "clinicalTrialListedLocations": 90, "clinicalTrialRecruitingLocations": 59, "clinicalTrialRecordsWithRecruitingLocations": 7, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07571005", "NCT07571109", "NCT07339423", "NCT07503210", "NCT07508020", "NCT07535307", "NCT07400107", "NCT06542874", "NCT06559527" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07571005", "https://clinicaltrials.gov/study/NCT07571109", "https://clinicaltrials.gov/study/NCT07339423", "https://clinicaltrials.gov/study/NCT07503210", "https://clinicaltrials.gov/study/NCT07508020", "https://clinicaltrials.gov/study/NCT07535307", "https://clinicaltrials.gov/study/NCT07400107", "https://clinicaltrials.gov/study/NCT06542874", "https://clinicaltrials.gov/study/NCT06559527" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Germany#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Germany", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=germany" }, { "recordId": "pl-compound-country-amycretin-spain", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Amycretin / Zenagamtide en España", "localizedAnswer": "Amycretin / Zenagamtide es un programa clínico en investigación. Ninguna oferta comercial en España puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Spain", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 7, "clinicalTrialListedLocations": 82, "clinicalTrialRecruitingLocations": 64, "clinicalTrialRecordsWithRecruitingLocations": 6, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07571005", "NCT07571109", "NCT07481630", "NCT07503210", "NCT07509307", "NCT06542874" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07571005", "https://clinicaltrials.gov/study/NCT07571109", "https://clinicaltrials.gov/study/NCT07481630", "https://clinicaltrials.gov/study/NCT07503210", "https://clinicaltrials.gov/study/NCT07509307", "https://clinicaltrials.gov/study/NCT06542874" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Spain#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Spain", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=spain" }, { "recordId": "pl-compound-country-amycretin-italy", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Amycretin / Zenagamtide in Italia", "localizedAnswer": "Amycretin / Zenagamtide è un programma clinico sperimentale. Nessuna offerta commerciale in Italia può ereditare l’identità clinica, i risultati degli studi o lo stato regolatorio dello sponsor. Verifica ogni prodotto e fornitore nei registri riportati sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Italy", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 62, "clinicalTrialRecruitingLocations": 25, "clinicalTrialRecordsWithRecruitingLocations": 5, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07481630", "NCT07503210", "NCT07509307", "NCT07533175" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07481630", "https://clinicaltrials.gov/study/NCT07503210", "https://clinicaltrials.gov/study/NCT07509307", "https://clinicaltrials.gov/study/NCT07533175" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Italy#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Italy", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=italy" }, { "recordId": "pl-compound-country-amycretin-netherlands", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Amycretin / Zenagamtide in Nederland", "localizedAnswer": "Amycretin / Zenagamtide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in Nederland neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Netherlands", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 25, "clinicalTrialRecruitingLocations": 12, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07503210" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07503210" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Netherlands#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Netherlands", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=netherlands" }, { "recordId": "pl-compound-country-amycretin-switzerland", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Amycretin / Zenagamtide in Switzerland", "localizedAnswer": "Amycretin / Zenagamtide is an investigational clinical program. No seller listing in Switzerland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Switzerland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Switzerland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Switzerland", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=switzerland" }, { "recordId": "pl-compound-country-amycretin-poland", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Amycretin / Zenagamtide w Polsce", "localizedAnswer": "Amycretin / Zenagamtide jest eksperymentalnym programem klinicznym. Żadna oferta handlowa w Polsce nie przejmuje automatycznie tożsamości klinicznej, wyników badań ani statusu regulacyjnego sponsora. Sprawdź każdy produkt i dostawcę w rejestrach poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Poland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 7, "clinicalTrialListedLocations": 120, "clinicalTrialRecruitingLocations": 61, "clinicalTrialRecordsWithRecruitingLocations": 5, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07571005", "NCT07571109", "NCT07481630", "NCT07509307", "NCT07400107", "NCT06542874" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07571005", "https://clinicaltrials.gov/study/NCT07571109", "https://clinicaltrials.gov/study/NCT07481630", "https://clinicaltrials.gov/study/NCT07509307", "https://clinicaltrials.gov/study/NCT07400107", "https://clinicaltrials.gov/study/NCT06542874" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Poland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Poland", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=poland" }, { "recordId": "pl-compound-country-amycretin-ireland", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Amycretin / Zenagamtide in Ireland", "localizedAnswer": "Amycretin / Zenagamtide is an investigational clinical program. No seller listing in Ireland can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Ireland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Ireland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Ireland", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=ireland" }, { "recordId": "pl-compound-country-amycretin-portugal", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Amycretin / Zenagamtide em Portugal", "localizedAnswer": "Amycretin / Zenagamtide é um programa clínico experimental. Nenhuma oferta comercial em Portugal pode herdar a identidade clínica, os resultados de ensaios ou o estatuto regulamentar do promotor. Verifique cada produto e fornecedor nos registos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Portugal", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 8, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07400107" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07400107" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Portugal#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Portugal", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=portugal" }, { "recordId": "pl-compound-country-amycretin-sweden", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Amycretin / Zenagamtide i Sverige", "localizedAnswer": "Amycretin / Zenagamtide är ett kliniskt prövningsprogram. Inget kommersiellt erbjudande i Sverige kan automatiskt ärva sponsorns kliniska identitet, studieresultat eller regulatoriska status. Kontrollera varje produkt och leverantör i registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Sweden", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Sweden#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Sweden", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=sweden" }, { "recordId": "pl-compound-country-amycretin-turkey", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Amycretin / Zenagamtide", "localizedAnswer": "Amycretin / Zenagamtide klinik geliştirme aşamasındaki bir programdır. Türkiye içindeki aynı adlı hiçbir ticari teklif sponsorun klinik kimliğini, çalışma sonuçlarını veya düzenleyici statüsünü otomatik olarak devralamaz. Belirli ürünü, ruhsat sahibini, kuruluşu ve tedarik yolunu aşağıdaki resmi hedef ülke kayıtlarında kontrol edin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Turkey (Türkiye)", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 6, "clinicalTrialListedLocations": 68, "clinicalTrialRecruitingLocations": 57, "clinicalTrialRecordsWithRecruitingLocations": 5, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07571005", "NCT07571109", "NCT07481630", "NCT07509307", "NCT07400107" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07571005", "https://clinicaltrials.gov/study/NCT07571109", "https://clinicaltrials.gov/study/NCT07481630", "https://clinicaltrials.gov/study/NCT07509307", "https://clinicaltrials.gov/study/NCT07400107" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Turkey%20(T%C3%BCrkiye)#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Turkey%20(T%C3%BCrkiye)", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=turkey" }, { "recordId": "pl-compound-country-amycretin-austria", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Amycretin / Zenagamtide in Österreich", "localizedAnswer": "Amycretin / Zenagamtide ist ein klinisches Prüfprogramm. Kein kommerzielles Angebot in Österreich übernimmt dadurch automatisch die klinische Identität, Studienergebnisse oder den regulatorischen Status des Sponsors. Prüfe jedes konkrete Produkt und jeden Anbieter in den Registern unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Austria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Austria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Austria", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=austria" }, { "recordId": "pl-compound-country-amycretin-belgium", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Amycretin / Zenagamtide in België", "localizedAnswer": "Amycretin / Zenagamtide is een klinisch onderzoeksprogramma. Geen commercieel aanbod in België neemt daardoor automatisch de klinische identiteit, onderzoeksresultaten of regelgevende status van de sponsor over. Controleer elk concreet product en elke aanbieder in de registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Belgium", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 10, "clinicalTrialRecruitingLocations": 9, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07339423", "NCT07503210" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07339423", "https://clinicaltrials.gov/study/NCT07503210" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Belgium#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Belgium", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=belgium" }, { "recordId": "pl-compound-country-amycretin-denmark", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Amycretin / Zenagamtide i Danmark", "localizedAnswer": "Amycretin / Zenagamtide er et klinisk udviklingsprogram. Et kommercielt tilbud med samme navn i Danmark arver ikke sponsorens kliniske identitet, forsøgsresultater eller regulatoriske status. Kontrollér det konkrete produkt, tilladelsesindehaveren, virksomheden og forsyningsvejen i de officielle registre for destinationen nedenfor.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Denmark", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 6, "clinicalTrialListedLocations": 26, "clinicalTrialRecruitingLocations": 25, "clinicalTrialRecordsWithRecruitingLocations": 6, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07571005", "NCT07339423", "NCT07481630", "NCT07503210", "NCT07509307" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07571005", "https://clinicaltrials.gov/study/NCT07339423", "https://clinicaltrials.gov/study/NCT07481630", "https://clinicaltrials.gov/study/NCT07503210", "https://clinicaltrials.gov/study/NCT07509307" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Denmark#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Denmark", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=denmark" }, { "recordId": "pl-compound-country-amycretin-finland", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Amycretin / Zenagamtide kohteessa Suomi", "localizedAnswer": "Amycretin / Zenagamtide on kliininen kehitysohjelma. Samanniminen kaupallinen tarjous kohteessa Suomi ei peri sponsorin kliinistä identiteettiä, tutkimustuloksia tai sääntelyasemaa. Tarkista täsmällinen tuote, luvanhaltija, toimija ja toimitusreitti alla olevista kohdemaan virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Finland", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Finland#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Finland", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=finland" }, { "recordId": "pl-compound-country-amycretin-mexico", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Amycretin / Zenagamtide en México", "localizedAnswer": "Amycretin / Zenagamtide es un programa clínico en investigación. Ninguna oferta comercial en México puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Mexico", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 29, "clinicalTrialRecruitingLocations": 10, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07533175", "NCT07400107" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07533175", "https://clinicaltrials.gov/study/NCT07400107" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Mexico#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Mexico", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=mexico" }, { "recordId": "pl-compound-country-amycretin-argentina", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Amycretin / Zenagamtide en Argentina", "localizedAnswer": "Amycretin / Zenagamtide es un programa clínico en investigación. Ninguna oferta comercial en Argentina puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Argentina", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 46, "clinicalTrialRecruitingLocations": 40, "clinicalTrialRecordsWithRecruitingLocations": 4, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07339423", "NCT07503210", "NCT07533175", "NCT07400107" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07339423", "https://clinicaltrials.gov/study/NCT07503210", "https://clinicaltrials.gov/study/NCT07533175", "https://clinicaltrials.gov/study/NCT07400107" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Argentina#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Argentina", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=argentina" }, { "recordId": "pl-compound-country-amycretin-colombia", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Amycretin / Zenagamtide en Colombia", "localizedAnswer": "Amycretin / Zenagamtide es un programa clínico en investigación. Ninguna oferta comercial en Colombia puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Colombia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Colombia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Colombia", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=colombia" }, { "recordId": "pl-compound-country-amycretin-chile", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Amycretin / Zenagamtide en Chile", "localizedAnswer": "Amycretin / Zenagamtide es un programa clínico en investigación. Ninguna oferta comercial en Chile puede heredar la identidad clínica, los resultados de ensayos ni el estado regulatorio del patrocinador. Comprueba cada producto y proveedor en los registros que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Chile", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Chile#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Chile", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=chile" }, { "recordId": "pl-compound-country-amycretin-brazil", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Amycretin / Zenagamtide no Brasil", "localizedAnswer": "Amycretin / Zenagamtide é um programa clínico experimental. Nenhuma oferta comercial no Brasil pode herdar a identidade clínica, os resultados de ensaios ou o status regulatório do patrocinador. Verifique cada produto e fornecedor nos registros abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Brazil", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 32, "clinicalTrialRecruitingLocations": 18, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07533175", "NCT07400107" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07533175", "https://clinicaltrials.gov/study/NCT07400107" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Brazil#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Brazil", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=brazil" }, { "recordId": "pl-compound-country-amycretin-china", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Amycretin / Zenagamtide 在中国的状态与官方记录", "localizedAnswer": "Amycretin / Zenagamtide在此对应一个临床与监管项目。项目在某一国家的试验、批准或公司公告，不能自动证明同名商品在中国获批、可得或由有资质的卖方提供。请分别核对目的地的具体药品记录、批准持有人、剂型规格、经营主体和供应路径，并保持临床证据与在线商品身份相互独立。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "China", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 34, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07571005", "NCT07571109", "NCT07121153", "NCT06820476" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07571005", "https://clinicaltrials.gov/study/NCT07571109", "https://clinicaltrials.gov/study/NCT07121153", "https://clinicaltrials.gov/study/NCT06820476" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=China#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=China", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=china" }, { "recordId": "pl-compound-country-amycretin-australia", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Amycretin / Zenagamtide in Australia", "localizedAnswer": "Amycretin / Zenagamtide is an investigational clinical program. No seller listing in Australia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Australia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 7, "clinicalTrialListedLocations": 44, "clinicalTrialRecruitingLocations": 40, "clinicalTrialRecordsWithRecruitingLocations": 7, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07571005", "NCT07571109", "NCT07339423", "NCT07481630", "NCT07503210", "NCT07509307" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07571005", "https://clinicaltrials.gov/study/NCT07571109", "https://clinicaltrials.gov/study/NCT07339423", "https://clinicaltrials.gov/study/NCT07481630", "https://clinicaltrials.gov/study/NCT07503210", "https://clinicaltrials.gov/study/NCT07509307" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Australia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Australia", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=australia" }, { "recordId": "pl-compound-country-amycretin-new-zealand", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Amycretin / Zenagamtide in New Zealand", "localizedAnswer": "Amycretin / Zenagamtide is an investigational clinical program. No seller listing in New Zealand can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "New Zealand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=New%20Zealand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=New%20Zealand", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=new-zealand" }, { "recordId": "pl-compound-country-amycretin-india", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Amycretin / Zenagamtide in India", "localizedAnswer": "Amycretin / Zenagamtide is an investigational clinical program. No seller listing in India can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "India", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 110, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07571005", "NCT07571109", "NCT07668401", "NCT07400107" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07571005", "https://clinicaltrials.gov/study/NCT07571109", "https://clinicaltrials.gov/study/NCT07668401", "https://clinicaltrials.gov/study/NCT07400107" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=India#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=India", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=india" }, { "recordId": "pl-compound-country-amycretin-japan", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のAmycretin / アミクレチン / Zenagamtide", "localizedAnswer": "Amycretin / アミクレチン / Zenagamtideは臨床開発中のプログラムです。スポンサーの臨床上の同一性、試験結果、規制上の位置付けを、日本の同名オンライン商品や販売者が自動的に引き継ぐことはありません。目的地の製品、承認保持者、施設、供給経路を下記の公的記録で確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Japan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 61, "clinicalTrialRecruitingLocations": 35, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07571109", "NCT07668401", "NCT06542874", "NCT06049329" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07571109", "https://clinicaltrials.gov/study/NCT07668401", "https://clinicaltrials.gov/study/NCT06542874", "https://clinicaltrials.gov/study/NCT06049329" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Japan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Japan", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=japan" }, { "recordId": "pl-compound-country-amycretin-south-korea", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Amycretin / 아미크레틴 / Zenagamtide", "localizedAnswer": "Amycretin / 아미크레틴 / Zenagamtide은 임상 개발 중인 프로그램입니다. 후원사의 임상 신원, 시험 결과 또는 규제 상태를 대한민국의 동명 온라인 상품이나 판매자가 자동으로 이어받을 수 없습니다. 목적지의 정확한 제품, 허가권자, 기관과 공급 경로를 아래 공식 기록에서 확인해야 합니다.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "South Korea", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 32, "clinicalTrialRecruitingLocations": 21, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07533175", "NCT07668401" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07533175", "https://clinicaltrials.gov/study/NCT07668401" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=South%20Korea#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=South%20Korea", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=south-korea" }, { "recordId": "pl-compound-country-amycretin-thailand", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Amycretin / อะไมเครติน / Zenagamtide ในประเทศไทย", "localizedAnswer": "Amycretin / อะไมเครติน / Zenagamtide เป็นโครงการที่อยู่ระหว่างการพัฒนาทางคลินิก สินค้าหรือผู้ขายชื่อเดียวกันในประเทศไทยไม่สามารถรับช่วงตัวตนทางคลินิก ผลการทดลอง หรือสถานะด้านกฎระเบียบของผู้สนับสนุนโดยอัตโนมัติ ให้ตรวจผลิตภัณฑ์ ผู้ถือทะเบียน สถานประกอบการ และเส้นทางการจัดหาที่แน่นอนในบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Thailand", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 9, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07668401", "NCT07400107" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07668401", "https://clinicaltrials.gov/study/NCT07400107" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Thailand#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Thailand", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=thailand" }, { "recordId": "pl-compound-country-amycretin-indonesia", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Amycretin / Zenagamtide di Indonesia", "localizedAnswer": "Amycretin / Zenagamtide adalah program yang sedang dikembangkan secara klinis. Produk atau penjual dengan nama sama di Indonesia tidak otomatis mewarisi identitas klinis sponsor, hasil uji, atau status regulasinya. Periksa produk, pemegang izin, fasilitas, dan jalur pasok yang tepat dalam catatan resmi tujuan di bawah.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Indonesia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Indonesia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Indonesia", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=indonesia" }, { "recordId": "pl-compound-country-amycretin-singapore", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Amycretin / Zenagamtide in Singapore", "localizedAnswer": "Amycretin / Zenagamtide is an investigational clinical program. No seller listing in Singapore can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Singapore", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Singapore#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Singapore", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=singapore" }, { "recordId": "pl-compound-country-amycretin-philippines", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Amycretin / Zenagamtide in the Philippines", "localizedAnswer": "Amycretin / Zenagamtide is an investigational clinical program. No seller listing in the Philippines can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Philippines", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Philippines#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Philippines", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=philippines" }, { "recordId": "pl-compound-country-amycretin-malaysia", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Amycretin / Zenagamtide in Malaysia", "localizedAnswer": "Amycretin / Zenagamtide is an investigational clinical program. No seller listing in Malaysia can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Malaysia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 2, "clinicalTrialListedLocations": 21, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07668401" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07668401" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Malaysia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Malaysia", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=malaysia" }, { "recordId": "pl-compound-country-amycretin-taiwan", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Amycretin / Zenagamtide 在台灣的紀錄", "localizedAnswer": "Amycretin / Zenagamtide是臨床開發中的計畫。贊助者的臨床身分、試驗結果或法規狀態，不會自動移轉給台灣的同名網路商品或提供者。必須利用下方紀錄核對目的地的具體產品、許可證持有者、機構與供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Taiwan", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 3, "clinicalTrialListedLocations": 15, "clinicalTrialRecruitingLocations": 6, "clinicalTrialRecordsWithRecruitingLocations": 2, "clinicalTrialRecordIds": [ "NCT07571005", "NCT07571109", "NCT07567001" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07571005", "https://clinicaltrials.gov/study/NCT07571109", "https://clinicaltrials.gov/study/NCT07567001" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Taiwan#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Taiwan", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=taiwan" }, { "recordId": "pl-compound-country-amycretin-hong-kong", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Amycretin / Zenagamtide 在香港的紀錄", "localizedAnswer": "Amycretin / Zenagamtide是臨床開發中的計劃。贊助者的臨床身分、試驗結果或監管狀態，不會自動轉移給香港的同名網上商品或銷售商。必須透過下方紀錄核對目的地的指定產品、註冊持有人、持牌實體和供應途徑。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Hong Kong", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Hong%20Kong#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Hong%20Kong", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=hong-kong" }, { "recordId": "pl-compound-country-amycretin-vietnam", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Amycretin / Zenagamtide tại Việt Nam", "localizedAnswer": "Amycretin / Zenagamtide là một chương trình đang phát triển lâm sàng. Không đề nghị thương mại nào tại Việt Nam tự động kế thừa danh tính lâm sàng, kết quả thử nghiệm hoặc tình trạng quản lý của nhà tài trợ. Cần kiểm tra sản phẩm, chủ sở hữu giấy phép, cơ sở và đường cung ứng cụ thể trong các hồ sơ chính thức của điểm đến ở dưới.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Vietnam", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Vietnam#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Vietnam", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=vietnam" }, { "recordId": "pl-compound-country-amycretin-united-states", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Amycretin / Zenagamtide in the United States", "localizedAnswer": "Amycretin / Zenagamtide is an investigational clinical program. No seller listing in the United States can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "United States", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 15, "clinicalTrialListedLocations": 462, "clinicalTrialRecruitingLocations": 237, "clinicalTrialRecordsWithRecruitingLocations": 8, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07571005", "NCT07571109", "NCT07339423", "NCT07481630", "NCT07503210", "NCT07509307", "NCT07533175", "NCT07720271", "NCT07668414", "NCT07400107", "NCT06542874", "NCT06064006", "NCT06478563", "NCT05369390" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07571005", "https://clinicaltrials.gov/study/NCT07571109", "https://clinicaltrials.gov/study/NCT07339423", "https://clinicaltrials.gov/study/NCT07481630", "https://clinicaltrials.gov/study/NCT07503210", "https://clinicaltrials.gov/study/NCT07509307", "https://clinicaltrials.gov/study/NCT07533175", "https://clinicaltrials.gov/study/NCT07720271", "https://clinicaltrials.gov/study/NCT07668414", "https://clinicaltrials.gov/study/NCT07400107", "https://clinicaltrials.gov/study/NCT06542874", "https://clinicaltrials.gov/study/NCT06064006", "https://clinicaltrials.gov/study/NCT06478563", "https://clinicaltrials.gov/study/NCT05369390" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=United%20States#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=United%20States", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=united-states" }, { "recordId": "pl-compound-country-amycretin-canada", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Amycretin / Zenagamtide in Canada", "localizedAnswer": "Amycretin / Zenagamtide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Canada", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 5, "clinicalTrialListedLocations": 44, "clinicalTrialRecruitingLocations": 25, "clinicalTrialRecordsWithRecruitingLocations": 4, "clinicalTrialRecordIds": [ "NCT07567001", "NCT07339423", "NCT07481630", "NCT07509307", "NCT06461039" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001", "https://clinicaltrials.gov/study/NCT07339423", "https://clinicaltrials.gov/study/NCT07481630", "https://clinicaltrials.gov/study/NCT07509307", "https://clinicaltrials.gov/study/NCT06461039" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Canada#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Canada", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=canada" }, { "recordId": "pl-compound-country-amycretin-united-arab-emirates", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Amycretin / أميكريتين / Zenagamtide في الإمارات العربية المتحدة", "localizedAnswer": "Amycretin / أميكريتين / Zenagamtide برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في الإمارات العربية المتحدة أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "United Arab Emirates", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=United%20Arab%20Emirates#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=United%20Arab%20Emirates", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=united-arab-emirates" }, { "recordId": "pl-compound-country-amycretin-saudi-arabia", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Amycretin / أميكريتين / Zenagamtide في المملكة العربية السعودية", "localizedAnswer": "Amycretin / أميكريتين / Zenagamtide برنامج سريري قيد البحث. لا يمكن لأي عرض تجاري في المملكة العربية السعودية أن يرث تلقائيا هوية الجهة الراعية أو نتائج التجارب أو الوضع التنظيمي للبرنامج. افحص المنتج المحدد والجهة الحاملة للتسجيل والبائع أو المنشأة ومسار التوريد في السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Saudi Arabia", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Saudi%20Arabia#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Saudi%20Arabia", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=saudi-arabia" }, { "recordId": "pl-compound-country-amycretin-south-africa", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Amycretin / Zenagamtide in South Africa", "localizedAnswer": "Amycretin / Zenagamtide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "South Africa", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 1, "clinicalTrialListedLocations": 24, "clinicalTrialRecruitingLocations": 4, "clinicalTrialRecordsWithRecruitingLocations": 1, "clinicalTrialRecordIds": [ "NCT07567001" ], "clinicalTrialRecordUrls": [ "https://clinicaltrials.gov/study/NCT07567001" ], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=South%20Africa#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=South%20Africa", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=south-africa" }, { "recordId": "pl-compound-country-amycretin-nigeria", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Amycretin / Zenagamtide in Nigeria", "localizedAnswer": "Amycretin / Zenagamtide is an investigational clinical program. No seller listing in Nigeria can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Nigeria", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Nigeria#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Nigeria", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=nigeria" }, { "recordId": "pl-compound-country-amycretin-kenya", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Amycretin / Zenagamtide in Kenya", "localizedAnswer": "Amycretin / Zenagamtide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "tracked-program", "clinicalTrialProgramName": "Zenagamtide", "clinicalTrialRegistryCountry": "Kenya", "clinicalTrialSnapshotDate": "2026-07-24", "clinicalTrialRecords": 0, "clinicalTrialListedLocations": 0, "clinicalTrialRecruitingLocations": 0, "clinicalTrialRecordsWithRecruitingLocations": 0, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": "https://peptidelocal.com/clinical-trials?program=amycretin&country=Kenya#trial-results", "clinicalTrialRegistrySearchUrl": "https://clinicaltrials.gov/search?intr=Zenagamtide&locStr=Kenya", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/amycretin", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/amycretin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=amycretin&country=kenya" }, { "recordId": "pl-compound-country-tirzepatide-france", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Tirzepatide en France", "localizedAnswer": "Tirzepatide commence ici par une référence de médicament de la FDA américaine. Cela ne prouve pas le même produit, la même présentation, l’autorisation, le statut de prescription ou la disponibilité actuelle en France. Consultez les registres locaux exacts ci-dessous.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=france" }, { "recordId": "pl-compound-country-tirzepatide-united-kingdom", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Tirzepatide in the United Kingdom", "localizedAnswer": "Tirzepatide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United Kingdom. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=united-kingdom" }, { "recordId": "pl-compound-country-tirzepatide-germany", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Tirzepatide in Deutschland", "localizedAnswer": "Tirzepatide beginnt hier mit einer Arzneimittelreferenz der US-FDA. Das belegt weder dasselbe Produkt noch Darreichungsform, Zulassung, Verschreibungsstatus oder aktuelle Verfügbarkeit in Deutschland. Prüfe die genauen lokalen Register unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=germany" }, { "recordId": "pl-compound-country-tirzepatide-spain", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Tirzepatide / tirzepatida en España", "localizedAnswer": "Tirzepatide / tirzepatida empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en España. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=spain" }, { "recordId": "pl-compound-country-tirzepatide-italy", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Tirzepatide in Italia", "localizedAnswer": "Tirzepatide parte qui da un riferimento di farmaco della FDA statunitense. Questo non dimostra stesso prodotto, presentazione, approvazione, stato di prescrizione o disponibilità attuale in Italia. Controlla i registri locali esatti qui sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=italy" }, { "recordId": "pl-compound-country-tirzepatide-netherlands", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Tirzepatide in Nederland", "localizedAnswer": "Tirzepatide begint hier met een geneesmiddelreferentie van de Amerikaanse FDA. Dat bewijst niet hetzelfde product, dezelfde presentatie, toelating, receptstatus of actuele beschikbaarheid in Nederland. Controleer de exacte lokale registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=netherlands" }, { "recordId": "pl-compound-country-tirzepatide-switzerland", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Tirzepatide in Switzerland", "localizedAnswer": "Tirzepatide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Switzerland. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=switzerland" }, { "recordId": "pl-compound-country-tirzepatide-poland", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Tirzepatide w Polsce", "localizedAnswer": "Tirzepatide zaczyna się tutaj od dokumentu leku amerykańskiej FDA. Nie dowodzi to tego samego produktu, postaci, dopuszczenia, statusu recepty ani bieżącej dostępności w Polsce. Sprawdź dokładne rejestry krajowe poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=poland" }, { "recordId": "pl-compound-country-tirzepatide-ireland", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Tirzepatide in Ireland", "localizedAnswer": "Tirzepatide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Ireland. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=ireland" }, { "recordId": "pl-compound-country-tirzepatide-portugal", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Tirzepatide / tirzepatida em Portugal", "localizedAnswer": "Tirzepatide / tirzepatida começa aqui com uma referência de medicamento da FDA dos EUA. Isso não comprova o mesmo produto, apresentação, autorização, estatuto de prescrição ou disponibilidade atual em Portugal. Consulte os registos locais exatos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=portugal" }, { "recordId": "pl-compound-country-tirzepatide-sweden", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Tirzepatide i Sverige", "localizedAnswer": "Tirzepatide börjar här med en läkemedelsreferens från amerikanska FDA. Det bevisar inte samma produkt, presentation, godkännande, receptstatus eller aktuell tillgänglighet i Sverige. Kontrollera de exakta nationella registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=sweden" }, { "recordId": "pl-compound-country-tirzepatide-turkey", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Tirzepatide / tirzepatid", "localizedAnswer": "Tirzepatide / tirzepatid kimliği burada bir ABD FDA ilaç kaydıyla başlar, ancak bu Türkiye için aynı ürünün, farmasötik şeklin, dozun, ruhsatın, reçete durumunun veya güncel tedarikin bulunduğunu kanıtlamaz. Aşağıdaki resmi kayıtlarla tam ürün ve satıcı kimliğini, güncel durumu ve iddia edilen yolu doğrulayın.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=turkey" }, { "recordId": "pl-compound-country-tirzepatide-austria", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Tirzepatide in Österreich", "localizedAnswer": "Tirzepatide beginnt hier mit einer Arzneimittelreferenz der US-FDA. Das belegt weder dasselbe Produkt noch Darreichungsform, Zulassung, Verschreibungsstatus oder aktuelle Verfügbarkeit in Österreich. Prüfe die genauen lokalen Register unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=austria" }, { "recordId": "pl-compound-country-tirzepatide-belgium", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Tirzepatide in België", "localizedAnswer": "Tirzepatide begint hier met een geneesmiddelreferentie van de Amerikaanse FDA. Dat bewijst niet hetzelfde product, dezelfde presentatie, toelating, receptstatus of actuele beschikbaarheid in België. Controleer de exacte lokale registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=belgium" }, { "recordId": "pl-compound-country-tirzepatide-denmark", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Tirzepatide / tirzepatid i Danmark", "localizedAnswer": "Tirzepatide / tirzepatid begynder her med en amerikansk FDA-lægemiddelidentitet, men det dokumenterer ikke samme produkt, form, styrke, godkendelse, receptstatus eller aktuelle forsyning i Danmark. Brug de officielle registre nedenfor til at kontrollere det nøjagtige lokale produkt, sælgeren, status og den påståede rute.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=denmark" }, { "recordId": "pl-compound-country-tirzepatide-finland", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Tirzepatide / tirzepatidi kohteessa Suomi", "localizedAnswer": "Tirzepatide / tirzepatidi alkaa tässä Yhdysvaltain FDA:n lääkeidentiteetistä, mutta se ei todista samaa tuotetta, lääkemuotoa, vahvuutta, hyväksyntää, reseptistatusta tai nykyistä toimitusta kohteessa Suomi. Tarkista täsmällinen paikallinen tuote, myyjä, tila ja väitetty reitti alla olevista virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=finland" }, { "recordId": "pl-compound-country-tirzepatide-mexico", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Tirzepatide / tirzepatida en México", "localizedAnswer": "Tirzepatide / tirzepatida empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en México. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=mexico" }, { "recordId": "pl-compound-country-tirzepatide-argentina", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Tirzepatide / tirzepatida en Argentina", "localizedAnswer": "Tirzepatide / tirzepatida empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Argentina. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=argentina" }, { "recordId": "pl-compound-country-tirzepatide-colombia", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Tirzepatide / tirzepatida en Colombia", "localizedAnswer": "Tirzepatide / tirzepatida empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Colombia. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=colombia" }, { "recordId": "pl-compound-country-tirzepatide-chile", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Tirzepatide / tirzepatida en Chile", "localizedAnswer": "Tirzepatide / tirzepatida empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Chile. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=chile" }, { "recordId": "pl-compound-country-tirzepatide-brazil", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Tirzepatide / tirzepatida no Brasil", "localizedAnswer": "Tirzepatide / tirzepatida começa aqui com uma referência de medicamento da FDA dos EUA. Isso não comprova o mesmo produto, apresentação, aprovação, status de prescrição ou disponibilidade atual no Brasil. Consulte os registros locais exatos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=brazil" }, { "recordId": "pl-compound-country-tirzepatide-china", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Tirzepatide / 替尔泊肽 在中国的状态与官方记录", "localizedAnswer": "Tirzepatide / 替尔泊肽在此从美国 FDA 药品身份记录开始，但这不能证明同一品牌、剂型、规格、适应症、处方状态或供应路径在中国同样获批或可得。应使用下方官方记录核对目的地的具体产品和卖方，并确认当前状态，而不是依据名称、包装图片或国外批准作出推断。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=china" }, { "recordId": "pl-compound-country-tirzepatide-australia", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Tirzepatide in Australia", "localizedAnswer": "Tirzepatide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Australia. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=australia" }, { "recordId": "pl-compound-country-tirzepatide-new-zealand", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Tirzepatide in New Zealand", "localizedAnswer": "Tirzepatide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in New Zealand. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=new-zealand" }, { "recordId": "pl-compound-country-tirzepatide-india", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Tirzepatide in India", "localizedAnswer": "Tirzepatide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in India. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=india" }, { "recordId": "pl-compound-country-tirzepatide-japan", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のTirzepatide / チルゼパチド", "localizedAnswer": "Tirzepatide / チルゼパチドはここでは米国FDAの医薬品記録から同一性を確認しますが、日本で同じ製品、剤形、規格、承認、処方区分、供給状況が存在することを証明しません。下記の公的記録で目的地の具体的な製品と販売主体を確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=japan" }, { "recordId": "pl-compound-country-tirzepatide-south-korea", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Tirzepatide / 티르제파타이드", "localizedAnswer": "Tirzepatide / 티르제파타이드은 여기서 미국 FDA 의약품 기록으로 신원을 시작하지만, 대한민국에서 같은 제품, 제형, 함량, 허가, 처방 상태 또는 현재 공급이 존재한다는 뜻은 아닙니다. 아래 공식 기록을 이용해 목적지의 구체적인 제품과 판매 주체를 확인하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=south-korea" }, { "recordId": "pl-compound-country-tirzepatide-thailand", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Tirzepatide / เทอร์เซพาไทด์ ในประเทศไทย", "localizedAnswer": "Tirzepatide / เทอร์เซพาไทด์ เริ่มจากบันทึกยาของ FDA สหรัฐฯ แต่ไม่ได้พิสูจน์ว่าผลิตภัณฑ์ รูปแบบ ความแรง การอนุมัติ สถานะใบสั่งยา หรือการจัดหาในประเทศไทยเหมือนกัน ให้ตรวจผลิตภัณฑ์และผู้ขายที่เฉพาะเจาะจงในประเทศปลายทางจากบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=thailand" }, { "recordId": "pl-compound-country-tirzepatide-indonesia", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Tirzepatide di Indonesia", "localizedAnswer": "Tirzepatide dimulai dari identitas obat dalam catatan FDA Amerika Serikat, tetapi hal itu tidak membuktikan produk, bentuk, kekuatan, persetujuan, status resep, atau pasokan yang sama di Indonesia. Gunakan catatan resmi di bawah untuk memeriksa produk dan penjual spesifik di negara tujuan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=indonesia" }, { "recordId": "pl-compound-country-tirzepatide-singapore", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Tirzepatide in Singapore", "localizedAnswer": "Tirzepatide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Singapore. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=singapore" }, { "recordId": "pl-compound-country-tirzepatide-philippines", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Tirzepatide in the Philippines", "localizedAnswer": "Tirzepatide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the Philippines. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=philippines" }, { "recordId": "pl-compound-country-tirzepatide-malaysia", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Tirzepatide in Malaysia", "localizedAnswer": "Tirzepatide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Malaysia. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=malaysia" }, { "recordId": "pl-compound-country-tirzepatide-taiwan", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Tirzepatide / 替爾泊肽 在台灣的紀錄", "localizedAnswer": "Tirzepatide / 替爾泊肽在此從美國 FDA 藥品紀錄確認身分，但這不能證明台灣有相同產品、劑型、含量、適應症、處方狀態或目前供應。請用下方官方紀錄查證目的地的特定產品、許可證、機構和提供者，不能只依名稱或外國核准推論。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=taiwan" }, { "recordId": "pl-compound-country-tirzepatide-hong-kong", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Tirzepatide / 替爾泊肽 在香港的紀錄", "localizedAnswer": "Tirzepatide / 替爾泊肽在此從美國 FDA 藥物紀錄確認身分，但這不能證明香港有相同產品、劑型、含量、適應症、處方狀態或目前供應。請用下方官方紀錄核實指定產品、註冊編號、持牌銷售商和現行狀態，不能只依名稱或外國批准推論。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=hong-kong" }, { "recordId": "pl-compound-country-tirzepatide-vietnam", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Tirzepatide tại Việt Nam", "localizedAnswer": "Tirzepatide bắt đầu ở đây bằng hồ sơ thuốc của FDA Hoa Kỳ, nhưng điều đó không chứng minh có cùng sản phẩm, dạng bào chế, hàm lượng, giấy phép, tình trạng kê đơn hay nguồn cung hiện tại tại Việt Nam. Hãy dùng các hồ sơ bên dưới để xác minh chính xác sản phẩm, người bán, tình trạng và đường cung ứng tại điểm đến.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=vietnam" }, { "recordId": "pl-compound-country-tirzepatide-united-states", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Tirzepatide in the United States", "localizedAnswer": "Tirzepatide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United States. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=united-states" }, { "recordId": "pl-compound-country-tirzepatide-canada", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Tirzepatide in Canada", "localizedAnswer": "Tirzepatide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Canada. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=canada" }, { "recordId": "pl-compound-country-tirzepatide-united-arab-emirates", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Tirzepatide / تيرزيباتايد في الإمارات العربية المتحدة", "localizedAnswer": "تبدأ هوية Tirzepatide / تيرزيباتايد هنا من سجل دواء لدى إدارة الغذاء والدواء الأمريكية، لكن ذلك لا يثبت أن المنتج أو الشكل أو التركيز أو الموافقة أو حالة الوصفة أو التوفر الحالي هي نفسها في الإمارات العربية المتحدة. تحقق من المنتج المحلي المحدد والمنشأة والبائع ومسار التوريد من خلال السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=united-arab-emirates" }, { "recordId": "pl-compound-country-tirzepatide-saudi-arabia", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Tirzepatide / تيرزيباتايد في المملكة العربية السعودية", "localizedAnswer": "تبدأ هوية Tirzepatide / تيرزيباتايد هنا من سجل دواء لدى إدارة الغذاء والدواء الأمريكية، لكن ذلك لا يثبت أن المنتج أو الشكل أو التركيز أو الموافقة أو حالة الوصفة أو التوفر الحالي هي نفسها في المملكة العربية السعودية. تحقق من المنتج المحلي المحدد والمنشأة والبائع ومسار التوريد من خلال السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=saudi-arabia" }, { "recordId": "pl-compound-country-tirzepatide-south-africa", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Tirzepatide in South Africa", "localizedAnswer": "Tirzepatide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in South Africa. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=south-africa" }, { "recordId": "pl-compound-country-tirzepatide-nigeria", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Tirzepatide in Nigeria", "localizedAnswer": "Tirzepatide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Nigeria. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=nigeria" }, { "recordId": "pl-compound-country-tirzepatide-kenya", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Tirzepatide in Kenya", "localizedAnswer": "Tirzepatide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Kenya. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/tirzepatide", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/tirzepatide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=tirzepatide&country=kenya" }, { "recordId": "pl-compound-country-orforglipron-france", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Orforglipron / Foundayo en France", "localizedAnswer": "Orforglipron / Foundayo commence ici par une référence de médicament de la FDA américaine. Cela ne prouve pas le même produit, la même présentation, l’autorisation, le statut de prescription ou la disponibilité actuelle en France. Consultez les registres locaux exacts ci-dessous.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=france" }, { "recordId": "pl-compound-country-orforglipron-united-kingdom", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Orforglipron / Foundayo in the United Kingdom", "localizedAnswer": "Orforglipron / Foundayo begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United Kingdom. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=united-kingdom" }, { "recordId": "pl-compound-country-orforglipron-germany", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Orforglipron / Foundayo in Deutschland", "localizedAnswer": "Orforglipron / Foundayo beginnt hier mit einer Arzneimittelreferenz der US-FDA. Das belegt weder dasselbe Produkt noch Darreichungsform, Zulassung, Verschreibungsstatus oder aktuelle Verfügbarkeit in Deutschland. Prüfe die genauen lokalen Register unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=germany" }, { "recordId": "pl-compound-country-orforglipron-spain", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Orforglipron / Foundayo en España", "localizedAnswer": "Orforglipron / Foundayo empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en España. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=spain" }, { "recordId": "pl-compound-country-orforglipron-italy", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Orforglipron / Foundayo in Italia", "localizedAnswer": "Orforglipron / Foundayo parte qui da un riferimento di farmaco della FDA statunitense. Questo non dimostra stesso prodotto, presentazione, approvazione, stato di prescrizione o disponibilità attuale in Italia. Controlla i registri locali esatti qui sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=italy" }, { "recordId": "pl-compound-country-orforglipron-netherlands", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Orforglipron / Foundayo in Nederland", "localizedAnswer": "Orforglipron / Foundayo begint hier met een geneesmiddelreferentie van de Amerikaanse FDA. Dat bewijst niet hetzelfde product, dezelfde presentatie, toelating, receptstatus of actuele beschikbaarheid in Nederland. Controleer de exacte lokale registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=netherlands" }, { "recordId": "pl-compound-country-orforglipron-switzerland", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Orforglipron / Foundayo in Switzerland", "localizedAnswer": "Orforglipron / Foundayo begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Switzerland. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=switzerland" }, { "recordId": "pl-compound-country-orforglipron-poland", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Orforglipron / Foundayo w Polsce", "localizedAnswer": "Orforglipron / Foundayo zaczyna się tutaj od dokumentu leku amerykańskiej FDA. Nie dowodzi to tego samego produktu, postaci, dopuszczenia, statusu recepty ani bieżącej dostępności w Polsce. Sprawdź dokładne rejestry krajowe poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=poland" }, { "recordId": "pl-compound-country-orforglipron-ireland", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Orforglipron / Foundayo in Ireland", "localizedAnswer": "Orforglipron / Foundayo begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Ireland. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=ireland" }, { "recordId": "pl-compound-country-orforglipron-portugal", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Orforglipron / Foundayo em Portugal", "localizedAnswer": "Orforglipron / Foundayo começa aqui com uma referência de medicamento da FDA dos EUA. Isso não comprova o mesmo produto, apresentação, autorização, estatuto de prescrição ou disponibilidade atual em Portugal. Consulte os registos locais exatos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=portugal" }, { "recordId": "pl-compound-country-orforglipron-sweden", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Orforglipron / Foundayo i Sverige", "localizedAnswer": "Orforglipron / Foundayo börjar här med en läkemedelsreferens från amerikanska FDA. Det bevisar inte samma produkt, presentation, godkännande, receptstatus eller aktuell tillgänglighet i Sverige. Kontrollera de exakta nationella registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=sweden" }, { "recordId": "pl-compound-country-orforglipron-turkey", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Orforglipron / Foundayo", "localizedAnswer": "Orforglipron / Foundayo kimliği burada bir ABD FDA ilaç kaydıyla başlar, ancak bu Türkiye için aynı ürünün, farmasötik şeklin, dozun, ruhsatın, reçete durumunun veya güncel tedarikin bulunduğunu kanıtlamaz. Aşağıdaki resmi kayıtlarla tam ürün ve satıcı kimliğini, güncel durumu ve iddia edilen yolu doğrulayın.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=turkey" }, { "recordId": "pl-compound-country-orforglipron-austria", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Orforglipron / Foundayo in Österreich", "localizedAnswer": "Orforglipron / Foundayo beginnt hier mit einer Arzneimittelreferenz der US-FDA. Das belegt weder dasselbe Produkt noch Darreichungsform, Zulassung, Verschreibungsstatus oder aktuelle Verfügbarkeit in Österreich. Prüfe die genauen lokalen Register unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=austria" }, { "recordId": "pl-compound-country-orforglipron-belgium", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Orforglipron / Foundayo in België", "localizedAnswer": "Orforglipron / Foundayo begint hier met een geneesmiddelreferentie van de Amerikaanse FDA. Dat bewijst niet hetzelfde product, dezelfde presentatie, toelating, receptstatus of actuele beschikbaarheid in België. Controleer de exacte lokale registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=belgium" }, { "recordId": "pl-compound-country-orforglipron-denmark", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Orforglipron / Foundayo i Danmark", "localizedAnswer": "Orforglipron / Foundayo begynder her med en amerikansk FDA-lægemiddelidentitet, men det dokumenterer ikke samme produkt, form, styrke, godkendelse, receptstatus eller aktuelle forsyning i Danmark. Brug de officielle registre nedenfor til at kontrollere det nøjagtige lokale produkt, sælgeren, status og den påståede rute.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=denmark" }, { "recordId": "pl-compound-country-orforglipron-finland", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Orforglipron / Foundayo kohteessa Suomi", "localizedAnswer": "Orforglipron / Foundayo alkaa tässä Yhdysvaltain FDA:n lääkeidentiteetistä, mutta se ei todista samaa tuotetta, lääkemuotoa, vahvuutta, hyväksyntää, reseptistatusta tai nykyistä toimitusta kohteessa Suomi. Tarkista täsmällinen paikallinen tuote, myyjä, tila ja väitetty reitti alla olevista virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=finland" }, { "recordId": "pl-compound-country-orforglipron-mexico", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Orforglipron / Foundayo en México", "localizedAnswer": "Orforglipron / Foundayo empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en México. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=mexico" }, { "recordId": "pl-compound-country-orforglipron-argentina", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Orforglipron / Foundayo en Argentina", "localizedAnswer": "Orforglipron / Foundayo empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Argentina. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=argentina" }, { "recordId": "pl-compound-country-orforglipron-colombia", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Orforglipron / Foundayo en Colombia", "localizedAnswer": "Orforglipron / Foundayo empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Colombia. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=colombia" }, { "recordId": "pl-compound-country-orforglipron-chile", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Orforglipron / Foundayo en Chile", "localizedAnswer": "Orforglipron / Foundayo empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Chile. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=chile" }, { "recordId": "pl-compound-country-orforglipron-brazil", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Orforglipron / Foundayo no Brasil", "localizedAnswer": "Orforglipron / Foundayo começa aqui com uma referência de medicamento da FDA dos EUA. Isso não comprova o mesmo produto, apresentação, aprovação, status de prescrição ou disponibilidade atual no Brasil. Consulte os registros locais exatos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=brazil" }, { "recordId": "pl-compound-country-orforglipron-china", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Orforglipron / Foundayo 在中国的状态与官方记录", "localizedAnswer": "Orforglipron / Foundayo在此从美国 FDA 药品身份记录开始，但这不能证明同一品牌、剂型、规格、适应症、处方状态或供应路径在中国同样获批或可得。应使用下方官方记录核对目的地的具体产品和卖方，并确认当前状态，而不是依据名称、包装图片或国外批准作出推断。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=china" }, { "recordId": "pl-compound-country-orforglipron-australia", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Orforglipron / Foundayo in Australia", "localizedAnswer": "Orforglipron / Foundayo begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Australia. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=australia" }, { "recordId": "pl-compound-country-orforglipron-new-zealand", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Orforglipron / Foundayo in New Zealand", "localizedAnswer": "Orforglipron / Foundayo begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in New Zealand. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=new-zealand" }, { "recordId": "pl-compound-country-orforglipron-india", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Orforglipron / Foundayo in India", "localizedAnswer": "Orforglipron / Foundayo begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in India. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=india" }, { "recordId": "pl-compound-country-orforglipron-japan", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のOrforglipron / Foundayo", "localizedAnswer": "Orforglipron / Foundayoはここでは米国FDAの医薬品記録から同一性を確認しますが、日本で同じ製品、剤形、規格、承認、処方区分、供給状況が存在することを証明しません。下記の公的記録で目的地の具体的な製品と販売主体を確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=japan" }, { "recordId": "pl-compound-country-orforglipron-south-korea", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Orforglipron / Foundayo", "localizedAnswer": "Orforglipron / Foundayo은 여기서 미국 FDA 의약품 기록으로 신원을 시작하지만, 대한민국에서 같은 제품, 제형, 함량, 허가, 처방 상태 또는 현재 공급이 존재한다는 뜻은 아닙니다. 아래 공식 기록을 이용해 목적지의 구체적인 제품과 판매 주체를 확인하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=south-korea" }, { "recordId": "pl-compound-country-orforglipron-thailand", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Orforglipron / Foundayo ในประเทศไทย", "localizedAnswer": "Orforglipron / Foundayo เริ่มจากบันทึกยาของ FDA สหรัฐฯ แต่ไม่ได้พิสูจน์ว่าผลิตภัณฑ์ รูปแบบ ความแรง การอนุมัติ สถานะใบสั่งยา หรือการจัดหาในประเทศไทยเหมือนกัน ให้ตรวจผลิตภัณฑ์และผู้ขายที่เฉพาะเจาะจงในประเทศปลายทางจากบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=thailand" }, { "recordId": "pl-compound-country-orforglipron-indonesia", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Orforglipron / Foundayo di Indonesia", "localizedAnswer": "Orforglipron / Foundayo dimulai dari identitas obat dalam catatan FDA Amerika Serikat, tetapi hal itu tidak membuktikan produk, bentuk, kekuatan, persetujuan, status resep, atau pasokan yang sama di Indonesia. Gunakan catatan resmi di bawah untuk memeriksa produk dan penjual spesifik di negara tujuan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=indonesia" }, { "recordId": "pl-compound-country-orforglipron-singapore", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Orforglipron / Foundayo in Singapore", "localizedAnswer": "Orforglipron / Foundayo begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Singapore. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=singapore" }, { "recordId": "pl-compound-country-orforglipron-philippines", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Orforglipron / Foundayo in the Philippines", "localizedAnswer": "Orforglipron / Foundayo begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the Philippines. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=philippines" }, { "recordId": "pl-compound-country-orforglipron-malaysia", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Orforglipron / Foundayo in Malaysia", "localizedAnswer": "Orforglipron / Foundayo begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Malaysia. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=malaysia" }, { "recordId": "pl-compound-country-orforglipron-taiwan", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Orforglipron / Foundayo 在台灣的紀錄", "localizedAnswer": "Orforglipron / Foundayo在此從美國 FDA 藥品紀錄確認身分，但這不能證明台灣有相同產品、劑型、含量、適應症、處方狀態或目前供應。請用下方官方紀錄查證目的地的特定產品、許可證、機構和提供者，不能只依名稱或外國核准推論。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=taiwan" }, { "recordId": "pl-compound-country-orforglipron-hong-kong", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Orforglipron / Foundayo 在香港的紀錄", "localizedAnswer": "Orforglipron / Foundayo在此從美國 FDA 藥物紀錄確認身分，但這不能證明香港有相同產品、劑型、含量、適應症、處方狀態或目前供應。請用下方官方紀錄核實指定產品、註冊編號、持牌銷售商和現行狀態，不能只依名稱或外國批准推論。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=hong-kong" }, { "recordId": "pl-compound-country-orforglipron-vietnam", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Orforglipron / Foundayo tại Việt Nam", "localizedAnswer": "Orforglipron / Foundayo bắt đầu ở đây bằng hồ sơ thuốc của FDA Hoa Kỳ, nhưng điều đó không chứng minh có cùng sản phẩm, dạng bào chế, hàm lượng, giấy phép, tình trạng kê đơn hay nguồn cung hiện tại tại Việt Nam. Hãy dùng các hồ sơ bên dưới để xác minh chính xác sản phẩm, người bán, tình trạng và đường cung ứng tại điểm đến.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=vietnam" }, { "recordId": "pl-compound-country-orforglipron-united-states", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved oral medicine in the United States", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Orforglipron / Foundayo in the United States", "localizedAnswer": "FOUNDAYO received FDA approval on April 1, 2026 under NDA 220934 for a defined adult weight-management population. The approval belongs to the exact tablets, label, manufacturer, prescription product, and US supply record. It does not transfer to a powder, research listing, imported presentation, or online product using the orforglipron name.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "National Library of Medicine, DailyMed" ], "statusEvidenceUrls": [ "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=united-states" }, { "recordId": "pl-compound-country-orforglipron-canada", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Orforglipron / Foundayo in Canada", "localizedAnswer": "Orforglipron / Foundayo begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Canada. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=canada" }, { "recordId": "pl-compound-country-orforglipron-united-arab-emirates", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Orforglipron / Foundayo في الإمارات العربية المتحدة", "localizedAnswer": "تبدأ هوية Orforglipron / Foundayo هنا من سجل دواء لدى إدارة الغذاء والدواء الأمريكية، لكن ذلك لا يثبت أن المنتج أو الشكل أو التركيز أو الموافقة أو حالة الوصفة أو التوفر الحالي هي نفسها في الإمارات العربية المتحدة. تحقق من المنتج المحلي المحدد والمنشأة والبائع ومسار التوريد من خلال السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=united-arab-emirates" }, { "recordId": "pl-compound-country-orforglipron-saudi-arabia", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Orforglipron / Foundayo في المملكة العربية السعودية", "localizedAnswer": "تبدأ هوية Orforglipron / Foundayo هنا من سجل دواء لدى إدارة الغذاء والدواء الأمريكية، لكن ذلك لا يثبت أن المنتج أو الشكل أو التركيز أو الموافقة أو حالة الوصفة أو التوفر الحالي هي نفسها في المملكة العربية السعودية. تحقق من المنتج المحلي المحدد والمنشأة والبائع ومسار التوريد من خلال السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=saudi-arabia" }, { "recordId": "pl-compound-country-orforglipron-south-africa", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Orforglipron / Foundayo in South Africa", "localizedAnswer": "Orforglipron / Foundayo begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in South Africa. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=south-africa" }, { "recordId": "pl-compound-country-orforglipron-nigeria", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Orforglipron / Foundayo in Nigeria", "localizedAnswer": "Orforglipron / Foundayo begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Nigeria. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=nigeria" }, { "recordId": "pl-compound-country-orforglipron-kenya", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Orforglipron / Foundayo in Kenya", "localizedAnswer": "Orforglipron / Foundayo begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Kenya. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/orforglipron", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/orforglipron/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=orforglipron&country=kenya" }, { "recordId": "pl-compound-country-semaglutide-france", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "EU-authorized Wegovy with France-specific access rules", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Semaglutide / sémaglutide en France", "localizedAnswer": "Wegovy, à base de sémaglutide, dispose d’une autorisation européenne et est commercialisé en France. L’Assurance Maladie indique qu’une prise en charge est possible depuis le 15 juin 2026 uniquement selon des critères précis d’éligibilité et de vérification. L’autorisation, le remboursement, la prescription, la présentation, l’approvisionnement actuel et l’habilitation du vendeur restent des faits distincts à confirmer dans les registres officiels.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "Assurance Maladie" ], "statusEvidenceUrls": [ "https://www.ameli.fr/assure/sante/themes/surpoids-obesite-adulte/traitement-medicamenteux-chirurgical" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=france" }, { "recordId": "pl-compound-country-semaglutide-united-kingdom", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Semaglutide in the United Kingdom", "localizedAnswer": "Semaglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United Kingdom. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=united-kingdom" }, { "recordId": "pl-compound-country-semaglutide-germany", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Semaglutide / Semaglutid in Deutschland", "localizedAnswer": "Semaglutide / Semaglutid beginnt hier mit einer Arzneimittelreferenz der US-FDA. Das belegt weder dasselbe Produkt noch Darreichungsform, Zulassung, Verschreibungsstatus oder aktuelle Verfügbarkeit in Deutschland. Prüfe die genauen lokalen Register unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=germany" }, { "recordId": "pl-compound-country-semaglutide-spain", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Semaglutide / semaglutida en España", "localizedAnswer": "Semaglutide / semaglutida empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en España. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=spain" }, { "recordId": "pl-compound-country-semaglutide-italy", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Semaglutide in Italia", "localizedAnswer": "Semaglutide parte qui da un riferimento di farmaco della FDA statunitense. Questo non dimostra stesso prodotto, presentazione, approvazione, stato di prescrizione o disponibilità attuale in Italia. Controlla i registri locali esatti qui sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=italy" }, { "recordId": "pl-compound-country-semaglutide-netherlands", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Semaglutide in Nederland", "localizedAnswer": "Semaglutide begint hier met een geneesmiddelreferentie van de Amerikaanse FDA. Dat bewijst niet hetzelfde product, dezelfde presentatie, toelating, receptstatus of actuele beschikbaarheid in Nederland. Controleer de exacte lokale registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=netherlands" }, { "recordId": "pl-compound-country-semaglutide-switzerland", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Semaglutide in Switzerland", "localizedAnswer": "Semaglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Switzerland. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=switzerland" }, { "recordId": "pl-compound-country-semaglutide-poland", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Semaglutide / semaglutyd w Polsce", "localizedAnswer": "Semaglutide / semaglutyd zaczyna się tutaj od dokumentu leku amerykańskiej FDA. Nie dowodzi to tego samego produktu, postaci, dopuszczenia, statusu recepty ani bieżącej dostępności w Polsce. Sprawdź dokładne rejestry krajowe poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=poland" }, { "recordId": "pl-compound-country-semaglutide-ireland", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Semaglutide in Ireland", "localizedAnswer": "Semaglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Ireland. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=ireland" }, { "recordId": "pl-compound-country-semaglutide-portugal", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Semaglutide / semaglutida em Portugal", "localizedAnswer": "Semaglutide / semaglutida começa aqui com uma referência de medicamento da FDA dos EUA. Isso não comprova o mesmo produto, apresentação, autorização, estatuto de prescrição ou disponibilidade atual em Portugal. Consulte os registos locais exatos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=portugal" }, { "recordId": "pl-compound-country-semaglutide-sweden", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Semaglutide / semaglutid i Sverige", "localizedAnswer": "Semaglutide / semaglutid börjar här med en läkemedelsreferens från amerikanska FDA. Det bevisar inte samma produkt, presentation, godkännande, receptstatus eller aktuell tillgänglighet i Sverige. Kontrollera de exakta nationella registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=sweden" }, { "recordId": "pl-compound-country-semaglutide-turkey", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Semaglutide / semaglutid", "localizedAnswer": "Semaglutide / semaglutid kimliği burada bir ABD FDA ilaç kaydıyla başlar, ancak bu Türkiye için aynı ürünün, farmasötik şeklin, dozun, ruhsatın, reçete durumunun veya güncel tedarikin bulunduğunu kanıtlamaz. Aşağıdaki resmi kayıtlarla tam ürün ve satıcı kimliğini, güncel durumu ve iddia edilen yolu doğrulayın.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=turkey" }, { "recordId": "pl-compound-country-semaglutide-austria", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Semaglutide / Semaglutid in Österreich", "localizedAnswer": "Semaglutide / Semaglutid beginnt hier mit einer Arzneimittelreferenz der US-FDA. Das belegt weder dasselbe Produkt noch Darreichungsform, Zulassung, Verschreibungsstatus oder aktuelle Verfügbarkeit in Österreich. Prüfe die genauen lokalen Register unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=austria" }, { "recordId": "pl-compound-country-semaglutide-belgium", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Semaglutide in België", "localizedAnswer": "Semaglutide begint hier met een geneesmiddelreferentie van de Amerikaanse FDA. Dat bewijst niet hetzelfde product, dezelfde presentatie, toelating, receptstatus of actuele beschikbaarheid in België. Controleer de exacte lokale registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=belgium" }, { "recordId": "pl-compound-country-semaglutide-denmark", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Semaglutide / semaglutid i Danmark", "localizedAnswer": "Semaglutide / semaglutid begynder her med en amerikansk FDA-lægemiddelidentitet, men det dokumenterer ikke samme produkt, form, styrke, godkendelse, receptstatus eller aktuelle forsyning i Danmark. Brug de officielle registre nedenfor til at kontrollere det nøjagtige lokale produkt, sælgeren, status og den påståede rute.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=denmark" }, { "recordId": "pl-compound-country-semaglutide-finland", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Semaglutide / semaglutidi kohteessa Suomi", "localizedAnswer": "Semaglutide / semaglutidi alkaa tässä Yhdysvaltain FDA:n lääkeidentiteetistä, mutta se ei todista samaa tuotetta, lääkemuotoa, vahvuutta, hyväksyntää, reseptistatusta tai nykyistä toimitusta kohteessa Suomi. Tarkista täsmällinen paikallinen tuote, myyjä, tila ja väitetty reitti alla olevista virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=finland" }, { "recordId": "pl-compound-country-semaglutide-mexico", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Semaglutide / semaglutida en México", "localizedAnswer": "Semaglutide / semaglutida empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en México. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=mexico" }, { "recordId": "pl-compound-country-semaglutide-argentina", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Semaglutide / semaglutida en Argentina", "localizedAnswer": "Semaglutide / semaglutida empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Argentina. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=argentina" }, { "recordId": "pl-compound-country-semaglutide-colombia", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Semaglutide / semaglutida en Colombia", "localizedAnswer": "Semaglutide / semaglutida empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Colombia. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=colombia" }, { "recordId": "pl-compound-country-semaglutide-chile", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Semaglutide / semaglutida en Chile", "localizedAnswer": "Semaglutide / semaglutida empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Chile. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=chile" }, { "recordId": "pl-compound-country-semaglutide-brazil", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Semaglutide / semaglutida no Brasil", "localizedAnswer": "Semaglutide / semaglutida começa aqui com uma referência de medicamento da FDA dos EUA. Isso não comprova o mesmo produto, apresentação, aprovação, status de prescrição ou disponibilidade atual no Brasil. Consulte os registros locais exatos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=brazil" }, { "recordId": "pl-compound-country-semaglutide-china", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Semaglutide / 司美格鲁肽 在中国的状态与官方记录", "localizedAnswer": "Semaglutide / 司美格鲁肽在此从美国 FDA 药品身份记录开始，但这不能证明同一品牌、剂型、规格、适应症、处方状态或供应路径在中国同样获批或可得。应使用下方官方记录核对目的地的具体产品和卖方，并确认当前状态，而不是依据名称、包装图片或国外批准作出推断。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=china" }, { "recordId": "pl-compound-country-semaglutide-australia", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Semaglutide in Australia", "localizedAnswer": "Semaglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Australia. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=australia" }, { "recordId": "pl-compound-country-semaglutide-new-zealand", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Semaglutide in New Zealand", "localizedAnswer": "Semaglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in New Zealand. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=new-zealand" }, { "recordId": "pl-compound-country-semaglutide-india", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Semaglutide in India", "localizedAnswer": "Semaglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in India. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=india" }, { "recordId": "pl-compound-country-semaglutide-japan", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のSemaglutide / セマグルチド", "localizedAnswer": "Semaglutide / セマグルチドはここでは米国FDAの医薬品記録から同一性を確認しますが、日本で同じ製品、剤形、規格、承認、処方区分、供給状況が存在することを証明しません。下記の公的記録で目的地の具体的な製品と販売主体を確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=japan" }, { "recordId": "pl-compound-country-semaglutide-south-korea", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Semaglutide / 세마글루타이드", "localizedAnswer": "Semaglutide / 세마글루타이드은 여기서 미국 FDA 의약품 기록으로 신원을 시작하지만, 대한민국에서 같은 제품, 제형, 함량, 허가, 처방 상태 또는 현재 공급이 존재한다는 뜻은 아닙니다. 아래 공식 기록을 이용해 목적지의 구체적인 제품과 판매 주체를 확인하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=south-korea" }, { "recordId": "pl-compound-country-semaglutide-thailand", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Semaglutide / เซมากลูไทด์ ในประเทศไทย", "localizedAnswer": "Semaglutide / เซมากลูไทด์ เริ่มจากบันทึกยาของ FDA สหรัฐฯ แต่ไม่ได้พิสูจน์ว่าผลิตภัณฑ์ รูปแบบ ความแรง การอนุมัติ สถานะใบสั่งยา หรือการจัดหาในประเทศไทยเหมือนกัน ให้ตรวจผลิตภัณฑ์และผู้ขายที่เฉพาะเจาะจงในประเทศปลายทางจากบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=thailand" }, { "recordId": "pl-compound-country-semaglutide-indonesia", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Semaglutide di Indonesia", "localizedAnswer": "Semaglutide dimulai dari identitas obat dalam catatan FDA Amerika Serikat, tetapi hal itu tidak membuktikan produk, bentuk, kekuatan, persetujuan, status resep, atau pasokan yang sama di Indonesia. Gunakan catatan resmi di bawah untuk memeriksa produk dan penjual spesifik di negara tujuan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=indonesia" }, { "recordId": "pl-compound-country-semaglutide-singapore", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Semaglutide in Singapore", "localizedAnswer": "Semaglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Singapore. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=singapore" }, { "recordId": "pl-compound-country-semaglutide-philippines", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Semaglutide in the Philippines", "localizedAnswer": "Semaglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the Philippines. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=philippines" }, { "recordId": "pl-compound-country-semaglutide-malaysia", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Semaglutide in Malaysia", "localizedAnswer": "Semaglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Malaysia. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=malaysia" }, { "recordId": "pl-compound-country-semaglutide-taiwan", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Semaglutide / 司美格魯肽 在台灣的紀錄", "localizedAnswer": "Semaglutide / 司美格魯肽在此從美國 FDA 藥品紀錄確認身分，但這不能證明台灣有相同產品、劑型、含量、適應症、處方狀態或目前供應。請用下方官方紀錄查證目的地的特定產品、許可證、機構和提供者，不能只依名稱或外國核准推論。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=taiwan" }, { "recordId": "pl-compound-country-semaglutide-hong-kong", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Semaglutide / 司美格魯肽 在香港的紀錄", "localizedAnswer": "Semaglutide / 司美格魯肽在此從美國 FDA 藥物紀錄確認身分，但這不能證明香港有相同產品、劑型、含量、適應症、處方狀態或目前供應。請用下方官方紀錄核實指定產品、註冊編號、持牌銷售商和現行狀態，不能只依名稱或外國批准推論。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=hong-kong" }, { "recordId": "pl-compound-country-semaglutide-vietnam", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Semaglutide tại Việt Nam", "localizedAnswer": "Semaglutide bắt đầu ở đây bằng hồ sơ thuốc của FDA Hoa Kỳ, nhưng điều đó không chứng minh có cùng sản phẩm, dạng bào chế, hàm lượng, giấy phép, tình trạng kê đơn hay nguồn cung hiện tại tại Việt Nam. Hãy dùng các hồ sơ bên dưới để xác minh chính xác sản phẩm, người bán, tình trạng và đường cung ứng tại điểm đến.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=vietnam" }, { "recordId": "pl-compound-country-semaglutide-united-states", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved product records in the United States", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Semaglutide in the United States", "localizedAnswer": "WEGOVY is an FDA-approved semaglutide product under NDA 215256. Ozempic and Rybelsus are separate semaglutide products with separate applications, presentations, and labeled uses. The ingredient name alone does not establish which product, indication, dose form, prescription record, pharmacy route, or seller applies, and it does not transfer FDA approval to compounded or unapproved semaglutide.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "National Library of Medicine, DailyMed" ], "statusEvidenceUrls": [ "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=united-states" }, { "recordId": "pl-compound-country-semaglutide-canada", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Authorized brand and generic semaglutide records in Canada", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Semaglutide in Canada", "localizedAnswer": "Health Canada authorized its first generic semaglutide injection referencing Ozempic in April 2026 and its first generic weight-management semaglutide referencing Wegovy in June 2026. Those decisions belong to exact products and indications. The authorization holder, presentation, current market status, prescription route, pharmacy record, and seller still need to match the current Canadian records linked on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 2, "statusEvidencePublishers": [ "Health Canada" ], "statusEvidenceUrls": [ "https://www.canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html", "https://www.canada.ca/fr/sante-canada/nouvelles/2026/06/le-canada-autorise-une-premiere-version-generique-du-semaglutide-destine-a-la-perte-de-poids.html" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=canada" }, { "recordId": "pl-compound-country-semaglutide-united-arab-emirates", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Semaglutide / سيماجلوتايد في الإمارات العربية المتحدة", "localizedAnswer": "تبدأ هوية Semaglutide / سيماجلوتايد هنا من سجل دواء لدى إدارة الغذاء والدواء الأمريكية، لكن ذلك لا يثبت أن المنتج أو الشكل أو التركيز أو الموافقة أو حالة الوصفة أو التوفر الحالي هي نفسها في الإمارات العربية المتحدة. تحقق من المنتج المحلي المحدد والمنشأة والبائع ومسار التوريد من خلال السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=united-arab-emirates" }, { "recordId": "pl-compound-country-semaglutide-saudi-arabia", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Semaglutide / سيماجلوتايد في المملكة العربية السعودية", "localizedAnswer": "تبدأ هوية Semaglutide / سيماجلوتايد هنا من سجل دواء لدى إدارة الغذاء والدواء الأمريكية، لكن ذلك لا يثبت أن المنتج أو الشكل أو التركيز أو الموافقة أو حالة الوصفة أو التوفر الحالي هي نفسها في المملكة العربية السعودية. تحقق من المنتج المحلي المحدد والمنشأة والبائع ومسار التوريد من خلال السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=saudi-arabia" }, { "recordId": "pl-compound-country-semaglutide-south-africa", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Semaglutide in South Africa", "localizedAnswer": "Semaglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in South Africa. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=south-africa" }, { "recordId": "pl-compound-country-semaglutide-nigeria", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Semaglutide in Nigeria", "localizedAnswer": "Semaglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Nigeria. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=nigeria" }, { "recordId": "pl-compound-country-semaglutide-kenya", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Semaglutide in Kenya", "localizedAnswer": "Semaglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Kenya. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/semaglutide", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/semaglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=semaglutide&country=kenya" }, { "recordId": "pl-compound-country-dsip-france", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "DSIP / Emideltide en France", "localizedAnswer": "DSIP / Emideltide est suivi comme identité du marché américain de la recherche, et non comme preuve d’autorisation ou d’approvisionnement local en France. Vérifiez la catégorie exacte, l’identité juridique du vendeur et le circuit revendiqué dans les registres officiels de cette page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=france" }, { "recordId": "pl-compound-country-dsip-united-kingdom", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "DSIP / Emideltide in the United Kingdom", "localizedAnswer": "DSIP / Emideltide is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=united-kingdom" }, { "recordId": "pl-compound-country-dsip-germany", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "DSIP / Emideltide in Deutschland", "localizedAnswer": "DSIP / Emideltide wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=germany" }, { "recordId": "pl-compound-country-dsip-spain", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "DSIP / Emideltide en España", "localizedAnswer": "DSIP / Emideltide se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=spain" }, { "recordId": "pl-compound-country-dsip-italy", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "DSIP / Emideltide in Italia", "localizedAnswer": "DSIP / Emideltide è seguito come identità del mercato di ricerca statunitense, non come prova di autorizzazione o fornitura locale in Italia. Confronta categoria esatta, identità giuridica del venditore e canale dichiarato con i registri ufficiali di questa pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=italy" }, { "recordId": "pl-compound-country-dsip-netherlands", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "DSIP / Emideltide in Nederland", "localizedAnswer": "DSIP / Emideltide wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=netherlands" }, { "recordId": "pl-compound-country-dsip-switzerland", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "DSIP / Emideltide in Switzerland", "localizedAnswer": "DSIP / Emideltide is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=switzerland" }, { "recordId": "pl-compound-country-dsip-poland", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "DSIP / Emideltide w Polsce", "localizedAnswer": "DSIP / Emideltide jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=poland" }, { "recordId": "pl-compound-country-dsip-ireland", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "DSIP / Emideltide in Ireland", "localizedAnswer": "DSIP / Emideltide is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=ireland" }, { "recordId": "pl-compound-country-dsip-portugal", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "DSIP / Emideltide em Portugal", "localizedAnswer": "DSIP / Emideltide é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=portugal" }, { "recordId": "pl-compound-country-dsip-sweden", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "DSIP / Emideltide i Sverige", "localizedAnswer": "DSIP / Emideltide följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=sweden" }, { "recordId": "pl-compound-country-dsip-turkey", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için DSIP / Emideltide", "localizedAnswer": "DSIP / Emideltide, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=turkey" }, { "recordId": "pl-compound-country-dsip-austria", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "DSIP / Emideltide in Österreich", "localizedAnswer": "DSIP / Emideltide wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=austria" }, { "recordId": "pl-compound-country-dsip-belgium", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "DSIP / Emideltide in België", "localizedAnswer": "DSIP / Emideltide wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=belgium" }, { "recordId": "pl-compound-country-dsip-denmark", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "DSIP / Emideltide i Danmark", "localizedAnswer": "DSIP / Emideltide følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=denmark" }, { "recordId": "pl-compound-country-dsip-finland", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "DSIP / Emideltide kohteessa Suomi", "localizedAnswer": "DSIP / Emideltide seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=finland" }, { "recordId": "pl-compound-country-dsip-mexico", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "DSIP / Emideltide en México", "localizedAnswer": "DSIP / Emideltide se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=mexico" }, { "recordId": "pl-compound-country-dsip-argentina", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "DSIP / Emideltide en Argentina", "localizedAnswer": "DSIP / Emideltide se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=argentina" }, { "recordId": "pl-compound-country-dsip-colombia", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "DSIP / Emideltide en Colombia", "localizedAnswer": "DSIP / Emideltide se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=colombia" }, { "recordId": "pl-compound-country-dsip-chile", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "DSIP / Emideltide en Chile", "localizedAnswer": "DSIP / Emideltide se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Chile. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=chile" }, { "recordId": "pl-compound-country-dsip-brazil", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "DSIP / Emideltide no Brasil", "localizedAnswer": "DSIP / Emideltide é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=brazil" }, { "recordId": "pl-compound-country-dsip-china", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "DSIP / Emideltide 在中国的状态与官方记录", "localizedAnswer": "DSIP / Emideltide在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=china" }, { "recordId": "pl-compound-country-dsip-australia", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "DSIP / Emideltide in Australia", "localizedAnswer": "DSIP / Emideltide is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=australia" }, { "recordId": "pl-compound-country-dsip-new-zealand", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "DSIP / Emideltide in New Zealand", "localizedAnswer": "DSIP / Emideltide is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=new-zealand" }, { "recordId": "pl-compound-country-dsip-india", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "DSIP / Emideltide in India", "localizedAnswer": "DSIP / Emideltide is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=india" }, { "recordId": "pl-compound-country-dsip-japan", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のDSIP / Emideltide", "localizedAnswer": "DSIP / Emideltideは米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=japan" }, { "recordId": "pl-compound-country-dsip-south-korea", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 DSIP / Emideltide", "localizedAnswer": "DSIP / Emideltide은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=south-korea" }, { "recordId": "pl-compound-country-dsip-thailand", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "DSIP / Emideltide ในประเทศไทย", "localizedAnswer": "DSIP / Emideltide ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=thailand" }, { "recordId": "pl-compound-country-dsip-indonesia", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "DSIP / Emideltide di Indonesia", "localizedAnswer": "DSIP / Emideltide dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=indonesia" }, { "recordId": "pl-compound-country-dsip-singapore", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "DSIP / Emideltide in Singapore", "localizedAnswer": "DSIP / Emideltide is tracked as a US research-market identity, not as an authorization or local supply finding for Singapore. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=singapore" }, { "recordId": "pl-compound-country-dsip-philippines", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "DSIP / Emideltide in the Philippines", "localizedAnswer": "DSIP / Emideltide is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=philippines" }, { "recordId": "pl-compound-country-dsip-malaysia", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "DSIP / Emideltide in Malaysia", "localizedAnswer": "DSIP / Emideltide is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=malaysia" }, { "recordId": "pl-compound-country-dsip-taiwan", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "DSIP / Emideltide 在台灣的紀錄", "localizedAnswer": "DSIP / Emideltide在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=taiwan" }, { "recordId": "pl-compound-country-dsip-hong-kong", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "DSIP / Emideltide 在香港的紀錄", "localizedAnswer": "DSIP / Emideltide在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=hong-kong" }, { "recordId": "pl-compound-country-dsip-vietnam", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "DSIP / Emideltide tại Việt Nam", "localizedAnswer": "DSIP / Emideltide được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=vietnam" }, { "recordId": "pl-compound-country-dsip-united-states", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "DSIP / Emideltide in the United States", "localizedAnswer": "DSIP / Emideltide is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=united-states" }, { "recordId": "pl-compound-country-dsip-canada", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "DSIP / Emideltide in Canada", "localizedAnswer": "DSIP / Emideltide is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=canada" }, { "recordId": "pl-compound-country-dsip-united-arab-emirates", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "DSIP / Emideltide في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع DSIP / Emideltide هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=united-arab-emirates" }, { "recordId": "pl-compound-country-dsip-saudi-arabia", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "DSIP / Emideltide في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع DSIP / Emideltide هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=saudi-arabia" }, { "recordId": "pl-compound-country-dsip-south-africa", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "DSIP / Emideltide in South Africa", "localizedAnswer": "DSIP / Emideltide is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=south-africa" }, { "recordId": "pl-compound-country-dsip-nigeria", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "DSIP / Emideltide in Nigeria", "localizedAnswer": "DSIP / Emideltide is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=nigeria" }, { "recordId": "pl-compound-country-dsip-kenya", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "DSIP / Emideltide in Kenya", "localizedAnswer": "DSIP / Emideltide is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/dsip", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/dsip/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=dsip&country=kenya" }, { "recordId": "pl-compound-country-igf-1-lr3-france", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "IGF-1 LR3 en France", "localizedAnswer": "IGF-1 LR3 est suivi comme identité du marché américain de la recherche, et non comme preuve d’autorisation ou d’approvisionnement local en France. Vérifiez la catégorie exacte, l’identité juridique du vendeur et le circuit revendiqué dans les registres officiels de cette page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=france" }, { "recordId": "pl-compound-country-igf-1-lr3-united-kingdom", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "IGF-1 LR3 in the United Kingdom", "localizedAnswer": "IGF-1 LR3 is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=united-kingdom" }, { "recordId": "pl-compound-country-igf-1-lr3-germany", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "IGF-1 LR3 in Deutschland", "localizedAnswer": "IGF-1 LR3 wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=germany" }, { "recordId": "pl-compound-country-igf-1-lr3-spain", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "IGF-1 LR3 en España", "localizedAnswer": "IGF-1 LR3 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=spain" }, { "recordId": "pl-compound-country-igf-1-lr3-italy", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "IGF-1 LR3 in Italia", "localizedAnswer": "IGF-1 LR3 è seguito come identità del mercato di ricerca statunitense, non come prova di autorizzazione o fornitura locale in Italia. Confronta categoria esatta, identità giuridica del venditore e canale dichiarato con i registri ufficiali di questa pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=italy" }, { "recordId": "pl-compound-country-igf-1-lr3-netherlands", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "IGF-1 LR3 in Nederland", "localizedAnswer": "IGF-1 LR3 wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=netherlands" }, { "recordId": "pl-compound-country-igf-1-lr3-switzerland", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "IGF-1 LR3 in Switzerland", "localizedAnswer": "IGF-1 LR3 is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=switzerland" }, { "recordId": "pl-compound-country-igf-1-lr3-poland", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "IGF-1 LR3 w Polsce", "localizedAnswer": "IGF-1 LR3 jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=poland" }, { "recordId": "pl-compound-country-igf-1-lr3-ireland", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "IGF-1 LR3 in Ireland", "localizedAnswer": "IGF-1 LR3 is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=ireland" }, { "recordId": "pl-compound-country-igf-1-lr3-portugal", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "IGF-1 LR3 em Portugal", "localizedAnswer": "IGF-1 LR3 é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=portugal" }, { "recordId": "pl-compound-country-igf-1-lr3-sweden", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "IGF-1 LR3 i Sverige", "localizedAnswer": "IGF-1 LR3 följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=sweden" }, { "recordId": "pl-compound-country-igf-1-lr3-turkey", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için IGF-1 LR3", "localizedAnswer": "IGF-1 LR3, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=turkey" }, { "recordId": "pl-compound-country-igf-1-lr3-austria", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "IGF-1 LR3 in Österreich", "localizedAnswer": "IGF-1 LR3 wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=austria" }, { "recordId": "pl-compound-country-igf-1-lr3-belgium", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "IGF-1 LR3 in België", "localizedAnswer": "IGF-1 LR3 wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=belgium" }, { "recordId": "pl-compound-country-igf-1-lr3-denmark", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "IGF-1 LR3 i Danmark", "localizedAnswer": "IGF-1 LR3 følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=denmark" }, { "recordId": "pl-compound-country-igf-1-lr3-finland", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "IGF-1 LR3 kohteessa Suomi", "localizedAnswer": "IGF-1 LR3 seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=finland" }, { "recordId": "pl-compound-country-igf-1-lr3-mexico", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "IGF-1 LR3 en México", "localizedAnswer": "IGF-1 LR3 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=mexico" }, { "recordId": "pl-compound-country-igf-1-lr3-argentina", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "IGF-1 LR3 en Argentina", "localizedAnswer": "IGF-1 LR3 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=argentina" }, { "recordId": "pl-compound-country-igf-1-lr3-colombia", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "IGF-1 LR3 en Colombia", "localizedAnswer": "IGF-1 LR3 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=colombia" }, { "recordId": "pl-compound-country-igf-1-lr3-chile", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "IGF-1 LR3 en Chile", "localizedAnswer": "IGF-1 LR3 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Chile. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=chile" }, { "recordId": "pl-compound-country-igf-1-lr3-brazil", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "IGF-1 LR3 no Brasil", "localizedAnswer": "IGF-1 LR3 é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=brazil" }, { "recordId": "pl-compound-country-igf-1-lr3-china", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "IGF-1 LR3 在中国的状态与官方记录", "localizedAnswer": "IGF-1 LR3在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=china" }, { "recordId": "pl-compound-country-igf-1-lr3-australia", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "IGF-1 LR3 in Australia", "localizedAnswer": "IGF-1 LR3 is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=australia" }, { "recordId": "pl-compound-country-igf-1-lr3-new-zealand", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "IGF-1 LR3 in New Zealand", "localizedAnswer": "IGF-1 LR3 is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=new-zealand" }, { "recordId": "pl-compound-country-igf-1-lr3-india", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "IGF-1 LR3 in India", "localizedAnswer": "IGF-1 LR3 is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=india" }, { "recordId": "pl-compound-country-igf-1-lr3-japan", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のIGF-1 LR3", "localizedAnswer": "IGF-1 LR3は米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=japan" }, { "recordId": "pl-compound-country-igf-1-lr3-south-korea", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 IGF-1 LR3", "localizedAnswer": "IGF-1 LR3은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=south-korea" }, { "recordId": "pl-compound-country-igf-1-lr3-thailand", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "IGF-1 LR3 ในประเทศไทย", "localizedAnswer": "IGF-1 LR3 ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=thailand" }, { "recordId": "pl-compound-country-igf-1-lr3-indonesia", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "IGF-1 LR3 di Indonesia", "localizedAnswer": "IGF-1 LR3 dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=indonesia" }, { "recordId": "pl-compound-country-igf-1-lr3-singapore", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "IGF-1 LR3 in Singapore", "localizedAnswer": "IGF-1 LR3 is tracked as a US research-market identity, not as an authorization or local supply finding for Singapore. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=singapore" }, { "recordId": "pl-compound-country-igf-1-lr3-philippines", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "IGF-1 LR3 in the Philippines", "localizedAnswer": "IGF-1 LR3 is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=philippines" }, { "recordId": "pl-compound-country-igf-1-lr3-malaysia", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "IGF-1 LR3 in Malaysia", "localizedAnswer": "IGF-1 LR3 is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=malaysia" }, { "recordId": "pl-compound-country-igf-1-lr3-taiwan", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "IGF-1 LR3 在台灣的紀錄", "localizedAnswer": "IGF-1 LR3在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=taiwan" }, { "recordId": "pl-compound-country-igf-1-lr3-hong-kong", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "IGF-1 LR3 在香港的紀錄", "localizedAnswer": "IGF-1 LR3在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=hong-kong" }, { "recordId": "pl-compound-country-igf-1-lr3-vietnam", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "IGF-1 LR3 tại Việt Nam", "localizedAnswer": "IGF-1 LR3 được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=vietnam" }, { "recordId": "pl-compound-country-igf-1-lr3-united-states", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "IGF-1 LR3 in the United States", "localizedAnswer": "IGF-1 LR3 is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=united-states" }, { "recordId": "pl-compound-country-igf-1-lr3-canada", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "IGF-1 LR3 in Canada", "localizedAnswer": "IGF-1 LR3 is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=canada" }, { "recordId": "pl-compound-country-igf-1-lr3-united-arab-emirates", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "IGF-1 LR3 في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع IGF-1 LR3 هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=united-arab-emirates" }, { "recordId": "pl-compound-country-igf-1-lr3-saudi-arabia", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "IGF-1 LR3 في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع IGF-1 LR3 هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=saudi-arabia" }, { "recordId": "pl-compound-country-igf-1-lr3-south-africa", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "IGF-1 LR3 in South Africa", "localizedAnswer": "IGF-1 LR3 is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=south-africa" }, { "recordId": "pl-compound-country-igf-1-lr3-nigeria", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "IGF-1 LR3 in Nigeria", "localizedAnswer": "IGF-1 LR3 is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=nigeria" }, { "recordId": "pl-compound-country-igf-1-lr3-kenya", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "IGF-1 LR3 in Kenya", "localizedAnswer": "IGF-1 LR3 is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/igf-1-lr3", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=igf-1-lr3&country=kenya" }, { "recordId": "pl-compound-country-kisspeptin-10-france", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Kisspeptin-10 / KP-10 en France", "localizedAnswer": "Kisspeptin-10 / KP-10 est suivi comme identité du marché américain de la recherche, et non comme preuve d’autorisation ou d’approvisionnement local en France. Vérifiez la catégorie exacte, l’identité juridique du vendeur et le circuit revendiqué dans les registres officiels de cette page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=france" }, { "recordId": "pl-compound-country-kisspeptin-10-united-kingdom", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Kisspeptin-10 / KP-10 in the United Kingdom", "localizedAnswer": "Kisspeptin-10 / KP-10 is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=united-kingdom" }, { "recordId": "pl-compound-country-kisspeptin-10-germany", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Kisspeptin-10 / KP-10 in Deutschland", "localizedAnswer": "Kisspeptin-10 / KP-10 wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=germany" }, { "recordId": "pl-compound-country-kisspeptin-10-spain", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Kisspeptin-10 / KP-10 en España", "localizedAnswer": "Kisspeptin-10 / KP-10 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=spain" }, { "recordId": "pl-compound-country-kisspeptin-10-italy", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Kisspeptin-10 / KP-10 in Italia", "localizedAnswer": "Kisspeptin-10 / KP-10 è seguito come identità del mercato di ricerca statunitense, non come prova di autorizzazione o fornitura locale in Italia. Confronta categoria esatta, identità giuridica del venditore e canale dichiarato con i registri ufficiali di questa pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=italy" }, { "recordId": "pl-compound-country-kisspeptin-10-netherlands", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Kisspeptin-10 / KP-10 in Nederland", "localizedAnswer": "Kisspeptin-10 / KP-10 wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=netherlands" }, { "recordId": "pl-compound-country-kisspeptin-10-switzerland", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Kisspeptin-10 / KP-10 in Switzerland", "localizedAnswer": "Kisspeptin-10 / KP-10 is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=switzerland" }, { "recordId": "pl-compound-country-kisspeptin-10-poland", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Kisspeptin-10 / KP-10 w Polsce", "localizedAnswer": "Kisspeptin-10 / KP-10 jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=poland" }, { "recordId": "pl-compound-country-kisspeptin-10-ireland", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Kisspeptin-10 / KP-10 in Ireland", "localizedAnswer": "Kisspeptin-10 / KP-10 is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=ireland" }, { "recordId": "pl-compound-country-kisspeptin-10-portugal", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Kisspeptin-10 / KP-10 em Portugal", "localizedAnswer": "Kisspeptin-10 / KP-10 é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=portugal" }, { "recordId": "pl-compound-country-kisspeptin-10-sweden", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Kisspeptin-10 / KP-10 i Sverige", "localizedAnswer": "Kisspeptin-10 / KP-10 följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=sweden" }, { "recordId": "pl-compound-country-kisspeptin-10-turkey", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Kisspeptin-10 / KP-10", "localizedAnswer": "Kisspeptin-10 / KP-10, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=turkey" }, { "recordId": "pl-compound-country-kisspeptin-10-austria", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Kisspeptin-10 / KP-10 in Österreich", "localizedAnswer": "Kisspeptin-10 / KP-10 wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=austria" }, { "recordId": "pl-compound-country-kisspeptin-10-belgium", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Kisspeptin-10 / KP-10 in België", "localizedAnswer": "Kisspeptin-10 / KP-10 wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=belgium" }, { "recordId": "pl-compound-country-kisspeptin-10-denmark", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Kisspeptin-10 / KP-10 i Danmark", "localizedAnswer": "Kisspeptin-10 / KP-10 følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=denmark" }, { "recordId": "pl-compound-country-kisspeptin-10-finland", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Kisspeptin-10 / KP-10 kohteessa Suomi", "localizedAnswer": "Kisspeptin-10 / KP-10 seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=finland" }, { "recordId": "pl-compound-country-kisspeptin-10-mexico", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Kisspeptin-10 / KP-10 en México", "localizedAnswer": "Kisspeptin-10 / KP-10 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=mexico" }, { "recordId": "pl-compound-country-kisspeptin-10-argentina", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Kisspeptin-10 / KP-10 en Argentina", "localizedAnswer": "Kisspeptin-10 / KP-10 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=argentina" }, { "recordId": "pl-compound-country-kisspeptin-10-colombia", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Kisspeptin-10 / KP-10 en Colombia", "localizedAnswer": "Kisspeptin-10 / KP-10 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=colombia" }, { "recordId": "pl-compound-country-kisspeptin-10-chile", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Kisspeptin-10 / KP-10 en Chile", "localizedAnswer": "Kisspeptin-10 / KP-10 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Chile. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=chile" }, { "recordId": "pl-compound-country-kisspeptin-10-brazil", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Kisspeptin-10 / KP-10 no Brasil", "localizedAnswer": "Kisspeptin-10 / KP-10 é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=brazil" }, { "recordId": "pl-compound-country-kisspeptin-10-china", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Kisspeptin-10 / KP-10 在中国的状态与官方记录", "localizedAnswer": "Kisspeptin-10 / KP-10在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=china" }, { "recordId": "pl-compound-country-kisspeptin-10-australia", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Kisspeptin-10 / KP-10 in Australia", "localizedAnswer": "Kisspeptin-10 / KP-10 is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=australia" }, { "recordId": "pl-compound-country-kisspeptin-10-new-zealand", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Kisspeptin-10 / KP-10 in New Zealand", "localizedAnswer": "Kisspeptin-10 / KP-10 is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=new-zealand" }, { "recordId": "pl-compound-country-kisspeptin-10-india", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Kisspeptin-10 / KP-10 in India", "localizedAnswer": "Kisspeptin-10 / KP-10 is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=india" }, { "recordId": "pl-compound-country-kisspeptin-10-japan", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のKisspeptin-10 / KP-10", "localizedAnswer": "Kisspeptin-10 / KP-10は米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=japan" }, { "recordId": "pl-compound-country-kisspeptin-10-south-korea", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Kisspeptin-10 / KP-10", "localizedAnswer": "Kisspeptin-10 / KP-10은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=south-korea" }, { "recordId": "pl-compound-country-kisspeptin-10-thailand", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Kisspeptin-10 / KP-10 ในประเทศไทย", "localizedAnswer": "Kisspeptin-10 / KP-10 ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=thailand" }, { "recordId": "pl-compound-country-kisspeptin-10-indonesia", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Kisspeptin-10 / KP-10 di Indonesia", "localizedAnswer": "Kisspeptin-10 / KP-10 dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=indonesia" }, { "recordId": "pl-compound-country-kisspeptin-10-singapore", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Kisspeptin-10 / KP-10 in Singapore", "localizedAnswer": "Kisspeptin-10 / KP-10 is tracked as a US research-market identity, not as an authorization or local supply finding for Singapore. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=singapore" }, { "recordId": "pl-compound-country-kisspeptin-10-philippines", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Kisspeptin-10 / KP-10 in the Philippines", "localizedAnswer": "Kisspeptin-10 / KP-10 is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=philippines" }, { "recordId": "pl-compound-country-kisspeptin-10-malaysia", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Kisspeptin-10 / KP-10 in Malaysia", "localizedAnswer": "Kisspeptin-10 / KP-10 is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=malaysia" }, { "recordId": "pl-compound-country-kisspeptin-10-taiwan", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Kisspeptin-10 / KP-10 在台灣的紀錄", "localizedAnswer": "Kisspeptin-10 / KP-10在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=taiwan" }, { "recordId": "pl-compound-country-kisspeptin-10-hong-kong", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Kisspeptin-10 / KP-10 在香港的紀錄", "localizedAnswer": "Kisspeptin-10 / KP-10在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=hong-kong" }, { "recordId": "pl-compound-country-kisspeptin-10-vietnam", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Kisspeptin-10 / KP-10 tại Việt Nam", "localizedAnswer": "Kisspeptin-10 / KP-10 được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=vietnam" }, { "recordId": "pl-compound-country-kisspeptin-10-united-states", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Kisspeptin-10 / KP-10 in the United States", "localizedAnswer": "Kisspeptin-10 / KP-10 is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=united-states" }, { "recordId": "pl-compound-country-kisspeptin-10-canada", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Kisspeptin-10 / KP-10 in Canada", "localizedAnswer": "Kisspeptin-10 / KP-10 is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=canada" }, { "recordId": "pl-compound-country-kisspeptin-10-united-arab-emirates", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Kisspeptin-10 / KP-10 في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع Kisspeptin-10 / KP-10 هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=united-arab-emirates" }, { "recordId": "pl-compound-country-kisspeptin-10-saudi-arabia", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Kisspeptin-10 / KP-10 في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع Kisspeptin-10 / KP-10 هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=saudi-arabia" }, { "recordId": "pl-compound-country-kisspeptin-10-south-africa", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Kisspeptin-10 / KP-10 in South Africa", "localizedAnswer": "Kisspeptin-10 / KP-10 is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=south-africa" }, { "recordId": "pl-compound-country-kisspeptin-10-nigeria", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Kisspeptin-10 / KP-10 in Nigeria", "localizedAnswer": "Kisspeptin-10 / KP-10 is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=nigeria" }, { "recordId": "pl-compound-country-kisspeptin-10-kenya", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Kisspeptin-10 / KP-10 in Kenya", "localizedAnswer": "Kisspeptin-10 / KP-10 is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/kisspeptin-10", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=kisspeptin-10&country=kenya" }, { "recordId": "pl-compound-country-melanotan-i-france", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Melanotan I en France", "localizedAnswer": "Melanotan I est suivi comme identité du marché américain de la recherche, et non comme preuve d’autorisation ou d’approvisionnement local en France. Vérifiez la catégorie exacte, l’identité juridique du vendeur et le circuit revendiqué dans les registres officiels de cette page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=france" }, { "recordId": "pl-compound-country-melanotan-i-united-kingdom", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Melanotan I in the United Kingdom", "localizedAnswer": "Melanotan I is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=united-kingdom" }, { "recordId": "pl-compound-country-melanotan-i-germany", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Melanotan I in Deutschland", "localizedAnswer": "Melanotan I wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=germany" }, { "recordId": "pl-compound-country-melanotan-i-spain", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Melanotan I en España", "localizedAnswer": "Melanotan I se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=spain" }, { "recordId": "pl-compound-country-melanotan-i-italy", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Melanotan I in Italia", "localizedAnswer": "Melanotan I è seguito come identità del mercato di ricerca statunitense, non come prova di autorizzazione o fornitura locale in Italia. Confronta categoria esatta, identità giuridica del venditore e canale dichiarato con i registri ufficiali di questa pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=italy" }, { "recordId": "pl-compound-country-melanotan-i-netherlands", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Melanotan I in Nederland", "localizedAnswer": "Melanotan I wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=netherlands" }, { "recordId": "pl-compound-country-melanotan-i-switzerland", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Melanotan I in Switzerland", "localizedAnswer": "Melanotan I is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=switzerland" }, { "recordId": "pl-compound-country-melanotan-i-poland", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Melanotan I w Polsce", "localizedAnswer": "Melanotan I jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=poland" }, { "recordId": "pl-compound-country-melanotan-i-ireland", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Melanotan I in Ireland", "localizedAnswer": "Melanotan I is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=ireland" }, { "recordId": "pl-compound-country-melanotan-i-portugal", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Melanotan I em Portugal", "localizedAnswer": "Melanotan I é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=portugal" }, { "recordId": "pl-compound-country-melanotan-i-sweden", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Melanotan I i Sverige", "localizedAnswer": "Melanotan I följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=sweden" }, { "recordId": "pl-compound-country-melanotan-i-turkey", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Melanotan I", "localizedAnswer": "Melanotan I, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=turkey" }, { "recordId": "pl-compound-country-melanotan-i-austria", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Melanotan I in Österreich", "localizedAnswer": "Melanotan I wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=austria" }, { "recordId": "pl-compound-country-melanotan-i-belgium", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Melanotan I in België", "localizedAnswer": "Melanotan I wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=belgium" }, { "recordId": "pl-compound-country-melanotan-i-denmark", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Melanotan I i Danmark", "localizedAnswer": "Melanotan I følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=denmark" }, { "recordId": "pl-compound-country-melanotan-i-finland", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Melanotan I kohteessa Suomi", "localizedAnswer": "Melanotan I seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=finland" }, { "recordId": "pl-compound-country-melanotan-i-mexico", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Melanotan I en México", "localizedAnswer": "Melanotan I se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=mexico" }, { "recordId": "pl-compound-country-melanotan-i-argentina", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Melanotan I en Argentina", "localizedAnswer": "Melanotan I se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=argentina" }, { "recordId": "pl-compound-country-melanotan-i-colombia", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Melanotan I en Colombia", "localizedAnswer": "Melanotan I se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=colombia" }, { "recordId": "pl-compound-country-melanotan-i-chile", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Melanotan I en Chile", "localizedAnswer": "Melanotan I se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Chile. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=chile" }, { "recordId": "pl-compound-country-melanotan-i-brazil", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Melanotan I no Brasil", "localizedAnswer": "Melanotan I é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=brazil" }, { "recordId": "pl-compound-country-melanotan-i-china", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Melanotan I 在中国的状态与官方记录", "localizedAnswer": "Melanotan I在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=china" }, { "recordId": "pl-compound-country-melanotan-i-australia", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Melanotan I in Australia", "localizedAnswer": "Melanotan I is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=australia" }, { "recordId": "pl-compound-country-melanotan-i-new-zealand", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Melanotan I in New Zealand", "localizedAnswer": "Melanotan I is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=new-zealand" }, { "recordId": "pl-compound-country-melanotan-i-india", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Melanotan I in India", "localizedAnswer": "Melanotan I is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=india" }, { "recordId": "pl-compound-country-melanotan-i-japan", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のMelanotan I", "localizedAnswer": "Melanotan Iは米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=japan" }, { "recordId": "pl-compound-country-melanotan-i-south-korea", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Melanotan I", "localizedAnswer": "Melanotan I은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=south-korea" }, { "recordId": "pl-compound-country-melanotan-i-thailand", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Melanotan I ในประเทศไทย", "localizedAnswer": "Melanotan I ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=thailand" }, { "recordId": "pl-compound-country-melanotan-i-indonesia", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Melanotan I di Indonesia", "localizedAnswer": "Melanotan I dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=indonesia" }, { "recordId": "pl-compound-country-melanotan-i-singapore", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Melanotan I in Singapore", "localizedAnswer": "Melanotan I is tracked as a US research-market identity, not as an authorization or local supply finding for Singapore. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=singapore" }, { "recordId": "pl-compound-country-melanotan-i-philippines", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Melanotan I in the Philippines", "localizedAnswer": "Melanotan I is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=philippines" }, { "recordId": "pl-compound-country-melanotan-i-malaysia", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Melanotan I in Malaysia", "localizedAnswer": "Melanotan I is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=malaysia" }, { "recordId": "pl-compound-country-melanotan-i-taiwan", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Melanotan I 在台灣的紀錄", "localizedAnswer": "Melanotan I在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=taiwan" }, { "recordId": "pl-compound-country-melanotan-i-hong-kong", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Melanotan I 在香港的紀錄", "localizedAnswer": "Melanotan I在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=hong-kong" }, { "recordId": "pl-compound-country-melanotan-i-vietnam", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Melanotan I tại Việt Nam", "localizedAnswer": "Melanotan I được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=vietnam" }, { "recordId": "pl-compound-country-melanotan-i-united-states", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Melanotan I in the United States", "localizedAnswer": "Melanotan I is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=united-states" }, { "recordId": "pl-compound-country-melanotan-i-canada", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Melanotan I in Canada", "localizedAnswer": "Melanotan I is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=canada" }, { "recordId": "pl-compound-country-melanotan-i-united-arab-emirates", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Melanotan I في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع Melanotan I هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=united-arab-emirates" }, { "recordId": "pl-compound-country-melanotan-i-saudi-arabia", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Melanotan I في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع Melanotan I هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=saudi-arabia" }, { "recordId": "pl-compound-country-melanotan-i-south-africa", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Melanotan I in South Africa", "localizedAnswer": "Melanotan I is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=south-africa" }, { "recordId": "pl-compound-country-melanotan-i-nigeria", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Melanotan I in Nigeria", "localizedAnswer": "Melanotan I is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=nigeria" }, { "recordId": "pl-compound-country-melanotan-i-kenya", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Melanotan I in Kenya", "localizedAnswer": "Melanotan I is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/melanotan-i", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/melanotan-i/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=melanotan-i&country=kenya" }, { "recordId": "pl-compound-country-nad-plus-france", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "NAD+ en France", "localizedAnswer": "NAD+ est suivi comme identité du marché américain de la recherche, et non comme preuve d’autorisation ou d’approvisionnement local en France. Vérifiez la catégorie exacte, l’identité juridique du vendeur et le circuit revendiqué dans les registres officiels de cette page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=france" }, { "recordId": "pl-compound-country-nad-plus-united-kingdom", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "NAD+ in the United Kingdom", "localizedAnswer": "NAD+ is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=united-kingdom" }, { "recordId": "pl-compound-country-nad-plus-germany", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "NAD+ in Deutschland", "localizedAnswer": "NAD+ wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=germany" }, { "recordId": "pl-compound-country-nad-plus-spain", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "NAD+ en España", "localizedAnswer": "NAD+ se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=spain" }, { "recordId": "pl-compound-country-nad-plus-italy", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "NAD+ in Italia", "localizedAnswer": "NAD+ è seguito come identità del mercato di ricerca statunitense, non come prova di autorizzazione o fornitura locale in Italia. Confronta categoria esatta, identità giuridica del venditore e canale dichiarato con i registri ufficiali di questa pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=italy" }, { "recordId": "pl-compound-country-nad-plus-netherlands", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "NAD+ in Nederland", "localizedAnswer": "NAD+ wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=netherlands" }, { "recordId": "pl-compound-country-nad-plus-switzerland", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "NAD+ in Switzerland", "localizedAnswer": "NAD+ is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=switzerland" }, { "recordId": "pl-compound-country-nad-plus-poland", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "NAD+ w Polsce", "localizedAnswer": "NAD+ jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=poland" }, { "recordId": "pl-compound-country-nad-plus-ireland", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "NAD+ in Ireland", "localizedAnswer": "NAD+ is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=ireland" }, { "recordId": "pl-compound-country-nad-plus-portugal", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "NAD+ em Portugal", "localizedAnswer": "NAD+ é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=portugal" }, { "recordId": "pl-compound-country-nad-plus-sweden", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "NAD+ i Sverige", "localizedAnswer": "NAD+ följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=sweden" }, { "recordId": "pl-compound-country-nad-plus-turkey", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için NAD+", "localizedAnswer": "NAD+, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=turkey" }, { "recordId": "pl-compound-country-nad-plus-austria", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "NAD+ in Österreich", "localizedAnswer": "NAD+ wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=austria" }, { "recordId": "pl-compound-country-nad-plus-belgium", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "NAD+ in België", "localizedAnswer": "NAD+ wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=belgium" }, { "recordId": "pl-compound-country-nad-plus-denmark", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "NAD+ i Danmark", "localizedAnswer": "NAD+ følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=denmark" }, { "recordId": "pl-compound-country-nad-plus-finland", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "NAD+ kohteessa Suomi", "localizedAnswer": "NAD+ seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=finland" }, { "recordId": "pl-compound-country-nad-plus-mexico", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "NAD+ en México", "localizedAnswer": "NAD+ se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=mexico" }, { "recordId": "pl-compound-country-nad-plus-argentina", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "NAD+ en Argentina", "localizedAnswer": "NAD+ se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=argentina" }, { "recordId": "pl-compound-country-nad-plus-colombia", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "NAD+ en Colombia", "localizedAnswer": "NAD+ se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=colombia" }, { "recordId": "pl-compound-country-nad-plus-chile", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "NAD+ en Chile", "localizedAnswer": "NAD+ se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Chile. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=chile" }, { "recordId": "pl-compound-country-nad-plus-brazil", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "NAD+ no Brasil", "localizedAnswer": "NAD+ é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=brazil" }, { "recordId": "pl-compound-country-nad-plus-china", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "NAD+ 在中国的状态与官方记录", "localizedAnswer": "NAD+在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=china" }, { "recordId": "pl-compound-country-nad-plus-australia", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "NAD+ in Australia", "localizedAnswer": "NAD+ is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=australia" }, { "recordId": "pl-compound-country-nad-plus-new-zealand", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "NAD+ in New Zealand", "localizedAnswer": "NAD+ is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=new-zealand" }, { "recordId": "pl-compound-country-nad-plus-india", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "NAD+ in India", "localizedAnswer": "NAD+ is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=india" }, { "recordId": "pl-compound-country-nad-plus-japan", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のNAD+", "localizedAnswer": "NAD+は米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=japan" }, { "recordId": "pl-compound-country-nad-plus-south-korea", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 NAD+", "localizedAnswer": "NAD+은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=south-korea" }, { "recordId": "pl-compound-country-nad-plus-thailand", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "NAD+ ในประเทศไทย", "localizedAnswer": "NAD+ ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=thailand" }, { "recordId": "pl-compound-country-nad-plus-indonesia", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "NAD+ di Indonesia", "localizedAnswer": "NAD+ dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=indonesia" }, { "recordId": "pl-compound-country-nad-plus-singapore", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "NAD+ in Singapore", "localizedAnswer": "NAD+ is tracked as a US research-market identity, not as an authorization or local supply finding for Singapore. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=singapore" }, { "recordId": "pl-compound-country-nad-plus-philippines", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "NAD+ in the Philippines", "localizedAnswer": "NAD+ is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=philippines" }, { "recordId": "pl-compound-country-nad-plus-malaysia", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "NAD+ in Malaysia", "localizedAnswer": "NAD+ is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=malaysia" }, { "recordId": "pl-compound-country-nad-plus-taiwan", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "NAD+ 在台灣的紀錄", "localizedAnswer": "NAD+在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=taiwan" }, { "recordId": "pl-compound-country-nad-plus-hong-kong", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "NAD+ 在香港的紀錄", "localizedAnswer": "NAD+在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=hong-kong" }, { "recordId": "pl-compound-country-nad-plus-vietnam", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "NAD+ tại Việt Nam", "localizedAnswer": "NAD+ được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=vietnam" }, { "recordId": "pl-compound-country-nad-plus-united-states", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "NAD+ in the United States", "localizedAnswer": "NAD+ is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=united-states" }, { "recordId": "pl-compound-country-nad-plus-canada", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "NAD+ in Canada", "localizedAnswer": "NAD+ is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=canada" }, { "recordId": "pl-compound-country-nad-plus-united-arab-emirates", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "NAD+ في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع NAD+ هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=united-arab-emirates" }, { "recordId": "pl-compound-country-nad-plus-saudi-arabia", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "NAD+ في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع NAD+ هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=saudi-arabia" }, { "recordId": "pl-compound-country-nad-plus-south-africa", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "NAD+ in South Africa", "localizedAnswer": "NAD+ is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=south-africa" }, { "recordId": "pl-compound-country-nad-plus-nigeria", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "NAD+ in Nigeria", "localizedAnswer": "NAD+ is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=nigeria" }, { "recordId": "pl-compound-country-nad-plus-kenya", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "NAD+ in Kenya", "localizedAnswer": "NAD+ is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/nad-plus", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/nad-plus/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=nad-plus&country=kenya" }, { "recordId": "pl-compound-country-sermorelin-france", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Sermorelin en France", "localizedAnswer": "Sermorelin est suivi comme identité du marché américain de la recherche, et non comme preuve d’autorisation ou d’approvisionnement local en France. Vérifiez la catégorie exacte, l’identité juridique du vendeur et le circuit revendiqué dans les registres officiels de cette page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=france" }, { "recordId": "pl-compound-country-sermorelin-united-kingdom", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Sermorelin in the United Kingdom", "localizedAnswer": "Sermorelin is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=united-kingdom" }, { "recordId": "pl-compound-country-sermorelin-germany", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Sermorelin in Deutschland", "localizedAnswer": "Sermorelin wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=germany" }, { "recordId": "pl-compound-country-sermorelin-spain", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Sermorelin en España", "localizedAnswer": "Sermorelin se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=spain" }, { "recordId": "pl-compound-country-sermorelin-italy", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Sermorelin in Italia", "localizedAnswer": "Sermorelin è seguito come identità del mercato di ricerca statunitense, non come prova di autorizzazione o fornitura locale in Italia. Confronta categoria esatta, identità giuridica del venditore e canale dichiarato con i registri ufficiali di questa pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=italy" }, { "recordId": "pl-compound-country-sermorelin-netherlands", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Sermorelin in Nederland", "localizedAnswer": "Sermorelin wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=netherlands" }, { "recordId": "pl-compound-country-sermorelin-switzerland", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Sermorelin in Switzerland", "localizedAnswer": "Sermorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=switzerland" }, { "recordId": "pl-compound-country-sermorelin-poland", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Sermorelin w Polsce", "localizedAnswer": "Sermorelin jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=poland" }, { "recordId": "pl-compound-country-sermorelin-ireland", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Sermorelin in Ireland", "localizedAnswer": "Sermorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=ireland" }, { "recordId": "pl-compound-country-sermorelin-portugal", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Sermorelin em Portugal", "localizedAnswer": "Sermorelin é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=portugal" }, { "recordId": "pl-compound-country-sermorelin-sweden", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Sermorelin i Sverige", "localizedAnswer": "Sermorelin följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=sweden" }, { "recordId": "pl-compound-country-sermorelin-turkey", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Sermorelin", "localizedAnswer": "Sermorelin, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=turkey" }, { "recordId": "pl-compound-country-sermorelin-austria", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Sermorelin in Österreich", "localizedAnswer": "Sermorelin wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=austria" }, { "recordId": "pl-compound-country-sermorelin-belgium", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Sermorelin in België", "localizedAnswer": "Sermorelin wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=belgium" }, { "recordId": "pl-compound-country-sermorelin-denmark", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Sermorelin i Danmark", "localizedAnswer": "Sermorelin følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=denmark" }, { "recordId": "pl-compound-country-sermorelin-finland", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Sermorelin kohteessa Suomi", "localizedAnswer": "Sermorelin seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=finland" }, { "recordId": "pl-compound-country-sermorelin-mexico", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Sermorelin en México", "localizedAnswer": "Sermorelin se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=mexico" }, { "recordId": "pl-compound-country-sermorelin-argentina", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Sermorelin en Argentina", "localizedAnswer": "Sermorelin se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=argentina" }, { "recordId": "pl-compound-country-sermorelin-colombia", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Sermorelin en Colombia", "localizedAnswer": "Sermorelin se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=colombia" }, { "recordId": "pl-compound-country-sermorelin-chile", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Sermorelin en Chile", "localizedAnswer": "Sermorelin se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Chile. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=chile" }, { "recordId": "pl-compound-country-sermorelin-brazil", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Sermorelin no Brasil", "localizedAnswer": "Sermorelin é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=brazil" }, { "recordId": "pl-compound-country-sermorelin-china", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Sermorelin 在中国的状态与官方记录", "localizedAnswer": "Sermorelin在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=china" }, { "recordId": "pl-compound-country-sermorelin-australia", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Sermorelin in Australia", "localizedAnswer": "Sermorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=australia" }, { "recordId": "pl-compound-country-sermorelin-new-zealand", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Sermorelin in New Zealand", "localizedAnswer": "Sermorelin is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=new-zealand" }, { "recordId": "pl-compound-country-sermorelin-india", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Sermorelin in India", "localizedAnswer": "Sermorelin is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=india" }, { "recordId": "pl-compound-country-sermorelin-japan", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のSermorelin", "localizedAnswer": "Sermorelinは米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=japan" }, { "recordId": "pl-compound-country-sermorelin-south-korea", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Sermorelin", "localizedAnswer": "Sermorelin은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=south-korea" }, { "recordId": "pl-compound-country-sermorelin-thailand", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Sermorelin ในประเทศไทย", "localizedAnswer": "Sermorelin ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=thailand" }, { "recordId": "pl-compound-country-sermorelin-indonesia", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Sermorelin di Indonesia", "localizedAnswer": "Sermorelin dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=indonesia" }, { "recordId": "pl-compound-country-sermorelin-singapore", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Sermorelin in Singapore", "localizedAnswer": "Sermorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Singapore. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=singapore" }, { "recordId": "pl-compound-country-sermorelin-philippines", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Sermorelin in the Philippines", "localizedAnswer": "Sermorelin is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=philippines" }, { "recordId": "pl-compound-country-sermorelin-malaysia", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Sermorelin in Malaysia", "localizedAnswer": "Sermorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=malaysia" }, { "recordId": "pl-compound-country-sermorelin-taiwan", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Sermorelin 在台灣的紀錄", "localizedAnswer": "Sermorelin在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=taiwan" }, { "recordId": "pl-compound-country-sermorelin-hong-kong", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Sermorelin 在香港的紀錄", "localizedAnswer": "Sermorelin在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=hong-kong" }, { "recordId": "pl-compound-country-sermorelin-vietnam", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Sermorelin tại Việt Nam", "localizedAnswer": "Sermorelin được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=vietnam" }, { "recordId": "pl-compound-country-sermorelin-united-states", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Sermorelin in the United States", "localizedAnswer": "Sermorelin is tracked as a US research-market identity, not as an authorization or local supply finding for the United States. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=united-states" }, { "recordId": "pl-compound-country-sermorelin-canada", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Sermorelin in Canada", "localizedAnswer": "Sermorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=canada" }, { "recordId": "pl-compound-country-sermorelin-united-arab-emirates", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Sermorelin في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع Sermorelin هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=united-arab-emirates" }, { "recordId": "pl-compound-country-sermorelin-saudi-arabia", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Sermorelin في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع Sermorelin هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=saudi-arabia" }, { "recordId": "pl-compound-country-sermorelin-south-africa", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Sermorelin in South Africa", "localizedAnswer": "Sermorelin is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=south-africa" }, { "recordId": "pl-compound-country-sermorelin-nigeria", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Sermorelin in Nigeria", "localizedAnswer": "Sermorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=nigeria" }, { "recordId": "pl-compound-country-sermorelin-kenya", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Sermorelin in Kenya", "localizedAnswer": "Sermorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/sermorelin", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/sermorelin/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=sermorelin&country=kenya" }, { "recordId": "pl-compound-country-thymosin-alpha-1-france", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Thymosin Alpha-1 en France", "localizedAnswer": "Thymosin Alpha-1 est suivi comme identité du marché américain de la recherche, et non comme preuve d’autorisation ou d’approvisionnement local en France. Vérifiez la catégorie exacte, l’identité juridique du vendeur et le circuit revendiqué dans les registres officiels de cette page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=france" }, { "recordId": "pl-compound-country-thymosin-alpha-1-united-kingdom", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Thymosin Alpha-1 in the United Kingdom", "localizedAnswer": "Thymosin Alpha-1 is tracked as a US research-market identity, not as an authorization or local supply finding for the United Kingdom. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=united-kingdom" }, { "recordId": "pl-compound-country-thymosin-alpha-1-germany", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Thymosin Alpha-1 in Deutschland", "localizedAnswer": "Thymosin Alpha-1 wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Deutschland. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=germany" }, { "recordId": "pl-compound-country-thymosin-alpha-1-spain", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Thymosin Alpha-1 en España", "localizedAnswer": "Thymosin Alpha-1 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en España. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=spain" }, { "recordId": "pl-compound-country-thymosin-alpha-1-italy", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Thymosin Alpha-1 in Italia", "localizedAnswer": "Thymosin Alpha-1 è seguito come identità del mercato di ricerca statunitense, non come prova di autorizzazione o fornitura locale in Italia. Confronta categoria esatta, identità giuridica del venditore e canale dichiarato con i registri ufficiali di questa pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=italy" }, { "recordId": "pl-compound-country-thymosin-alpha-1-netherlands", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Thymosin Alpha-1 in Nederland", "localizedAnswer": "Thymosin Alpha-1 wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in Nederland. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=netherlands" }, { "recordId": "pl-compound-country-thymosin-alpha-1-switzerland", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Thymosin Alpha-1 in Switzerland", "localizedAnswer": "Thymosin Alpha-1 is tracked as a US research-market identity, not as an authorization or local supply finding for Switzerland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=switzerland" }, { "recordId": "pl-compound-country-thymosin-alpha-1-poland", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Thymosin Alpha-1 w Polsce", "localizedAnswer": "Thymosin Alpha-1 jest tu identyfikatorem z amerykańskiego rynku badawczego, a nie dowodem dopuszczenia lub lokalnej dostawy w Polsce. Sprawdź dokładną kategorię, prawną tożsamość sprzedawcy i deklarowaną drogę w urzędowych rejestrach na tej stronie.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=poland" }, { "recordId": "pl-compound-country-thymosin-alpha-1-ireland", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Thymosin Alpha-1 in Ireland", "localizedAnswer": "Thymosin Alpha-1 is tracked as a US research-market identity, not as an authorization or local supply finding for Ireland. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=ireland" }, { "recordId": "pl-compound-country-thymosin-alpha-1-portugal", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Thymosin Alpha-1 em Portugal", "localizedAnswer": "Thymosin Alpha-1 é acompanhado como identidade do mercado de investigação dos EUA, não como prova de autorização ou fornecimento local em Portugal. Compare a categoria exata, a identidade jurídica do vendedor e a via alegada com os registos oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=portugal" }, { "recordId": "pl-compound-country-thymosin-alpha-1-sweden", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Thymosin Alpha-1 i Sverige", "localizedAnswer": "Thymosin Alpha-1 följs som en identitet på den amerikanska forskningsmarknaden, inte som bevis på godkännande eller lokal leverans i Sverige. Kontrollera exakt kategori, säljarens juridiska identitet och den påstådda vägen i de officiella registren på sidan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=sweden" }, { "recordId": "pl-compound-country-thymosin-alpha-1-turkey", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Thymosin Alpha-1", "localizedAnswer": "Thymosin Alpha-1, ABD araştırma pazarında kullanılan bir kimlik olarak izlenir; Türkiye için ruhsat, yasal tedarik veya gerçek bulunabilirlik kanıtı değildir. Ürün sınıfını, satıcının hukuki kimliğini, güncel faaliyet durumunu ve iddia edilen tedarik yolunu bu sayfadaki resmi ürün ve kuruluş kayıtlarında ayrı ayrı eşleştirin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=turkey" }, { "recordId": "pl-compound-country-thymosin-alpha-1-austria", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Thymosin Alpha-1 in Österreich", "localizedAnswer": "Thymosin Alpha-1 wird als Identität im US-Forschungsmarkt geführt, nicht als Nachweis einer Zulassung oder lokalen Versorgung in Österreich. Prüfe die genaue Kategorie, die rechtliche Anbieteridentität und den behaupteten Bezugsweg in den amtlichen Registern dieser Seite.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=austria" }, { "recordId": "pl-compound-country-thymosin-alpha-1-belgium", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Thymosin Alpha-1 in België", "localizedAnswer": "Thymosin Alpha-1 wordt gevolgd als identiteit op de Amerikaanse onderzoeksmarkt, niet als bewijs van toelating of lokale levering in België. Controleer de exacte categorie, juridische identiteit van de aanbieder en opgegeven route in de officiële registers op deze pagina.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=belgium" }, { "recordId": "pl-compound-country-thymosin-alpha-1-denmark", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Thymosin Alpha-1 i Danmark", "localizedAnswer": "Thymosin Alpha-1 følges som en identitet på det amerikanske forskningsmarked, ikke som dokumentation for godkendelse, lovlig forsyning eller faktisk tilgængelighed i Danmark. Sammenhold produktkategori, sælgerens juridiske identitet, aktuel registerstatus og den påståede forsyningsvej med de separate officielle registre på denne side.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=denmark" }, { "recordId": "pl-compound-country-thymosin-alpha-1-finland", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Thymosin Alpha-1 kohteessa Suomi", "localizedAnswer": "Thymosin Alpha-1 seurataan Yhdysvaltain tutkimusmarkkinassa käytettynä identiteettinä, ei todisteena hyväksynnästä, laillisesta toimituksesta tai todellisesta saatavuudesta kohteessa Suomi. Vertaa tuoteluokka, myyjän oikeudellinen identiteetti, nykyinen rekisteritila ja väitetty toimitusreitti erikseen tämän sivun virallisiin rekistereihin.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=finland" }, { "recordId": "pl-compound-country-thymosin-alpha-1-mexico", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Thymosin Alpha-1 en México", "localizedAnswer": "Thymosin Alpha-1 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en México. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=mexico" }, { "recordId": "pl-compound-country-thymosin-alpha-1-argentina", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Thymosin Alpha-1 en Argentina", "localizedAnswer": "Thymosin Alpha-1 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Argentina. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=argentina" }, { "recordId": "pl-compound-country-thymosin-alpha-1-colombia", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Thymosin Alpha-1 en Colombia", "localizedAnswer": "Thymosin Alpha-1 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Colombia. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=colombia" }, { "recordId": "pl-compound-country-thymosin-alpha-1-chile", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Thymosin Alpha-1 en Chile", "localizedAnswer": "Thymosin Alpha-1 se registra como identidad del mercado estadounidense de investigación, no como prueba de autorización o suministro local en Chile. Contrasta la categoría exacta, la identidad legal del vendedor y la vía declarada con los registros oficiales de esta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=chile" }, { "recordId": "pl-compound-country-thymosin-alpha-1-brazil", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Thymosin Alpha-1 no Brasil", "localizedAnswer": "Thymosin Alpha-1 é acompanhado como identidade do mercado de pesquisa dos EUA, não como prova de autorização ou fornecimento local no Brasil. Compare a categoria exata, a identidade jurídica do vendedor e a rota alegada com os registros oficiais desta página.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=brazil" }, { "recordId": "pl-compound-country-thymosin-alpha-1-china", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Thymosin Alpha-1 在中国的状态与官方记录", "localizedAnswer": "Thymosin Alpha-1在此仅作为美国科研市场中的名称身份跟踪，并不是其在中国获批、合法供应或实际可得的证明。必须通过本页链接的官方记录，分别核对具体类别、产品信息、法律经营主体、登记状态与声称的供应路径，不能让科研标签继承药品批准或临床项目证据。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=china" }, { "recordId": "pl-compound-country-thymosin-alpha-1-australia", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Thymosin Alpha-1 in Australia", "localizedAnswer": "Thymosin Alpha-1 is tracked as a US research-market identity, not as an authorization or local supply finding for Australia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=australia" }, { "recordId": "pl-compound-country-thymosin-alpha-1-new-zealand", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Thymosin Alpha-1 in New Zealand", "localizedAnswer": "Thymosin Alpha-1 is tracked as a US research-market identity, not as an authorization or local supply finding for New Zealand. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=new-zealand" }, { "recordId": "pl-compound-country-thymosin-alpha-1-india", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Thymosin Alpha-1 in India", "localizedAnswer": "Thymosin Alpha-1 is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=india" }, { "recordId": "pl-compound-country-thymosin-alpha-1-japan", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のThymosin Alpha-1", "localizedAnswer": "Thymosin Alpha-1は米国の研究市場で使われる名称として追跡しており、日本での承認、合法な供給、実際の入手可能性を示すものではありません。このページの公的記録で、製品区分、販売主体の法的名称、現在の登録状態、主張される供給経路を個別に照合してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=japan" }, { "recordId": "pl-compound-country-thymosin-alpha-1-south-korea", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Thymosin Alpha-1", "localizedAnswer": "Thymosin Alpha-1은 미국 연구 시장에서 사용되는 명칭으로 추적되며, 대한민국에서의 허가, 합법적 공급 또는 실제 이용 가능성을 의미하지 않습니다. 이 페이지의 공식 기록에서 정확한 제품 유형, 판매 주체의 법적 신원, 현재 등록 상태와 주장된 공급 경로를 각각 대조하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=south-korea" }, { "recordId": "pl-compound-country-thymosin-alpha-1-thailand", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Thymosin Alpha-1 ในประเทศไทย", "localizedAnswer": "Thymosin Alpha-1 ถูกติดตามในฐานะชื่อที่ใช้ในตลาดวัสดุวิจัยของสหรัฐฯ ไม่ใช่หลักฐานการอนุมัติ การจัดหาโดยชอบด้วยกฎหมาย หรือความพร้อมขายจริงในประเทศไทย ต้องเทียบประเภทผลิตภัณฑ์ นิติบุคคลของผู้ขาย สถานะทะเบียนปัจจุบัน และเส้นทางการจัดหาที่อ้างกับบันทึกทางการในหน้านี้", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=thailand" }, { "recordId": "pl-compound-country-thymosin-alpha-1-indonesia", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Thymosin Alpha-1 di Indonesia", "localizedAnswer": "Thymosin Alpha-1 dilacak sebagai identitas yang digunakan di pasar riset Amerika Serikat, bukan sebagai bukti persetujuan, pasokan yang legal, atau ketersediaan nyata di Indonesia. Cocokkan kategori produk, identitas hukum penjual, status catatan terkini, dan jalur pasok yang diklaim dengan catatan resmi di halaman ini.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=indonesia" }, { "recordId": "pl-compound-country-thymosin-alpha-1-singapore", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "Exact prescription-only Zadaxin product registered", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Thymosin Alpha-1 in Singapore", "localizedAnswer": "Singapore's National Drug Formulary lists Zadaxin Injection, Thymosin Alpha-1 1.6 mg per vial, as prescription-only product SIN07483P with defined hepatitis indications. That exact registration does not authenticate a research vial, another manufacturer, online seller, imported package, or availability claim.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 1, "statusEvidencePublishers": [ "Singapore National Drug Formulary" ], "statusEvidenceUrls": [ "https://www.ndf.gov.sg/about-drugs/product-information/sin07483p/" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=singapore" }, { "recordId": "pl-compound-country-thymosin-alpha-1-philippines", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Thymosin Alpha-1 in the Philippines", "localizedAnswer": "Thymosin Alpha-1 is tracked as a US research-market identity, not as an authorization or local supply finding for the Philippines. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=philippines" }, { "recordId": "pl-compound-country-thymosin-alpha-1-malaysia", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Thymosin Alpha-1 in Malaysia", "localizedAnswer": "Thymosin Alpha-1 is tracked as a US research-market identity, not as an authorization or local supply finding for Malaysia. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=malaysia" }, { "recordId": "pl-compound-country-thymosin-alpha-1-taiwan", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Thymosin Alpha-1 在台灣的紀錄", "localizedAnswer": "Thymosin Alpha-1在此僅作為美國研究市場名稱追蹤，不能證明其在台灣獲准、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、許可證資料、賣方或機構法律身分、目前狀態與宣稱的供應途徑，研究用途標示不能承接藥品許可。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=taiwan" }, { "recordId": "pl-compound-country-thymosin-alpha-1-hong-kong", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Thymosin Alpha-1 在香港的紀錄", "localizedAnswer": "Thymosin Alpha-1在此只作為美國研究市場名稱追蹤，不能證明其在香港已註冊、合法供應或實際可得。請在本頁官方紀錄中分別核對產品類別、註冊資料、銷售商法定身分、牌照狀態和聲稱的供應途徑，研究用途標籤不能承接藥劑製品註冊。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=hong-kong" }, { "recordId": "pl-compound-country-thymosin-alpha-1-vietnam", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Thymosin Alpha-1 tại Việt Nam", "localizedAnswer": "Thymosin Alpha-1 được theo dõi như một danh tính trên thị trường nghiên cứu Hoa Kỳ, không phải bằng chứng về giấy phép, nguồn cung hợp pháp hay khả năng có hàng tại Việt Nam. Hãy đối chiếu riêng loại sản phẩm, pháp nhân người bán, tình trạng hồ sơ hiện hành và đường cung ứng được tuyên bố trong các nguồn chính thức trên trang này.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=vietnam" }, { "recordId": "pl-compound-country-thymosin-alpha-1-united-states", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved product and current compounding safety concerns", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Thymosin Alpha-1 in the United States", "localizedAnswer": "FDA stated in December 2024 that products containing Thymosin Alpha-1 are not approved in the United States. The advisory committee voted 4 to 17 against placing both reviewed forms on the 503A Bulks List, and FDA currently identifies potential immunogenicity, impurity, and API-characterization concerns. These records do not authenticate a seller listing or decide every state pharmacy question.", "reviewedDate": "2026-07-24", "statusSpecificity": "compound-country-source", "statusEvidenceBasis": "Compound and destination-specific sources are attached to this status summary. Product, presentation, seller, and current market facts still require exact record matching.", "statusEvidenceSourceCount": 2, "statusEvidencePublishers": [ "U.S. Food and Drug Administration" ], "statusEvidenceUrls": [ "https://www.fda.gov/media/185642/download", "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" ], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=united-states" }, { "recordId": "pl-compound-country-thymosin-alpha-1-canada", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Thymosin Alpha-1 in Canada", "localizedAnswer": "Thymosin Alpha-1 is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=canada" }, { "recordId": "pl-compound-country-thymosin-alpha-1-united-arab-emirates", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Thymosin Alpha-1 في الإمارات العربية المتحدة", "localizedAnswer": "يتم تتبع Thymosin Alpha-1 هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في الإمارات العربية المتحدة. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=united-arab-emirates" }, { "recordId": "pl-compound-country-thymosin-alpha-1-saudi-arabia", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Thymosin Alpha-1 في المملكة العربية السعودية", "localizedAnswer": "يتم تتبع Thymosin Alpha-1 هنا كهوية مستخدمة في سوق الأبحاث الأمريكي، وليس كدليل على الترخيص أو التوريد المحلي في المملكة العربية السعودية. يجب مطابقة الفئة المحددة والهوية القانونية للبائع ومسار التوريد المعلن مع سجلات المنتج والمنشأة الرسمية في هذه الصفحة قبل استنتاج التوفر أو المشروعية.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=saudi-arabia" }, { "recordId": "pl-compound-country-thymosin-alpha-1-south-africa", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Thymosin Alpha-1 in South Africa", "localizedAnswer": "Thymosin Alpha-1 is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=south-africa" }, { "recordId": "pl-compound-country-thymosin-alpha-1-nigeria", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Thymosin Alpha-1 in Nigeria", "localizedAnswer": "Thymosin Alpha-1 is tracked as a US research-market identity, not as an authorization or local supply finding for Nigeria. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=nigeria" }, { "recordId": "pl-compound-country-thymosin-alpha-1-kenya", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Thymosin Alpha-1 in Kenya", "localizedAnswer": "Thymosin Alpha-1 is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/thymosin-alpha-1", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=thymosin-alpha-1&country=kenya" }, { "recordId": "pl-compound-country-egrifta-wr-france", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "EGRIFTA WR en France", "localizedAnswer": "EGRIFTA WR commence ici par une référence de médicament de la FDA américaine. Cela ne prouve pas le même produit, la même présentation, l’autorisation, le statut de prescription ou la disponibilité actuelle en France. Consultez les registres locaux exacts ci-dessous.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=france" }, { "recordId": "pl-compound-country-egrifta-wr-united-kingdom", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "EGRIFTA WR in the United Kingdom", "localizedAnswer": "EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United Kingdom. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=united-kingdom" }, { "recordId": "pl-compound-country-egrifta-wr-germany", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "EGRIFTA WR in Deutschland", "localizedAnswer": "EGRIFTA WR beginnt hier mit einer Arzneimittelreferenz der US-FDA. Das belegt weder dasselbe Produkt noch Darreichungsform, Zulassung, Verschreibungsstatus oder aktuelle Verfügbarkeit in Deutschland. Prüfe die genauen lokalen Register unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=germany" }, { "recordId": "pl-compound-country-egrifta-wr-spain", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "EGRIFTA WR en España", "localizedAnswer": "EGRIFTA WR empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en España. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=spain" }, { "recordId": "pl-compound-country-egrifta-wr-italy", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "EGRIFTA WR in Italia", "localizedAnswer": "EGRIFTA WR parte qui da un riferimento di farmaco della FDA statunitense. Questo non dimostra stesso prodotto, presentazione, approvazione, stato di prescrizione o disponibilità attuale in Italia. Controlla i registri locali esatti qui sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=italy" }, { "recordId": "pl-compound-country-egrifta-wr-netherlands", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "EGRIFTA WR in Nederland", "localizedAnswer": "EGRIFTA WR begint hier met een geneesmiddelreferentie van de Amerikaanse FDA. Dat bewijst niet hetzelfde product, dezelfde presentatie, toelating, receptstatus of actuele beschikbaarheid in Nederland. Controleer de exacte lokale registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=netherlands" }, { "recordId": "pl-compound-country-egrifta-wr-switzerland", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "EGRIFTA WR in Switzerland", "localizedAnswer": "EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Switzerland. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=switzerland" }, { "recordId": "pl-compound-country-egrifta-wr-poland", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "EGRIFTA WR w Polsce", "localizedAnswer": "EGRIFTA WR zaczyna się tutaj od dokumentu leku amerykańskiej FDA. Nie dowodzi to tego samego produktu, postaci, dopuszczenia, statusu recepty ani bieżącej dostępności w Polsce. Sprawdź dokładne rejestry krajowe poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=poland" }, { "recordId": "pl-compound-country-egrifta-wr-ireland", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "EGRIFTA WR in Ireland", "localizedAnswer": "EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Ireland. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=ireland" }, { "recordId": "pl-compound-country-egrifta-wr-portugal", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "EGRIFTA WR em Portugal", "localizedAnswer": "EGRIFTA WR começa aqui com uma referência de medicamento da FDA dos EUA. Isso não comprova o mesmo produto, apresentação, autorização, estatuto de prescrição ou disponibilidade atual em Portugal. Consulte os registos locais exatos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=portugal" }, { "recordId": "pl-compound-country-egrifta-wr-sweden", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "EGRIFTA WR i Sverige", "localizedAnswer": "EGRIFTA WR börjar här med en läkemedelsreferens från amerikanska FDA. Det bevisar inte samma produkt, presentation, godkännande, receptstatus eller aktuell tillgänglighet i Sverige. Kontrollera de exakta nationella registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=sweden" }, { "recordId": "pl-compound-country-egrifta-wr-turkey", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için EGRIFTA WR", "localizedAnswer": "EGRIFTA WR kimliği burada bir ABD FDA ilaç kaydıyla başlar, ancak bu Türkiye için aynı ürünün, farmasötik şeklin, dozun, ruhsatın, reçete durumunun veya güncel tedarikin bulunduğunu kanıtlamaz. Aşağıdaki resmi kayıtlarla tam ürün ve satıcı kimliğini, güncel durumu ve iddia edilen yolu doğrulayın.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=turkey" }, { "recordId": "pl-compound-country-egrifta-wr-austria", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "EGRIFTA WR in Österreich", "localizedAnswer": "EGRIFTA WR beginnt hier mit einer Arzneimittelreferenz der US-FDA. Das belegt weder dasselbe Produkt noch Darreichungsform, Zulassung, Verschreibungsstatus oder aktuelle Verfügbarkeit in Österreich. Prüfe die genauen lokalen Register unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=austria" }, { "recordId": "pl-compound-country-egrifta-wr-belgium", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "EGRIFTA WR in België", "localizedAnswer": "EGRIFTA WR begint hier met een geneesmiddelreferentie van de Amerikaanse FDA. Dat bewijst niet hetzelfde product, dezelfde presentatie, toelating, receptstatus of actuele beschikbaarheid in België. Controleer de exacte lokale registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=belgium" }, { "recordId": "pl-compound-country-egrifta-wr-denmark", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "EGRIFTA WR i Danmark", "localizedAnswer": "EGRIFTA WR begynder her med en amerikansk FDA-lægemiddelidentitet, men det dokumenterer ikke samme produkt, form, styrke, godkendelse, receptstatus eller aktuelle forsyning i Danmark. Brug de officielle registre nedenfor til at kontrollere det nøjagtige lokale produkt, sælgeren, status og den påståede rute.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=denmark" }, { "recordId": "pl-compound-country-egrifta-wr-finland", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "EGRIFTA WR kohteessa Suomi", "localizedAnswer": "EGRIFTA WR alkaa tässä Yhdysvaltain FDA:n lääkeidentiteetistä, mutta se ei todista samaa tuotetta, lääkemuotoa, vahvuutta, hyväksyntää, reseptistatusta tai nykyistä toimitusta kohteessa Suomi. Tarkista täsmällinen paikallinen tuote, myyjä, tila ja väitetty reitti alla olevista virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=finland" }, { "recordId": "pl-compound-country-egrifta-wr-mexico", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "EGRIFTA WR en México", "localizedAnswer": "EGRIFTA WR empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en México. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=mexico" }, { "recordId": "pl-compound-country-egrifta-wr-argentina", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "EGRIFTA WR en Argentina", "localizedAnswer": "EGRIFTA WR empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Argentina. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=argentina" }, { "recordId": "pl-compound-country-egrifta-wr-colombia", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "EGRIFTA WR en Colombia", "localizedAnswer": "EGRIFTA WR empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Colombia. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=colombia" }, { "recordId": "pl-compound-country-egrifta-wr-chile", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "EGRIFTA WR en Chile", "localizedAnswer": "EGRIFTA WR empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Chile. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=chile" }, { "recordId": "pl-compound-country-egrifta-wr-brazil", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "EGRIFTA WR no Brasil", "localizedAnswer": "EGRIFTA WR começa aqui com uma referência de medicamento da FDA dos EUA. Isso não comprova o mesmo produto, apresentação, aprovação, status de prescrição ou disponibilidade atual no Brasil. Consulte os registros locais exatos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=brazil" }, { "recordId": "pl-compound-country-egrifta-wr-china", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "EGRIFTA WR 在中国的状态与官方记录", "localizedAnswer": "EGRIFTA WR在此从美国 FDA 药品身份记录开始，但这不能证明同一品牌、剂型、规格、适应症、处方状态或供应路径在中国同样获批或可得。应使用下方官方记录核对目的地的具体产品和卖方，并确认当前状态，而不是依据名称、包装图片或国外批准作出推断。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=china" }, { "recordId": "pl-compound-country-egrifta-wr-australia", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "EGRIFTA WR in Australia", "localizedAnswer": "EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Australia. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=australia" }, { "recordId": "pl-compound-country-egrifta-wr-new-zealand", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "EGRIFTA WR in New Zealand", "localizedAnswer": "EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in New Zealand. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=new-zealand" }, { "recordId": "pl-compound-country-egrifta-wr-india", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "EGRIFTA WR in India", "localizedAnswer": "EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in India. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=india" }, { "recordId": "pl-compound-country-egrifta-wr-japan", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のEGRIFTA WR", "localizedAnswer": "EGRIFTA WRはここでは米国FDAの医薬品記録から同一性を確認しますが、日本で同じ製品、剤形、規格、承認、処方区分、供給状況が存在することを証明しません。下記の公的記録で目的地の具体的な製品と販売主体を確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=japan" }, { "recordId": "pl-compound-country-egrifta-wr-south-korea", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 EGRIFTA WR", "localizedAnswer": "EGRIFTA WR은 여기서 미국 FDA 의약품 기록으로 신원을 시작하지만, 대한민국에서 같은 제품, 제형, 함량, 허가, 처방 상태 또는 현재 공급이 존재한다는 뜻은 아닙니다. 아래 공식 기록을 이용해 목적지의 구체적인 제품과 판매 주체를 확인하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=south-korea" }, { "recordId": "pl-compound-country-egrifta-wr-thailand", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "EGRIFTA WR ในประเทศไทย", "localizedAnswer": "EGRIFTA WR เริ่มจากบันทึกยาของ FDA สหรัฐฯ แต่ไม่ได้พิสูจน์ว่าผลิตภัณฑ์ รูปแบบ ความแรง การอนุมัติ สถานะใบสั่งยา หรือการจัดหาในประเทศไทยเหมือนกัน ให้ตรวจผลิตภัณฑ์และผู้ขายที่เฉพาะเจาะจงในประเทศปลายทางจากบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=thailand" }, { "recordId": "pl-compound-country-egrifta-wr-indonesia", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "EGRIFTA WR di Indonesia", "localizedAnswer": "EGRIFTA WR dimulai dari identitas obat dalam catatan FDA Amerika Serikat, tetapi hal itu tidak membuktikan produk, bentuk, kekuatan, persetujuan, status resep, atau pasokan yang sama di Indonesia. Gunakan catatan resmi di bawah untuk memeriksa produk dan penjual spesifik di negara tujuan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=indonesia" }, { "recordId": "pl-compound-country-egrifta-wr-singapore", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "EGRIFTA WR in Singapore", "localizedAnswer": "EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Singapore. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=singapore" }, { "recordId": "pl-compound-country-egrifta-wr-philippines", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "EGRIFTA WR in the Philippines", "localizedAnswer": "EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the Philippines. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=philippines" }, { "recordId": "pl-compound-country-egrifta-wr-malaysia", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "EGRIFTA WR in Malaysia", "localizedAnswer": "EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Malaysia. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=malaysia" }, { "recordId": "pl-compound-country-egrifta-wr-taiwan", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "EGRIFTA WR 在台灣的紀錄", "localizedAnswer": "EGRIFTA WR在此從美國 FDA 藥品紀錄確認身分，但這不能證明台灣有相同產品、劑型、含量、適應症、處方狀態或目前供應。請用下方官方紀錄查證目的地的特定產品、許可證、機構和提供者，不能只依名稱或外國核准推論。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=taiwan" }, { "recordId": "pl-compound-country-egrifta-wr-hong-kong", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "EGRIFTA WR 在香港的紀錄", "localizedAnswer": "EGRIFTA WR在此從美國 FDA 藥物紀錄確認身分，但這不能證明香港有相同產品、劑型、含量、適應症、處方狀態或目前供應。請用下方官方紀錄核實指定產品、註冊編號、持牌銷售商和現行狀態，不能只依名稱或外國批准推論。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=hong-kong" }, { "recordId": "pl-compound-country-egrifta-wr-vietnam", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "EGRIFTA WR tại Việt Nam", "localizedAnswer": "EGRIFTA WR bắt đầu ở đây bằng hồ sơ thuốc của FDA Hoa Kỳ, nhưng điều đó không chứng minh có cùng sản phẩm, dạng bào chế, hàm lượng, giấy phép, tình trạng kê đơn hay nguồn cung hiện tại tại Việt Nam. Hãy dùng các hồ sơ bên dưới để xác minh chính xác sản phẩm, người bán, tình trạng và đường cung ứng tại điểm đến.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=vietnam" }, { "recordId": "pl-compound-country-egrifta-wr-united-states", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "EGRIFTA WR in the United States", "localizedAnswer": "EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United States. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=united-states" }, { "recordId": "pl-compound-country-egrifta-wr-canada", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "EGRIFTA WR in Canada", "localizedAnswer": "EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Canada. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=canada" }, { "recordId": "pl-compound-country-egrifta-wr-united-arab-emirates", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "EGRIFTA WR في الإمارات العربية المتحدة", "localizedAnswer": "تبدأ هوية EGRIFTA WR هنا من سجل دواء لدى إدارة الغذاء والدواء الأمريكية، لكن ذلك لا يثبت أن المنتج أو الشكل أو التركيز أو الموافقة أو حالة الوصفة أو التوفر الحالي هي نفسها في الإمارات العربية المتحدة. تحقق من المنتج المحلي المحدد والمنشأة والبائع ومسار التوريد من خلال السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=united-arab-emirates" }, { "recordId": "pl-compound-country-egrifta-wr-saudi-arabia", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "EGRIFTA WR في المملكة العربية السعودية", "localizedAnswer": "تبدأ هوية EGRIFTA WR هنا من سجل دواء لدى إدارة الغذاء والدواء الأمريكية، لكن ذلك لا يثبت أن المنتج أو الشكل أو التركيز أو الموافقة أو حالة الوصفة أو التوفر الحالي هي نفسها في المملكة العربية السعودية. تحقق من المنتج المحلي المحدد والمنشأة والبائع ومسار التوريد من خلال السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=saudi-arabia" }, { "recordId": "pl-compound-country-egrifta-wr-south-africa", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "EGRIFTA WR in South Africa", "localizedAnswer": "EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in South Africa. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=south-africa" }, { "recordId": "pl-compound-country-egrifta-wr-nigeria", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "EGRIFTA WR in Nigeria", "localizedAnswer": "EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Nigeria. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=nigeria" }, { "recordId": "pl-compound-country-egrifta-wr-kenya", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "EGRIFTA WR in Kenya", "localizedAnswer": "EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Kenya. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/egrifta-wr", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=egrifta-wr&country=kenya" }, { "recordId": "pl-compound-country-liraglutide-france", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "Liraglutide en France", "localizedAnswer": "Liraglutide commence ici par une référence de médicament de la FDA américaine. Cela ne prouve pas le même produit, la même présentation, l’autorisation, le statut de prescription ou la disponibilité actuelle en France. Consultez les registres locaux exacts ci-dessous.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=france" }, { "recordId": "pl-compound-country-liraglutide-united-kingdom", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Liraglutide in the United Kingdom", "localizedAnswer": "Liraglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United Kingdom. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=united-kingdom" }, { "recordId": "pl-compound-country-liraglutide-germany", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Liraglutide in Deutschland", "localizedAnswer": "Liraglutide beginnt hier mit einer Arzneimittelreferenz der US-FDA. Das belegt weder dasselbe Produkt noch Darreichungsform, Zulassung, Verschreibungsstatus oder aktuelle Verfügbarkeit in Deutschland. Prüfe die genauen lokalen Register unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=germany" }, { "recordId": "pl-compound-country-liraglutide-spain", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "Liraglutide en España", "localizedAnswer": "Liraglutide empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en España. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=spain" }, { "recordId": "pl-compound-country-liraglutide-italy", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "Liraglutide in Italia", "localizedAnswer": "Liraglutide parte qui da un riferimento di farmaco della FDA statunitense. Questo non dimostra stesso prodotto, presentazione, approvazione, stato di prescrizione o disponibilità attuale in Italia. Controlla i registri locali esatti qui sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=italy" }, { "recordId": "pl-compound-country-liraglutide-netherlands", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Liraglutide in Nederland", "localizedAnswer": "Liraglutide begint hier met een geneesmiddelreferentie van de Amerikaanse FDA. Dat bewijst niet hetzelfde product, dezelfde presentatie, toelating, receptstatus of actuele beschikbaarheid in Nederland. Controleer de exacte lokale registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=netherlands" }, { "recordId": "pl-compound-country-liraglutide-switzerland", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Liraglutide in Switzerland", "localizedAnswer": "Liraglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Switzerland. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=switzerland" }, { "recordId": "pl-compound-country-liraglutide-poland", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "Liraglutide w Polsce", "localizedAnswer": "Liraglutide zaczyna się tutaj od dokumentu leku amerykańskiej FDA. Nie dowodzi to tego samego produktu, postaci, dopuszczenia, statusu recepty ani bieżącej dostępności w Polsce. Sprawdź dokładne rejestry krajowe poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=poland" }, { "recordId": "pl-compound-country-liraglutide-ireland", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "Liraglutide in Ireland", "localizedAnswer": "Liraglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Ireland. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=ireland" }, { "recordId": "pl-compound-country-liraglutide-portugal", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "Liraglutide em Portugal", "localizedAnswer": "Liraglutide começa aqui com uma referência de medicamento da FDA dos EUA. Isso não comprova o mesmo produto, apresentação, autorização, estatuto de prescrição ou disponibilidade atual em Portugal. Consulte os registos locais exatos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=portugal" }, { "recordId": "pl-compound-country-liraglutide-sweden", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "Liraglutide i Sverige", "localizedAnswer": "Liraglutide börjar här med en läkemedelsreferens från amerikanska FDA. Det bevisar inte samma produkt, presentation, godkännande, receptstatus eller aktuell tillgänglighet i Sverige. Kontrollera de exakta nationella registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=sweden" }, { "recordId": "pl-compound-country-liraglutide-turkey", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için Liraglutide", "localizedAnswer": "Liraglutide kimliği burada bir ABD FDA ilaç kaydıyla başlar, ancak bu Türkiye için aynı ürünün, farmasötik şeklin, dozun, ruhsatın, reçete durumunun veya güncel tedarikin bulunduğunu kanıtlamaz. Aşağıdaki resmi kayıtlarla tam ürün ve satıcı kimliğini, güncel durumu ve iddia edilen yolu doğrulayın.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=turkey" }, { "recordId": "pl-compound-country-liraglutide-austria", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "Liraglutide in Österreich", "localizedAnswer": "Liraglutide beginnt hier mit einer Arzneimittelreferenz der US-FDA. Das belegt weder dasselbe Produkt noch Darreichungsform, Zulassung, Verschreibungsstatus oder aktuelle Verfügbarkeit in Österreich. Prüfe die genauen lokalen Register unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=austria" }, { "recordId": "pl-compound-country-liraglutide-belgium", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "Liraglutide in België", "localizedAnswer": "Liraglutide begint hier met een geneesmiddelreferentie van de Amerikaanse FDA. Dat bewijst niet hetzelfde product, dezelfde presentatie, toelating, receptstatus of actuele beschikbaarheid in België. Controleer de exacte lokale registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=belgium" }, { "recordId": "pl-compound-country-liraglutide-denmark", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "Liraglutide i Danmark", "localizedAnswer": "Liraglutide begynder her med en amerikansk FDA-lægemiddelidentitet, men det dokumenterer ikke samme produkt, form, styrke, godkendelse, receptstatus eller aktuelle forsyning i Danmark. Brug de officielle registre nedenfor til at kontrollere det nøjagtige lokale produkt, sælgeren, status og den påståede rute.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=denmark" }, { "recordId": "pl-compound-country-liraglutide-finland", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "Liraglutide kohteessa Suomi", "localizedAnswer": "Liraglutide alkaa tässä Yhdysvaltain FDA:n lääkeidentiteetistä, mutta se ei todista samaa tuotetta, lääkemuotoa, vahvuutta, hyväksyntää, reseptistatusta tai nykyistä toimitusta kohteessa Suomi. Tarkista täsmällinen paikallinen tuote, myyjä, tila ja väitetty reitti alla olevista virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=finland" }, { "recordId": "pl-compound-country-liraglutide-mexico", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Liraglutide en México", "localizedAnswer": "Liraglutide empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en México. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=mexico" }, { "recordId": "pl-compound-country-liraglutide-argentina", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Liraglutide en Argentina", "localizedAnswer": "Liraglutide empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Argentina. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=argentina" }, { "recordId": "pl-compound-country-liraglutide-colombia", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Liraglutide en Colombia", "localizedAnswer": "Liraglutide empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Colombia. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=colombia" }, { "recordId": "pl-compound-country-liraglutide-chile", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "Liraglutide en Chile", "localizedAnswer": "Liraglutide empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Chile. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=chile" }, { "recordId": "pl-compound-country-liraglutide-brazil", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "Liraglutide no Brasil", "localizedAnswer": "Liraglutide começa aqui com uma referência de medicamento da FDA dos EUA. Isso não comprova o mesmo produto, apresentação, aprovação, status de prescrição ou disponibilidade atual no Brasil. Consulte os registros locais exatos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=brazil" }, { "recordId": "pl-compound-country-liraglutide-china", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "Liraglutide 在中国的状态与官方记录", "localizedAnswer": "Liraglutide在此从美国 FDA 药品身份记录开始，但这不能证明同一品牌、剂型、规格、适应症、处方状态或供应路径在中国同样获批或可得。应使用下方官方记录核对目的地的具体产品和卖方，并确认当前状态，而不是依据名称、包装图片或国外批准作出推断。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=china" }, { "recordId": "pl-compound-country-liraglutide-australia", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Liraglutide in Australia", "localizedAnswer": "Liraglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Australia. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=australia" }, { "recordId": "pl-compound-country-liraglutide-new-zealand", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Liraglutide in New Zealand", "localizedAnswer": "Liraglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in New Zealand. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=new-zealand" }, { "recordId": "pl-compound-country-liraglutide-india", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Liraglutide in India", "localizedAnswer": "Liraglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in India. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=india" }, { "recordId": "pl-compound-country-liraglutide-japan", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のLiraglutide", "localizedAnswer": "Liraglutideはここでは米国FDAの医薬品記録から同一性を確認しますが、日本で同じ製品、剤形、規格、承認、処方区分、供給状況が存在することを証明しません。下記の公的記録で目的地の具体的な製品と販売主体を確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=japan" }, { "recordId": "pl-compound-country-liraglutide-south-korea", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 Liraglutide", "localizedAnswer": "Liraglutide은 여기서 미국 FDA 의약품 기록으로 신원을 시작하지만, 대한민국에서 같은 제품, 제형, 함량, 허가, 처방 상태 또는 현재 공급이 존재한다는 뜻은 아닙니다. 아래 공식 기록을 이용해 목적지의 구체적인 제품과 판매 주체를 확인하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=south-korea" }, { "recordId": "pl-compound-country-liraglutide-thailand", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "Liraglutide ในประเทศไทย", "localizedAnswer": "Liraglutide เริ่มจากบันทึกยาของ FDA สหรัฐฯ แต่ไม่ได้พิสูจน์ว่าผลิตภัณฑ์ รูปแบบ ความแรง การอนุมัติ สถานะใบสั่งยา หรือการจัดหาในประเทศไทยเหมือนกัน ให้ตรวจผลิตภัณฑ์และผู้ขายที่เฉพาะเจาะจงในประเทศปลายทางจากบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=thailand" }, { "recordId": "pl-compound-country-liraglutide-indonesia", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "Liraglutide di Indonesia", "localizedAnswer": "Liraglutide dimulai dari identitas obat dalam catatan FDA Amerika Serikat, tetapi hal itu tidak membuktikan produk, bentuk, kekuatan, persetujuan, status resep, atau pasokan yang sama di Indonesia. Gunakan catatan resmi di bawah untuk memeriksa produk dan penjual spesifik di negara tujuan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=indonesia" }, { "recordId": "pl-compound-country-liraglutide-singapore", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Liraglutide in Singapore", "localizedAnswer": "Liraglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Singapore. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=singapore" }, { "recordId": "pl-compound-country-liraglutide-philippines", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Liraglutide in the Philippines", "localizedAnswer": "Liraglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the Philippines. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=philippines" }, { "recordId": "pl-compound-country-liraglutide-malaysia", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "Liraglutide in Malaysia", "localizedAnswer": "Liraglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Malaysia. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=malaysia" }, { "recordId": "pl-compound-country-liraglutide-taiwan", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "Liraglutide 在台灣的紀錄", "localizedAnswer": "Liraglutide在此從美國 FDA 藥品紀錄確認身分，但這不能證明台灣有相同產品、劑型、含量、適應症、處方狀態或目前供應。請用下方官方紀錄查證目的地的特定產品、許可證、機構和提供者，不能只依名稱或外國核准推論。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=taiwan" }, { "recordId": "pl-compound-country-liraglutide-hong-kong", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "Liraglutide 在香港的紀錄", "localizedAnswer": "Liraglutide在此從美國 FDA 藥物紀錄確認身分，但這不能證明香港有相同產品、劑型、含量、適應症、處方狀態或目前供應。請用下方官方紀錄核實指定產品、註冊編號、持牌銷售商和現行狀態，不能只依名稱或外國批准推論。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=hong-kong" }, { "recordId": "pl-compound-country-liraglutide-vietnam", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "Liraglutide tại Việt Nam", "localizedAnswer": "Liraglutide bắt đầu ở đây bằng hồ sơ thuốc của FDA Hoa Kỳ, nhưng điều đó không chứng minh có cùng sản phẩm, dạng bào chế, hàm lượng, giấy phép, tình trạng kê đơn hay nguồn cung hiện tại tại Việt Nam. Hãy dùng các hồ sơ bên dưới để xác minh chính xác sản phẩm, người bán, tình trạng và đường cung ứng tại điểm đến.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=vietnam" }, { "recordId": "pl-compound-country-liraglutide-united-states", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Liraglutide in the United States", "localizedAnswer": "Liraglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United States. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=united-states" }, { "recordId": "pl-compound-country-liraglutide-canada", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "Liraglutide in Canada", "localizedAnswer": "Liraglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Canada. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=canada" }, { "recordId": "pl-compound-country-liraglutide-united-arab-emirates", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Liraglutide في الإمارات العربية المتحدة", "localizedAnswer": "تبدأ هوية Liraglutide هنا من سجل دواء لدى إدارة الغذاء والدواء الأمريكية، لكن ذلك لا يثبت أن المنتج أو الشكل أو التركيز أو الموافقة أو حالة الوصفة أو التوفر الحالي هي نفسها في الإمارات العربية المتحدة. تحقق من المنتج المحلي المحدد والمنشأة والبائع ومسار التوريد من خلال السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=united-arab-emirates" }, { "recordId": "pl-compound-country-liraglutide-saudi-arabia", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "Liraglutide في المملكة العربية السعودية", "localizedAnswer": "تبدأ هوية Liraglutide هنا من سجل دواء لدى إدارة الغذاء والدواء الأمريكية، لكن ذلك لا يثبت أن المنتج أو الشكل أو التركيز أو الموافقة أو حالة الوصفة أو التوفر الحالي هي نفسها في المملكة العربية السعودية. تحقق من المنتج المحلي المحدد والمنشأة والبائع ومسار التوريد من خلال السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=saudi-arabia" }, { "recordId": "pl-compound-country-liraglutide-south-africa", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Liraglutide in South Africa", "localizedAnswer": "Liraglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in South Africa. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=south-africa" }, { "recordId": "pl-compound-country-liraglutide-nigeria", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Liraglutide in Nigeria", "localizedAnswer": "Liraglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Nigeria. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=nigeria" }, { "recordId": "pl-compound-country-liraglutide-kenya", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "Liraglutide in Kenya", "localizedAnswer": "Liraglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Kenya. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/liraglutide", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/liraglutide/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=liraglutide&country=kenya" }, { "recordId": "pl-compound-country-scenesse-france", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "SCENESSE en France", "localizedAnswer": "SCENESSE commence ici par une référence de médicament de la FDA américaine. Cela ne prouve pas le même produit, la même présentation, l’autorisation, le statut de prescription ou la disponibilité actuelle en France. Consultez les registres locaux exacts ci-dessous.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=france" }, { "recordId": "pl-compound-country-scenesse-united-kingdom", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "SCENESSE in the United Kingdom", "localizedAnswer": "SCENESSE begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United Kingdom. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=united-kingdom" }, { "recordId": "pl-compound-country-scenesse-germany", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "SCENESSE in Deutschland", "localizedAnswer": "SCENESSE beginnt hier mit einer Arzneimittelreferenz der US-FDA. Das belegt weder dasselbe Produkt noch Darreichungsform, Zulassung, Verschreibungsstatus oder aktuelle Verfügbarkeit in Deutschland. Prüfe die genauen lokalen Register unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=germany" }, { "recordId": "pl-compound-country-scenesse-spain", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "SCENESSE en España", "localizedAnswer": "SCENESSE empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en España. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=spain" }, { "recordId": "pl-compound-country-scenesse-italy", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "SCENESSE in Italia", "localizedAnswer": "SCENESSE parte qui da un riferimento di farmaco della FDA statunitense. Questo non dimostra stesso prodotto, presentazione, approvazione, stato di prescrizione o disponibilità attuale in Italia. Controlla i registri locali esatti qui sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=italy" }, { "recordId": "pl-compound-country-scenesse-netherlands", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "SCENESSE in Nederland", "localizedAnswer": "SCENESSE begint hier met een geneesmiddelreferentie van de Amerikaanse FDA. Dat bewijst niet hetzelfde product, dezelfde presentatie, toelating, receptstatus of actuele beschikbaarheid in Nederland. Controleer de exacte lokale registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=netherlands" }, { "recordId": "pl-compound-country-scenesse-switzerland", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "SCENESSE in Switzerland", "localizedAnswer": "SCENESSE begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Switzerland. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=switzerland" }, { "recordId": "pl-compound-country-scenesse-poland", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "SCENESSE w Polsce", "localizedAnswer": "SCENESSE zaczyna się tutaj od dokumentu leku amerykańskiej FDA. Nie dowodzi to tego samego produktu, postaci, dopuszczenia, statusu recepty ani bieżącej dostępności w Polsce. Sprawdź dokładne rejestry krajowe poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=poland" }, { "recordId": "pl-compound-country-scenesse-ireland", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "SCENESSE in Ireland", "localizedAnswer": "SCENESSE begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Ireland. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=ireland" }, { "recordId": "pl-compound-country-scenesse-portugal", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "SCENESSE em Portugal", "localizedAnswer": "SCENESSE começa aqui com uma referência de medicamento da FDA dos EUA. Isso não comprova o mesmo produto, apresentação, autorização, estatuto de prescrição ou disponibilidade atual em Portugal. Consulte os registos locais exatos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=portugal" }, { "recordId": "pl-compound-country-scenesse-sweden", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "SCENESSE i Sverige", "localizedAnswer": "SCENESSE börjar här med en läkemedelsreferens från amerikanska FDA. Det bevisar inte samma produkt, presentation, godkännande, receptstatus eller aktuell tillgänglighet i Sverige. Kontrollera de exakta nationella registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=sweden" }, { "recordId": "pl-compound-country-scenesse-turkey", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için SCENESSE", "localizedAnswer": "SCENESSE kimliği burada bir ABD FDA ilaç kaydıyla başlar, ancak bu Türkiye için aynı ürünün, farmasötik şeklin, dozun, ruhsatın, reçete durumunun veya güncel tedarikin bulunduğunu kanıtlamaz. Aşağıdaki resmi kayıtlarla tam ürün ve satıcı kimliğini, güncel durumu ve iddia edilen yolu doğrulayın.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=turkey" }, { "recordId": "pl-compound-country-scenesse-austria", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "SCENESSE in Österreich", "localizedAnswer": "SCENESSE beginnt hier mit einer Arzneimittelreferenz der US-FDA. Das belegt weder dasselbe Produkt noch Darreichungsform, Zulassung, Verschreibungsstatus oder aktuelle Verfügbarkeit in Österreich. Prüfe die genauen lokalen Register unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=austria" }, { "recordId": "pl-compound-country-scenesse-belgium", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "SCENESSE in België", "localizedAnswer": "SCENESSE begint hier met een geneesmiddelreferentie van de Amerikaanse FDA. Dat bewijst niet hetzelfde product, dezelfde presentatie, toelating, receptstatus of actuele beschikbaarheid in België. Controleer de exacte lokale registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=belgium" }, { "recordId": "pl-compound-country-scenesse-denmark", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "SCENESSE i Danmark", "localizedAnswer": "SCENESSE begynder her med en amerikansk FDA-lægemiddelidentitet, men det dokumenterer ikke samme produkt, form, styrke, godkendelse, receptstatus eller aktuelle forsyning i Danmark. Brug de officielle registre nedenfor til at kontrollere det nøjagtige lokale produkt, sælgeren, status og den påståede rute.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=denmark" }, { "recordId": "pl-compound-country-scenesse-finland", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "SCENESSE kohteessa Suomi", "localizedAnswer": "SCENESSE alkaa tässä Yhdysvaltain FDA:n lääkeidentiteetistä, mutta se ei todista samaa tuotetta, lääkemuotoa, vahvuutta, hyväksyntää, reseptistatusta tai nykyistä toimitusta kohteessa Suomi. Tarkista täsmällinen paikallinen tuote, myyjä, tila ja väitetty reitti alla olevista virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=finland" }, { "recordId": "pl-compound-country-scenesse-mexico", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "SCENESSE en México", "localizedAnswer": "SCENESSE empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en México. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=mexico" }, { "recordId": "pl-compound-country-scenesse-argentina", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "SCENESSE en Argentina", "localizedAnswer": "SCENESSE empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Argentina. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=argentina" }, { "recordId": "pl-compound-country-scenesse-colombia", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "SCENESSE en Colombia", "localizedAnswer": "SCENESSE empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Colombia. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=colombia" }, { "recordId": "pl-compound-country-scenesse-chile", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "SCENESSE en Chile", "localizedAnswer": "SCENESSE empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Chile. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=chile" }, { "recordId": "pl-compound-country-scenesse-brazil", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "SCENESSE no Brasil", "localizedAnswer": "SCENESSE começa aqui com uma referência de medicamento da FDA dos EUA. Isso não comprova o mesmo produto, apresentação, aprovação, status de prescrição ou disponibilidade atual no Brasil. Consulte os registros locais exatos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=brazil" }, { "recordId": "pl-compound-country-scenesse-china", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "SCENESSE 在中国的状态与官方记录", "localizedAnswer": "SCENESSE在此从美国 FDA 药品身份记录开始，但这不能证明同一品牌、剂型、规格、适应症、处方状态或供应路径在中国同样获批或可得。应使用下方官方记录核对目的地的具体产品和卖方，并确认当前状态，而不是依据名称、包装图片或国外批准作出推断。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=china" }, { "recordId": "pl-compound-country-scenesse-australia", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "SCENESSE in Australia", "localizedAnswer": "SCENESSE begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Australia. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=australia" }, { "recordId": "pl-compound-country-scenesse-new-zealand", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "SCENESSE in New Zealand", "localizedAnswer": "SCENESSE begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in New Zealand. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=new-zealand" }, { "recordId": "pl-compound-country-scenesse-india", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "SCENESSE in India", "localizedAnswer": "SCENESSE begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in India. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=india" }, { "recordId": "pl-compound-country-scenesse-japan", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のSCENESSE", "localizedAnswer": "SCENESSEはここでは米国FDAの医薬品記録から同一性を確認しますが、日本で同じ製品、剤形、規格、承認、処方区分、供給状況が存在することを証明しません。下記の公的記録で目的地の具体的な製品と販売主体を確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=japan" }, { "recordId": "pl-compound-country-scenesse-south-korea", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 SCENESSE", "localizedAnswer": "SCENESSE은 여기서 미국 FDA 의약품 기록으로 신원을 시작하지만, 대한민국에서 같은 제품, 제형, 함량, 허가, 처방 상태 또는 현재 공급이 존재한다는 뜻은 아닙니다. 아래 공식 기록을 이용해 목적지의 구체적인 제품과 판매 주체를 확인하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=south-korea" }, { "recordId": "pl-compound-country-scenesse-thailand", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "SCENESSE ในประเทศไทย", "localizedAnswer": "SCENESSE เริ่มจากบันทึกยาของ FDA สหรัฐฯ แต่ไม่ได้พิสูจน์ว่าผลิตภัณฑ์ รูปแบบ ความแรง การอนุมัติ สถานะใบสั่งยา หรือการจัดหาในประเทศไทยเหมือนกัน ให้ตรวจผลิตภัณฑ์และผู้ขายที่เฉพาะเจาะจงในประเทศปลายทางจากบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=thailand" }, { "recordId": "pl-compound-country-scenesse-indonesia", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "SCENESSE di Indonesia", "localizedAnswer": "SCENESSE dimulai dari identitas obat dalam catatan FDA Amerika Serikat, tetapi hal itu tidak membuktikan produk, bentuk, kekuatan, persetujuan, status resep, atau pasokan yang sama di Indonesia. Gunakan catatan resmi di bawah untuk memeriksa produk dan penjual spesifik di negara tujuan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=indonesia" }, { "recordId": "pl-compound-country-scenesse-singapore", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "SCENESSE in Singapore", "localizedAnswer": "SCENESSE begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Singapore. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=singapore" }, { "recordId": "pl-compound-country-scenesse-philippines", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "SCENESSE in the Philippines", "localizedAnswer": "SCENESSE begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the Philippines. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=philippines" }, { "recordId": "pl-compound-country-scenesse-malaysia", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "SCENESSE in Malaysia", "localizedAnswer": "SCENESSE begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Malaysia. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=malaysia" }, { "recordId": "pl-compound-country-scenesse-taiwan", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "SCENESSE 在台灣的紀錄", "localizedAnswer": "SCENESSE在此從美國 FDA 藥品紀錄確認身分，但這不能證明台灣有相同產品、劑型、含量、適應症、處方狀態或目前供應。請用下方官方紀錄查證目的地的特定產品、許可證、機構和提供者，不能只依名稱或外國核准推論。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=taiwan" }, { "recordId": "pl-compound-country-scenesse-hong-kong", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "SCENESSE 在香港的紀錄", "localizedAnswer": "SCENESSE在此從美國 FDA 藥物紀錄確認身分，但這不能證明香港有相同產品、劑型、含量、適應症、處方狀態或目前供應。請用下方官方紀錄核實指定產品、註冊編號、持牌銷售商和現行狀態，不能只依名稱或外國批准推論。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=hong-kong" }, { "recordId": "pl-compound-country-scenesse-vietnam", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "SCENESSE tại Việt Nam", "localizedAnswer": "SCENESSE bắt đầu ở đây bằng hồ sơ thuốc của FDA Hoa Kỳ, nhưng điều đó không chứng minh có cùng sản phẩm, dạng bào chế, hàm lượng, giấy phép, tình trạng kê đơn hay nguồn cung hiện tại tại Việt Nam. Hãy dùng các hồ sơ bên dưới để xác minh chính xác sản phẩm, người bán, tình trạng và đường cung ứng tại điểm đến.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=vietnam" }, { "recordId": "pl-compound-country-scenesse-united-states", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "SCENESSE in the United States", "localizedAnswer": "SCENESSE begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United States. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=united-states" }, { "recordId": "pl-compound-country-scenesse-canada", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "SCENESSE in Canada", "localizedAnswer": "SCENESSE begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Canada. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=canada" }, { "recordId": "pl-compound-country-scenesse-united-arab-emirates", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "SCENESSE في الإمارات العربية المتحدة", "localizedAnswer": "تبدأ هوية SCENESSE هنا من سجل دواء لدى إدارة الغذاء والدواء الأمريكية، لكن ذلك لا يثبت أن المنتج أو الشكل أو التركيز أو الموافقة أو حالة الوصفة أو التوفر الحالي هي نفسها في الإمارات العربية المتحدة. تحقق من المنتج المحلي المحدد والمنشأة والبائع ومسار التوريد من خلال السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=united-arab-emirates" }, { "recordId": "pl-compound-country-scenesse-saudi-arabia", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "SCENESSE في المملكة العربية السعودية", "localizedAnswer": "تبدأ هوية SCENESSE هنا من سجل دواء لدى إدارة الغذاء والدواء الأمريكية، لكن ذلك لا يثبت أن المنتج أو الشكل أو التركيز أو الموافقة أو حالة الوصفة أو التوفر الحالي هي نفسها في المملكة العربية السعودية. تحقق من المنتج المحلي المحدد والمنشأة والبائع ومسار التوريد من خلال السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=saudi-arabia" }, { "recordId": "pl-compound-country-scenesse-south-africa", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "SCENESSE in South Africa", "localizedAnswer": "SCENESSE begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in South Africa. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=south-africa" }, { "recordId": "pl-compound-country-scenesse-nigeria", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "SCENESSE in Nigeria", "localizedAnswer": "SCENESSE begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Nigeria. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=nigeria" }, { "recordId": "pl-compound-country-scenesse-kenya", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "SCENESSE in Kenya", "localizedAnswer": "SCENESSE begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Kenya. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/scenesse", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/scenesse/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=scenesse&country=kenya" }, { "recordId": "pl-compound-country-vyleesi-france", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "France", "countrySlug": "france", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fr", "localizedQuery": "VYLEESI en France", "localizedAnswer": "VYLEESI commence ici par une référence de médicament de la FDA américaine. Cela ne prouve pas le même produit, la même présentation, l’autorisation, le statut de prescription ou la disponibilité actuelle en France. Consultez les registres locaux exacts ci-dessous.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Base de données publique des médicaments", "productRecordPublisher": "Ministère de la Santé", "productRecordUrl": "https://base-donnees-publique.medicaments.gouv.fr/", "sellerOrSupplyRecordLabel": "Alerte sur les peptides vendus en ligne", "sellerOrSupplyRecordPublisher": "ANSM", "sellerOrSupplyRecordUrl": "https://ansm.sante.fr/actualites/peptides-vendus-en-ligne-ne-les-utilisez-pas-ils-peuvent-etre-dangereux", "canonicalGuideUrl": "https://peptidelocal.com/locations/france/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/france", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=france" }, { "recordId": "pl-compound-country-vyleesi-united-kingdom", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "United Kingdom", "countrySlug": "united-kingdom", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "VYLEESI in the United Kingdom", "localizedAnswer": "VYLEESI begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United Kingdom. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Search licensed medicine product information", "productRecordPublisher": "Medicines and Healthcare products Regulatory Agency", "productRecordUrl": "https://products.mhra.gov.uk/", "sellerOrSupplyRecordLabel": "Search the register", "sellerOrSupplyRecordPublisher": "General Pharmaceutical Council", "sellerOrSupplyRecordUrl": "https://www.pharmacyregulation.org/registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-kingdom/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/united-kingdom", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=united-kingdom" }, { "recordId": "pl-compound-country-vyleesi-germany", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Deutschland", "countrySlug": "germany", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "VYLEESI in Deutschland", "localizedAnswer": "VYLEESI beginnt hier mit einer Arzneimittelreferenz der US-FDA. Das belegt weder dasselbe Produkt noch Darreichungsform, Zulassung, Verschreibungsstatus oder aktuelle Verfügbarkeit in Deutschland. Prüfe die genauen lokalen Register unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Arzneimittelinformationen", "productRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "productRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/_node.html", "sellerOrSupplyRecordLabel": "Versandhandels-Register", "sellerOrSupplyRecordPublisher": "Bundesinstitut für Arzneimittel und Medizinprodukte", "sellerOrSupplyRecordUrl": "https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Versandhandels-Register/_node.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/germany/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/germany", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=germany" }, { "recordId": "pl-compound-country-vyleesi-spain", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "España", "countrySlug": "spain", "region": "Europe", "regionSlug": "europe", "contentLanguage": "es", "localizedQuery": "VYLEESI en España", "localizedAnswer": "VYLEESI empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en España. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "CIMA: Centro de Información online de Medicamentos", "productRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "productRecordUrl": "https://cima.aemps.es/cima/publico/home.html", "sellerOrSupplyRecordLabel": "Distafarma", "sellerOrSupplyRecordPublisher": "Agencia Española de Medicamentos y Productos Sanitarios", "sellerOrSupplyRecordUrl": "https://distafarma.aemps.es/farmacom/faces/inicio.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/spain/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/spain", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=spain" }, { "recordId": "pl-compound-country-vyleesi-italy", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Italia", "countrySlug": "italy", "region": "Europe", "regionSlug": "europe", "contentLanguage": "it", "localizedQuery": "VYLEESI in Italia", "localizedAnswer": "VYLEESI parte qui da un riferimento di farmaco della FDA statunitense. Questo non dimostra stesso prodotto, presentazione, approvazione, stato di prescrizione o disponibilità attuale in Italia. Controlla i registri locali esatti qui sotto.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Banca dati AIFA Medicinali", "productRecordPublisher": "Agenzia Italiana del Farmaco", "productRecordUrl": "https://medicinali.aifa.gov.it/it/", "sellerOrSupplyRecordLabel": "Venditori online di medicinali autorizzati", "sellerOrSupplyRecordPublisher": "Ministero della Salute", "sellerOrSupplyRecordUrl": "https://www.salute.gov.it/new/it/banche-dati/elenco-delle-farmacie-e-degli-esercizi-commerciali-autorizzati-al-commercio-line-di/", "canonicalGuideUrl": "https://peptidelocal.com/locations/italy/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/italy", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=italy" }, { "recordId": "pl-compound-country-vyleesi-netherlands", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Nederland", "countrySlug": "netherlands", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "VYLEESI in Nederland", "localizedAnswer": "VYLEESI begint hier met een geneesmiddelreferentie van de Amerikaanse FDA. Dat bewijst niet hetzelfde product, dezelfde presentatie, toelating, receptstatus of actuele beschikbaarheid in Nederland. Controleer de exacte lokale registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Geneesmiddeleninformatiebank", "productRecordPublisher": "College ter Beoordeling van Geneesmiddelen", "productRecordUrl": "https://db.cbg-meb.nl/nl/prodinfo/help.htm", "sellerOrSupplyRecordLabel": "Online aanbieder van medicijnen controleren", "sellerOrSupplyRecordPublisher": "Rijksoverheid", "sellerOrSupplyRecordUrl": "https://www.rijksoverheid.nl/vraag-en-antwoord/geneesmiddelen/controleren-betrouwbaarheid-online-aanbieder-van-medicijnen", "canonicalGuideUrl": "https://peptidelocal.com/locations/netherlands/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/netherlands", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=netherlands" }, { "recordId": "pl-compound-country-vyleesi-switzerland", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Switzerland", "countrySlug": "switzerland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "VYLEESI in Switzerland", "localizedAnswer": "VYLEESI begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Switzerland. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Lists of authorized medicinal products", "productRecordPublisher": "Swissmedic", "productRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html/1000", "sellerOrSupplyRecordLabel": "Guideline on medicines and the Internet", "sellerOrSupplyRecordPublisher": "Swissmedic", "sellerOrSupplyRecordUrl": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/medicinal-products-from-the-internet/leitfaden-arzneimittel-aus-dem-internet.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/switzerland/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/switzerland", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=switzerland" }, { "recordId": "pl-compound-country-vyleesi-poland", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Polska", "countrySlug": "poland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pl", "localizedQuery": "VYLEESI w Polsce", "localizedAnswer": "VYLEESI zaczyna się tutaj od dokumentu leku amerykańskiej FDA. Nie dowodzi to tego samego produktu, postaci, dopuszczenia, statusu recepty ani bieżącej dostępności w Polsce. Sprawdź dokładne rejestry krajowe poniżej.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Rejestr Produktów Leczniczych", "productRecordPublisher": "Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych", "productRecordUrl": "https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3", "sellerOrSupplyRecordLabel": "Sprzedaż leków w Internecie", "sellerOrSupplyRecordPublisher": "Główny Inspektorat Farmaceutyczny", "sellerOrSupplyRecordUrl": "https://www.gov.pl/web/chief-pharmaceutical-inspectorate/online-medicines-sale", "canonicalGuideUrl": "https://peptidelocal.com/locations/poland/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/poland", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=poland" }, { "recordId": "pl-compound-country-vyleesi-ireland", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Ireland", "countrySlug": "ireland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "en", "localizedQuery": "VYLEESI in Ireland", "localizedAnswer": "VYLEESI begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Ireland. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Find a medicine for human use", "productRecordPublisher": "Health Products Regulatory Authority", "productRecordUrl": "https://www.hpra.ie/find-a-medicine/for-human-use", "sellerOrSupplyRecordLabel": "PSI public registers", "sellerOrSupplyRecordPublisher": "Pharmaceutical Society of Ireland", "sellerOrSupplyRecordUrl": "https://www.psi.ie/information-and-resources/information-about-our-public-registers", "canonicalGuideUrl": "https://peptidelocal.com/locations/ireland/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/ireland", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=ireland" }, { "recordId": "pl-compound-country-vyleesi-portugal", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Portugal", "countrySlug": "portugal", "region": "Europe", "regionSlug": "europe", "contentLanguage": "pt-PT", "localizedQuery": "VYLEESI em Portugal", "localizedAnswer": "VYLEESI começa aqui com uma referência de medicamento da FDA dos EUA. Isso não comprova o mesmo produto, apresentação, autorização, estatuto de prescrição ou disponibilidade atual em Portugal. Consulte os registos locais exatos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Base de dados nacional de medicamentos Infomed", "productRecordPublisher": "INFARMED", "productRecordUrl": "https://extranet.infarmed.pt/INFOMED-fo/", "sellerOrSupplyRecordLabel": "Lista pública de farmácias licenciadas", "sellerOrSupplyRecordPublisher": "INFARMED", "sellerOrSupplyRecordUrl": "https://extranet.infarmed.pt/LicenciamentoMais-fo/pages/public/listaFarmacias.xhtml", "canonicalGuideUrl": "https://peptidelocal.com/locations/portugal/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/portugal", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=portugal" }, { "recordId": "pl-compound-country-vyleesi-sweden", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Sverige", "countrySlug": "sweden", "region": "Europe", "regionSlug": "europe", "contentLanguage": "sv", "localizedQuery": "VYLEESI i Sverige", "localizedAnswer": "VYLEESI börjar här med en läkemedelsreferens från amerikanska FDA. Det bevisar inte samma produkt, presentation, godkännande, receptstatus eller aktuell tillgänglighet i Sverige. Kontrollera de exakta nationella registren nedan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Nationellt produktregister för läkemedel", "productRecordPublisher": "Läkemedelsverket", "productRecordUrl": "https://www.lakemedelsverket.se/sv/e-tjanster-och-hjalpmedel/substans-och-produktregister/npl", "sellerOrSupplyRecordLabel": "Sök apotek som har tillstånd", "sellerOrSupplyRecordPublisher": "Läkemedelsverket", "sellerOrSupplyRecordUrl": "https://www.lakemedelsverket.se/sv/handel-med-lakemedel/apotek/sok-apotek-som-har-tillstand", "canonicalGuideUrl": "https://peptidelocal.com/locations/sweden/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/sweden", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=sweden" }, { "recordId": "pl-compound-country-vyleesi-turkey", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Türkiye", "countrySlug": "turkey", "region": "Europe", "regionSlug": "europe", "contentLanguage": "tr", "localizedQuery": "Türkiye için VYLEESI", "localizedAnswer": "VYLEESI kimliği burada bir ABD FDA ilaç kaydıyla başlar, ancak bu Türkiye için aynı ürünün, farmasötik şeklin, dozun, ruhsatın, reçete durumunun veya güncel tedarikin bulunduğunu kanıtlamaz. Aşağıdaki resmi kayıtlarla tam ürün ve satıcı kimliğini, güncel durumu ve iddia edilen yolu doğrulayın.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Ruhsatlı Ürünler Listesi", "productRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "productRecordUrl": "https://www.titck.gov.tr/dinamikmodul/85", "sellerOrSupplyRecordLabel": "Ruhsatlı Ecza Ticarethaneleri", "sellerOrSupplyRecordPublisher": "Türkiye İlaç ve Tıbbi Cihaz Kurumu", "sellerOrSupplyRecordUrl": "https://ebs.titck.gov.tr/ecza/depobilgi/ruhsatlidepolar", "canonicalGuideUrl": "https://peptidelocal.com/locations/turkey/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/turkey", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=turkey" }, { "recordId": "pl-compound-country-vyleesi-austria", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Österreich", "countrySlug": "austria", "region": "Europe", "regionSlug": "europe", "contentLanguage": "de", "localizedQuery": "VYLEESI in Österreich", "localizedAnswer": "VYLEESI beginnt hier mit einer Arzneimittelreferenz der US-FDA. Das belegt weder dasselbe Produkt noch Darreichungsform, Zulassung, Verschreibungsstatus oder aktuelle Verfügbarkeit in Österreich. Prüfe die genauen lokalen Register unten.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Arzneispezialitätenregister", "productRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "productRecordUrl": "https://basg.gv.at/fuer-unternehmen/zulassung-life-cycle/faq-zulassung-life-cycle/arzneispezialitaetenregister", "sellerOrSupplyRecordLabel": "Öffentliche Register für Arzneimittelbetriebe und Versandapotheken", "sellerOrSupplyRecordPublisher": "Bundesamt für Sicherheit im Gesundheitswesen", "sellerOrSupplyRecordUrl": "https://www.basg.gv.at/marktbeobachtung/oeffentliche-register", "canonicalGuideUrl": "https://peptidelocal.com/locations/austria/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/austria", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=austria" }, { "recordId": "pl-compound-country-vyleesi-belgium", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "België", "countrySlug": "belgium", "region": "Europe", "regionSlug": "europe", "contentLanguage": "nl", "localizedQuery": "VYLEESI in België", "localizedAnswer": "VYLEESI begint hier met een geneesmiddelreferentie van de Amerikaanse FDA. Dat bewijst niet hetzelfde product, dezelfde presentatie, toelating, receptstatus of actuele beschikbaarheid in België. Controleer de exacte lokale registers hieronder.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Databank van geneesmiddelen met geldige vergunningen", "productRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "productRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/information_about_medicines/medicinal_products_database", "sellerOrSupplyRecordLabel": "Officiële route voor internetapotheken", "sellerOrSupplyRecordPublisher": "Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten", "sellerOrSupplyRecordUrl": "https://www.famhp.be/en/human_use/medicines/medicines/distribution_delivery/pharmacy_public/website_pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/belgium/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/belgium", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=belgium" }, { "recordId": "pl-compound-country-vyleesi-denmark", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Danmark", "countrySlug": "denmark", "region": "Europe", "regionSlug": "europe", "contentLanguage": "da", "localizedQuery": "VYLEESI i Danmark", "localizedAnswer": "VYLEESI begynder her med en amerikansk FDA-lægemiddelidentitet, men det dokumenterer ikke samme produkt, form, styrke, godkendelse, receptstatus eller aktuelle forsyning i Danmark. Brug de officielle registre nedenfor til at kontrollere det nøjagtige lokale produkt, sælgeren, status og den påståede rute.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Lister med oplysninger om lægemidler", "productRecordPublisher": "Lægemiddelstyrelsen", "productRecordUrl": "https://laegemiddelstyrelsen.dk/en/sideeffects/find-medicines/lists-with-information-about-medicines", "sellerOrSupplyRecordLabel": "Apoteker der lovligt sælger medicin på nettet", "sellerOrSupplyRecordPublisher": "Lægemiddelstyrelsen", "sellerOrSupplyRecordUrl": "https://laegemiddelstyrelsen.dk/da/apoteker/koeb-og-salg-af-medicin-paa-internettet/apoteker-der-lovligt-saelger-medicin-paa-nettet", "canonicalGuideUrl": "https://peptidelocal.com/locations/denmark/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/denmark", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=denmark" }, { "recordId": "pl-compound-country-vyleesi-finland", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Suomi", "countrySlug": "finland", "region": "Europe", "regionSlug": "europe", "contentLanguage": "fi", "localizedQuery": "VYLEESI kohteessa Suomi", "localizedAnswer": "VYLEESI alkaa tässä Yhdysvaltain FDA:n lääkeidentiteetistä, mutta se ei todista samaa tuotetta, lääkemuotoa, vahvuutta, hyväksyntää, reseptistatusta tai nykyistä toimitusta kohteessa Suomi. Tarkista täsmällinen paikallinen tuote, myyjä, tila ja väitetty reitti alla olevista virallisista rekistereistä.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Fimean lääkehaku ja myyntiluvalliset lääkkeet Suomessa", "productRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "productRecordUrl": "https://fimea.fi/kansalaisen_laaketieto/myyntiluvalliset-laakkeet-suomessa", "sellerOrSupplyRecordLabel": "Luettelo laillisista apteekin verkkopalveluista", "sellerOrSupplyRecordPublisher": "Lääkealan turvallisuus- ja kehittämiskeskus Fimea", "sellerOrSupplyRecordUrl": "https://fimea.fi/apteekit/verkkopalvelutoiminta/lailliset_apteekin_verkkopalvelut", "canonicalGuideUrl": "https://peptidelocal.com/locations/finland/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/finland", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=finland" }, { "recordId": "pl-compound-country-vyleesi-mexico", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "México", "countrySlug": "mexico", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "VYLEESI en México", "localizedAnswer": "VYLEESI empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en México. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Visor de registros de medicamentos", "productRecordPublisher": "COFEPRIS", "productRecordUrl": "https://registros.cofepris.gob.mx/", "sellerOrSupplyRecordLabel": "Distribuidores irregulares", "sellerOrSupplyRecordPublisher": "COFEPRIS", "sellerOrSupplyRecordUrl": "https://www.gob.mx/cofepris/acciones-y-programas/plataforma-de-proveedores-irreulares-de-medicamentos", "canonicalGuideUrl": "https://peptidelocal.com/locations/mexico/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/mexico", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=mexico" }, { "recordId": "pl-compound-country-vyleesi-argentina", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Argentina", "countrySlug": "argentina", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "VYLEESI en Argentina", "localizedAnswer": "VYLEESI empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Argentina. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Medicamentos, registro y Vademécum Nacional", "productRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "productRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos", "sellerOrSupplyRecordLabel": "Droguerías y establecimientos habilitados", "sellerOrSupplyRecordPublisher": "Administración Nacional de Medicamentos, Alimentos y Tecnología Médica", "sellerOrSupplyRecordUrl": "https://www.argentina.gob.ar/anmat/regulados/medicamentos/otros-listados", "canonicalGuideUrl": "https://peptidelocal.com/locations/argentina/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/argentina", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=argentina" }, { "recordId": "pl-compound-country-vyleesi-colombia", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Colombia", "countrySlug": "colombia", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "VYLEESI en Colombia", "localizedAnswer": "VYLEESI empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Colombia. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Consulta de registros sanitarios", "productRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "productRecordUrl": "https://www.invima.gov.co/consulta-registros-sanitarios", "sellerOrSupplyRecordLabel": "Establecimientos nacionales de medicamentos certificados", "sellerOrSupplyRecordPublisher": "Instituto Nacional de Vigilancia de Medicamentos y Alimentos", "sellerOrSupplyRecordUrl": "https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-de-sintesis-quimica-y-biologicos/licenciamiento-auditorias-y-certificaciones/certificaciones-bpx/GTM-6", "canonicalGuideUrl": "https://peptidelocal.com/locations/colombia/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/colombia", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=colombia" }, { "recordId": "pl-compound-country-vyleesi-chile", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Chile", "countrySlug": "chile", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "es", "localizedQuery": "VYLEESI en Chile", "localizedAnswer": "VYLEESI empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Chile. Verifica los registros locales exactos que aparecen abajo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Registro sanitario de productos farmacéuticos", "productRecordPublisher": "Instituto de Salud Pública de Chile", "productRecordUrl": "https://www.ispch.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/", "sellerOrSupplyRecordLabel": "Farmacias y listados de autorizaciones", "sellerOrSupplyRecordPublisher": "Instituto de Salud Pública de Chile", "sellerOrSupplyRecordUrl": "https://www.ispch.cl/anamed/establecimientos-farmaceuticos-y-cosmeticos/farmacias/", "canonicalGuideUrl": "https://peptidelocal.com/locations/chile/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/chile", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=chile" }, { "recordId": "pl-compound-country-vyleesi-brazil", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Brasil", "countrySlug": "brazil", "region": "Latin America", "regionSlug": "latin-america", "contentLanguage": "pt-BR", "localizedQuery": "VYLEESI no Brasil", "localizedAnswer": "VYLEESI começa aqui com uma referência de medicamento da FDA dos EUA. Isso não comprova o mesmo produto, apresentação, aprovação, status de prescrição ou disponibilidade atual no Brasil. Consulte os registros locais exatos abaixo.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Consulta a registro de medicamentos", "productRecordPublisher": "Agência Nacional de Vigilância Sanitária", "productRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-a-registro-de-medicamentos", "sellerOrSupplyRecordLabel": "Consulta de drogarias e farmácias", "sellerOrSupplyRecordPublisher": "Agência Nacional de Vigilância Sanitária", "sellerOrSupplyRecordUrl": "https://www.gov.br/anvisa/pt-br/sistemas/consulta-de-drogarias-e-farmacias", "canonicalGuideUrl": "https://peptidelocal.com/locations/brazil/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/brazil", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=brazil" }, { "recordId": "pl-compound-country-vyleesi-china", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "中国", "countrySlug": "china", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-CN", "localizedQuery": "VYLEESI 在中国的状态与官方记录", "localizedAnswer": "VYLEESI在此从美国 FDA 药品身份记录开始，但这不能证明同一品牌、剂型、规格、适应症、处方状态或供应路径在中国同样获批或可得。应使用下方官方记录核对目的地的具体产品和卖方，并确认当前状态，而不是依据名称、包装图片或国外批准作出推断。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "国家药品监督管理局数据查询", "productRecordPublisher": "国家药品监督管理局", "productRecordUrl": "https://www.nmpa.gov.cn/datasearch/home-index.html", "sellerOrSupplyRecordLabel": "国家企业信用信息公示系统", "sellerOrSupplyRecordPublisher": "国家市场监督管理总局", "sellerOrSupplyRecordUrl": "https://www.gsxt.gov.cn/index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/china/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/china", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=china" }, { "recordId": "pl-compound-country-vyleesi-australia", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Australia", "countrySlug": "australia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "VYLEESI in Australia", "localizedAnswer": "VYLEESI begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Australia. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "sellerOrSupplyRecordLabel": "Personal Importation Scheme", "sellerOrSupplyRecordPublisher": "Therapeutic Goods Administration", "sellerOrSupplyRecordUrl": "https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme", "canonicalGuideUrl": "https://peptidelocal.com/locations/australia/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/australia", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=australia" }, { "recordId": "pl-compound-country-vyleesi-new-zealand", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "New Zealand", "countrySlug": "new-zealand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "VYLEESI in New Zealand", "localizedAnswer": "VYLEESI begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in New Zealand. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Unapproved peptide products health warning", "productRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "productRecordUrl": "https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp", "sellerOrSupplyRecordLabel": "Product and application search", "sellerOrSupplyRecordPublisher": "New Zealand Medicines and Medical Devices Safety Authority", "sellerOrSupplyRecordUrl": "https://www.medsafe.govt.nz/regulatory/ProductDetail.asp", "canonicalGuideUrl": "https://peptidelocal.com/locations/new-zealand/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/new-zealand", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=new-zealand" }, { "recordId": "pl-compound-country-vyleesi-india", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "India", "countrySlug": "india", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "VYLEESI in India", "localizedAnswer": "VYLEESI begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in India. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Approved new drugs", "productRecordPublisher": "Central Drugs Standard Control Organization", "productRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs", "sellerOrSupplyRecordLabel": "Drug and quality alerts", "sellerOrSupplyRecordPublisher": "Central Drugs Standard Control Organization", "sellerOrSupplyRecordUrl": "https://cdsco.gov.in/opencms/opencms/en/Latest-Alerts/", "canonicalGuideUrl": "https://peptidelocal.com/locations/india/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/india", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=india" }, { "recordId": "pl-compound-country-vyleesi-japan", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "日本", "countrySlug": "japan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ja", "localizedQuery": "日本のVYLEESI", "localizedAnswer": "VYLEESIはここでは米国FDAの医薬品記録から同一性を確認しますが、日本で同じ製品、剤形、規格、承認、処方区分、供給状況が存在することを証明しません。下記の公的記録で目的地の具体的な製品と販売主体を確認してください。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "承認品目情報", "productRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "productRecordUrl": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html", "sellerOrSupplyRecordLabel": "製品、安全性、電子添文、審査情報の検索入口", "sellerOrSupplyRecordPublisher": "独立行政法人医薬品医療機器総合機構（PMDA）", "sellerOrSupplyRecordUrl": "https://www.pmda.go.jp/english/search_index.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/japan/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/japan", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=japan" }, { "recordId": "pl-compound-country-vyleesi-south-korea", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "대한민국", "countrySlug": "south-korea", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "ko", "localizedQuery": "대한민국의 VYLEESI", "localizedAnswer": "VYLEESI은 여기서 미국 FDA 의약품 기록으로 신원을 시작하지만, 대한민국에서 같은 제품, 제형, 함량, 허가, 처방 상태 또는 현재 공급이 존재한다는 뜻은 아닙니다. 아래 공식 기록을 이용해 목적지의 구체적인 제품과 판매 주체를 확인하세요.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "식품의약품안전처 의약품 품목 허가 정보", "productRecordPublisher": "대한민국 공공데이터포털", "productRecordUrl": "https://www.data.go.kr/en/data/15095677/openapi.do", "sellerOrSupplyRecordLabel": "병원·약국 찾기", "sellerOrSupplyRecordPublisher": "건강보험심사평가원", "sellerOrSupplyRecordUrl": "https://www.hira.or.kr/ra/hosp/getHealthMap.do?pgmid=HIRAA030002010000", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-korea/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/south-korea", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=south-korea" }, { "recordId": "pl-compound-country-vyleesi-thailand", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "ประเทศไทย", "countrySlug": "thailand", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "th", "localizedQuery": "VYLEESI ในประเทศไทย", "localizedAnswer": "VYLEESI เริ่มจากบันทึกยาของ FDA สหรัฐฯ แต่ไม่ได้พิสูจน์ว่าผลิตภัณฑ์ รูปแบบ ความแรง การอนุมัติ สถานะใบสั่งยา หรือการจัดหาในประเทศไทยเหมือนกัน ให้ตรวจผลิตภัณฑ์และผู้ขายที่เฉพาะเจาะจงในประเทศปลายทางจากบันทึกทางการด้านล่าง", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "ระบบค้นหาข้อมูลผลิตภัณฑ์ยา", "productRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "productRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx", "sellerOrSupplyRecordLabel": "ระบบค้นหาสถานที่และผู้ดำเนินการด้านยา", "sellerOrSupplyRecordPublisher": "สำนักงานคณะกรรมการอาหารและยา", "sellerOrSupplyRecordUrl": "https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_LOCATION_DRUG_OPERATOR.aspx", "canonicalGuideUrl": "https://peptidelocal.com/locations/thailand/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/thailand", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=thailand" }, { "recordId": "pl-compound-country-vyleesi-indonesia", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Indonesia", "countrySlug": "indonesia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "id", "localizedQuery": "VYLEESI di Indonesia", "localizedAnswer": "VYLEESI dimulai dari identitas obat dalam catatan FDA Amerika Serikat, tetapi hal itu tidak membuktikan produk, bentuk, kekuatan, persetujuan, status resep, atau pasokan yang sama di Indonesia. Gunakan catatan resmi di bawah untuk memeriksa produk dan penjual spesifik di negara tujuan.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Pencarian produk terdaftar Cek BPOM", "productRecordPublisher": "Badan Pengawas Obat dan Makanan", "productRecordUrl": "https://cekbpom.pom.go.id/", "sellerOrSupplyRecordLabel": "Informasi publik sertifikat dan pencabutan CDOB", "sellerOrSupplyRecordPublisher": "Badan Pengawas Obat dan Makanan", "sellerOrSupplyRecordUrl": "https://sertifikasicdob.pom.go.id/wasdisobat/informasi-publik-ppid/", "canonicalGuideUrl": "https://peptidelocal.com/locations/indonesia/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/indonesia", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=indonesia" }, { "recordId": "pl-compound-country-vyleesi-singapore", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Singapore", "countrySlug": "singapore", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "VYLEESI in Singapore", "localizedAnswer": "VYLEESI begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Singapore. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "HSA Infosearch", "productRecordPublisher": "Singapore Health Sciences Authority", "productRecordUrl": "https://www.hsa.gov.sg/e-services/infosearch/", "sellerOrSupplyRecordLabel": "Supply through e-pharmacy", "sellerOrSupplyRecordPublisher": "Singapore Health Sciences Authority", "sellerOrSupplyRecordUrl": "https://www.hsa.gov.sg/other-regulations/retail-pharmacy-licence/supply-of-registered-therapeutic-products-through-e-pharmacy/", "canonicalGuideUrl": "https://peptidelocal.com/locations/singapore/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/singapore", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=singapore" }, { "recordId": "pl-compound-country-vyleesi-philippines", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Philippines", "countrySlug": "philippines", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "VYLEESI in the Philippines", "localizedAnswer": "VYLEESI begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the Philippines. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "FDA Verification Portal", "productRecordPublisher": "Food and Drug Administration Philippines", "productRecordUrl": "https://verification.fda.gov.ph/Home.php", "sellerOrSupplyRecordLabel": "FDA advisory on Verification Portal use", "sellerOrSupplyRecordPublisher": "Food and Drug Administration Philippines", "sellerOrSupplyRecordUrl": "https://www.fda.gov.ph/fda-advisory-no-2023-2238-utilization-of-the-food-and-drug-administration-fda-verification-portal/", "canonicalGuideUrl": "https://peptidelocal.com/locations/philippines/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/philippines", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=philippines" }, { "recordId": "pl-compound-country-vyleesi-malaysia", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Malaysia", "countrySlug": "malaysia", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "en", "localizedQuery": "VYLEESI in Malaysia", "localizedAnswer": "VYLEESI begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Malaysia. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "QUEST3+ Product Search", "productRecordPublisher": "National Pharmaceutical Regulatory Agency", "productRecordUrl": "https://quest3plus.bpfk.gov.my/pmo2/index.php", "sellerOrSupplyRecordLabel": "Product registration FAQ", "sellerOrSupplyRecordPublisher": "National Pharmaceutical Regulatory Agency", "sellerOrSupplyRecordUrl": "https://npra.gov.my/index.php/en/component/content/article/37-faq/623-product-registration?Itemid=437", "canonicalGuideUrl": "https://peptidelocal.com/locations/malaysia/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/malaysia", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=malaysia" }, { "recordId": "pl-compound-country-vyleesi-taiwan", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "台灣", "countrySlug": "taiwan", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-TW", "localizedQuery": "VYLEESI 在台灣的紀錄", "localizedAnswer": "VYLEESI在此從美國 FDA 藥品紀錄確認身分，但這不能證明台灣有相同產品、劑型、含量、適應症、處方狀態或目前供應。請用下方官方紀錄查證目的地的特定產品、許可證、機構和提供者，不能只依名稱或外國核准推論。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "西藥、醫療器材、特定用途化粧品許可證查詢", "productRecordPublisher": "衛生福利部食品藥物管理署", "productRecordUrl": "https://info.fda.gov.tw/MLMS/H0001.aspx", "sellerOrSupplyRecordLabel": "醫事機構查詢", "sellerOrSupplyRecordPublisher": "衛生福利部", "sellerOrSupplyRecordUrl": "https://ma.mohw.gov.tw/Accessibility/BASSearch/MASearchBAS", "canonicalGuideUrl": "https://peptidelocal.com/locations/taiwan/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/taiwan", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=taiwan" }, { "recordId": "pl-compound-country-vyleesi-hong-kong", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "香港", "countrySlug": "hong-kong", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "zh-HK", "localizedQuery": "VYLEESI 在香港的紀錄", "localizedAnswer": "VYLEESI在此從美國 FDA 藥物紀錄確認身分，但這不能證明香港有相同產品、劑型、含量、適應症、處方狀態或目前供應。請用下方官方紀錄核實指定產品、註冊編號、持牌銷售商和現行狀態，不能只依名稱或外國批准推論。", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "搜尋藥物資料庫", "productRecordPublisher": "香港衞生署藥物辦公室", "productRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_database.html", "sellerOrSupplyRecordLabel": "搜尋持牌藥物銷售商", "sellerOrSupplyRecordPublisher": "香港衞生署藥物辦公室", "sellerOrSupplyRecordUrl": "https://www.drugoffice.gov.hk/eps/do/tc/pharmaceutical_trade/search_drug_dealers.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/hong-kong/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/hong-kong", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=hong-kong" }, { "recordId": "pl-compound-country-vyleesi-vietnam", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Việt Nam", "countrySlug": "vietnam", "region": "Asia-Pacific", "regionSlug": "asia-pacific", "contentLanguage": "vi", "localizedQuery": "VYLEESI tại Việt Nam", "localizedAnswer": "VYLEESI bắt đầu ở đây bằng hồ sơ thuốc của FDA Hoa Kỳ, nhưng điều đó không chứng minh có cùng sản phẩm, dạng bào chế, hàm lượng, giấy phép, tình trạng kê đơn hay nguồn cung hiện tại tại Việt Nam. Hãy dùng các hồ sơ bên dưới để xác minh chính xác sản phẩm, người bán, tình trạng và đường cung ứng tại điểm đến.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Công bố giấy đăng ký thuốc và nguyên liệu làm thuốc", "productRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "productRecordUrl": "https://dichvucong.dav.gov.vn/congbothuoc/index", "sellerOrSupplyRecordLabel": "Thông tin cơ sở bán buôn thuốc", "sellerOrSupplyRecordPublisher": "Cục Quản lý Dược, Bộ Y tế", "sellerOrSupplyRecordUrl": "https://dav.gov.vn/co-so-ban-buon-thuoc-cua-co-so-co-quyen-nhap-khau-nhung-khong-duoc-quyen-phan-phoi-cn97.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/vietnam/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/vietnam", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=vietnam" }, { "recordId": "pl-compound-country-vyleesi-united-states", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "United States", "countrySlug": "united-states", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "VYLEESI in the United States", "localizedAnswer": "VYLEESI begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United States. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Drugs@FDA approved drug database", "productRecordPublisher": "U.S. Food and Drug Administration", "productRecordUrl": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm", "sellerOrSupplyRecordLabel": "Locate a state-licensed online pharmacy", "sellerOrSupplyRecordPublisher": "U.S. Food and Drug Administration", "sellerOrSupplyRecordUrl": "https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-states/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/united-states", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=united-states" }, { "recordId": "pl-compound-country-vyleesi-canada", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Canada", "countrySlug": "canada", "region": "North America", "regionSlug": "north-america", "contentLanguage": "en", "localizedQuery": "VYLEESI in Canada", "localizedAnswer": "VYLEESI begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Canada. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Drug Product Database", "productRecordPublisher": "Health Canada", "productRecordUrl": "https://health-products.canada.ca/dpd-bdpp/search?lang=eng", "sellerOrSupplyRecordLabel": "Choosing a safe online pharmacy", "sellerOrSupplyRecordPublisher": "Health Canada", "sellerOrSupplyRecordUrl": "https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html", "canonicalGuideUrl": "https://peptidelocal.com/locations/canada/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/canada", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=canada" }, { "recordId": "pl-compound-country-vyleesi-united-arab-emirates", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "الإمارات العربية المتحدة", "countrySlug": "united-arab-emirates", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "VYLEESI في الإمارات العربية المتحدة", "localizedAnswer": "تبدأ هوية VYLEESI هنا من سجل دواء لدى إدارة الغذاء والدواء الأمريكية، لكن ذلك لا يثبت أن المنتج أو الشكل أو التركيز أو الموافقة أو حالة الوصفة أو التوفر الحالي هي نفسها في الإمارات العربية المتحدة. تحقق من المنتج المحلي المحدد والمنشأة والبائع ومسار التوريد من خلال السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "دليل المنتجات الطبية المسجلة لدى مؤسسة الإمارات للدواء", "productRecordPublisher": "مؤسسة الإمارات للدواء", "productRecordUrl": "https://services.ede.gov.ae/drugdirectory?lang=en-US", "sellerOrSupplyRecordLabel": "ترخيص الصيادلة", "sellerOrSupplyRecordPublisher": "وزارة الصحة ووقاية المجتمع الإماراتية", "sellerOrSupplyRecordUrl": "https://mohap.gov.ae/en/w/licensing-of-pharmacists", "canonicalGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/united-arab-emirates", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=united-arab-emirates" }, { "recordId": "pl-compound-country-vyleesi-saudi-arabia", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "المملكة العربية السعودية", "countrySlug": "saudi-arabia", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "ar", "localizedQuery": "VYLEESI في المملكة العربية السعودية", "localizedAnswer": "تبدأ هوية VYLEESI هنا من سجل دواء لدى إدارة الغذاء والدواء الأمريكية، لكن ذلك لا يثبت أن المنتج أو الشكل أو التركيز أو الموافقة أو حالة الوصفة أو التوفر الحالي هي نفسها في المملكة العربية السعودية. تحقق من المنتج المحلي المحدد والمنشأة والبائع ومسار التوريد من خلال السجلات الرسمية أدناه.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "قائمة الأدوية", "productRecordPublisher": "الهيئة العامة للغذاء والدواء", "productRecordUrl": "https://www.sfda.gov.sa/en/drugs-list", "sellerOrSupplyRecordLabel": "قائمة المنشآت المرخصة", "sellerOrSupplyRecordPublisher": "الهيئة العامة للغذاء والدواء", "sellerOrSupplyRecordUrl": "https://www.sfda.gov.sa/en/licensed-establishments-list", "canonicalGuideUrl": "https://peptidelocal.com/locations/saudi-arabia/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/saudi-arabia", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=saudi-arabia" }, { "recordId": "pl-compound-country-vyleesi-south-africa", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "South Africa", "countrySlug": "south-africa", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "VYLEESI in South Africa", "localizedAnswer": "VYLEESI begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in South Africa. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Medicines Online Directory", "productRecordPublisher": "South African Health Products Regulatory Authority", "productRecordUrl": "https://medsinfo.sahpra.org.za/", "sellerOrSupplyRecordLabel": "Pharmaceutical establishment licensing", "sellerOrSupplyRecordPublisher": "South African Health Products Regulatory Authority", "sellerOrSupplyRecordUrl": "https://www.sahpra.org.za/pharma-licencing/", "canonicalGuideUrl": "https://peptidelocal.com/locations/south-africa/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/south-africa", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=south-africa" }, { "recordId": "pl-compound-country-vyleesi-nigeria", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Nigeria", "countrySlug": "nigeria", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "VYLEESI in Nigeria", "localizedAnswer": "VYLEESI begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Nigeria. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "NAFDAC Greenbook registered product database", "productRecordPublisher": "National Agency for Food and Drug Administration and Control", "productRecordUrl": "https://greenbook.nafdac.gov.ng/", "sellerOrSupplyRecordLabel": "Pharmacist and premises verification", "sellerOrSupplyRecordPublisher": "Pharmacy Council of Nigeria", "sellerOrSupplyRecordUrl": "https://pcncore.azurewebsites.net/", "canonicalGuideUrl": "https://peptidelocal.com/locations/nigeria/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/nigeria", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=nigeria" }, { "recordId": "pl-compound-country-vyleesi-kenya", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "country": "Kenya", "countrySlug": "kenya", "region": "Middle East and Africa", "regionSlug": "middle-east-africa", "contentLanguage": "en", "localizedQuery": "VYLEESI in Kenya", "localizedAnswer": "VYLEESI begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Kenya. Verify the exact local records below.", "reviewedDate": "2026-07-24", "statusSpecificity": "identity-plus-country-routes", "statusEvidenceBasis": "The row combines a compound identity record with general official destination verification routes. It is not a compound-specific authorization, prohibition, availability, or seller finding.", "statusEvidenceSourceCount": 0, "statusEvidencePublishers": [], "statusEvidenceUrls": [], "clinicalTrialScope": "outside-current-snapshot", "clinicalTrialProgramName": null, "clinicalTrialRegistryCountry": null, "clinicalTrialSnapshotDate": null, "clinicalTrialRecords": null, "clinicalTrialListedLocations": null, "clinicalTrialRecruitingLocations": null, "clinicalTrialRecordsWithRecruitingLocations": null, "clinicalTrialRecordIds": [], "clinicalTrialRecordUrls": [], "clinicalTrialFinderUrl": null, "clinicalTrialRegistrySearchUrl": null, "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "productRecordLabel": "Public pharmaceutical products register", "productRecordPublisher": "Kenya Pharmacy and Poisons Board", "productRecordUrl": "https://prims.pharmacyboardkenya.org/pharma_register_public/", "sellerOrSupplyRecordLabel": "Public facilities licence register", "sellerOrSupplyRecordPublisher": "Kenya Pharmacy and Poisons Board", "sellerOrSupplyRecordUrl": "https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities", "canonicalGuideUrl": "https://peptidelocal.com/locations/kenya/vyleesi", "countryGuideUrl": "https://peptidelocal.com/locations/kenya", "worldGuideUrl": "https://peptidelocal.com/peptides/vyleesi/countries", "checkerUrl": "https://peptidelocal.com/tools/global-peptide-status-checker?peptide=vyleesi&country=kenya" } ] }